<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006731.pub2" GROUP_ID="EPOC" ID="710205062711015831" MERGED_FROM="" MODIFIED="2015-05-26 10:32:04 +0100" MODIFIED_BY="Elizabeth Paulsen" REVIEW_NO="5" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2015-05-26 10:32:04 +0100" MODIFIED_BY="Elizabeth Paulsen">
<TITLE MODIFIED="2014-11-07 12:01:01 +0100" MODIFIED_BY="[Empty name]">Pharmaceutical policies: effects of financial incentives for prescribers</TITLE>
<CONTACT MODIFIED="2015-05-26 10:32:04 +0100" MODIFIED_BY="Elizabeth Paulsen"><PERSON ID="19990" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Arash</FIRST_NAME><LAST_NAME>Rashidian</LAST_NAME><SUFFIX>MD PhD</SUFFIX><POSITION>Associate Professor</POSITION><EMAIL_1>arashidian@tums.ac.ir</EMAIL_1><EMAIL_2>arash.rashidian@gmail.com</EMAIL_2><MOBILE_PHONE>0098 912 6770973</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Health Management and Economics, School of Public Health</DEPARTMENT><ORGANISATION>Tehran University of Medical Sciences</ORGANISATION><ADDRESS_1>Poursina Ave</ADDRESS_1><CITY>Tehran</CITY><ZIP>1417613191</ZIP><COUNTRY CODE="IR">Iran</COUNTRY><PHONE_1>00982188991112</PHONE_1><FAX_1>00982188991113</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-05-26 10:32:04 +0100" MODIFIED_BY="Elizabeth Paulsen"><PERSON ID="19990" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Arash</FIRST_NAME><LAST_NAME>Rashidian</LAST_NAME><SUFFIX>MD PhD</SUFFIX><POSITION>Associate Professor</POSITION><EMAIL_1>arashidian@tums.ac.ir</EMAIL_1><EMAIL_2>arash.rashidian@gmail.com</EMAIL_2><MOBILE_PHONE>0098 912 6770973</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Health Management and Economics, School of Public Health</DEPARTMENT><ORGANISATION>Tehran University of Medical Sciences</ORGANISATION><ADDRESS_1>Poursina Ave</ADDRESS_1><CITY>Tehran</CITY><ZIP>1417613191</ZIP><COUNTRY CODE="IR">Iran</COUNTRY><PHONE_1>00982188991112</PHONE_1><FAX_1>00982188991113</FAX_1></ADDRESS></PERSON><PERSON ID="72274606695290280317101028023800" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Amir-Houshang</FIRST_NAME><LAST_NAME>Omidvari</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>aomidvari@student.tums.ac.ir</EMAIL_1><EMAIL_2>ahomidvari@gmail.com</EMAIL_2><MOBILE_PHONE>+98-912-4275337</MOBILE_PHONE><ADDRESS><DEPARTMENT>Knowledge Utilization Research Center (KURC)</DEPARTMENT><ORGANISATION>Tehran University of Medical Sciences</ORGANISATION><ADDRESS_1>16 Azar</ADDRESS_1><CITY>Tehran</CITY><REGION>Tehran</REGION><COUNTRY CODE="IR">Iran</COUNTRY><PHONE_1>+98-912-4275337</PHONE_1></ADDRESS></PERSON><PERSON ID="36602006352749372805120312153644" ROLE="AUTHOR"><FIRST_NAME>Yasaman</FIRST_NAME><LAST_NAME>Vali</LAST_NAME><EMAIL_1>yasaman.vaali@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>School of Medicine</DEPARTMENT><ORGANISATION>Tehran University of Medical Sciences</ORGANISATION><CITY>Tehran</CITY><COUNTRY CODE="IR">Iran</COUNTRY><PHONE_1>0098 912 7057133</PHONE_1></ADDRESS></PERSON><PERSON ID="13512" ROLE="AUTHOR"><FIRST_NAME>Heidrun</FIRST_NAME><LAST_NAME>Sturm</LAST_NAME><POSITION>Medical Managing Director</POSITION><EMAIL_1>heidrunsturm@web.de</EMAIL_1><ADDRESS><DEPARTMENT>Comprehensive Cancer Center</DEPARTMENT><ORGANISATION>University Medical Center Tübingen</ORGANISATION><ADDRESS_1>Herrenberger Str. 23</ADDRESS_1><CITY>Tübingen</CITY><ZIP>D 72070</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 (0)7071 29-87060</PHONE_1></ADDRESS></PERSON><PERSON ID="6765" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Andrew</FIRST_NAME><MIDDLE_INITIALS>D</MIDDLE_INITIALS><LAST_NAME>Oxman</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>oxman@online.no</EMAIL_1><ADDRESS><DEPARTMENT>Global Health Unit</DEPARTMENT><ORGANISATION>Norwegian Knowledge Centre for the Health Services</ORGANISATION><ADDRESS_1>P.O. Box 7004, St. Olavs plass</ADDRESS_1><CITY>Oslo</CITY><ZIP>N-0130</ZIP><COUNTRY CODE="NO">Norway</COUNTRY><PHONE_1>+47 48 25 49 24</PHONE_1><FAX_1>+47 23 25 50 40</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-04-21 09:33:49 +0200" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="30" MONTH="1" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="1" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="1" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-05-26 10:53:45 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-05-26 10:53:45 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="4" YEAR="2015"/>
<DESCRIPTION>
<P>We included 6 new studies in this update and excluded 1 previously included study. The total included studies in the review is now 18.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-05-26 10:53:43 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="1" YEAR="2015"/>
<DESCRIPTION>
<P>This is the first update of the original review. We conducted a new search and updated other content.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-05-16 01:19:01 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-01-03 07:29:01 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="9" YEAR="2011"/>
<DESCRIPTION>
<P>Minor change to plain language summary</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-05-16 01:18:32 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="3" YEAR="2009"/>
<DESCRIPTION>
<P>Correction to typographical error
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-03-18 17:49:15 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Minor changes</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-05-16 01:18:38 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2015-05-16 01:19:01 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="5" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendments
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-01-03 10:07:41 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2014-01-03 10:06:40 +0100" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>Norwegian Knowledge Centre for the Health Services</NAME>
<COUNTRY CODE="NO">Norway</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2012-12-04 11:12:27 +0100" MODIFIED_BY="[Empty name]">
<NAME>Tehran University of Medical Sciences</NAME>
<COUNTRY CODE="IR">Iran</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2014-01-03 10:07:41 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-01-03 10:07:41 +0100" MODIFIED_BY="[Empty name]">
<NAME>Alliance for Health Policy and Systems Research, WHO</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION>
<P>The Alliance funded the conduct of the update of this systematic review. </P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-05-26 11:29:38 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-05-26 10:28:37 +0200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2015-05-22 11:45:00 +0200" MODIFIED_BY="Arash Rashidian">The effects of financial incentives for prescribers</TITLE>
<SUMMARY_BODY MODIFIED="2015-05-26 10:28:37 +0200" MODIFIED_BY="[Empty name]">
<P>This review is the first update of the Cochrane review of the effects of different financial policies seeking to influence prescriber behaviour. Researchers at The Cochrane Collaboration searched for all studies that could answer this question and found 18 studies. Their findings are summarised below.</P>
<P>
<B>What are financial incentives for prescribers?</B>
</P>
<P>Large amounts of healthcare funds are spent on medicines, and these amounts are increasing. Increased spending on medicines could mean less money for other healthcare or non-healthcare services. Health insurers and policy-makers are therefore looking for ways to ensure better use of medicines and to control the costs of medicines while still ensuring that patients get the medicines they need.</P>
<P>One way to try to control medicine spending is to influence the people who prescribe medicines, for instance, through financial incentives. One way of doing this involves introducing a budget cap or a budget target. Here, doctors and healthcare organisations are given a budget and the responsibility of staying within this budget. Another approach is to enforce a pay for performance policy, whereby doctors or their organisations are financially rewarded or punished for their prescribing behaviour. A third approach is to apply a reimbursement rate policy. Here, the amount of money doctors are reimbursed for medicine prescriptions is reduced, making the prescription of medicines less financially attractive to doctors.</P>
<P>These policies may lead doctors to prescribe fewer or cheaper medicines. This may reduce the use of unnecessary medicines but may also lead to poorer health outcomes.</P>
<P>
<B>What happens when financial incentives for prescribers are introduced?</B>
</P>
<P>
<I>Pharmaceutical budget caps or targets:</I>
</P>
<P>- This policy may lead to a modest reduction in overall drug use per patient (low-certainty evidence).</P>
<P>- We are uncertain of the effects of this policy on drug costs or on healthcare utilisation, as the certainty of the evidence has been assessed as very low.</P>
<P>- The effects of this policy on health outcomes have not been measured.</P>
<P>
<I>Pay for performance policies:</I>
</P>
<P>- We are uncertain of the effects of these policies on drug use or health outcomes, as the certainty of the evidence has been assessed as very low.</P>
<P>- The effects of this policy on drug costs or on healthcare utilisation have not been measured.</P>
<P>
<I>Reimbursement rate policies:</I>
</P>
<P>- We are uncertain about the effects of reimbursement rate policies because the quality of the evidence has been assessed as very low.</P>
<P>
<B>How up-to-date is this review?</B>
</P>
<P>The review authors searched for studies that had been published up to January 2015.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-05-22 11:44:51 +0200" MODIFIED_BY="Arash Rashidian">
<ABS_BACKGROUND MODIFIED="2015-05-22 11:43:12 +0200" MODIFIED_BY="Arash Rashidian">
<P>The proportion of total healthcare expenditures spent on drugs has continued to grow in countries of all income categories. Policy-makers are under pressure to control pharmaceutical expenditures without adversely affecting quality of care. Financial incentives seeking to influence prescribers' behaviour include budgetary arrangements at primary care and hospital settings (pharmaceutical budget caps or targets), financial rewards for target behaviours or outcomes (pay for performance interventions) and reduced benefit margin for prescribers based on medicine sales and prescriptions (pharmaceutical reimbursement rate reduction policies). This is the first update of the original version of this review.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-05-22 11:43:22 +0200" MODIFIED_BY="Arash Rashidian">
<P>To determine the effects of pharmaceutical policies using financial incentives to influence prescribers' practices on drug use, healthcare utilisation, health outcomes and costs (expenditures).</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-05-22 11:43:34 +0200" MODIFIED_BY="Arash Rashidian">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (searched 29/01/2015); MEDLINE, Ovid SP (searched 29/01/2015); EMBASE, Ovid SP (searched 29/01/2015); International Network for Rational Use of Drugs (INRUD) Bibliography (searched 29/01/2015); National Health Service (NHS) Economic Evaluation Database (searched 29/01/2015); EconLit - ProQuest (searched 02/02/2015); and Science Citation Index and Social Sciences Citation Index, Institute for Scientific Information (ISI) Web of Knowledge (citation search for included studies searched 10/02/2015). We screened the reference lists of relevant reports and contacted study authors and organisations to identify additional studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-05-22 11:43:47 +0200" MODIFIED_BY="Arash Rashidian">
<P>We included policies that intend to affect prescribing by means of financial incentives for prescribers. Included in this category are pharmaceutical budget caps or targets, pay for performance and drug reimbursement rate reductions and other financial policies, if they were specifically targeted at prescribing or drug utilisation. Policies in this review were defined as laws, rules, regulations and financial and administrative orders made or implemented by payers such as national or local governments, non-government organisations, private or social insurers and insurance-like organisations. One of the following outcomes had to be reported: drug use, healthcare utilisation, health outcomes or costs. The study had to be a randomised or non-randomised trial, an interrupted time series (ITS) analysis, a repeated measures study or a controlled before-after (CBA) study.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-05-22 11:44:00 +0200" MODIFIED_BY="Arash Rashidian">
<P>At least two review authors independently assessed eligibility for inclusion of studies and risks of bias using Cochrane Effective Practice and Organisation of Care (EPOC) criteria and extracted data from the included studies. For CBA studies, we reported relative effects (e.g. adjusted relative change). The review team re-analysed all ITS results. When possible, the review team also re-analysed CBA data as ITS data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-05-22 11:44:33 +0200" MODIFIED_BY="Arash Rashidian">
<P>Eighteen evaluations (six new studies) of pharmaceutical policies from six high-income countries met our inclusion criteria. Fourteen studies evaluated pharmaceutical budget policies in the UK (nine studies), two in Germany and Ireland and one each in Sweden and Taiwan. Three studies assessed pay for performance policies in the UK (two) and the Netherlands (one). One study from Taiwan assessed a reimbursement rate reduction policy. ITS analyses had some limitations. All CBA studies had serious limitations. No study from low-income or middle-income countries met the inclusion criteria.</P>
<P>Pharmaceutical budgets may lead to a modest reduction in drug use (median relative change -2.8%; low-certainty evidence). We are uncertain of the effects of the policy on drug costs or healthcare utilisation, as the certainty of such evidence has been assessed as very low. Effects of this policy on health outcomes were not reported. Effects of pay for performance policies on drug use and health outcomes are uncertain, as the certainty of such evidence has been assessed as very low. Effects of this policy on drug costs and healthcare utilisation have not been measured. Effects of the reimbursement rate reduction policy on drug use and drug costs are uncertain, as the certainty of such evidence has been assessed as very low. No included study assessed the effects of this policy on healthcare utilisation or health outcomes. Administration costs of the policies were not reported in any of the included studies.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-05-22 11:44:51 +0200" MODIFIED_BY="Arash Rashidian">
<P>Although financial incentives are considered an important element in strategies to change prescribing patterns, limited evidence of their effects can be found. Effects of policies, including pay for performance policies, in improving quality of care and health outcomes remain uncertain. Because pharmaceutical policies have uncertain effects, and because they might cause harm as well as benefit, proper evaluation of these policies is needed. Future studies should consider the impact of these policies on health outcomes, drug use and overall healthcare expenditures, as well as on drug expenditures.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-05-26 11:29:38 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-05-26 11:29:23 +0200" MODIFIED_BY="[Empty name]">
<P>This is the first update of the original review (<LINK REF="REF-Sturm-2007" TYPE="REFERENCE">Sturm 2007</LINK>).<BR/>
</P>
<CONDITION MODIFIED="2015-05-22 11:48:44 +0200" MODIFIED_BY="Arash Rashidian">
<P>The proportion of total healthcare expenditures spent on drugs has continued to grow in numerous countries over past decades (<LINK REF="REF-Reinhardt-2002" TYPE="REFERENCE">Reinhardt 2002</LINK>; <LINK REF="STD-Granlund-2006" TYPE="STUDY">Granlund 2006</LINK>; <LINK REF="REF-Okunade-2006" TYPE="REFERENCE">Okunade 2006</LINK>; <LINK REF="STD-Martens-2007" TYPE="STUDY">Martens 2007</LINK>), and it has increased about 50% from 1995 to 2006 (<LINK REF="REF-Lu-2011" TYPE="REFERENCE">Lu 2011</LINK>). For instance in the UK and Spain, drug costs in primary care consumed over 50% of total primary care expenditures (<LINK REF="STD-Bradlow-1993" TYPE="STUDY">Bradlow 1993</LINK>; <LINK REF="REF-Antonanzas-2003" TYPE="REFERENCE">Antonanzas 2003</LINK>). Although the growth rate has slowed in recent years, growth in pharmaceutical expenditures continues at a considerably faster rate than the general economy (<LINK REF="REF-Doloresco-2011" TYPE="REFERENCE">Doloresco 2011</LINK>). Middle-income countries have observed a faster pace of pharmaceutical expenditure growth than low- or high-income countries (<LINK REF="REF-Lu-2011" TYPE="REFERENCE">Lu 2011</LINK>). This is particularly the case for the high-growth pharmaceutical markets of 17 low- and middle-income 'pharmerging' countries as defined by IMS Health (<LINK REF="REF-Campbell-2013" TYPE="REFERENCE">Campbell 2013</LINK>) and a few others not covered by IMS analyses.</P>
<P>In many low- and middle-income countries, prescribing costs represent a major portion of total healthcare expenditures (<LINK REF="REF-Lu-2011" TYPE="REFERENCE">Lu 2011</LINK>). In low- and lower-middle-income countries, an even bigger proportion of the total health expenditures is spent on medicines (on average about 27% to 30% of total health expenditures), and affordability barriers hinder access to medicines, as many households are not supported by reliable financial mechanisms to secure such access (<LINK REF="REF-Steinbrook-2007" TYPE="REFERENCE">Steinbrook 2007</LINK>; <LINK REF="REF-Lu-2011" TYPE="REFERENCE">Lu 2011</LINK>). Recent studies in different regions of the world have highlighted important concerns about access to and use of medicines in low- and middle-income countries (<LINK REF="REF-Bigdeli-2013" TYPE="REFERENCE">Bigdeli 2013</LINK>; <LINK REF="REF-Zaidi-2013" TYPE="REFERENCE">Zaidi 2013</LINK>; <LINK REF="REF-Sarayani-2014" TYPE="REFERENCE">Sarayani 2014</LINK>), and limited research evidence is available to guide the decisions of policy-makers (<LINK REF="REF-Rashidian-2013" TYPE="REFERENCE">Rashidian 2013</LINK>; <LINK REF="REF-Emmerick-2013" TYPE="REFERENCE">Emmerick 2013</LINK>). It has been demonstrated that evidence on financing and health systems-related decisions in low- and middle-income countries is meagre (<LINK REF="REF-Rashidian-2013" TYPE="REFERENCE">Rashidian 2013</LINK>).</P>
<P>Thus, policy-makers are under pressure to control pharmaceutical expenditures without adversely affecting the quality of care. Unexplained variations in prescribing between individual physicians, differences among settings and countries (<LINK REF="REF-Sturm-2005" TYPE="REFERENCE">Sturm 2005</LINK>) and the fact that evidence and prescribing recommendations reflected in clinical practice guidelines often are not adequately put into practice (<LINK REF="REF-Feely-1999" TYPE="REFERENCE">Feely 1999</LINK>; <LINK REF="REF-Rashidian-2008" TYPE="REFERENCE">Rashidian 2008</LINK>) are reasons for implementing regulatory measures, including financial policies, targeted at prescribers to improve the quality of prescribing. Policy-makers&#8217; need for evidence continues to grow, but rigorous evaluations of regulatory measures are sparse.</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-05-22 11:50:46 +0200" MODIFIED_BY="Arash Rashidian">
<P>Financial incentives for influencing prescribers' behaviour can be categorised into the following groups: budgetary arrangements at primary care and hospital settings (pharmaceutical budget caps or targets), financial rewards for target behaviours or outcomes (pay for performance interventions) and reduced benefit margins for prescribers based on medicine sales and prescriptions (pharmaceutical reimbursement rate reduction policies).</P>
<P>Budgetary arrangements for pharmaceuticals may be included in global budget decisions, whereby a proportion of a global budget is earmarked for prescribing pharmaceuticals, or they may be enacted as stand-alone budgetary decisions for prescribing. For example, in the UK, a Primary Care Trust was "responsible for setting a prescribing budget against each practice" within its catchment area, and in Taiwan, global budgets were used to influence prescribers' behaviour in hospitals (<LINK REF="STD-Chou-2010" TYPE="STUDY">Chou 2010</LINK>). Financial rewards or incentives for target behaviours and outcomes constitute another type of financial incentive that is used with increasing frequency around the world (<LINK REF="REF-Giuffrida-2000" TYPE="REFERENCE">Giuffrida 2000</LINK>; <LINK REF="REF-Rosenthal-2006" TYPE="REFERENCE">Rosenthal 2006</LINK>; <LINK REF="REF-Rowe-2006" TYPE="REFERENCE">Rowe 2006</LINK>; <LINK REF="REF-Trude-2006" TYPE="REFERENCE">Trude 2006</LINK>). Other interventions, including interventions that target the margin of benefit from medicine sales for dispensing physicians, may impact prescribing behaviours. For example, in 2004, Medicare changed the way it pays for injectable medicines administered in the office, to reduce physicians' margins of financial benefit derived from certain prescriptions (<LINK REF="REF-Painter-2005" TYPE="REFERENCE">Painter 2005</LINK>).</P>
<P>Other monetary regulations, such as remuneration for physicians, can also influence prescribing. However, these do not specifically target prescribing and generally are not considered pharmaceutical policies. Restriction of reimbursement for patients might also affect prescribing by physicians (<LINK REF="REF-Austvoll_x002d_Dahlgren-2008" TYPE="REFERENCE">Austvoll-Dahlgren 2008</LINK>), as might other pharmaceutical policies such as reference pricing. These policies are not intended as financial incentives for prescribers and are covered in other systematic reviews (<LINK REF="REF-Aaserud-2006a" TYPE="REFERENCE">Aaserud 2006a</LINK>; <LINK REF="REF-Acosta-2014" TYPE="REFERENCE">Acosta 2014</LINK>). Pharmaceutical policies that use financial incentives for prescribers, which are included in this review, are therefore limited to the three categories of interventions explained below.</P>
</INTERVENTION>
<THEORY MODIFIED="2015-05-22 11:55:36 +0200" MODIFIED_BY="Arash Rashidian">
<SUBSECTION>
<HEADING LEVEL="3">Pharmaceutical budget caps or targets</HEADING>
<P>Budgets are funds allocated by payers to an individual physician or a group of physicians, thereby giving physicians financial responsibility for management of their own budget (<LINK REF="REF-Wilton-1998" TYPE="REFERENCE">Wilton 1998</LINK>). Budgets therefore encourage economic behaviours and offer incentives for savings. Drug budgets in particular seek to decrease prescribing costs. Budgets vary with respect to the level at which they are set (individual practice or collective budgets), the range of services covered and the intensity of the incentives (rewards or risks).</P>
<P>In general, individual providers or institutions or physician representatives and the payer negotiate a budget, depending on whether the budget is prepared on a practice, group or regional/national level. Payers are represented by a (regional) health authority (e.g. in the UK and Ireland), a social health insurance scheme (e.g. in Germany) or a managed care organisation (e.g. in the USA). Budgets usually are based on previous spending, adjusted to patient mix or a defined target (e.g. average spending on comparable practices; reduction in overall health care spending, as in Italy). Most budgetary interventions were introduced in the early to mid 1990s and have been adapted or abolished over time. Budgets provide incentives to prescribe fewer and less expensive drugs. Physicians can modify drug volume by changing the dosage or duration of treatment. Costs per item can be limited by increasing the use of generics or other less expensive drugs with equivalent effects. Theoretically this approach can slow the uptake of expensive new drugs with marginal benefits.</P>
<P>The intensity of the incentive is modified by several factors, such as the magnitude of the financial risk involved. Incentives can take the form of potential fines (Germany, France) (<LINK REF="REF-Mossialos-2005" TYPE="REFERENCE">Mossialos 2005</LINK>), savings to be used for improvement of medical services as in the UK (<LINK REF="STD-Coulter-1993" TYPE="STUDY">Coulter 1993</LINK>) or Ireland (<LINK REF="STD-Walley--2000" TYPE="STUDY">Walley 2000</LINK>) or salary bonuses as in Spain or the USA (<LINK REF="REF-Antonanzas-2003" TYPE="REFERENCE">Antonanzas 2003</LINK>; <LINK REF="REF-Conrad-2004" TYPE="REFERENCE">Conrad 2004</LINK>). Incentives seems to be more direct and stronger if applied at an individual level rather than at a group level. Also the effect of incentives may depend on how much the budget level (target) is adapted to provider-specific circumstances. For instance, in the UK high-cost patients and in Germany specific drug classes are exempt (<LINK REF="REF-Wilton-1998" TYPE="REFERENCE">Wilton 1998</LINK>). The amount, type and timing of prescribing information available to budget holders are important for enabling prescribers to react (<LINK REF="STD-Schrey_x00f6_gg-2005" TYPE="STUDY">Schreyögg 2005</LINK>). Lack of useful information can be an impediment to effective contracting (<LINK REF="REF-Wilton-1998" TYPE="REFERENCE">Wilton 1998</LINK>). Low perceived financial risk will decrease the strength of the incentive and will vary according to the likelihood that fines are actually executed or whether the results are derived through personal behaviour versus behaviours of a whole group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pay for performance interventions</HEADING>
<P>Quality-based payment systems may take a variety of forms. Most often they are directed at all physician services - not just at prescribing. Targets for these policies include administrative goals, waiting time, patient satisfaction and diagnostic and treatment goals. Prescribing policies include pay for performance and the potential for bonuses or penalties to encourage improvement in prescribing. On the basis of set performance standards, physicians are rewarded or punished for their prescribing (<LINK REF="REF-McNamara-2005" TYPE="REFERENCE">McNamara 2005</LINK>). Interventions vary greatly in terms of implementation approaches, magnitude of the 'incentives' (e.g. from 2% to 25% of physician total earnings) and whether accompanying interventions are included (<LINK REF="STD-O_x0027_Malley-2006" TYPE="STUDY">O'Malley 2006</LINK>; <LINK REF="STD-Chung-2010a" TYPE="STUDY">Chung 2010a</LINK>; <LINK REF="STD-Serumaga-2011" TYPE="STUDY">Serumaga 2011</LINK>). Pay for performance interventions can include prescribing targets as part of a wider set of performance objectives (e.g. in the UK general practice (<LINK REF="STD-Serumaga-2011" TYPE="STUDY">Serumaga 2011</LINK>) and in the Iran rural family physician programme (<LINK REF="REF-Takian-2011" TYPE="REFERENCE">Takian 2011</LINK>)) or can be focused on prescribing targets only (<LINK REF="STD-Chung-2010a" TYPE="STUDY">Chung 2010a</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pharmaceutical reimbursement rate reduction</HEADING>
<P>In certain countries (e.g. in East Asia), physicians can directly benefit from prescribing medicines. This is the case when the physician can purchase medicines from wholesalers, prescribe and dispense medicines for patients and then charge payers a higher price (<LINK REF="STD-Chu-2008" TYPE="STUDY">Chu 2008</LINK>). This practice has been reported in other countries as well, for example, among oncologists in the USA, where 'chemotherapy concessions' were applied (<LINK REF="STD-Chu-2008" TYPE="STUDY">Chu 2008</LINK>; <LINK REF="STD-Chang-2009" TYPE="STUDY">Chang 2009</LINK>). Oncologists could profit from prescribing medicines used to treat patients covered under Medicaid. In Taiwan, hospitals have traditionally benefited from using medicines they bought at a lower price from pharmaceutical companies and wholesalers. The tendency has been to transfer part of this benefit to the physicians who contributed to the hospitals' earnings, hence providing a direct financial incentive for overprescribing of medicines with the potential for increasing physician earnings (<LINK REF="STD-Chu-2008" TYPE="STUDY">Chu 2008</LINK>). Pharmaceutical reimbursement rate reduction policies involve reducing reimbursement rates for physicians, hence reducing the financial benefit they derive from prescribing medicines.<BR/>
</P>
</SUBSECTION>
</THEORY>
<IMPORTANCE MODIFIED="2015-05-26 11:29:23 +0200" MODIFIED_BY="[Empty name]">
<P>This review is part of a series of Cochrane reviews of pharmaceutical policies, undertaken to investigate the effects of different categories of pharmaceutical policies on drug and healthcare utilisation, costs and health outcomes. This review focuses on financial policies targeted at prescribers. It updates a previous Cochrane review (<LINK REF="REF-Sturm-2007" TYPE="REFERENCE">Sturm 2007</LINK>). The conduct of this update was supported by the World Health Organization (WHO) Alliance for Health Policy and Systems Research. The previous version of this Cochrane review included 13 studies of limited quality originating from three high-income European countries (the UK, Ireland and Germany). No other studies published at that time met the inclusion criteria. Despite limitations, existing evidence suggested that appropriately designed financial incentives may have a positive influence on prescribers' behaviour.</P>
<P>Previously published reviews have focused on individual financial policies, such as fund-holding and the indicative prescribing scheme in the UK and Ireland (<LINK REF="REF-Coulter-1995" TYPE="REFERENCE">Coulter 1995</LINK>; <LINK REF="REF-Walley-1995" TYPE="REFERENCE">Walley 1995</LINK>; <LINK REF="REF-Griffin-1996" TYPE="REFERENCE">Griffin 1996</LINK>; <LINK REF="REF-Harrison-1996" TYPE="REFERENCE">Harrison 1996</LINK>; <LINK REF="REF-Schwartz-1996" TYPE="REFERENCE">Schwartz 1996</LINK>; <LINK REF="REF-Gosden-1997" TYPE="REFERENCE">Gosden 1997</LINK>; <LINK REF="REF-Smith-1998" TYPE="REFERENCE">Smith 1998</LINK>; <LINK REF="REF-Garrison-2003" TYPE="REFERENCE">Garrison 2003</LINK>) and have included broad reviews of pharmaceutical policies (<LINK REF="REF-Soumerai-1993" TYPE="REFERENCE">Soumerai 1993</LINK>; <LINK REF="REF-Bloor-1996" TYPE="REFERENCE">Bloor 1996</LINK>; <LINK REF="REF-Narine-1997" TYPE="REFERENCE">Narine 1997</LINK>; <LINK REF="REF-Armour-2001" TYPE="REFERENCE">Armour 2001</LINK>; <LINK REF="REF-Ess-2003" TYPE="REFERENCE">Ess 2003</LINK>; <LINK REF="REF-Maynard-2003" TYPE="REFERENCE">Maynard 2003</LINK>; <LINK REF="REF-Mossialos-2004" TYPE="REFERENCE">Mossialos 2004</LINK>; <LINK REF="REF-Lu-2008" TYPE="REFERENCE">Lu 2008</LINK>; <LINK REF="REF-Ostini-2009" TYPE="REFERENCE">Ostini 2009</LINK>) and financial incentives (Flodgren 2012). Most of these reviews are not systematic reviews of evidence. Other identified reviews focusing on effects of various financial incentives on general medical practice only occasionally have addressed prescribing or reported drug-related outcomes (<LINK REF="REF-Chaix_x002d_Couturier-2000" TYPE="REFERENCE">Chaix-Couturier 2000</LINK>). Reviews investigating the effects of different remuneration systems for physicians (<LINK REF="REF-Bloor-1996" TYPE="REFERENCE">Bloor 1996</LINK>; <LINK REF="REF-Gosden-1997" TYPE="REFERENCE">Gosden 1997</LINK>; <LINK REF="REF-Chaix_x002d_Couturier-2000" TYPE="REFERENCE">Chaix-Couturier 2000</LINK>; <LINK REF="REF-Giuffrida-2000" TYPE="REFERENCE">Giuffrida 2000</LINK>; <LINK REF="REF-Gosden-2001" TYPE="REFERENCE">Gosden 2001</LINK>; <LINK REF="REF-Maynard-2003" TYPE="REFERENCE">Maynard 2003</LINK>) included only one study out of a total of 25 that reported effects on drug utilisation or related costs (excluding immunisation) for renewal of prescriptions. Pay for performance interventions are a relatively new approach, and evaluations are scarce (<LINK REF="REF-Giuffrida-2000" TYPE="REFERENCE">Giuffrida 2000</LINK>; <LINK REF="REF-Roland-2004" TYPE="REFERENCE">Roland 2004</LINK>; <LINK REF="REF-Rosenthal-2004" TYPE="REFERENCE">Rosenthal 2004</LINK>; <LINK REF="REF-McNamara-2005" TYPE="REFERENCE">McNamara 2005</LINK>; <LINK REF="REF-Witter-2012" TYPE="REFERENCE">Witter 2012</LINK>). Although in some countries physicians have gained financial benefits for years from prescribing certain medicines, the impact of reimbursement rate reduction policies on prescribing has not been assessed in previous reviews of pharmaceutical policies.</P>
<P>In recent years, financial incentives have been used more frequently to affect prescriber behaviour, including prescribers in low- and middle-income countries. More robust evaluation studies have assessed such interventions in high-income countries. This updated review is intended to improve our understanding of interventions and their wanted (and potentially unwanted) consequences. The aims of this review are to support informed decisions about pharmaceutical policies and to guide future evaluations by presenting an up-to-date, comprehensive summary of what is known from well-designed research about the effects on drug use, healthcare utilisation, health outcomes and cost (expenditures) of financial incentives targeted at prescribing.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-05-22 11:56:48 +0200" MODIFIED_BY="Arash Rashidian">
<P>To determine the effects of pharmaceutical policies using financial incentives to influence prescribers' practices on drug use, healthcare utilisation, health outcomes and costs (expenditures).</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-05-26 11:29:38 +0200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-05-26 10:14:58 +0200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2015-05-26 10:10:06 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs), non-randomised controlled trials (NRCTs), repeated
-measures (RM) studies, interrupted time series (ITS) analyses and controlled before-after (CBA) studies.</P>
<P>We used the Cochrane Effective Practice and Organisation of Care (EPOC) definition of RCT, NRCT, CBA and ITS studies (<LINK REF="REF-EPOC-2013a" TYPE="REFERENCE">EPOC 2013a</LINK>). An ITS study is defined as follows: &#8220;The study must have a clearly defined time of intervention and must have at least three data points before and three data points after the intervention.&#8221; We also considered designs that include a control ITS group. Controlled ITS (CITS) designs are conceptually similar to CBA designs, but the addition of multiple time points before and after the intervention decreases the likelihood of secular change bias.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-05-22 11:57:05 +0200" MODIFIED_BY="Arash Rashidian">
<P>Healthcare consumers and providers within a large jurisdiction or system of care. Jurisdictions could be regional, national or international. Studies within organisations, such as health maintenance organisations, were included if the organisation was multi-sited and served a wide population.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-05-22 11:57:05 +0200" MODIFIED_BY="Arash Rashidian">
<P>Prescribing policies (financial incentives): policies that intend to affect prescribing by means of financial incentives for prescribers. Included in this category are pharmaceutical budget caps or targets, pay for performance and drug reimbursement rate reductions and other financial policies specifically targeted at prescribing or drug utilisation.</P>
<P>Policies in this review are defined as laws, rules, regulations and financial and administrative orders made or implemented by payers such as national or local governments, non-government organisations, private or social insurers and insurance-like organisations.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-05-26 10:14:58 +0200" MODIFIED_BY="[Empty name]">
<P>To be included, a study had to use an objective measure from at least one of the following outcome categories.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<UL>
<LI>Drug use (prescribed, dispensed or actually used).</LI>
<LI>Health outcomes.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<UL>
<LI>Drug costs.</LI>
<LI>Healthcare utilisation.</LI>
<LI>Other healthcare costs and policy administration costs.</LI>
</UL>
<P>We used Grades of Recommendation, Assessment, Development and Evaluation (GRADE) worksheets in preparing 'Summary of findings' tables to identify the list of all reported relevant outcomes (within the above four categories of outcomes) (<LINK REF="REF-EPOC-2013b" TYPE="REFERENCE">EPOC 2013b</LINK>). Three review authors (A-HO, YV and AR) independently assessed the relative importance of each outcome for inclusion in the 'Summary of findings' tables.</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-05-22 11:57:41 +0200" MODIFIED_BY="Arash Rashidian">
<SUBSECTION>
<HEADING LEVEL="3">Electronic searches</HEADING>
<P>We searched the following databases with no language restrictions (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<UL>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 12) (including the Cochrane Effective Practice and Organisation of Care (EPOC) Group Specialised Register) (searched 29/01/2015).</LI>
<LI>MEDLINE In-Process &amp; Other Non-Indexed Citations, MEDLINE Daily, MEDLINE and Ovid, OLDMEDLINE, 1946 to present, Ovid SP (searched 29/01/2015).</LI>
<LI>EMBASE, 1980 to 2015 Week 4, Ovid SP (searched 29/01/2015).</LI>
<LI>International Network for Rational Use of Drugs (INRUD) Bibliography (searched 29/01/2015).</LI>
<LI>National Health Service (NHS) Economic Evaluation Database (2014, Issue 4) (searched 29/01/2015).</LI>
<LI>EconLit, 1969 to present, ProQuest (searched 02/02/2015).</LI>
</UL>
<P>See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for all search strategies run in 2015. Search strategies for the previous version of this review (<LINK REF="REF-Sturm-2007" TYPE="REFERENCE">Sturm 2007</LINK>) can be found in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Searching other resources</HEADING>
<P>We also did the following.</P>
<UL>
<LI>Conducted cited reference searches for all included studies in Science Citation Index 1975 to present and Social Sciences Citation Index 1975 to present, Institute for Scientific Information (ISI) Web of Knowledge (searched 10/02/2015).</LI>
<LI>Screened the reference lists of all relevant reports that we retrieved.</LI>
<LI>Contacted authors of relevant papers, relevant organisations and authors of discussion lists to identify additional studies, including unpublished and ongoing studies.</LI>
</UL>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-05-26 11:29:38 +0200" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2015-05-22 12:03:10 +0200" MODIFIED_BY="Arash Rashidian">
<P>Two review authors independently reviewed all search results, abstracts and reference lists of relevant reports. The full text of potentially relevant reports was retrieved, and two review authors independently assessed the relevance of those studies and the limitations of included studies. One author (A-HO, YV or HS) extracted data from the included studies in collaboration with one other review author. For all steps in the above process, we resolved disagreements by discussion, if necessary including another review author (AR or ADO).</P>
<P>
<BR/>
</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-05-22 13:20:52 +0200" MODIFIED_BY="Arash Rashidian">
<P>We extracted the following information for each included study:</P>
<UL>
<LI>First author, year of publication, language of publication and study title.</LI>
</UL>
<UL>
<LI>Study design (randomised trial, non-randomised trial, repeated-measures study, interrupted time series, controlled before-after).</LI>
<LI>Study setting (country, key features of the healthcare system, concurrent pharmaceutical policies).</LI>
<LI>Characteristics of policies and interventions.</LI>
<LI>Study duration and period (preintervention, intervention, postintervention).</LI>
<LI>Characteristics of study participants (consumers, physicians, practices, hospitals, etc.).</LI>
<LI>Main outcome measures.</LI>
<LI>Results for main outcome measures.</LI>
<LI>Sources of data and data collection approaches (routine data, databases, surveys, etc.).</LI>
<LI>Analytical methods and sample sizes.</LI>
</UL>
<P>

<BR/>
We attempted to identify important factors that might be taken into consideration by anyone contemplating implementing any of the policy alternatives, including possible trade-offs (of expected benefits vs harms and costs), different effects of varying policy conditions and background situations, short-term versus long-term effects, limitations of available evidence and other important factors that might affect the translation of available evidence into practice in specific settings. When included studies did not provide detailed information about the implemented policy and interventions, we noted further details of the intervention from excluded studies or from other published literature that gave a more detailed account of the policies and interventions.</P>
<P>
<BR/>
</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-05-26 10:24:50 +0200" MODIFIED_BY="[Empty name]">
<P>At least two review authors (from AR, A-HO, YV) assessed risk of bias for included studies. We accepted risk of bias assessments of the studies included in the previous version of this review (<LINK REF="REF-Sturm-2007" TYPE="REFERENCE">Sturm 2007</LINK>). Risk of bias assessments followed the approaches recommended by the EPOC Review Group (<LINK REF="REF-GRADE-2004" TYPE="REFERENCE">GRADE 2004</LINK>; <LINK REF="REF-EPOC-2015" TYPE="REFERENCE">EPOC 2015</LINK>; <LINK REF="REF-Ramsay-2003" TYPE="REFERENCE">Ramsay 2003</LINK>) (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>). Since the time of publication of the previous version of this review, two new criteria had been added to the EPOC risk of bias assessment criteria. Hence two review authors (AR, A-HO) assessed all previously included studies, and resulting judgements were added to the tables. We recorded potential sources of bias in the included studies and expounded the implication of those biases for reported outcomes.</P>
</QUALITY_ASSESSMENT>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-05-22 12:04:16 +0200" MODIFIED_BY="Arash Rashidian">
<P>We noted substantial differences between policies and interventions and the settings of included studies. Even for interventions within a similar category (e.g. budget caps, pay for performance), we observed that the specifications of policies and interventions had major differences, as did measured outcomes. We discerned substantial differences in health system characteristics (e.g. financing mechanisms) that could influence the effects of policies and interventions. Therefore, we did not calculate average effects across studies and did not assess statistical heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-05-26 11:29:38 +0200" MODIFIED_BY="[Empty name]">
<P>We followed the recommendations of EPOC regarding reanalyses of individual studies and data synthesis. For CBA studies, we reported relative effects. For continuous variables, we reported, when possible, the relative change, adjusted for baseline differences, in outcome measures. For this, we calculated absolute difference-in-differences, which we adjusted for the postintervention level in the control group, that is, [(the absolute postintervention difference between intervention and control groups - the absolute preintervention difference between intervention and control groups)/the postintervention level in control groups].</P>
<P>We considered CBA studies for CITS or ITS analyses if adequate data were presented in the paper. If such analyses were conducted, we presented the results as CITS analyses. For CITS, we assessed the time series part of the studies independently from the control part, using the above described criteria for ITS. We assessed the control series part of the study using the CBA criteria above. If the control part had serious limitations, we did not include the study but classified it as an ITS; otherwise we used the control data as a control in the review.</P>
<P>The preferred analysis method for ITS studies was a regression analysis with time trends before and after the intervention, which adjusted for autocorrelation and periodic changes, or ARIMA analysis. We agreed that the results of outcomes should be presented as changes along two dimensions: change in level and change in slope. Change in level is the immediate effect of the policy and is measured as the difference between fitted values for the first postintervention data point (one month after the intervention) minus the predicted outcome one month after the intervention based on the preintervention slope only. We calculated the relative change in level by dividing the change in level by the predicted outcome one month after the intervention based on the preintervention slope only, and then multiplying by 100%.</P>
<P>Change in slope is the change in the trend from preintervention to postintervention that reflects the "long"-term effect of the intervention. As interpretation of change in slope could be difficult, we chose to calculate and present long-term effects and relative immediate effects in a similar way. We presented the effects after half a year by determining the difference between the fitted value for the sixth month postintervention data point (half a year after the intervention) and the predicted outcome six months after the intervention based on the preintervention slope only, and then dividing by the predicted outcome six months after the intervention based on the preintervention slope only, and multiplying by 100%. We measured the effects after one year and after two years in a similar way.</P>
<P>Given that policy changes are often announced some months before official implementation, a transition phase is often defined as the six months after the official announcement. If applied, all results excluded data from the transition phase. However, if studies provided only a few data points, if the data itself did not suggest a transition phase and, most important, if study authors did not state a transition phase, we did not apply it. Transition phase was used in two studies included in this review (<LINK REF="STD-Harris-1996" TYPE="STUDY">Harris 1996</LINK>; <LINK REF="STD-Doran-2011" TYPE="STUDY">Doran 2011</LINK>).</P>
<P>If papers with ITS design did not provide appropriate analysis or reporting of results, but presented the data points in a scannable graph or in a table, we reanalysed the data using methods described in <LINK REF="REF-EPOC-2013c" TYPE="REFERENCE">EPOC 2013c</LINK>. The following segmented time series regression model was specified: Y(t) = B0 + B1*Pre-slope + B2*Post-slope + B3*intervention + e(t) where Y(t) is the outcome in month t. Pre-slope is a continuous variable indicating time from the start of the study to the last point in the preintervention phase and coded constant thereafter. Post-slope is coded 0 up to and including the first point post intervention and is coded sequentially from 1 thereafter. Intervention is coded 0 for preintervention time points and 1 for postintervention time points. In this model, B1 estimates the slope of the preintervention data, B2 estimates the slope of the postintervention data and B3 estimates the change in level of outcome as the difference between the estimated first point post intervention and the extrapolated first point post intervention if the preintervention line was continued into the postintervention phase. The difference in slope is calculated by B2 - B1. The error term e(t) was assumed to be first order autoregressive. For CITS studies, we have presented differences between relative changes in the intervention and control groups. We calculated confidence intervals (95%) for all effect measures. If possible, we calculated the effects at three, six, nine, 12 and 24 months after the intervention.</P>
<P>As in the previous version of the review (<LINK REF="REF-Sturm-2007" TYPE="REFERENCE">Sturm 2007</LINK>), we did not conduct a meta-analysis, as this was not deemed appropriate. We conducted a structured analysis and presented the findings for each policy. We calculated median effects across policies for similar outcomes when more than two ITS or CITS comparisons were available, and we reported these in the 'Summary of findings' tables. The structured analysis and 'Summary of findings' tables focus mainly on outcomes at 12 months after the intervention.</P>
<P>We used GRADE worksheets to assess the certainty of evidence across studies for each selected outcome. We populated the worksheet for each selected outcome to document study designs of included primary studies; risks of bias of the primary studies; inconsistency, indirectness and imprecision in the findings; and other factors that might influence risks of bias across the included studies for each outcome.We assessed the certainty of evidence for each outcome as high, moderate, low or very low in keeping with GRADE recommendations (<LINK REF="REF-EPOC-2013d" TYPE="REFERENCE">EPOC 2013d</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-05-22 12:05:59 +0200" MODIFIED_BY="Arash Rashidian">
<P>We prepared tables for each subcategory of policy interventions and included the following information: study identification, characteristics of the intervention, results of drug use, healthcare utilisation, health outcomes and costs. These tables form the basis for the structured synthesis that we conducted. In <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>, we described potential mechanisms through which the policies were intended to affect drug use and costs, and we postulated mechanisms for other effects, both intended and unintended. In addition, in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> we briefly listed and described other important policy options for which we included no evaluations.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-05-26 10:36:10 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-05-22 12:06:40 +0200" MODIFIED_BY="Arash Rashidian">
<SEARCH_RESULTS MODIFIED="2015-05-22 12:06:11 +0200" MODIFIED_BY="Arash Rashidian">
<P>The search in 2015 yielded 8388 records. We excluded 7191 records upon review of the titles. We screened the remaining 1197 records by reviewing abstracts, assessed 56 full-text papers and included six studies. Thirteen studies were previously included (<LINK REF="REF-Sturm-2007" TYPE="REFERENCE">Sturm 2007</LINK>), one of which was excluded for this update because outcomes were irrelevant. Studies included in the review now total 18. See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for additional details.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-05-22 12:06:28 +0200" MODIFIED_BY="Arash Rashidian">
<P>In total, we included 18 studies in this review, consisting of studies on pharmaceutical budget, pay for performance and drug reimbursement rate reduction policies. Thirteen studies (16 papers) had been included in the previous version of the review (<LINK REF="REF-Sturm-2005" TYPE="REFERENCE">Sturm 2005</LINK>), of which one study was excluded from the current review. We excluded the <LINK REF="STD-Kammerling-1996" TYPE="STUDY">Kammerling 1996</LINK> study, as it did not include specific prescribing outcome measures, and because it was difficult to argue that changes in reported outcomes were the result of financial incentives for prescribing.</P>
<P>Nine included studies assessed the effects of British fund-holding (<LINK REF="STD-Burr-1992" TYPE="STUDY">Burr 1992</LINK>; <LINK REF="STD-Bradlow-1993" TYPE="STUDY">Bradlow 1993</LINK>; <LINK REF="STD-Wilson-1995" TYPE="STUDY">Wilson 1995</LINK>; <LINK REF="STD-Harris-1996" TYPE="STUDY">Harris 1996</LINK>; <LINK REF="STD-Baines-1997c" TYPE="STUDY">Baines 1997c</LINK>; <LINK REF="STD-Corney-1997" TYPE="STUDY">Corney 1997</LINK>; <LINK REF="STD-Rafferty-1997" TYPE="STUDY">Rafferty 1997</LINK>; <LINK REF="STD-Whynes-1997" TYPE="STUDY">Whynes 1997</LINK>; <LINK REF="STD-Wilson-1999" TYPE="STUDY">Wilson 1999</LINK>), one study analysed the effects of the indicative prescribing scheme in Ireland (<LINK REF="STD-Walley--2000" TYPE="STUDY">Walley 2000</LINK>) and two studies reported on drug expenditure budgets in Germany (<LINK REF="STD-Guether-1995" TYPE="STUDY">Guether 1995</LINK>; <LINK REF="STD-Sch_x00f6_ffski-1997" TYPE="STUDY">Schöffski 1997</LINK>). Three studies were reported in more than one paper (<LINK REF="STD-Bradlow-1993" TYPE="STUDY">Bradlow 1993</LINK>; <LINK REF="STD-Wilson-1995" TYPE="STUDY">Wilson 1995</LINK>; <LINK REF="STD-Sch_x00f6_ffski-1997" TYPE="STUDY">Schöffski 1997</LINK>). The update resulted in the inclusion of six additional studies. Three studies assessed pay for performance and target payments in the UK and the Netherlands (<LINK REF="STD-Martens-2007" TYPE="STUDY">Martens 2007</LINK>; <LINK REF="STD-Doran-2011" TYPE="STUDY">Doran 2011</LINK>; <LINK REF="STD-Serumaga-2011" TYPE="STUDY">Serumaga 2011</LINK>), two studies assessed different forms of pharmaceutical budgets in Sweden and Taiwan (<LINK REF="STD-Granlund-2006" TYPE="STUDY">Granlund 2006</LINK>; <LINK REF="STD-Chou-2008" TYPE="STUDY">Chou 2008</LINK>) and one study assessed the effects of changing providers' benefit margin for dispensing of medicines in Taiwan (<LINK REF="STD-Chu-2008" TYPE="STUDY">Chu 2008</LINK>). None of the included studies were RCTs, CCTs or RM studies. We included three CITS analyses (<LINK REF="STD-Wilson-1995" TYPE="STUDY">Wilson 1995</LINK>; <LINK REF="STD-Harris-1996" TYPE="STUDY">Harris 1996</LINK>; <LINK REF="STD-Rafferty-1997" TYPE="STUDY">Rafferty 1997</LINK>), six ITS studies (<LINK REF="STD-Guether-1995" TYPE="STUDY">Guether 1995</LINK>; <LINK REF="STD-Sch_x00f6_ffski-1997" TYPE="STUDY">Schöffski 1997</LINK>; Walley 2000; <LINK REF="STD-Chou-2008" TYPE="STUDY">Chou 2008</LINK>; <LINK REF="STD-Doran-2011" TYPE="STUDY">Doran 2011</LINK>; <LINK REF="STD-Serumaga-2011" TYPE="STUDY">Serumaga 2011</LINK>) and nine CBA studies (<LINK REF="STD-Burr-1992" TYPE="STUDY">Burr 1992</LINK>; <LINK REF="STD-Bradlow-1993" TYPE="STUDY">Bradlow 1993</LINK>; <LINK REF="STD-Baines-1997c" TYPE="STUDY">Baines 1997c</LINK>; <LINK REF="STD-Corney-1997" TYPE="STUDY">Corney 1997</LINK>; <LINK REF="STD-Whynes-1997" TYPE="STUDY">Whynes 1997</LINK>; <LINK REF="STD-Wilson-1999" TYPE="STUDY">Wilson 1999</LINK>; <LINK REF="STD-Granlund-2006" TYPE="STUDY">Granlund 2006</LINK>; <LINK REF="STD-Martens-2007" TYPE="STUDY">Martens 2007</LINK>; <LINK REF="STD-Chu-2008" TYPE="STUDY">Chu 2008</LINK>; ). See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for further details.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-05-22 12:06:40 +0200" MODIFIED_BY="Arash Rashidian">
<P>The <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table provides reasons for exclusion of studies for which it is plausible to expect that a reader would question why the study was not included. The main reason for excluding these studies was the study design (37 studies), for example, lack of a control group (in a before-after study). Other reasons for exclusion include an intervention that did not provide financial incentives for prescribers (13 studies), confounding (five studies), lack of reporting of a relevant outcome (four studies), lack of reporting of a primary study (three studies) and insufficient data (two studies).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-05-22 12:07:27 +0200" MODIFIED_BY="Arash Rashidian">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>, <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>, <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>, <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK> and <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>.</P>
<P>We assessed all CBA studies as having serious limitations due to marked differences between experimental and control groups (selection bias). More important, it must be noted that for CBA studies that assessed the British fund-holding policy, intervention group members had voluntarily joined the policy. We assessed three studies (<LINK REF="STD-Wilson-1995" TYPE="STUDY">Wilson 1995</LINK>; <LINK REF="STD-Harris-1996" TYPE="STUDY">Harris 1996</LINK>; <LINK REF="STD-Rafferty-1997" TYPE="STUDY">Rafferty 1997</LINK>) as having some limitations, as they were CBA studies that had been reanalysed as CITS studies.</P>
<P>One ITS study assessed a pharmaceutical budget policy in Ireland (<LINK REF="STD-Walley--2000" TYPE="STUDY">Walley 2000</LINK>). We rated the quality as having some limitations. We included two ITS studies that evaluated German drug budgets. Drug volume was assessed by one (<LINK REF="STD-Guether-1995" TYPE="STUDY">Guether 1995</LINK>), and referrals by two (<LINK REF="STD-Guether-1995" TYPE="STUDY">Guether 1995</LINK>; <LINK REF="STD-Sch_x00f6_ffski-1997" TYPE="STUDY">Schöffski 1997</LINK>). These findings had some limitations, as data were presented quarterly rather than monthly, time series included too few data points (<LINK REF="STD-Guether-1995" TYPE="STUDY">Guether 1995</LINK>) or limitations were the result of incomplete data (<LINK REF="STD-Sch_x00f6_ffski-1997" TYPE="STUDY">Schöffski 1997</LINK>). In <LINK REF="STD-Guether-1995" TYPE="STUDY">Guether 1995</LINK>, data were reported with a "quasi control group" (prescriptions for privately insured patients not subject to budgets as opposed to socially insured), but investigators found the groups to be too different to be used as reliable comparators; therefore only ITS data of the intervention group were used in the analysis. Two ITS studies assessed the pay for performance policy in the UK (<LINK REF="STD-Doran-2011" TYPE="STUDY">Doran 2011</LINK>; <LINK REF="STD-Serumaga-2011" TYPE="STUDY">Serumaga 2011</LINK>). We determined that <LINK REF="STD-Doran-2011" TYPE="STUDY">Doran 2011</LINK> had some limitations, as it provided few data points for analysis. Another ITS study (<LINK REF="STD-Chou-2008" TYPE="STUDY">Chou 2008</LINK>) assessed a pharmaceutical budget policy in Taiwan and provided quarterly data points; we assessed this study as having some limitations.</P>
<P>Most of the included studies did not provide adequate information about simultaneous confounding interventions that might have been introduced during the study period, or about important economic or other changes that might have affected the findings (e.g. see <LINK REF="REF-Healey-1994" TYPE="REFERENCE">Healey 1994</LINK> as an example of how self selection among fund-holding practices in the UK might have affected observed outcomes of the policy).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-05-26 10:36:10 +0200" MODIFIED_BY="[Empty name]">
<P>We described in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> the settings and policies of the included studies. Here we described in further detail the pharmaceutical policies assessed in the included studies together with the main findings.</P>
<SUBSECTION>
<HEADING LEVEL="3">Characteristics of pharmaceutical budget policies</HEADING>
<P>Although budgetary policies were applied in at least 10 countries (see <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>; see also <LINK REF="REF-Garrison-2003" TYPE="REFERENCE">Garrison 2003</LINK> and <LINK REF="STD-Mossalios-2005" TYPE="STUDY">Mossalios 2005</LINK> for further examples in Europe), we could include evaluation studies from only five countries (Germany, Ireland, Sweden, Taiwan and the UK).</P>
<SUBSECTION>
<HEADING LEVEL="4">UK fundholding</HEADING>
<P>Fund-holding for general practitioners (GPs) in the UK was introduced with the first wave of voluntary practices in the early 1990s. Each year, practices with at least 11,000 registered patients could join the fund-holding scheme in "waves", until in 1997, healthcare trusts were introduced. With each wave, regulations on requisites for joining practices were relaxed. The aim of fund-holding was to increase efficiency of care by giving GPs financial control over some of their provided services (<LINK REF="REF-Weiner-1990" TYPE="REFERENCE">Weiner 1990</LINK>; <LINK REF="REF-Glynn-1992" TYPE="REFERENCE">Glynn 1992</LINK>; <LINK REF="STD-Wilson-1995" TYPE="STUDY">Wilson 1995</LINK>; <LINK REF="REF-Audit-Comm.-1996" TYPE="REFERENCE">Audit Comm. 1996</LINK>). Besides costs of prescribed drugs, separate budgets covered practice staff and a range of secondary care services such as specialist services and elective surgical services, with the drug budget offering the greatest savings potential (<LINK REF="STD-Harris-1996" TYPE="STUDY">Harris 1996</LINK>). Overspending in one budget had to be covered by funds from another budget, and savings could be used in other areas of patient care (<LINK REF="STD-Coulter-1993" TYPE="STUDY">Coulter 1993</LINK>). Budgets were set on the basis of previous expenditures and at the discretion of the local health authority medical advisor. Therefore budgets varied substantially from practice to practice (<LINK REF="REF-Day-1991" TYPE="REFERENCE">Day 1991</LINK>). Concurrently all practices, fund-holders and non-fund-holders alike were exposed to practice level feedback on their own performance in comparison with others (benchmarking), as well as to regular visits of independent pharmaceutical advisors from the local health authority. Initiatives to reduce costs of individual prescriptions such as use of limited lists and promotion of generics were launched (<LINK REF="STD-Baines-1997c" TYPE="STUDY">Baines 1997c</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Irish indicative drug budget</HEADING>
<P>In 1993 in Ireland, a comparable scheme called the Indicative Drug Targeting Savings Scheme (IDTSS) was introduced (<LINK REF="STD-Walley--2000" TYPE="STUDY">Walley 2000</LINK>). Individual indicative or hypothetical budgets of GPs covered prescribing and associated costs and were calculated on the basis of previous spending and the national average. Savings were split between the GP and the local health authority for use in the development of services. No penalties were imposed for overspending.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">German drug budget</HEADING>
<P>Collective budgets for drug expenditures for physicians in private practice in Germany were in use from 1993 to 2002 with the stated goal to maximise effectiveness by using less costly and more effective drugs. It was expected that although generic use would increase, use of drugs with disputed effects would decrease (<LINK REF="REF-Gross-1994" TYPE="REFERENCE">Gross 1994</LINK>; <LINK REF="REF-Busse-1996" TYPE="REFERENCE">Busse 1996</LINK>; <LINK REF="REF-Schwartz-1996" TYPE="REFERENCE">Schwartz 1996</LINK>; <LINK REF="REF-Schwermann-2003" TYPE="REFERENCE">Schwermann 2003</LINK>; <LINK REF="STD-Schrey_x00f6_gg-2005" TYPE="STUDY">Schreyögg 2005</LINK>). Although spending caps were regionally negotiated or nationally set each year and made all physicians in private practice in one region collectively liable, target volumes for each individual practice were only theoretically established. From 2002, budgets were abolished and were replaced by practice level target volumes (negotiated between the physician association and insurers). Parallel to initiation of budgets, reference pricing, changing levels of co-payment and price cuts for pharmaceuticals were introduced.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Taiwan pharmaceutical budget</HEADING>
<P>Before 2002, Taiwan's National Health Insurance paid providers on a fee-for-service basis, and patients were free to choose among providers. Concerns surrounded increases in costs and subsequent increases in insurance premiums. The global budget was implemented by hospitals in 2002, and it involved an expenditure cap. The cap was determined before each fiscal year. As a result, if providers delivered more services, their profit would be reduced. The global budget was later expanded to include hospital-specific targets such as prescription caps (<LINK REF="STD-Chou-2008" TYPE="STUDY">Chou 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sweden pharmaceutical budget</HEADING>
<P>Since 1998, the county councils in Sweden have been responsible for pharmaceutical costs not covered by patient co-payments. Hence they have been investigating routes to contain pharmaceutical costs. The approach involved a local county council's policy of imposing a fixed pharmaceutical budget on the health centres, which were expected to cover any pharmaceutical budget deficits and were allowed to keep any surplus generated each fiscal year (<LINK REF="STD-Granlund-2006" TYPE="STUDY">Granlund 2006</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Effects of pharmaceutical budget policies</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Drug use</HEADING>
<P>Twelve studies (six ITS or CITS studies and six CBA studies) assessed the effects of pharmaceutical budget interventions on drug use in five countries (<LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Drug use per patient or prescription</HEADING>
<P>Seven studies reported effects of different waves of British fund-holding in the UK (<LINK REF="STD-Burr-1992" TYPE="STUDY">Burr 1992</LINK>; <LINK REF="STD-Bradlow-1993" TYPE="STUDY">Bradlow 1993</LINK>; <LINK REF="STD-Wilson-1995" TYPE="STUDY">Wilson 1995</LINK>; <LINK REF="STD-Harris-1996" TYPE="STUDY">Harris 1996</LINK>; <LINK REF="STD-Rafferty-1997" TYPE="STUDY">Rafferty 1997</LINK>; <LINK REF="STD-Whynes-1997" TYPE="STUDY">Whynes 1997</LINK>; <LINK REF="STD-Wilson-1999" TYPE="STUDY">Wilson 1999</LINK>). In CITS studies (median effect at 12 months -1.5%, range -28.9% to +1.5%) and in CBA studies (median effect at 12 months 0.8%, range -1.2% to +1.8%), a relative reduction in prescribed drugs among fund-holders compared with controls was observed. The effect seemed to decrease with later waves of fund-holding. One ITS study of the Irish Indicative Drug Target Savings Scheme observed a relative reduction in the number of prescribed items over follow-up periods of one year (-8.2%) and two years (-10.1%) (<LINK REF="STD-Walley--2000" TYPE="STUDY">Walley 2000</LINK>). Another ITS study of the German drug budget (<LINK REF="STD-Guether-1995" TYPE="STUDY">Guether 1995</LINK>) observed that the overall number of prescriptions decreased from -11.2% at three months to -13.4% at 12 months. A further ITS study assessed the effects of the Taiwan National Health Insurance drug budget programme (<LINK REF="STD-Chou-2008" TYPE="STUDY">Chou 2008</LINK>), and found negligible reductions in drug use. Similarly, a CBA study of Sweden fixed budgets for pharmaceutical expenditures observed small reductions or increases in overall prescriptions (<LINK REF="STD-Granlund-2006" TYPE="STUDY">Granlund 2006</LINK>).</P>
<P>Findings of six ITS and CITS studies suggest that pharmaceutical budgets might result in a modest reduction in overall drug use (median relative change -2.8%), although the effect is uncertain, given the limitations of the included studies (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Generic percentage</HEADING>
<P>Six studies reported on the effects of UK fund-holding on generic prescribing. The effect on generic drug use was most consistent across waves and follow-up periods: All results reported in the studies almost uniformly showed a greater increase in use of generic drugs among fund-holders. CITS studies suggest a median of +15.0% (range -43.7% to 190.5%) at 12 months and +18.3% (13.6% to 23.0%) at 24 months (<LINK REF="STD-Rafferty-1997" TYPE="STUDY">Rafferty 1997</LINK>; <LINK REF="STD-Wilson-1995" TYPE="STUDY">Wilson 1995</LINK>). Effects of CBA studies ranged between 4.0% and 17.2% (median 10.1%) at 24 months (<LINK REF="STD-Bradlow-1993" TYPE="STUDY">Bradlow 1993</LINK>; <LINK REF="STD-Baines-1997c" TYPE="STUDY">Baines 1997c</LINK>; <LINK REF="STD-Wilson-1999" TYPE="STUDY">Wilson 1999</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Drug cost</HEADING>
<P>Twelve studies (five ITS or CITS studies and seven CBA studies) assessed the effects of pharmaceutical budget interventions on drug expenditures in four countries (<LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Drug cost per item</HEADING>
<P>Mean costs for dispensed drugs per item in UK fund-holding were reported in three CBA (<LINK REF="STD-Bradlow-1993" TYPE="STUDY">Bradlow 1993</LINK>; <LINK REF="STD-Rafferty-1997" TYPE="STUDY">Rafferty 1997</LINK>; <LINK REF="STD-Wilson-1999" TYPE="STUDY">Wilson 1999</LINK>) and two CITS analyses (<LINK REF="STD-Wilson-1995" TYPE="STUDY">Wilson 1995</LINK>; <LINK REF="STD-Rafferty-1997" TYPE="STUDY">Rafferty 1997</LINK>). All measured outcomes suggested that the expenditure levels of fund-holders relative to expected levels dropped more after intervention than those of non-fund-holders. Relative changes in levels of fund-holders compared with controls for the two CITS studies ranged from -49.2% to -6.2% at one-year follow-up (<LINK REF="STD-Wilson-1995" TYPE="STUDY">Wilson 1995</LINK>; <LINK REF="STD-Rafferty-1997" TYPE="STUDY">Rafferty 1997</LINK>) and most often showed a slight increase for longer follow-up periods. Relative effects in CBA studies reporting results at one-year follow-up (<LINK REF="STD-Bradlow-1993" TYPE="STUDY">Bradlow 1993</LINK>; <LINK REF="STD-Rafferty-1997" TYPE="STUDY">Rafferty 1997</LINK>) ranged from -6.3% to -5.3%. One ITS study evaluated the effects of the Irish indicative drug budget policy (<LINK REF="STD-Walley--2000" TYPE="STUDY">Walley 2000</LINK>) and reported a slight increase in costs per item at 12 months (relative change in level 0.6%).</P>
<P>Findings of three ITS and CITS studies from two countries (<LINK REF="STD-Wilson-1995" TYPE="STUDY">Wilson 1995</LINK>; <LINK REF="STD-Rafferty-1997" TYPE="STUDY">Rafferty 1997</LINK>; <LINK REF="STD-Walley--2000" TYPE="STUDY">Walley 2000</LINK>) suggest that pharmaceutical budgets might result in a possible reduction in cost per drug item (median relative change -25.6%), although the effect is uncertain, given the limitations of the included studies (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Drug cost per patient or prescription</HEADING>
<P>Almost all available effects on costs per patient across different waves and follow-up periods of UK fund-holding (reported in eight CBA and three CITS studies) consistently showed a bigger relative reduction in expenditure levels among fund-holders. Relative level changes of fund-holders compared with controls for CITS studies ranged from -79.7% to 66.8%, with a median of -2.8% at one-year follow-up (<LINK REF="STD-Wilson-1995" TYPE="STUDY">Wilson 1995</LINK>; <LINK REF="STD-Harris-1996" TYPE="STUDY">Harris 1996</LINK>; <LINK REF="STD-Rafferty-1997" TYPE="STUDY">Rafferty 1997</LINK>). Effects most often increased over time. The effects appeared somewhat smaller in later waves. CBA results from the same studies were consistent with these findings, with a median of -4.6% and a range between -6.2% and 0.5% after 12 months (<LINK REF="STD-Burr-1992" TYPE="STUDY">Burr 1992</LINK>; <LINK REF="STD-Bradlow-1993" TYPE="STUDY">Bradlow 1993</LINK>; <LINK REF="STD-Corney-1997" TYPE="STUDY">Corney 1997</LINK>). Studies from Sweden and Taiwan reported slight changes in costs per patient at 12-month follow-up. A CBA study of Sweden fixed budgets for pharmaceutical expenditures described an adjusted relative change of -0.02 (<LINK REF="STD-Granlund-2006" TYPE="STUDY">Granlund 2006</LINK>). An ITS study of the Taiwan National Health Insurance drug budget programme reported a relative change of 0.01 (<LINK REF="STD-Chou-2008" TYPE="STUDY">Chou 2008</LINK>).</P>
<P>Findings of four ITS and CITS studies from two countries (<LINK REF="STD-Wilson-1995" TYPE="STUDY">Wilson 1995</LINK>; <LINK REF="STD-Harris-1996" TYPE="STUDY">Harris 1996</LINK>; <LINK REF="STD-Rafferty-1997" TYPE="STUDY">Rafferty 1997</LINK>; <LINK REF="STD-Chou-2008" TYPE="STUDY">Chou 2008</LINK>) suggest that a modest decrease in drug expenditures per patient was possible (median relative change -2.5%), although the effect is uncertain, given the limitations of the included studies (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Total cost</HEADING>
<P>One CITS study reported changes in total prescribing costs in UK fund-holding (<LINK REF="STD-Harris-1996" TYPE="STUDY">Harris 1996</LINK>) and described reductions in prescribing costs for most follow-up periods (range at 12-month follow-up -69.6% to -27.3%). One ITS study evaluated the effects of Irish indicative drug budget policy on overall prescribing costs at 12 months and observed an important reduction of -18.0% (<LINK REF="STD-Walley--2000" TYPE="STUDY">Walley 2000</LINK>). Findings of two ITS and CITS studies from two countries suggest that pharmaceutical budgets might result in a possible reduction in total drug expenditures (median relative change, -38.9%), although the effect is uncertain, given the limitations of the included studies (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Healthcare utilisation and health outcomes</HEADING>
<P>No study reported effects on health outcomes (<LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>). Two ITS studies assessed German drug budget policies (<LINK REF="STD-Guether-1995" TYPE="STUDY">Guether 1995</LINK>; <LINK REF="STD-Sch_x00f6_ffski-1997" TYPE="STUDY">Schöffski 1997</LINK>) for effects on healthcare utilisation. One study (<LINK REF="STD-Sch_x00f6_ffski-1997" TYPE="STUDY">Schöffski 1997</LINK>) reported results on referrals to hospitals and observed a 13.3% increase at three months and at 12 months. Rates of referral of socially insured patients to outpatient specialists were reported in both studies (<LINK REF="STD-Guether-1995" TYPE="STUDY">Guether 1995</LINK>; <LINK REF="STD-Sch_x00f6_ffski-1997" TYPE="STUDY">Schöffski 1997</LINK>) and were inconclusive (median relative change -1.1% at 12 months; <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Characteristics of pay for performance policies</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Pay for performance policy of the Netherlands</HEADING>
<P>In 2001, a local insurance company introduced financial incentives for physicians to reduce prescribing costs and improve prescribing outcomes derived by adhering to a one-page formulary. The incentive was behaviour independent and was given to general practitioners beforehand. All general practitioners working in the intervention areas agreed to participate in the scheme (<LINK REF="STD-Martens-2007" TYPE="STUDY">Martens 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">UK pay for performance policy</HEADING>
<P>In 2004, a quality and outcomes framework was introduced in the UK with the aim of improving the quality of general practice services. It included 136 quality indicators, including prescribing indicators, and provided an important financial incentive (up to 25% of a physician's earnings) for general practitioners (<LINK REF="STD-Doran-2011" TYPE="STUDY">Doran 2011</LINK>; <LINK REF="STD-Serumaga-2011" TYPE="STUDY">Serumaga 2011</LINK>). Joining the framework was compulsory for all practicing general practitioners in the UK.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Effects of pay for performance policies</HEADING>
<P>One CBA and two ITS studies assessed the effects of pay for performance policies on relevant outcomes in two countries (<LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Drug use</HEADING>
<P>One CBA study in the Netherlands assessed the effects on prescriber performance of financial incentives for prescribing according to local guidelines (<LINK REF="STD-Martens-2007" TYPE="STUDY">Martens 2007</LINK>). Findings suggest a modest and temporary effect on prescribing of different target drugs, with adjusted relative changes that varied from -0.13 to 0.27. One ITS study assessed the effects on prescribing outcomes of the UK national pay for performance policy intended to improve quality of care (<LINK REF="STD-Doran-2011" TYPE="STUDY">Doran 2011</LINK>). This study reported modest improvements in five relevant prescribing outcomes, which consisted of prescribing outcomes that were not covered by the 'pay for performance' policy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Health outcomes</HEADING>
<P>One ITS study of moderate to high quality assessed effects of the UK pay for performance policy in improving health outcomes (<LINK REF="STD-Serumaga-2011" TYPE="STUDY">Serumaga 2011</LINK>). This study observed no clear improvements in the percentage of patients with controlled blood pressure at 12-month follow-up (relative change -1.49%, range -6.32 to 3.34) (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Characteristics of reimbursement rate reduction policies</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Taiwan's reimbursement rate reduction policies</HEADING>
<P>Hospitals in Taiwan may reimburse the National Health Insurance for drugs prescribed for their patients at a much higher price than the acquisition prices. Hospitals also tend to increase physicians' payments linked to the extra earnings they obtained from prescribed medicines. This policy, which was introduced in 2000, involves two aspects: reduced agreed upon prices for many medicines, and the requirement for hospitals to report drug acquisition prices. This policy could affect both hospital revenues and physician potential earnings based on medicine prescribing (<LINK REF="STD-Chu-2008" TYPE="STUDY">Chu 2008</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Effects of drug reimbursement reduction policies</HEADING>
<P>Although the policy has been used in different countries (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>), only one study met the inclusion criteria (<LINK REF="TBL-10" TYPE="TABLE">Table 10</LINK>). One CBA study assessed the effects of this policy on drug costs and items per prescription in Taiwan (<LINK REF="STD-Chu-2008" TYPE="STUDY">Chu 2008</LINK>). Investigators observed a very modest adjusted relative change of 0.01 in drug costs per patient and of 0.03 drug items prescribed per prescription.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-05-26 10:29:43 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2015-05-22 12:13:06 +0200" MODIFIED_BY="Arash Rashidian">
<P>Financial incentive prescribing policies are applied in various countries (see <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). However, studies that met the inclusion criteria for this review came from only six high-income countries and evaluated eight different programmes that used financial incentive policies. We identified studies that assessed budgetary policies, pay for performance policies and reimbursement rate reduction policies targeting prescribers' behaviour.</P>
<P>
<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> and <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK> provide summaries of the main findings from more robust ITS and CITS studies. <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK> (effect of budgetary policies on drug use), <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK> (effect of budgetary policies on cost), <LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK> (effect of budgetary policies on healthcare utilisation), <LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK> (effects of pay for performance policies) and <LINK REF="TBL-10" TYPE="TABLE">Table 10</LINK> (effects of drug reimbursement reduction) provide further details. As in the previous version of this review, evidence on the effects of budgetary policies is strongest, although the certainty of evidence for these policies is low or very low. On the basis of studies from four countries, budgetary policies may result in a reduction in drug use. Studies from two countries indicate that budgetary policies might also result in a reduction in prescribing costs, but the certainty of this evidence is very low. For all other outcome measures and other financial incentive policies, the certainty of the evidence is very low, or no evidence is available from the studies included in this review.</P>
<P>Overall the current version of the review provides wider coverage of financial incentive policies than was provided in the previous version of the review (<LINK REF="REF-Sturm-2007" TYPE="REFERENCE">Sturm 2007</LINK>). In the previous version, included studies originated from three high-income countries and evaluated budgetary policies only. Still, in this update, limited research evidence was available to assess the effects of financial incentive policies, and none of the included studies originated from a middle- or low-income country.</P>
<SUBSECTION>
<HEADING LEVEL="3">Pharmaceutical budgets</HEADING>
<P>Pharmaceutical budgets can apply to individual doctors or practices (as in UK fund-holding, the Irish indicative drug budget and Swedish health centre pharmaceutical budgets), or collectively to areas and regions (as in Germany pharmaceutical budgets) or at a national level. Pharmaceutical budgets that apply collectively to large areas are less likely to act as financial incentives for prescribers, unless they transfer part of the responsibility for budgets to individual prescribers. The focus of studies included in this review has been on pharmaceutical budgets that can act as financial incentives for prescribers (i.e. when budgets apply to individual doctors or practices, or when regional budgets are used to provide financial incentives for doctors to remain within budgets). These incentives include rewards when pharmaceutical expenses remain within the budget or penalties when expenses exceed real or indicative budgets.</P>
<P>Findings suggest that pharmaceutical budgets might result in a modest reduction in drug use and an increase in the generic percentage of drug use, although the effects are uncertain, given the limitations of the included studies. Also wide variations in observed effects on drug expenditures per patient suggest that other confounding factors might moderate potential policy effects. The studies were more likely to suggest reductions in total prescribing costs, probably via reductions in cost per drug item. Whether such reductions are the result of physicians' decision making or policy level decisions regarding formularies or medicine pricing needs to be assessed in future studies.</P>
<P>Reductions in pharmaceutical costs (e.g. as a result of pharmaceutical budgets for primary care) may encourage cost shifting to other services or settings (e.g. referral to secondary care) (<LINK REF="REF-Croxson-2001" TYPE="REFERENCE">Croxson 2001</LINK>). Such potential effects of pharmaceutical budgets were not clearly supported by the evidence included in our review. Evidence from this review does not clarify effects of pharmaceutical budgets on quality of care or health outcomes. Assessing effects on quality of care is more difficult than measuring effects on drug expenditure or use. Although the explicit objectives of pharmaceutical budget policies often involved controlling pharmaceutical expenditures, it was a major oversight that none of the included studies reported effects on health outcomes or quality of care.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pay for performance policies</HEADING>
<P>Pay for performance policies to improve prescribing behaviour in the UK and the Netherlands met our inclusion criteria. In the Netherlands, the policy involved encouraging prescribing based on clinical practice guidelines (<LINK REF="STD-Martens-2007" TYPE="STUDY">Martens 2007</LINK>). Although the policy had been mutually agreed upon by local physicians, an approach that is likely to improve the acceptability of the policy (<LINK REF="REF-Trude-2006" TYPE="REFERENCE">Trude 2006</LINK>), the pay for performance incentive resulted in only modest and temporary effects (<LINK REF="STD-Martens-2007" TYPE="STUDY">Martens 2007</LINK>).</P>
<P>One ITS study assessed the effects of UK national pay for performance policy in improving quality of care (<LINK REF="STD-Doran-2011" TYPE="STUDY">Doran 2011</LINK>). This study showed only modest improvements in prescribing outcomes with no substantial differences between improvements observed for prescribing outcomes that were incentivised under the pay for performance policy versus outcomes that were not incentivised. Another ITS study (<LINK REF="STD-Serumaga-2011" TYPE="STUDY">Serumaga 2011</LINK>) observed no improvements in the percentage of patients with controlled blood pressure at 12 months after introduction of the pay for performance policy in the UK. This study had a methodological advantage over other included ITS studies, as it included monthly collected data in the analyses. Our findings from included studies were also supported by the findings of studies that did not meet our inclusion criteria (<LINK REF="STD-Campbell-2007" TYPE="STUDY">Campbell 2007</LINK>; <LINK REF="STD-Campbell-2009" TYPE="STUDY">Campbell 2009</LINK>).</P>
<P>Despite expectations (<LINK REF="REF-Roland-2004" TYPE="REFERENCE">Roland 2004</LINK>; <LINK REF="STD-Mossalios-2005" TYPE="STUDY">Mossalios 2005</LINK>), the UK quality and outcomes framework pay for performance policy did not result in major improvements in prescribing or health outcomes. As a result, review findings did not provide a favourable picture for the effects of pay for performance.</P>
<P>The size of pay for performance may affect its effectiveness, although it has been suggested that even small financial rewards can have a strong influence on prescribers' behaviour (<LINK REF="STD-Ashworth-2004" TYPE="STUDY">Ashworth 2004</LINK>). Studies in the USA that did not meet the inclusion criteria reported little change in prescribing outcomes (<LINK REF="STD-O_x0027_Malley-2006" TYPE="STUDY">O'Malley 2006</LINK>; <LINK REF="STD-Chung-2010a" TYPE="STUDY">Chung 2010a</LINK>; <LINK REF="STD-Chung-2010b" TYPE="STUDY">Chung 2010b</LINK>) when they offered small incentives of about 2% of physician earnings (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). It was also observed that it did not make much difference whether a small financial incentive was offered as one annual bonus payment or as monthly payments (<LINK REF="STD-Chung-2010b" TYPE="STUDY">Chung 2010b</LINK>). Contrary to these experiences, the UK pay for performance policy involved a 25% rise in earning potential. Lack of substantial improvement in outcomes in the UK might be linked to a better baseline performance before implementation of the policy (<LINK REF="STD-Doran-2011" TYPE="STUDY">Doran 2011</LINK>; <LINK REF="STD-Serumaga-2011" TYPE="STUDY">Serumaga 2011</LINK>). It might be argued that lack of effect from pay for performance in the Netherlands was due to the nature of the incentive, as it was behaviour independent (i.e. physicians received the small incentive up front) (<LINK REF="STD-Martens-2007" TYPE="STUDY">Martens 2007</LINK>). Well-designed studies, preferably randomised trials, of pay for performance policies are needed, especially because many policy-makers and international organisations promote pay for performance policies for improved quality of care (<LINK REF="REF-Rosenthal-2004" TYPE="REFERENCE">Rosenthal 2004</LINK>) in settings including low-income and middle-income countries (<LINK REF="REF-Eichler-2009" TYPE="REFERENCE">Eichler 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Reimbursement rate reduction policies</HEADING>
<P>For many years, certain specialist physicians in the USA gained financial benefits from dispensing expensive medicines under Medicare Part B plans. Physicians purchased medicines from wholesalers, prescribed them for patients and were reimbursed by Medicare at a higher rate (<LINK REF="STD-Jacobson-2006" TYPE="STUDY">Jacobson 2006</LINK>; <LINK REF="STD-Doshi-2010" TYPE="STUDY">Doshi 2010</LINK>). This provided direct financial incentives for physicians to prescribe certain medicines. In 2003, the Medicare Prescription Drug, Improvement, and Modernization Act substantially reduced physician financial incentives for such prescriptions. A similar financial incentive is available in many other countries where physicians can dispense (usually a limited list of) medicines or equipment. Still few studies have assessed the effects of policies aimed at reducing such financial incentives, and only one study met our inclusion criteria. The included study in Taiwan demonstrated small changes in prescribing after implementation of the policy (<LINK REF="STD-Chu-2008" TYPE="STUDY">Chu 2008</LINK>). Non-included studies from the USA suggest that the effects of the policy in that country on prescribing certain expensive chemotherapy medicines might have been substantial (<LINK REF="STD-Jacobson-2006" TYPE="STUDY">Jacobson 2006</LINK>; <LINK REF="STD-Chang-2009" TYPE="STUDY">Chang 2009</LINK>; <LINK REF="STD-Doshi-2010" TYPE="STUDY">Doshi 2010</LINK>; <LINK REF="STD-Elliott-2010" TYPE="STUDY">Elliott 2010</LINK>).</P>
<P>As <LINK REF="STD-Mossalios-2005" TYPE="STUDY">Mossalios 2005</LINK> researchers have argued, from the third party payer point of view, financial incentive policies for prescribers offer advantages over other restrictive policies such as withdrawing reimbursement for certain medicines. With financial incentives, payers give doctors the opportunity to use their decision-making powers to stay in line with the objectives of the payer or policy-maker. Such decisions are less likely to be criticised by patients or doctors, and can be balanced by quality of care concerns of doctors (<LINK REF="STD-Mossalios-2005" TYPE="STUDY">Mossalios 2005</LINK>). Hence it is important to improve our understanding of the effects of such policies. Although our review provides a picture of available evidence on effects of different policies, our findings are subject to substantial uncertainty concerning the transferability of results to other settings.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-05-26 10:29:43 +0200" MODIFIED_BY="[Empty name]">
<P>Investigators in the included studies did not pay enough attention to potential side effects of the policies. Only two studies from one country assessed the effects of pharmaceutical budget policies on referrals to other healthcare settings (<LINK REF="STD-Guether-1995" TYPE="STUDY">Guether 1995</LINK>; <LINK REF="STD-Sch_x00f6_ffski-1997" TYPE="STUDY">Schöffski 1997</LINK>). Previous assessments suggest that the technical details of how a budget is established and how it is implemented may result in important consequences not intended by the policy (<LINK REF="REF-Delnoij-2000" TYPE="REFERENCE">Delnoij 2000</LINK>; <LINK REF="REF-Schwermann-2003" TYPE="REFERENCE">Schwermann 2003</LINK>). Also we were not able to identify any evidence to assess the applicability of the review findings to disadvantaged groups. Still the policies considered here might have side effects that disproportionately affect disadvantaged groups (<LINK REF="REF-Schwermann-2003" TYPE="REFERENCE">Schwermann 2003</LINK>). For example, pharmaceutical budget policies, if conducted in low-resource settings without due attention to population needs, may result in reduced access to medicines. Additionally in cases of implementation of such budgets at the level of individual physicians, the policy may impact patients from different socioeconomic groups in different ways.</P>
<P>Disadvantaged populations might be at greater risk of adverse effects, if any, of all financial incentive policies for prescribers. Such concerns have not been adequately assessed in the literature and warrant further attention. Pay for performance might increase inequities or could decrease them, depending on the design of the policy. Non-targeted outcomes and behaviours might be negatively affected by pay for performance (<LINK REF="STD-Doran-2011" TYPE="STUDY">Doran 2011</LINK>). A recent systematic review of pay for performance policies in health care (not limited to pharmaceutical policies) found no randomised controlled trials that assessed equity outcomes (<LINK REF="REF-Van-Herck-2010" TYPE="REFERENCE">Van Herck 2010</LINK>). Still review authors found no evidence of negative effects of pay for performance on equitable access to health care.</P>
<P>As noted above, different policy designs and context characteristics may affect the effectiveness and outcomes of financial incentive policies. Given the expected lack of evidence to elaborate on these modifiers, we did not plan to conduct any subgroup analyses within policies of interest in this review. Still findings of previous studies and evidence that we gathered from the included studies provide some general guidance on the factors that must be considered in the design of financial incentive policies, which should be assessed in future research (<LINK REF="TBL-11" TYPE="TABLE">Table 11</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="2">Certainty of the evidence</HEADING>
<P>Comparability of presented results, even from within one country, is limited for the following reasons: (1) Studies from one country might use different units (e.g. per prescribing unit or per patient, median or mean); (2) prescribing volume was measured most often in dispensed items per patient, where a change in the true volume (e.g. shorter prescriptions, lower dosages) cannot be detected; and (3) policies evolve and change over time in countries, hence different evaluative studies conducted in different years or in different regions of a country might be assessing different versions of a policy.</P>
<P>None of the included studies were randomised trials. Hence for all included policies, selection bias may occur, especially when policies are implemented on a voluntary basis or on the basis of presumed 'readiness' for policy implementation (<LINK REF="REF-Moon-2002" TYPE="REFERENCE">Moon 2002</LINK>). Risk of selection bias for all included CBA study results might lead to overestimation of the effects (<LINK REF="REF-Baines-1996" TYPE="REFERENCE">Baines 1996</LINK>).</P>
<P>When possible, CBA studies were reanalysed as CITS studies. Although the effect sizes cannot be directly compared, consistency of the direction of effect over time strengthens the evidence. Most ITS studies also suffered from limitations, as they included few data points in the analyses.</P>
</SUBSECTION>
</APPLICABILITY_OF_FINDINGS>
<AGREEMENT MODIFIED="2015-05-22 12:13:40 +0200" MODIFIED_BY="Arash Rashidian">
<P>Evidence from this review is largely consistent with common interpretations of the effects of pharmaceutical budget policies in the UK and Germany. Although drug costs continued to grow, the budget policies seemed to be effective in containing increases in drug cost, sometimes resulting in an immediate short-lived reduction in total pharmaceutical costs (<LINK REF="STD-Wilson-1995" TYPE="STUDY">Wilson 1995</LINK>; <LINK REF="REF-Bloor-1996" TYPE="REFERENCE">Bloor 1996</LINK>; <LINK REF="REF-Narine-1997" TYPE="REFERENCE">Narine 1997</LINK>; <LINK REF="REF-Ess-2003" TYPE="REFERENCE">Ess 2003</LINK>; <LINK REF="REF-Schwermann-2003" TYPE="REFERENCE">Schwermann 2003</LINK>; <LINK REF="REF-Walley-2004" TYPE="REFERENCE">Walley 2004</LINK>; <LINK REF="REF-Mannion-2005" TYPE="REFERENCE">Mannion 2005</LINK>; <LINK REF="REF-Walley-2005" TYPE="REFERENCE">Walley 2005</LINK>). This effect seems to result in part from switching to generics or other less expensive drugs (<LINK REF="REF-Bloor-1996" TYPE="REFERENCE">Bloor 1996</LINK>; <LINK REF="REF-Gosden-1997" TYPE="REFERENCE">Gosden 1997</LINK>; <LINK REF="REF-Narine-1997" TYPE="REFERENCE">Narine 1997</LINK>; <LINK REF="REF-Ess-2003" TYPE="REFERENCE">Ess 2003</LINK>; <LINK REF="REF-Walley-2004" TYPE="REFERENCE">Walley 2004</LINK>), and in part from decreased prescribing volume (<LINK REF="REF-Gosden-1997" TYPE="REFERENCE">Gosden 1997</LINK>; <LINK REF="REF-Narine-1997" TYPE="REFERENCE">Narine 1997</LINK>; <LINK REF="REF-Rietveld-2002" TYPE="REFERENCE">Rietveld 2002</LINK>; <LINK REF="REF-Walley-2004" TYPE="REFERENCE">Walley 2004</LINK>). Other national policies such as price cuts or co-payments also might have contributed to the effects (<LINK REF="REF-Walley-2004" TYPE="REFERENCE">Walley 2004</LINK>), although these policies were not used in the UK. Effects might decrease over time (<LINK REF="REF-Bloor-1996" TYPE="REFERENCE">Bloor 1996</LINK>; <LINK REF="REF-Rietveld-2002" TYPE="REFERENCE">Rietveld 2002</LINK>), but the evidence provided in this review does not support this.</P>
<P>Our findings on the effects of pay for performance pharmaceutical policies reflect ongoing and current debates and disagreements on the effects of pay for performance policies on different outcomes (<LINK REF="REF-Oxman-2009" TYPE="REFERENCE">Oxman 2009</LINK>; <LINK REF="REF-Van-Herck-2010" TYPE="REFERENCE">Van Herck 2010</LINK>; <LINK REF="REF-Witter-2012" TYPE="REFERENCE">Witter 2012</LINK>; <LINK REF="REF-Eijkenaar-2013" TYPE="REFERENCE">Eijkenaar 2013</LINK>). A recent systematic review of pay for performance studies concluded that despite all the positive coverage, the evidence of effect is limited and such policies on non-incentivised provision of care may be associated with side effects (<LINK REF="REF-Eijkenaar-2013" TYPE="REFERENCE">Eijkenaar 2013</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-05-22 12:14:13 +0200" MODIFIED_BY="Arash Rashidian">
<IMPLICATIONS_PRACTICE MODIFIED="2015-05-22 12:13:52 +0200" MODIFIED_BY="Arash Rashidian">
<P>Although financial incentives are considered to be an important element of strategies to change prescribing patterns, limited studies on budgetary policies, pay for performance and reimbursement rate reduction policies from six countries met our inclusion criteria. The certainty of the evidence is low, very low or lacking for all types of financial incentives for prescribers. Drug budgets may decrease drug use (low-certainty evidence) and might decrease drug costs (very low-certainty evidence). Effects of other policies, including pay for performance policies, on improving quality of care and health outcomes are uncertain. Administration costs and overall healthcare costs were not reported.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-05-22 12:14:13 +0200" MODIFIED_BY="Arash Rashidian">
<P>Our review found few well-designed evaluations of pharmaceutical prescribing policies. Although we performed an extensive literature search, we are aware that additional studies could be available in the grey literature, such as working papers or internal government reports that we have not identified.</P>
<P>In contrast to budgetary policies elsewhere, British fund-holding has been relatively extensively evaluated, albeit with important limitations. Since the time of the previous version of this review (<LINK REF="REF-Sturm-2007" TYPE="REFERENCE">Sturm 2007</LINK>), no newly published studies of budgetary policies in the UK or Germany have met our inclusion criteria. Given that in these countries, as well as elsewhere, new pharmaceutical budget policies have been examined, the need for further research is ongoing. We included no randomised trials. However studies that were performed well, including trials and ITS studies, could be applied to evaluate drug policy interventions if planned in advance, and could reduce the risk of bias.</P>
<P>Evaluations in most included studies focused on relatively short-term outcomes. Longer-term analyses would provide important supplementary evidence, but risk for bias related to other confounding interventions are increased with the length of the observation period.</P>
<P>Because pharmaceutical policies have uncertain effects and might cause harms as well as benefits, proper evaluation of these policies is important. Evaluations should be planned before the policies are introduced and should be a routine part of the policy process. Future studies should consider the impact of these policies on health outcomes and on drug use, as well as on overall healthcare expenditures, in addition to drug expenditures. Only one included study assessed a health outcome (<LINK REF="STD-Serumaga-2011" TYPE="STUDY">Serumaga 2011</LINK>).</P>
<P>None of the included studies originated from a low-income or middle-income country. As use of pharmaceuticals increases in low-income and middle-income countries, it is increasingly important that resources are made available for evaluative studies of pharmaceutical policies in these countries.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-05-26 10:30:28 +0200" MODIFIED_BY="[Empty name]">
<P>We gratefully acknowledge the following.<BR/>
</P>
<UL>
<LI>H Sturm, A Austvoll-Dahlgren, M Aaserud, AD Oxman, C Ramsay, Å Vernby and JP Kösters, for conducting the first version of this systematic review.</LI>
<LI>Jan Odgaard-Jensen, for providing invaluable statistical advice and support, and detailed comments.</LI>
<LI>Marit Johansen and John Eyers, for conducting the literature searches, and Marit Johansen, for helping to retrieve papers.</LI>
<LI>The following primary paper authors who kindly responded to our queries and questions: A James O&#8217;Malley, Michal Proke&#353;, Rajesh Shinghal, Mary E. Deily, Hsien-Ming Lien, Hsuan-Lein Chu, and P Pechlivanoglou.</LI>
<LI>Maryam Bigdeli, for providing helpful comments on the conduct of the review.</LI>
<LI>Vera Luiza Lucia, for reading a paper published in the Portuguese language.</LI>
<LI>The Alliance for Health Policy and Systems Research secretariat, for funding the study and providing continuous support.</LI>
<LI>The EPOC Norwegian satellite editorial team, especially Elizabeth Paulsen, for continuous support; and Claire Glenton, for useful comments and preparation of the Plain Language Summary.</LI>
</UL>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-05-22 12:17:48 +0200" MODIFIED_BY="Arash Rashidian">
<P>AR has conducted short consultancies on health financing for the World Health Organization (WHO), Ministries of Health and social health insurance organisations in a few countries that included consideration of pharmaceutical policies. HS was supported by the Dutch Health Care Insurance Board (CVZ).</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-05-22 12:17:34 +0200" MODIFIED_BY="Arash Rashidian">
<P>For this version of the review: AR prepared the plans for the update with contributions from ADO and HS. A-HO and YV conducted the initial screenings. YV, A-HO and AR assessed the abstracts and full texts for inclusion. HS and ADO contributed in assessing some papers. YV, A-HO and AR extracted data. A-HO and AR conducted the CBA and ITS analyses. AR conducted final data synthesis and wrote the manuscript with contributions from A-HO. All review authors read, commented on and approved the final manuscript.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-05-22 12:17:57 +0200" MODIFIED_BY="Arash Rashidian">
<P>The protocol had identified two distinctive groups of financial incentive policies (budgetary and pay for performance), and had considered other policies without specifying them. As a result of the updated searches, we identified a third group of financial incentive policies as reimbursement rate reduction policies that have been used in some countries.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-05-26 11:29:23 +0200" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-05-26 10:37:59 +0200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-05-22 12:54:05 +0200" MODIFIED_BY="Arash Rashidian">
<STUDY DATA_SOURCE="PUB" ID="STD-Baines-1997c" NAME="Baines 1997c" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Baines DL, Brigham P, Phillips DR, Tolley KH, Whynes DK</AU>
<TI>GP fundholding and prescribing in UK general practice: evidence from two rural, English Family health Services Authorities</TI>
<SO>Public Health</SO>
<YR>1997</YR>
<VL>111</VL>
<PG>321-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="4531"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bradlow-1993" MODIFIED="2015-05-18 10:07:31 +0200" MODIFIED_BY="[Empty name]" NAME="Bradlow 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bradlow J, Coulter A</AU>
<TI>Effect of fundholding and indicative prescribing schemes on general practitioners prescribing cost</TI>
<SO>BMJ</SO>
<YR>1993</YR>
<VL>307</VL>
<NO>6913</NO>
<PG>1186-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-18 10:07:31 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stewart- Brown S, Surender K. Bradlow J. Coulter A. Doll H
</AU>
<TI>The effects of fundholding in general practice on prescribing habits three years after the introduction of the scheme</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>311</VL>
<PG>1543-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burr-1992" NAME="Burr 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Burr AJ, Walker R, Stent SJ</AU>
<TI>Impact of fundholding on general practice prescribing patterns</TI>
<SO>The Pharmaceutical Journal</SO>
<YR>1992</YR>
<VL>249</VL>
<PG>R8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chou-2008" MODIFIED="2015-05-22 12:51:13 +0200" MODIFIED_BY="Arash Rashidian" NAME="Chou 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-05-22 12:51:13 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chou CC, Hu KY, Wu NR, Cheng YH, Loh CH, Yeh MK</AU>
<TI>Changes in drug prescription utilization for diabetic and hypertensive outpatients after initiation of the National Health Insurance&#8217;s Global Budget Program in Taiwan</TI>
<SO>Medical Science Monitor</SO>
<YR>2008</YR>
<VL>14</VL>
<NO>5</NO>
<PG>PH33-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chu-2008" MODIFIED="2015-05-22 12:51:41 +0200" MODIFIED_BY="Arash Rashidian" NAME="Chu 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-05-22 12:51:41 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chu HL, Liu SZ, Romeis JC</AU>
<TI>Changes in prescribing behaviors after implementing drug reimbursement rate reduction policy in Taiwan: implications for the Medicare system</TI>
<SO>Journal of Health Care Finance</SO>
<YR>2008</YR>
<VL>34</VL>
<NO>3</NO>
<PG>45-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corney-1997" MODIFIED="2015-05-22 12:51:53 +0200" MODIFIED_BY="Arash Rashidian" NAME="Corney 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-05-22 12:51:53 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Corney RH, Kerrison S</AU>
<TI>Fundholding in the South Thames region</TI>
<SO>British Journal of General Practice</SO>
<YR>1997</YR>
<VL>47</VL>
<NO>422</NO>
<PG>553-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doran-2011" MODIFIED="2015-05-22 12:52:04 +0200" MODIFIED_BY="Arash Rashidian" NAME="Doran 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-05-22 12:52:04 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doran T, Kontopantelis E, Valderas JM, Campbell S, Roland M, Salisbury C, et al</AU>
<TI>Effect of financial incentives on incentivised and non-incentivised clinical activities: longitudinal analysis of data from the UK Quality and Outcomes Framework</TI>
<SO>British Medical Journal</SO>
<YR>2011</YR>
<VL>342</VL>
<PG>d3590</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Granlund-2006" MODIFIED="2015-05-22 12:52:16 +0200" MODIFIED_BY="Arash Rashidian" NAME="Granlund 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-05-22 12:52:16 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Granlund D, Rudholm N, Wikström M</AU>
<TI>Fixed bud gets as a cost containment measure for pharmaceuticals</TI>
<SO>The European Journal of Health Economics</SO>
<YR>2006</YR>
<VL>7</VL>
<NO>1</NO>
<PG>35-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guether-1995" MODIFIED="2015-05-22 12:52:26 +0200" MODIFIED_BY="Arash Rashidian" NAME="Guether 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-05-22 12:52:26 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Guether B</AU>
<TI>Effects of German health legislation on the prescriptions of GPs</TI>
<TO>Auswirkungen des GSG auf das Verordnungsverhalten niedergelassener Aerzte</TO>
<SO>Gesundheitswesen</SO>
<YR>1995</YR>
<VL>57</VL>
<PG>185-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harris-1996" MODIFIED="2015-05-22 12:52:34 +0200" MODIFIED_BY="Arash Rashidian" NAME="Harris 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-05-22 12:52:34 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Harris CM, Scrivener G</AU>
<TI>Fundholders' prescribing cost: the first five years</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1531-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martens-2007" MODIFIED="2015-05-22 12:52:43 +0200" MODIFIED_BY="Arash Rashidian" NAME="Martens 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-05-22 12:52:43 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martens JD, Werkhoven MJ, Severens JL, Winkens RA</AU>
<TI>Effects of a behaviour independent &#64257;nancial incentive on prescribing behaviour of general practitioners</TI>
<SO>Journal of Evaluation in Clinical Practice</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>3</NO>
<PG>369-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rafferty-1997" MODIFIED="2015-05-22 12:52:56 +0200" MODIFIED_BY="Arash Rashidian" NAME="Rafferty 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-05-22 12:52:56 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rafferty T. Wilson- Davis K, McGavock H</AU>
<TI>How has fundholding in Northern Ireland affected prescribing patterns? A longitudinal study</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>166-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sch_x00f6_ffski-1997" MODIFIED="2014-05-16 12:31:15 +0200" MODIFIED_BY="[Empty name]" NAME="Schöffski 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-05-16 12:31:15 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schöffski O</AU>
<TI>Consequences of implementing a drug budget for office-based physicians in Germany</TI>
<SO>Pharmaeconomics</SO>
<YR>1996</YR>
<VL>10 Suppl. 2</VL>
<PG>37-47</PG>
<IDENTIFIERS MODIFIED="2014-05-16 12:31:15 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serumaga-2011" MODIFIED="2015-05-22 12:53:17 +0200" MODIFIED_BY="Arash Rashidian" NAME="Serumaga 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-05-22 12:53:17 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serumaga B, Ross-Degnan D, Avery AJ, Elliott RA, Majumdar SR, Zhang F, et al</AU>
<TI>Effect of pay for performance on the management and outcomes of hypertension in the United Kingdom:interrupted time series study</TI>
<SO>British Medical Journal</SO>
<YR>2011</YR>
<VL>342</VL>
<PG>d108</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walley--2000" MODIFIED="2015-05-22 12:53:28 +0200" MODIFIED_BY="Arash Rashidian" NAME="Walley  2000" YEAR="2000">
<REFERENCE MODIFIED="2015-05-22 12:53:28 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walley T, Murphy M, Codd M, Johnston Z, Quirke T</AU>
<TI>Effects of monetary incentive on primary care prescribing in Ireland: changes in prescribing patterns in one health board 1990-1995</TI>
<SO>Pharmacoepidemiology and Drug Safety</SO>
<YR>2000</YR>
<VL>9</VL>
<PG>591-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whynes-1997" MODIFIED="2015-05-22 12:53:38 +0200" MODIFIED_BY="Arash Rashidian" NAME="Whynes 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-05-22 12:53:38 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Whynes DK, Baines DL, Tolley KH</AU>
<TI>GP fundholding and the costs of prescribing: further results</TI>
<SO>Journal of Public Health Medicine</SO>
<YR>1997</YR>
<VL>19</VL>
<NO>1</NO>
<PG>18-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-1995" MODIFIED="2015-05-22 12:53:55 +0200" MODIFIED_BY="Arash Rashidian" NAME="Wilson 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-05-22 12:53:47 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wilson RP, Buchan I, Walley T</AU>
<TI>Alterations in prescribing by general practitioner fundholders: an observational study</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>311</VL>
<NO>7016</NO>
<PG>1347-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson RP, Hatcher J, Barton S, Walley T</AU>
<TI>General practice fundholders' prescribing savings in one region of the United Kingdom</TI>
<SO>Health Policy</SO>
<YR>1997</YR>
<VL>42</VL>
<PG>29-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-22 12:53:55 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson RP, Hatcher J, Barton S, Walley T</AU>
<TI>Influences of practice characteristics on prescribing in fundholding and non-fundholding general practices: an observational study</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>595-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-1999" MODIFIED="2015-05-22 12:54:05 +0200" MODIFIED_BY="Arash Rashidian" NAME="Wilson 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-05-22 12:54:05 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wilson RPH, Hatcher J, Barton S, Walley T</AU>
<TI>Therapeutic substitution and therapeutic conservatism as cost-containment strategies in primary care: a study of fundholders and non-fundholders</TI>
<SO>British Journal of General Practice</SO>
<YR>1999</YR>
<VL>443</VL>
<PG>431-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-05-22 13:12:36 +0200" MODIFIED_BY="Arash Rashidian">
<STUDY DATA_SOURCE="PUB" ID="STD-Andersson-2009" MODIFIED="2015-05-22 12:54:24 +0200" MODIFIED_BY="Arash Rashidian" NAME="Andersson 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-05-22 12:54:24 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andersson K, Carlsten A, Hedenrud T</AU>
<TI>Prescribing behaviour after the introduction of decentralized drug budgets: is there an association with employer and type of care facility?</TI>
<SO>Scandinavian Journal of Primary Health Care</SO>
<YR>2009</YR>
<VL>27</VL>
<PG>117-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ashworth-2004" MODIFIED="2015-05-22 12:54:32 +0200" MODIFIED_BY="Arash Rashidian" NAME="Ashworth 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-05-22 12:54:32 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ashworth M, Lea R, Gray H, Rowlands G, Gravelle H, Majeed A</AU>
<TI>How are primary care organizations using financial incentives to influence prescribing?</TI>
<SO>Journal of Public Health</SO>
<YR>2004</YR>
<VL>26</VL>
<NO>1</NO>
<PG>48-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bain-1993" MODIFIED="2015-05-22 12:54:52 +0200" MODIFIED_BY="Arash Rashidian" NAME="Bain 1993" YEAR="1993">
<REFERENCE MODIFIED="2015-05-22 12:54:52 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bain J</AU>
<TI>Budget holding in Calverton: one year on</TI>
<SO>BMJ</SO>
<YR>1992</YR>
<VL>304</VL>
<NO>6832</NO>
<PG>971-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-22 12:54:43 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bain J</AU>
<TI>The New NHS: the second year. Budget holding: here to stay?</TI>
<SO>BMJ</SO>
<YR>1993</YR>
<VL>306</VL>
<NO>6886</NO>
<PG>1185-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baines-1997" MODIFIED="2015-05-22 12:55:07 +0200" MODIFIED_BY="Arash Rashidian" NAME="Baines 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-05-22 12:55:07 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baines DL, Whynes DK, Tolley KH</AU>
<TI>General practitioner fundholding and prescribing expenditure control. Evidence from a rural English health authority</TI>
<SO>Pharmacoeconomics</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>4</NO>
<PG>350-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="13861"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baines-1997b" MODIFIED="2015-05-22 13:02:45 +0200" MODIFIED_BY="Arash Rashidian" NAME="Baines 1997b" YEAR="1997">
<REFERENCE MODIFIED="2015-05-22 13:02:45 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baines DL, Brigham P, Phillips DR, Tolley KH, Whynes DK</AU>
<TI>GP fundholding and prescribing in UK general practice: evidence from two rural English family health authorities</TI>
<SO>Public Health</SO>
<YR>1997</YR>
<VL>111</VL>
<NO>5</NO>
<PG>321-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bateman-1996" MODIFIED="2015-05-22 13:02:54 +0200" MODIFIED_BY="Arash Rashidian" NAME="Bateman 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-05-22 13:02:54 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bateman DN, Campbell M, Donaldson LJ, Roberts SJ, Smith JM</AU>
<TI>A prescribing incentive scheme for non-fundholding general practices: an observational study</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>535-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergstr_x00f6_m-2007" MODIFIED="2015-05-22 13:03:11 +0200" MODIFIED_BY="Arash Rashidian" NAME="Bergström 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-05-22 13:03:11 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergström G, Karlberg I</AU>
<TI>Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden. Assessment of models for decentralized financing of subsidies from a management perspective</TI>
<SO>Health Policy</SO>
<YR>2007</YR>
<VL>81</VL>
<NO>2-3</NO>
<PG>358-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bhargava-2010" MODIFIED="2015-05-22 13:03:02 +0200" MODIFIED_BY="Arash Rashidian" NAME="Bhargava 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-05-22 13:03:02 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bhargava V, Greg ME, Shields MC</AU>
<TI>Addition of generic medication vouchers to a pharmacist academic detailing program: effects on the generic dispensing ratio in a physician-hospital organization</TI>
<SO>Journal of Managed Care Pharmacy</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>6</NO>
<PG>384-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bhatti-2007" MODIFIED="2015-05-22 13:03:23 +0200" MODIFIED_BY="Arash Rashidian" NAME="Bhatti 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-05-22 13:03:23 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bhatti TA, Einarson TH, Austin Z, Grootendorst P</AU>
<TI>The impact of financial incentives on pharmacist dispensing habits: evidence from the British Columbia Product Incentive Plan</TI>
<SO>Journal of Pharmaceutical Finance, Economics and Policy</SO>
<YR>2007</YR>
<VL>16</VL>
<NO>4</NO>
<PG>35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Black--2009" MODIFIED="2015-05-22 13:03:31 +0200" MODIFIED_BY="Arash Rashidian" NAME="Black  2009" YEAR="2009">
<REFERENCE MODIFIED="2015-05-22 13:03:31 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blak BT, Mullins CD, Shaya FT, Simoni-Wastila L, Cooke CE, Weir MR</AU>
<TI>Prescribing trends and drug budget impact of the ARBs in the UK</TI>
<SO>Value Health</SO>
<YR>2009</YR>
<VL>12</VL>
<NO>2</NO>
<PG>302-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bryant-2005" MODIFIED="2015-05-22 13:03:38 +0200" MODIFIED_BY="Arash Rashidian" NAME="Bryant 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-05-22 13:03:38 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bryant J, Prohmmo A</AU>
<TI>Payment mechanisms and prescriptions in four Thai hospitals</TI>
<SO>Health Policy</SO>
<YR>2005</YR>
<VL>73</VL>
<NO>2</NO>
<PG>160-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Campbell-2007" MODIFIED="2014-01-02 22:36:30 +0100" MODIFIED_BY="[Empty name]" NAME="Campbell 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-01-02 22:36:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Campbell S, Reeves D, Kontopantelis E, Sibbald B, Roland M</AU>
<TI>Quality of primary care in England with the introduction of pay for performance</TI>
<SO>New England Journal of Medicine</SO>
<YR>2007</YR>
<VL>357</VL>
<NO>2</NO>
<PG>181-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Campbell-2009" MODIFIED="2015-05-18 10:23:48 +0200" MODIFIED_BY="[Empty name]" NAME="Campbell 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-05-18 10:23:48 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Campbell S, Reeves D, Kontopantelis E, Sibbald B, Roland M</AU>
<TI>Effects of pay-for-performance on the quality of primary care in England</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>361</VL>
<NO>4</NO>
<PG>368-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chang-2009" MODIFIED="2015-05-22 13:03:52 +0200" MODIFIED_BY="Arash Rashidian" NAME="Chang 2009" YEAR="">
<REFERENCE MODIFIED="2015-05-22 13:03:52 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chang SL, Liao JC, Shinghal R</AU>
<TI>Decreasing use of luteinizing hormone-releasing hormone agonists in the United States is Independent of Reimbursement Changes: a Medicare and Veterans Health Administration claims analysis</TI>
<SO>Journal of Urology</SO>
<YR>2009</YR>
<VL>182</VL>
<PG>255-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2008" MODIFIED="2013-12-28 07:56:35 +0100" MODIFIED_BY="[Empty name]" NAME="Chen 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-12-28 07:56:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen CL, Chen L, Yang WC</AU>
<TI>The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugs</TI>
<SO>BMC Public Health</SO>
<YR>2008</YR>
<VL>8</VL>
<PG>118</PG>
<IDENTIFIERS MODIFIED="2013-12-28 07:56:35 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-28 07:56:35 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1186/1471-2458-8-118."/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chernew-2000" MODIFIED="2015-05-22 13:04:07 +0200" MODIFIED_BY="Arash Rashidian" NAME="Chernew 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-05-22 13:04:07 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chernew M, Cowen ME, Kirking DM, Smith DG, Valenstein P, Fendrick AM</AU>
<TI>Pharmaceutical cost growth under capitation: a case study</TI>
<SO>Health Affairs</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>6</NO>
<PG>266-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chou-2010" MODIFIED="2015-05-22 13:04:24 +0200" MODIFIED_BY="Arash Rashidian" NAME="Chou 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-05-22 13:04:24 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chou SY, Deily ME, Lien HM, Zhang JH</AU>
<TI>Global budgets and provider incentives: hospitals' drug expenditures in Taiwan</TI>
<SO>Advances in Health Economics and Health Services Research</SO>
<YR>2010</YR>
<VL>22</VL>
<PG>103-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chu-2008b" MODIFIED="2012-09-29 19:48:51 +0200" MODIFIED_BY="[Empty name]" NAME="Chu 2008b" YEAR="">
<REFERENCE MODIFIED="2012-09-29 19:48:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chu HL, Liu SZ, Romeis JC</AU>
<TI>The effects of physicians' financial incentives on the effectiveness of Taiwan's outpatient drug copayment policy</TI>
<SO>Drug Information Journal</SO>
<YR>2008</YR>
<VL>42</VL>
<PG>493-502</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chu-2010" MODIFIED="2015-05-22 13:04:43 +0200" MODIFIED_BY="Arash Rashidian" NAME="Chu 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-05-22 13:04:43 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chu HL, Liu SZ, Romeis JC</AU>
<TI>Do drug price adjustment policies work? The impact of physician financial incentive plans on the implementation of drug cost containment mechanisms</TI>
<SO>Drug Information Journal</SO>
<YR>2010</YR>
<VL>44</VL>
<PG>189-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chung-2010a" MODIFIED="2015-05-22 13:04:59 +0200" MODIFIED_BY="Arash Rashidian" NAME="Chung 2010a" YEAR="2010">
<REFERENCE MODIFIED="2015-05-22 13:04:59 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chung S, Palaniappan LP, Trujillo LM, Rubin HR, Luft HS</AU>
<TI>Effect of physician-specific pay-for-performance incentives in a large group practice</TI>
<SO>The American Journal of Managed Care</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>2</NO>
<PG>e35-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chung-2010b" MODIFIED="2015-05-22 13:05:25 +0200" MODIFIED_BY="Arash Rashidian" NAME="Chung 2010b" YEAR="2010">
<REFERENCE MODIFIED="2015-05-22 13:05:25 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chung S, Palaniappan L, Wong E, Rubin H, Luft H</AU>
<TI>Does the frequency of pay-for-performance payment matter? Experience from a randomized trial</TI>
<SO>Health Services Research</SO>
<YR>2010</YR>
<VL>45</VL>
<NO>2</NO>
<PG>553-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coulter-1993" MODIFIED="2015-05-22 13:05:42 +0200" MODIFIED_BY="Arash Rashidian" NAME="Coulter 1993" YEAR="1993">
<REFERENCE MODIFIED="2015-05-22 13:05:34 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Coulter A, Bradlow J</AU>
<TI>Effect of NHS reforms on general practitioners' referral patterns</TI>
<SO>BMJ</SO>
<YR>1993</YR>
<VL>306</VL>
<PG>433-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-22 13:05:42 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Surender R</AU>
<TI>Prospective study of trends in referral patterns in fundholding and non-fundholding practices in the Oxford region, 1990-4</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>311</VL>
<PG>1205-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Curttis-2003" MODIFIED="2015-05-22 13:05:49 +0200" MODIFIED_BY="Arash Rashidian" NAME="Curttis 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-05-22 13:05:49 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Curtiss FR</AU>
<TI>Effects of physician report cards, knowledge of drug prices, and financial incentives in prescription drug costs</TI>
<SO>Journal of Managed Care Pharmacy</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>4</NO>
<PG>368-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Danzon-1997" MODIFIED="2015-05-22 13:05:58 +0200" MODIFIED_BY="Arash Rashidian" NAME="Danzon 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-05-22 13:05:58 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="OTHER">
<AU>Danzon PM, Liu H</AU>
<TI>Reference pricing and physician drug budgets: the German experience in controlling pharmaceutical expenditures</TI>
<SO>Philadelphia, PA: Wharton School Working Paper, University of Philadelphia,</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delmar-2006" MODIFIED="2015-05-22 13:06:11 +0200" MODIFIED_BY="Arash Rashidian" NAME="Delmar 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-05-22 13:06:11 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delmar C</AU>
<TI>Improving prescribing practices in primary care. A randomised trial and economic analysis of a multicomponent intervention showed small, but important, gains</TI>
<SO>PLoS Medicine</SO>
<YR>2006</YR>
<VL>3</VL>
<NO>6</NO>
<PG>e229</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doshi-2010" MODIFIED="2015-05-22 13:06:20 +0200" MODIFIED_BY="Arash Rashidian" NAME="Doshi 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-05-22 13:06:20 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doshi JA, Li P, Puig A</AU>
<TI>Impact of the Medicare Modernization Act of 2003 on utilization and spending for Medicare part B-covered biologics in rheumatoid arthritis</TI>
<SO>Arthritis Care Research (Hoboken)</SO>
<YR>2010</YR>
<VL>62</VL>
<NO>3</NO>
<PG>354-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dusheiko-2003" MODIFIED="2015-05-22 13:06:28 +0200" MODIFIED_BY="Arash Rashidian" NAME="Dusheiko 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-05-22 13:06:28 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="OTHER">
<AU>Dusheiko M, Gravelle H, Jacobs R, Smith PC</AU>
<TI>The effects of budgets on doctor behaviour: evidence from a natural experiment</TI>
<SO>York, UK: University of York Discussion Paper,</SO>
<YR>2003</YR>
<PB>University of York</PB>
<CY>York, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edgar-1999" MODIFIED="2015-05-22 13:06:36 +0200" MODIFIED_BY="Arash Rashidian" NAME="Edgar 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-05-22 13:06:36 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edgar S, Girvin B</AU>
<TI>Effects of hospital-led prescribing on the cardiovascular budget of a fundholding general practice</TI>
<SO>The Pharmaceutical Journal</SO>
<YR>1999</YR>
<VL>263</VL>
<PG>292-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elhayany-2001" MODIFIED="2015-05-22 13:06:43 +0200" MODIFIED_BY="Arash Rashidian" NAME="Elhayany 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-05-22 13:06:43 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elhayany A, Regev S, Sherf M, Reuveni H, Shvartzman P</AU>
<TI>Effects of a fundholding discontinuation</TI>
<SO>An Israeli Health Maintenance Organization Natural Experiment</SO>
<YR>2001</YR>
<VL>19</VL>
<PG>223-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elliott-2010" MODIFIED="2015-05-22 13:06:51 +0200" MODIFIED_BY="Arash Rashidian" NAME="Elliott 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-05-22 13:06:51 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elliott SP, Jarosek SL, Wilt TJ, Virnig BA</AU>
<TI>Reduction in physician reimbursement and use of hormone therapy in prostate cancer</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2010</YR>
<VL>102</VL>
<NO>24</NO>
<PG>1826-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Etter-1998" MODIFIED="2015-05-22 13:07:11 +0200" MODIFIED_BY="Arash Rashidian" NAME="Etter 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-05-22 13:07:11 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Etter J-F, Perneger TV</AU>
<TI>Health care expenditures after introduction of a gatekeeper and a global budget in a Swiss health insurance plan</TI>
<SO>Journal of Epidemiology and Community Health</SO>
<YR>1997</YR>
<VL>52</VL>
<NO>6</NO>
<PG>370-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fear-1994" MODIFIED="2015-05-22 13:07:18 +0200" MODIFIED_BY="Arash Rashidian" NAME="Fear 1994" YEAR="1994">
<REFERENCE MODIFIED="2015-05-22 13:07:18 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fear CF, Cattell HR</AU>
<TI>Fund-holding general practices and old age psychiatry</TI>
<SO>Psychiatric Bulletin</SO>
<YR>1994</YR>
<VL>18</VL>
<PG>263-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hespanhol-2005" MODIFIED="2015-05-22 13:07:33 +0200" MODIFIED_BY="Arash Rashidian" NAME="Hespanhol 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-05-22 13:07:33 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hespanhol A, Sousa Pinto A</AU>
<TI>The payment model in Sao Joao Health Center - "Tubo de Ensaio"</TI>
<SO>Arquivos De Medicina</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>3</NO>
<PG>113-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoffman-2010" MODIFIED="2015-05-22 13:07:26 +0200" MODIFIED_BY="Arash Rashidian" NAME="Hoffman 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-05-22 13:07:26 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoffmann F, Windt R, Glaeske G</AU>
<TI>Implementation of "aut idem" before and after introduction of rebate contracts</TI>
<TO>Umsetzung der Aut-idem-Regelung vor und nachEinführung der Rabattverträge</TO>
<SO>Deutsch Medizinische Wochenschrift</SO>
<YR>2010</YR>
<VL>135</VL>
<PG>739-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoopmann-1995" MODIFIED="2015-05-22 13:07:41 +0200" MODIFIED_BY="Arash Rashidian" NAME="Hoopmann 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-05-22 13:07:41 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoopmann M, Schwartz FW, Weber J</AU>
<TI>Effects of the German 1993 health reform law upon primary care practitioners individual performance: results form an empirical study in sentinel practices</TI>
<SO>Journal of Epidemiology and Community Health</SO>
<YR>1995</YR>
<VL>49</VL>
<PG>33-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Houghton-1998" MODIFIED="2015-05-22 13:07:53 +0200" MODIFIED_BY="Arash Rashidian" NAME="Houghton 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-05-22 13:07:53 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Houghton G, Gilthorpe MS</AU>
<TI>Variations in general practice prescribing: a multilevel model approach to determine the impact of characteristics, including fundholding and training status</TI>
<SO>Journal of Clinical Effectiveness</SO>
<YR>1998</YR>
<VL>3</VL>
<NO>2</NO>
<PG>75-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Howie-1995" MODIFIED="2015-05-22 13:08:07 +0200" MODIFIED_BY="Arash Rashidian" NAME="Howie 1995" YEAR="">
<REFERENCE MODIFIED="2015-05-22 13:08:07 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="OTHER">
<AU>Howie JGR, Heaney DJ, Maxwell M</AU>
<TI>General practice fund-holding: shadow project - an evaluation</TI>
<SO>Edinburgh, Scotland: The Department of General Practice, University of Edinburgh,</SO>
<YR>1995</YR>
<PB>The Department of General Practice, University of Edinburgh</PB>
<CY>Edinburgh</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacobson-2006" MODIFIED="2015-05-22 13:08:14 +0200" MODIFIED_BY="Arash Rashidian" NAME="Jacobson 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-05-22 13:08:14 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jacobson M, O'Malley AJ, Earle CC, Pakes J, Gaccione P, Newhouse JP</AU>
<TI>Does reimbursement influence chemotherapy treatment for cancer patients?</TI>
<SO>Health Affairs</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>2</NO>
<PG>437-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-J_x00fc_nger-2000" MODIFIED="2015-05-22 13:08:30 +0200" MODIFIED_BY="Arash Rashidian" NAME="Jünger 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-05-22 13:08:22 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jünger C, Rathmann W, Giani G</AU>
<TI>Prescribing practices of general practitioners and internists in the treatment of diabetic patients: influence of drug budgeting</TI>
<TO>Primaeraerztliches Verordnungsverhalten bei der Diabetestherapie: Einfluss der Arzneimittelbudgetierung</TO>
<SO>Deutsch Medizinische Wochenschrift</SO>
<YR>2000</YR>
<VL>125</VL>
<PG>103-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-22 13:08:30 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jünger C, Rathmann W, Giani G</AU>
<TI>Prescription drug use of primary care physicians in Germany among diabetic and nondiabetic patients</TI>
<TO>Primaeraerztliche Arzneimittelverordnungen bei Diabetikern und Nichtdiabetikern: Einfluss der Arzneimittelbudgetierung</TO>
<SO>Gesundheitswesen</SO>
<YR>1999</YR>
<VL>61</VL>
<PG>607-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaestner-2012" MODIFIED="2015-05-22 13:08:41 +0200" MODIFIED_BY="Arash Rashidian" NAME="Kaestner 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-05-22 13:08:41 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaestner R, Khan N</AU>
<TI>Medicare Part D and its effect on the use of prescription drugs and use of other health care services of the elderly</TI>
<SO>Journal of Policy Analysis and Management</SO>
<YR>2012</YR>
<VL>31</VL>
<NO>2</NO>
<PG>253-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kammerling-1996" MODIFIED="2015-05-22 13:08:48 +0200" MODIFIED_BY="Arash Rashidian" NAME="Kammerling 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-05-22 13:08:48 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kammerling R. Kinnear A</AU>
<TI>The extent of the two tier service for fundholders</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>312</VL>
<PG>1399-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Landon-2007" MODIFIED="2015-05-22 13:09:26 +0200" MODIFIED_BY="Arash Rashidian" NAME="Landon 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-05-22 13:09:26 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Landon BE, Rosenthal MB, Normand SL, Spettell C, Lessler A, Underwood HR, et al</AU>
<TI>Incentive formularies and changes in prescription drug spending</TI>
<SO>American Journal of Managed Care</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>6 Pt 2</NO>
<PG>360-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2007" MODIFIED="2015-05-22 13:09:10 +0200" MODIFIED_BY="Arash Rashidian" NAME="Lee 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-05-22 13:09:10 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee YC, Huang KH, Huang YT</AU>
<TI>Adverse pharmaceutical payment incentives and providers' behaviour: the emergence of GP-owned gateway pharmacies in Taiwan</TI>
<SO>Health Policy and Planing</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>6</NO>
<PG>427-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2008" MODIFIED="2015-05-22 13:09:37 +0200" MODIFIED_BY="Arash Rashidian" NAME="Li 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-05-22 13:09:37 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li L, Chen Y, Yao L, Li Y</AU>
<TI>Evaluation of the effects of implementing the policy "Without Added Profit" to sale drug in community health service institutions of Chengdu</TI>
<SO>Chinese Journal of New Drugs</SO>
<YR>2008</YR>
<VL>17</VL>
<NO>21</NO>
<PG>1820-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ling-2008" MODIFIED="2015-05-22 13:09:46 +0200" MODIFIED_BY="Arash Rashidian" NAME="Ling 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-05-22 13:09:46 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ling DC, Berndt ER, Frank RG</AU>
<TI>Economic incentives and contracts: the use of psychotropic medications</TI>
<SO>Contemporary Economic Policy</SO>
<YR>2008</YR>
<VL>1</VL>
<PG>49-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2009" MODIFIED="2015-05-22 13:10:00 +0200" MODIFIED_BY="Arash Rashidian" NAME="Liu 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-05-22 13:10:00 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu YM, Yang YH, Hsieh CR</AU>
<TI>Financial incentives and physicians' prescription decisions on the choice between brand-name and generic drugs: evidence from Taiwan</TI>
<SO>Journal of Health Economics</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>2</NO>
<PG>341-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malcolm-1999" MODIFIED="2015-05-22 13:10:08 +0200" MODIFIED_BY="Arash Rashidian" NAME="Malcolm 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-05-22 13:10:08 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malcolm L, Wright L, Seers M, Guthrie J</AU>
<TI>An evaluation of pharmaceutical management and budget holding in Pegasus Medical Group</TI>
<SO>New Zealand Medical Journal</SO>
<YR>1999</YR>
<VL>112</VL>
<NO>1087</NO>
<PG>162-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malcolm-2001" MODIFIED="2015-05-22 13:10:16 +0200" MODIFIED_BY="Arash Rashidian" NAME="Malcolm 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-05-22 13:10:16 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malcolm L, Barry M, MacLean I</AU>
<TI>Pharmaceutical management in ProCare Health Limited</TI>
<SO>New Zealand Medical Journal</SO>
<YR>2001</YR>
<VL>114</VL>
<NO>1134</NO>
<PG>283-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maxwell-1993" MODIFIED="2015-05-22 13:10:32 +0200" MODIFIED_BY="Arash Rashidian" NAME="Maxwell 1993" YEAR="1993">
<REFERENCE MODIFIED="2015-05-22 13:10:23 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="OTHER">
<AU>Howie JGR, Heaney DJ, Maxwell M</AU>
<TI>General practice fund-holding: shadow project - an evaluation</TI>
<SO>Edinburgh, Scotland: The Department of General Practice, University of Edinburgh,</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-22 13:10:32 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maxwell M, Heaney D, Howie JGR, Noble S</AU>
<TI>General practice fundholding: observations on prescribing patterns and cost using the defined daily dose method</TI>
<SO>BMJ</SO>
<YR>1993</YR>
<VL>307</VL>
<NO>6913</NO>
<PG>1190-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maynard-2010" MODIFIED="2015-01-06 16:50:56 +0100" MODIFIED_BY="Arash Rashidian" NAME="Maynard 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-01-06 16:50:56 +0100" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maynard A, Bloor K</AU>
<TI>Will financial incentives and penalties improve hospital care?</TI>
<SO>British Medical Journal</SO>
<YR>2010</YR>
<VL>340</VL>
<PG>c88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Millet-2007" MODIFIED="2015-05-22 13:10:42 +0200" MODIFIED_BY="Arash Rashidian" NAME="Millet 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-05-22 13:10:42 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Millett C, Gray J, Saxena S, Netuveli G, Khunti K, Majeed A</AU>
<TI>Ethnic disparities in diabetes management and pay-for-performance in the UK: the Wandsworth Prospective Diabetes Study</TI>
<SO>PLOS Medicine</SO>
<YR>2007</YR>
<VL>4</VL>
<NO>6</NO>
<PG>191</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mossalios-2005" MODIFIED="2015-05-22 13:10:55 +0200" MODIFIED_BY="Arash Rashidian" NAME="Mossalios 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-05-22 13:10:55 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mossialos E, Walley T, Rudisill C</AU>
<TI>Provider incentives and prescribing behavior in Europe</TI>
<SO>Expert Review on Pharmacoeconomics and Outcomes Research</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>1</NO>
<PG>81-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newton-1993" MODIFIED="2015-05-22 13:11:02 +0200" MODIFIED_BY="Arash Rashidian" NAME="Newton 1993" YEAR="1993">
<REFERENCE MODIFIED="2015-05-22 13:11:02 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newton J, Fraser M, Robinson J, Wainwright D</AU>
<TI>Fundholding in the northern region: the first year</TI>
<SO>BMJ</SO>
<YR>1993</YR>
<VL>306</VL>
<PG>375-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Malley-2006" MODIFIED="2015-05-22 13:11:09 +0200" MODIFIED_BY="Arash Rashidian" NAME="O'Malley 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-05-22 13:11:09 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Malley AJ, Frank RG, Kaddis A, Rothenberg BM, McNeil BJ</AU>
<TI>Impact of alternative interventions on changes in generic dispensing rates</TI>
<SO>Health Services Research</SO>
<YR>2006</YR>
<VL>41</VL>
<NO>5</NO>
<PG>1876-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohlsson-2007" MODIFIED="2015-05-22 13:11:17 +0200" MODIFIED_BY="Arash Rashidian" NAME="Ohlsson 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-05-22 13:11:17 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohlsson H, Merlo J</AU>
<TI>Understanding the effects of a decentralized budget on physicians' compliance with guidelines for statin prescription &#8211; a multilevel methodological approach</TI>
<SO>BMC Health Services Research</SO>
<YR>2007</YR>
<VL>7</VL>
<PG>68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peabody-2011" MODIFIED="2015-05-22 13:11:25 +0200" MODIFIED_BY="Arash Rashidian" NAME="Peabody 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-05-22 13:11:25 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peabody J, Shimkhada R, Quimbo S, Florentino J, Bacate M, McCulloch CE, et al</AU>
<TI>Financial incentives and measurement improved physicians' quality of care in the Philippines</TI>
<SO>Health Affairs (Millwood)</SO>
<YR>2011</YR>
<VL>30</VL>
<NO>6</NO>
<PG>1217</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prokes-2009" MODIFIED="2015-05-22 13:11:38 +0200" MODIFIED_BY="Arash Rashidian" NAME="Prokes 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-05-22 13:11:38 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prokes M, Suchopar J</AU>
<TI>Effect of drug budgets on drug prescription in Czech Republic in 2006</TI>
<SO>Klinicka Farmakologie a Farmacie</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>2</NO>
<PG>90-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sakshaug-2007" MODIFIED="2015-05-22 13:11:45 +0200" MODIFIED_BY="Arash Rashidian" NAME="Sakshaug 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-05-22 13:11:45 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sakshaug S, Furu K, Karlstad Ø, Rønning M, Skurtveit S</AU>
<TI>Switching statins in Norway after new reimbursement policy &#8211; a nationwide prescription study</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>2007</YR>
<VL>64</VL>
<NO>4</NO>
<PG>476-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmidt-2006" MODIFIED="2015-05-22 13:11:53 +0200" MODIFIED_BY="Arash Rashidian" NAME="Schmidt 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-05-22 13:11:53 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt K</AU>
<TI>Incentives for especially cost effective prescribing. The physician protects his budget, the patient saves co-pay</TI>
<SO>MMW Fortschritte dir medizin</SO>
<YR>2006</YR>
<VL>148</VL>
<NO>44</NO>
<PG>57-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Schrey_x00f6_gg-2004" MODIFIED="2015-05-22 13:12:01 +0200" MODIFIED_BY="Arash Rashidian" NAME="Schreyögg 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-05-22 13:12:01 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Schreyögg J</AU>
<TI>Physician Prescribing Budgets in Germany: Effects on Prescribing Behaviour</TI>
<SO>Berlin, Germany: Department of Health Care Management, Faculty of Economics and Management, Berlin University of Technology,</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schrey_x00f6_gg-2005" MODIFIED="2015-05-22 13:12:09 +0200" MODIFIED_BY="Arash Rashidian" NAME="Schreyögg 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-05-22 13:12:09 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schreyögg J, Busse R</AU>
<TI>Physician drug budgets in Germany: effects on prescription behaviour</TI>
<SO>Journal of Pharmaceutical Finance</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>3</NO>
<PG>77-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trifirio-2008" MODIFIED="2015-05-22 13:12:16 +0200" MODIFIED_BY="Arash Rashidian" NAME="Trifirio 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-05-22 13:12:16 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trifirò G, Alacqua M, Corrao S, Moretti S, Tari DU, Galdo M, et al; UVEC Group</AU>
<TI>Lipid-lowering drug use in Italian primary care: effects of reimbursement criteria revision</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>2008</YR>
<VL>64</VL>
<NO>6</NO>
<PG>619-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whynes-1995" MODIFIED="2015-05-22 13:12:28 +0200" MODIFIED_BY="Arash Rashidian" NAME="Whynes 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-05-22 13:12:28 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whynes DK, Baines DL, Tolley KH</AU>
<TI>GP fundholding and the cost of prescribing</TI>
<SO>Journal of Public Health Medicine</SO>
<YR>1995</YR>
<VL>17</VL>
<PG>323-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whynes-1997b" MODIFIED="2015-05-18 10:54:33 +0200" MODIFIED_BY="[Empty name]" NAME="Whynes 1997b" YEAR="1997">
<REFERENCE MODIFIED="2015-05-18 10:54:33 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson RP, Hatcher J, Barton S, Walley T</AU>
<TI>General practice fundholders' prescribing savings in one region of the United Kingdom, 1991-1994</TI>
<SO>Health Policy</SO>
<YR>1997</YR>
<VL>42</VL>
<PG>29-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2012" MODIFIED="2015-05-22 13:12:36 +0200" MODIFIED_BY="Arash Rashidian" NAME="Zhang 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-05-22 13:12:36 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Y, Baik SH, Zhou L, Reynolds CF, Lave JR</AU>
<TI>Effects of Medicare Part D coverage gap on medication and medical treatment among elderly beneficiaries with depression</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2012</YR>
<VL>69</VL>
<NO>7</NO>
<PG>672-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-05-26 10:37:59 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Chang-2013" MODIFIED="2015-05-22 13:12:45 +0200" MODIFIED_BY="Arash Rashidian" NAME="Chang 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-05-22 13:12:45 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chang J, Freed GL, Prosser LA, Patel I, Erickson SR, Bagozzi RP, Balkrishnan R</AU>
<TI>Associations between physician financial incentives and the prescribing of anti-asthmatic medications in children in US outpatient settings</TI>
<SO>Journal of Child Health Care.</SO>
<YR>2013</YR>
<VL>17</VL>
<NO>2</NO>
<PG>125-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harrison-2014" MODIFIED="2015-02-27 01:57:06 +0100" MODIFIED_BY="[Empty name]" NAME="Harrison 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-02-27 01:57:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harrison MJ, Dusheiko M, Sutton M, Gravelle H, Doran T, Roland M</AU>
<TI>Effect of a national primary care pay for performance scheme on emergency hospital admissions for ambulatory care sensitive conditions: controlled longitudinal study</TI>
<SO>BMJ.</SO>
<YR>2014</YR>
<VL>349</VL>
<PG>g6423</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kontopantelis-2013" MODIFIED="2015-05-22 13:12:58 +0200" MODIFIED_BY="Arash Rashidian" NAME="Kontopantelis 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-05-22 13:12:58 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kontopantelis E, Reeves D, Valderas JM, Campbell S, Doran T</AU>
<TI>Recorded quality of primary care for patients with diabetes in England before and after the introduction of a financial incentive scheme: a longitudinal observational study</TI>
<SO>BMJ Quality and Safety</SO>
<YR>2013</YR>
<VL>22</VL>
<NO>1</NO>
<PG>53-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kristensen-2014" MODIFIED="2015-05-22 13:13:06 +0200" MODIFIED_BY="Arash Rashidian" NAME="Kristensen 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-05-22 13:13:06 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kristensen SR, Meacock R, Turner AJ, Boaden R, McDonald R, Roland M, et al</AU>
<TI>Long-term effect of hospital pay for performance on mortality in England</TI>
<SO>New England Journal of Medicine</SO>
<YR>2014</YR>
<VL>371</VL>
<NO>6</NO>
<PG>540-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2014" MODIFIED="2015-05-22 13:13:13 +0200" MODIFIED_BY="Arash Rashidian" NAME="Li 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-05-22 13:13:13 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li J, Hurley J, DeCicca P, Buckley G</AU>
<TI>Physician response to pay-for-performance: evidence from a natural experiment</TI>
<SO>Health Economics</SO>
<YR>2014</YR>
<VL>23</VL>
<NO>8</NO>
<PG>962-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MacBride_x002d_Stewart-2008" MODIFIED="2015-05-22 13:13:22 +0200" MODIFIED_BY="Arash Rashidian" NAME="MacBride-Stewart 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-05-22 13:13:22 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MacBride-Stewart SP, Elton R, Walley T</AU>
<TI>Do quality incentives change prescribing patterns in primary care? An observational study in Scotland</TI>
<SO>Family Practice</SO>
<YR>2008</YR>
<VL>25</VL>
<NO>1</NO>
<PG>27-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naomh-Gallagher-2012" MODIFIED="2015-05-22 13:13:34 +0200" MODIFIED_BY="Arash Rashidian" NAME="Naomh Gallagher 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-05-22 13:13:34 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naomh Gallagher N</AU>
<TI>Type 2 diabetes and cardiovascular drug therapy on the island of Ireland: do financial incentives change prescribing behaviour?</TI>
<SO>European Journal of Preventive Cardiology</SO>
<YR>2012</YR>
<VL>1</VL>
<PG>S20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Park-2014" MODIFIED="2015-05-22 13:13:42 +0200" MODIFIED_BY="Arash Rashidian" NAME="Park 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-05-22 13:13:42 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Park S, et al</AU>
<TI>Differential effects of two pharmaceutical cost containment policies on outpatient prescription drug expenditures in Korea</TI>
<SO>Value in Health</SO>
<YR>2014</YR>
<VL>17</VL>
<NO>3</NO>
<PG>A14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2014" MODIFIED="2015-05-26 10:37:59 +0200" MODIFIED_BY="[Empty name]" NAME="Sun 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-05-26 10:37:59 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun X, Liu X, Sun Q, Yip W, Wagstaff A, Meng Q</AU>
<TI>The impact of a pay-for-performance scheme on prescription quality in rural China: an impact evaluation</TI>
<SO>Policy Research Working Paper Series</SO>
<YR>2014</YR>
<VL>6892</VL>
<PG>No 750</PG>
<PB>The World Bank</PB>
<CY>Record no 750</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-02-27 01:48:16 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2014" MODIFIED="2015-05-22 13:13:58 +0200" MODIFIED_BY="Arash Rashidian" NAME="Zhang 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-05-22 13:13:58 +0200" MODIFIED_BY="Arash Rashidian" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang JH, Chou SY, Deily ME, Lien HM</AU>
<TI>Hospital ownership and drug utilization under a global budget: a quantile regression analysis</TI>
<SO>International Health</SO>
<YR>2014</YR>
<VL>6</VL>
<NO>1</NO>
<PG>62-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-05-26 11:29:23 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-05-26 11:29:23 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Aaserud-2006a" MODIFIED="2015-05-22 13:14:21 +0200" MODIFIED_BY="Arash Rashidian" NAME="Aaserud 2006a" TYPE="COCHRANE_REVIEW">
<AU>Aaserud M, Dahlgren AT, Sturm H, Koesters JP, Hill S, Furberg CD, et al</AU>
<TI>Pharmaceutical policies: effects on rational drug use</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-11-07 17:31:12 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-07 17:31:12 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004397.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Acosta-2014" MODIFIED="2015-05-22 13:14:29 +0200" MODIFIED_BY="Arash Rashidian" NAME="Acosta 2014" TYPE="COCHRANE_REVIEW">
<AU>Acosta A, Ciapponi A, Aaserud M, Vietto V, Austvoll-Dahlgren A, Kösters JP, et al</AU>
<TI>Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2015-04-21 10:19:45 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-04-21 10:19:45 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005979.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Antonanzas-2003" MODIFIED="2015-05-22 13:14:40 +0200" MODIFIED_BY="Arash Rashidian" NAME="Antonanzas 2003" TYPE="JOURNAL_ARTICLE">
<AU>Antonanzas F</AU>
<TI>Challenges to achieving value in drug spending in a decentralized country: the Spanish case</TI>
<SO>Value in Health</SO>
<YR>2003</YR>
<VL>6</VL>
<PG>52-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Armour-2001" MODIFIED="2015-05-22 13:14:49 +0200" MODIFIED_BY="Arash Rashidian" NAME="Armour 2001" TYPE="JOURNAL_ARTICLE">
<AU>Armour BS, Pitts MM, Maclean R, Cangialose C, Kishel M, Imai H, Etchason J</AU>
<TI>The effect of explicit financial incentives on physician behavior</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2001</YR>
<VL>161</VL>
<NO>10</NO>
<PG>1261-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Atella-2000" MODIFIED="2015-05-18 11:04:59 +0200" MODIFIED_BY="[Empty name]" NAME="Atella 2000" TYPE="JOURNAL_ARTICLE">
<AU>Atella V</AU>
<TI>Drug cost containment policies in Italy: are they really effective in the long-run? The case of minimum reference price</TI>
<SO>Health Policy</SO>
<YR>2000</YR>
<VL>50</VL>
<NO>3</NO>
<PG>197-218</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Audit-Comm.-1996" MODIFIED="2015-05-22 13:15:01 +0200" MODIFIED_BY="Arash Rashidian" NAME="Audit Comm. 1996" TYPE="OTHER">
<AU>Audit Commission</AU>
<TI>What the Doctor Ordered: A Study of GP Fundholders in England and Wales</TI>
<SO>London: HMSO,</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Austvoll_x002d_Dahlgren-2008" MODIFIED="2015-05-22 13:15:10 +0200" MODIFIED_BY="Arash Rashidian" NAME="Austvoll-Dahlgren 2008" TYPE="JOURNAL_ARTICLE">
<AU>Austvoll-Dahlgren A, Aaserud M, Vist G, Ramsay C, Oxman AD, Sturm H, et al</AU>
<TI>Pharmaceutical policies: effects of cap and co-payment on rational drug use</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<VL>CD007017</VL>
<PG>doi: 10.1002/14651858.CD007017</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baines-1996" MODIFIED="2015-05-22 13:15:26 +0200" MODIFIED_BY="Arash Rashidian" NAME="Baines 1996" TYPE="JOURNAL_ARTICLE">
<AU>Baines DL, Whynes DK</AU>
<TI>Selection bias in GP fundholding</TI>
<SO>Health Economics</SO>
<YR>1996</YR>
<VL>5</VL>
<PG>129-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bigdeli-2013" MODIFIED="2015-05-22 13:15:36 +0200" MODIFIED_BY="Arash Rashidian" NAME="Bigdeli 2013" TYPE="JOURNAL_ARTICLE">
<AU>Bigdeli M, Jacobs B, Tomson G, Laing R, Ghaffar A, Dujardin B, et al</AU>
<TI>Access to medicines from a health system perspective</TI>
<SO>Health Policy Plan</SO>
<YR>2013</YR>
<VL>28</VL>
<NO>7</NO>
<PG>692-704. doi:10.1093/heapol/czs108</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bloor-1996" MODIFIED="2015-05-22 13:15:44 +0200" MODIFIED_BY="Arash Rashidian" NAME="Bloor 1996" TYPE="JOURNAL_ARTICLE">
<AU>Bloor K, Freemantle N</AU>
<TI>Fortnightly review: lessons from international experience in controlling pharmaceutical expenditure II: influencing doctors</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>312</VL>
<NO>7045</NO>
<PG>1525-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Busse-1996" MODIFIED="2015-05-22 13:16:10 +0200" MODIFIED_BY="Arash Rashidian" NAME="Busse 1996" TYPE="BOOK_SECTION">
<AU>Busse R, Howorth C</AU>
<TI>Fixed budgets in the pharmaceutical sector in Germany: effects on costs and quality</TI>
<SO>Fixing Health Budgets: Experience from Europe and North America</SO>
<YR>1996</YR>
<PG>93-108</PG>
<ED>Schwartz FW, Glennerster H, Saltman RB, Busse R</ED>
<PB>John Wiley and Sons</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Calltorp-1996" MODIFIED="2015-05-22 13:16:29 +0200" MODIFIED_BY="Arash Rashidian" NAME="Calltorp 1996" TYPE="BOOK_SECTION">
<AU>Calltorp J</AU>
<TI>Swedish experience with regional budgets</TI>
<SO>Fixing Health Budgets</SO>
<YR>1996</YR>
<PG>155-64</PG>
<PB>John Wiley and Sons</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Calltorp-1999" NAME="Calltorp 1999" TYPE="JOURNAL_ARTICLE">
<AU>Calltorp J</AU>
<TI>Priority setting in health policy in Sweden and a comparison with Norway</TI>
<SO>Health Policy</SO>
<YR>1999</YR>
<VL>50</VL>
<PG>1-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Campbell-2013" MODIFIED="2015-05-22 13:16:54 +0200" MODIFIED_BY="Arash Rashidian" NAME="Campbell 2013" TYPE="BOOK">
<AU>Campbell D, Chui M</AU>
<SO>Pharmerging Shake-up: New Imperatives in a Re-defined World</SO>
<YR>2013</YR>
<PB>IMS Health</PB>
<CY>Norwalk, CT</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chaix_x002d_Couturier-2000" MODIFIED="2015-05-22 13:17:03 +0200" MODIFIED_BY="Arash Rashidian" NAME="Chaix-Couturier 2000" TYPE="JOURNAL_ARTICLE">
<AU>Chaix-Couturier C, Durand-Zaleski I, Jolly D, Durieux P</AU>
<TI>Effects of financial incentives on medical practice: results from a systematic review of the literature and methodological issues</TI>
<SO>International Journal of Quality Health Care</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>2</NO>
<PG>133-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Conrad-2004" MODIFIED="2015-05-22 13:17:10 +0200" MODIFIED_BY="Arash Rashidian" NAME="Conrad 2004" TYPE="JOURNAL_ARTICLE">
<AU>Conrad DA, Christianson JB</AU>
<TI>Penetrating the "black box": financial incentives for enhancing the quality of physician services</TI>
<SO>Medical Care Research and Review</SO>
<YR>2004</YR>
<VL>61</VL>
<NO>3</NO>
<PG>37-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coulter-1995" MODIFIED="2015-05-22 13:17:18 +0200" MODIFIED_BY="Arash Rashidian" NAME="Coulter 1995" TYPE="JOURNAL_ARTICLE">
<AU>Coulter A</AU>
<TI>Evaluating general practice fundholding in the United Kingdom</TI>
<SO>European Journal of Public Health</SO>
<YR>1995</YR>
<VL>5</VL>
<PG>233-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Croxson-2001" MODIFIED="2015-05-22 13:17:26 +0200" MODIFIED_BY="Arash Rashidian" NAME="Croxson 2001" TYPE="JOURNAL_ARTICLE">
<AU>Croxson B, Propper C, Perkins A</AU>
<TI>Do doctors respond to financial incentives? UK family doctors and the GP fundholder scheme</TI>
<SO>Journal of Public Economics</SO>
<YR>2001</YR>
<VL>79</VL>
<PG>375-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Day-1991" MODIFIED="2015-05-22 13:17:38 +0200" MODIFIED_BY="Arash Rashidian" NAME="Day 1991" TYPE="JOURNAL_ARTICLE">
<AU>Day P, Klein R</AU>
<TI>Variations in budgets of fundholding practices</TI>
<SO>BMJ</SO>
<YR>1991</YR>
<VL>303</VL>
<NO>6795</NO>
<PG>168-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Delnoij-2000" MODIFIED="2015-05-22 13:17:50 +0200" MODIFIED_BY="Arash Rashidian" NAME="Delnoij 2000" TYPE="JOURNAL_ARTICLE">
<AU>Delnoij D, Brenner G</AU>
<TI>Importing budget systems from other countries: what can we learn from the German drug budget and the British GP fundholding?</TI>
<SO>Health Policy</SO>
<YR>2000</YR>
<VL>52</VL>
<NO>3</NO>
<PG>157-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Doloresco-2011" MODIFIED="2015-05-22 13:17:58 +0200" MODIFIED_BY="Arash Rashidian" NAME="Doloresco 2011" TYPE="JOURNAL_ARTICLE">
<AU>Doloresco F, Fominaya C, Schumock GT, Vermeulen LC, Matusiak L, Hunkler RJ, et al</AU>
<TI>Projecting future drug expenditures: 2011</TI>
<SO>American Journal of Health-System Pharmacy</SO>
<YR>2011</YR>
<VL>68</VL>
<NO>10</NO>
<PG>921-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eichler-2009" MODIFIED="2015-05-22 13:18:07 +0200" MODIFIED_BY="Arash Rashidian" NAME="Eichler 2009" TYPE="BOOK">
<AU>Eichler R, Levine R</AU>
<SO>Performance Incentives for Global Health: Potential and Pitfalls</SO>
<YR>2009</YR>
<PB>Center for Global Development</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eijkenaar-2013" MODIFIED="2015-05-22 13:18:16 +0200" MODIFIED_BY="Arash Rashidian" NAME="Eijkenaar 2013" TYPE="JOURNAL_ARTICLE">
<AU>Eijkenaar F, Emmert M, Scheppach M, Schoffski O</AU>
<TI>Effects of pay for performance in health care: a systematic review of systematic reviews</TI>
<SO>Health Policy</SO>
<YR>2013</YR>
<VL>110</VL>
<PG>115-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Emmerick-2013" MODIFIED="2015-05-22 13:18:24 +0200" MODIFIED_BY="Arash Rashidian" NAME="Emmerick 2013" TYPE="JOURNAL_ARTICLE">
<AU>Emmerick IC, Oliveira MA, Luiza VL, Azeredo TB, Bigdeli M</AU>
<TI>Access to medicines in Latin America and the Caribbean (LAC): a scoping study</TI>
<SO>BMJ Open</SO>
<YR>2013</YR>
<VL>3</VL>
<NO>5</NO>
<PG>pii: e002224. doi: 10.1136/bmjopen-2012-002224.</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EPOC-2013a" MODIFIED="2015-05-26 10:10:06 +0200" MODIFIED_BY="[Empty name]" NAME="EPOC 2013a" TYPE="OTHER">
<AU>Effective Practice and Organisation of Care (EPOC)</AU>
<TI>What study designs should be included in an EPOC review and what should they be called?</TI>
<SO>EPOC Resources for Review Authors. Oslo: Norwegian Knowledge Centre for the Health Services</SO>
<YR>2013. Available at: http://epocoslo.cochrane.org/epoc-specific-resources-review-authors</YR>
<IDENTIFIERS MODIFIED="2015-05-26 10:09:45 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-05-26 10:09:45 +0200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-EPOC-2013b" MODIFIED="2015-05-26 10:14:10 +0200" MODIFIED_BY="[Empty name]" NAME="EPOC 2013b" TYPE="OTHER">
<AU>Effective Practice and Organisation of Care (EPOC)</AU>
<TI>What outcomes should be reported in EPOC reviews?</TI>
<SO>EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services</SO>
<YR>2013. Available at: http://epocoslo.cochrane.org/epoc-specific-resources-review-authors</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EPOC-2013c" MODIFIED="2015-05-26 10:25:21 +0200" MODIFIED_BY="[Empty name]" NAME="EPOC 2013c" TYPE="OTHER">
<AU>Effective Practice and Organisation of Care (EPOC)</AU>
<TI>Interrupted time series (ITS) analyses</TI>
<SO>EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services</SO>
<YR>2013. Available at: http://epocoslo.cochrane.org/epoc-specific-resources-review-authors</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EPOC-2013d" MODIFIED="2015-05-26 10:25:43 +0200" MODIFIED_BY="[Empty name]" NAME="EPOC 2013d" TYPE="OTHER">
<AU>Effective Practice and Organisation of Care (EPOC)</AU>
<TI>EPOC worksheets for preparing a Summary of Findings (SoF) table using GRADE</TI>
<SO>EPOC Resources for Review Authors. Oslo: Norwegian Knowledge Centre for the Health Services</SO>
<YR>2013. Available at: http://epocoslo.cochrane.org/epoc-specific-resources-review-authors</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EPOC-2015" MODIFIED="2015-05-26 10:24:50 +0200" MODIFIED_BY="[Empty name]" NAME="EPOC 2015" TYPE="OTHER">
<AU>Effective Practice and Organisation of Care (EPOC)</AU>
<TI>Suggested risk of bias criteria for EPOC reviews</TI>
<SO>EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services</SO>
<YR>2015. Available at: http://epocoslo.cochrane.org/epoc-specific-resources-review-authors</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ess-2003" NAME="Ess 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ess SM, Schneeweiss S, Szucs TD</AU>
<TI>European healthcare policies for controlling drug expenditure</TI>
<SO>Pharmacoeconomics</SO>
<YR>2003</YR>
<VL>21(2)</VL>
<PG>89-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fattore-1998" NAME="Fattore 1998" TYPE="JOURNAL_ARTICLE">
<AU>Fattore G, Jommi C</AU>
<TI>The new pharmaceutical policy in Italy</TI>
<SO>Health Policy</SO>
<YR>1998</YR>
<VL>46</VL>
<NO>1</NO>
<PG>21-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feely-1999" MODIFIED="2015-05-22 13:21:29 +0200" MODIFIED_BY="Arash Rashidian" NAME="Feely 1999" TYPE="JOURNAL_ARTICLE">
<AU>Feely J</AU>
<TI>The therapeutic gap - compliance with medication and guidelines</TI>
<SO>Atherosclerosis</SO>
<YR>1999</YR>
<VL>147</VL>
<NO>Suppl 1</NO>
<PG>31-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garrison-2003" MODIFIED="2015-05-22 13:21:49 +0200" MODIFIED_BY="Arash Rashidian" NAME="Garrison 2003" TYPE="JOURNAL_ARTICLE">
<AU>Garrison L, Towse A</AU>
<TI>The drug budget silo mentality in Europe: an overview</TI>
<SO>Value in Health</SO>
<YR>2003</YR>
<VL>6</VL>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Giuffrida-2000" MODIFIED="2015-05-22 13:21:56 +0200" MODIFIED_BY="Arash Rashidian" NAME="Giuffrida 2000" TYPE="COCHRANE_REVIEW">
<AU>Giuffrida A, Gosden T, Forland F, Kristiansen IS, Sergison M, Leese B, et al</AU>
<TI>Target payments in primary care: effects on professional practice and health care outcomes</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-11-07 17:27:50 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-07 17:27:50 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000531"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glynn-1992" MODIFIED="2015-05-22 13:22:04 +0200" MODIFIED_BY="Arash Rashidian" NAME="Glynn 1992" TYPE="JOURNAL_ARTICLE">
<AU>Glynn J, Murphy M, Perkins D</AU>
<TI>GP practice budgets: an evaluation of the financial risks and rewards</TI>
<SO>Financial Accountability and Management</SO>
<YR>1992</YR>
<VL>8</VL>
<PG>149-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gosden-1997" MODIFIED="2015-05-22 13:22:14 +0200" MODIFIED_BY="Arash Rashidian" NAME="Gosden 1997" TYPE="JOURNAL_ARTICLE">
<AU>Gosden T, Torgerson DJ</AU>
<TI>The effect of fundholding on prescribing and referral costs: a review of the evidence</TI>
<SO>Health Policy</SO>
<YR>1997</YR>
<VL>40(2)</VL>
<PG>103-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gosden-2001" MODIFIED="2015-05-22 13:22:35 +0200" MODIFIED_BY="Arash Rashidian" NAME="Gosden 2001" TYPE="JOURNAL_ARTICLE">
<AU>Gosden T, Forland F, Kristiansen IS, Sutton M, Leese B, Giuffrida A, et al</AU>
<TI>Impact of payment method on behaviour of primary care physicians: a systematic review</TI>
<SO>Health Services Research and Policy</SO>
<YR>2001</YR>
<VL>6</VL>
<NO>1</NO>
<PG>44-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADE-2004" MODIFIED="2015-05-22 13:22:44 +0200" MODIFIED_BY="Arash Rashidian" NAME="GRADE 2004" TYPE="JOURNAL_ARTICLE">
<AU>The GRADE Working Group</AU>
<TI>Grading quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<NO>7454</NO>
<PG>1490-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Griffin-1996" MODIFIED="2015-05-22 13:22:59 +0200" MODIFIED_BY="Arash Rashidian" NAME="Griffin 1996" TYPE="JOURNAL_ARTICLE">
<AU>Griffin JP</AU>
<TI>An historical survey of UK government measures to control the NHS medicines expenditure from 1948 to 1996</TI>
<SO>Pharmacoeconomics</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>3</NO>
<PG>210-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gross-1994" MODIFIED="2015-05-22 13:23:10 +0200" MODIFIED_BY="Arash Rashidian" NAME="Gross 1994" TYPE="JOURNAL_ARTICLE">
<AU>Gross DJ, Ratner J, Perez J, Glavin SL</AU>
<TI>International pharmaceutical spending controls: France, Germany, Sweden, and the United Kingdom</TI>
<SO>Health Care Financing Review</SO>
<YR>1994</YR>
<VL>15</VL>
<NO>3</NO>
<PG>127-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harrison-1996" MODIFIED="2015-05-22 13:23:21 +0200" MODIFIED_BY="Arash Rashidian" NAME="Harrison 1996" TYPE="JOURNAL_ARTICLE">
<AU>Harrison S, Choudhry N</AU>
<TI>General practice fundholding in the UK National Health Service: evidence to date</TI>
<SO>Journal of Public Health Policy</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>3</NO>
<PG>331-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Healey-1994" MODIFIED="2015-05-22 13:23:29 +0200" MODIFIED_BY="Arash Rashidian" NAME="Healey 1994" TYPE="JOURNAL_ARTICLE">
<AU>Healey AT</AU>
<TI>Do prospective fundholders inflate their prescribing costs? A study of the Grampian fundholding and non-fundholding practices</TI>
<SO>Health Bulletin</SO>
<YR>1994</YR>
<VL>52</VL>
<NO>4</NO>
<PG>282-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klein-2004" NAME="Klein 2004" TYPE="JOURNAL_ARTICLE">
<AU>Klein R</AU>
<TI>Britain's National Health Service revisited</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>350</VL>
<NO>9</NO>
<PG>937-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lopez-Bastida-2000" MODIFIED="2015-05-22 13:23:38 +0200" MODIFIED_BY="Arash Rashidian" NAME="Lopez Bastida 2000" TYPE="JOURNAL_ARTICLE">
<AU>Lopez Bastida J, Mossialos E</AU>
<TI>Pharmaceutical expenditure in Spain: cost and control</TI>
<SO>International Journal of Health Services</SO>
<YR>2000</YR>
<VL>30</VL>
<NO>3</NO>
<PG>597-616</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lu-2008" MODIFIED="2015-05-22 13:23:50 +0200" MODIFIED_BY="Arash Rashidian" NAME="Lu 2008" TYPE="JOURNAL_ARTICLE">
<AU>Lu CY, Ross-Degnan D, Soumerai SB, Pearson SA</AU>
<TI>Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature - 2001-2007</TI>
<SO>BMC Health Services Research</SO>
<YR>2008</YR>
<VL>8</VL>
<NO>75</NO>
<PG>doi:10.1186/1472-6963-8-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lu-2011" MODIFIED="2015-05-22 13:24:01 +0200" MODIFIED_BY="Arash Rashidian" NAME="Lu 2011" TYPE="OTHER">
<AU>Lu Y, Hernandez P, Abegunde D, Edejer T</AU>
<TI>The world medicines situation 2011; medicine expenditure</TI>
<SO>WHO/EMP/MIE</SO>
<YR>2011</YR>
<VL>2.6</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lundkvist-2002" MODIFIED="2015-05-22 13:24:09 +0200" MODIFIED_BY="Arash Rashidian" NAME="Lundkvist 2002" TYPE="JOURNAL_ARTICLE">
<AU>Lundkvist J</AU>
<TI>Pricing and reimbursement of drugs in Sweden</TI>
<SO>European Journal of Health Economics</SO>
<YR>2002</YR>
<VL>3</VL>
<NO>1</NO>
<PG>66-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mannion-2005" MODIFIED="2015-05-22 13:24:17 +0200" MODIFIED_BY="Arash Rashidian" NAME="Mannion 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mannion R</AU>
<TI>Practice based commissioning: a summary of the evidence</TI>
<SO>Health Policy</SO>
<YR>2005</YR>
<VL>11</VL>
<PG>1-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mapelli-2003" MODIFIED="2015-05-22 13:24:24 +0200" MODIFIED_BY="Arash Rashidian" NAME="Mapelli 2003" TYPE="JOURNAL_ARTICLE">
<AU>Mapelli V, Lucioni C</AU>
<TI>Spending on pharmaceuticals in Italy: macro constraints with local autonomy</TI>
<SO>Value in Health</SO>
<YR>2003</YR>
<VL>6</VL>
<PG>31-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maynard-2003" MODIFIED="2015-05-22 13:24:32 +0200" MODIFIED_BY="Arash Rashidian" NAME="Maynard 2003" TYPE="JOURNAL_ARTICLE">
<AU>Maynard A, Bloor K</AU>
<TI>Dilemmas In regulation of the market for pharmaceuticals</TI>
<SO>Health Affairs</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>3</NO>
<PG>31-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McNamara-2005" MODIFIED="2015-05-22 13:24:41 +0200" MODIFIED_BY="Arash Rashidian" NAME="McNamara 2005" TYPE="JOURNAL_ARTICLE">
<AU>McNamara P</AU>
<TI>Quality-based payment: six case examples</TI>
<SO>International Journal of Quality Health Care</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>4</NO>
<PG>357-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moon-2002" MODIFIED="2015-05-22 13:24:54 +0200" MODIFIED_BY="Arash Rashidian" NAME="Moon 2002" TYPE="JOURNAL_ARTICLE">
<AU>Moon G, Mohan J, Twigg L, McGrath K, Pollock A</AU>
<TI>Catching waves: the historical geography of the general practice fundholding initiative in England and Wales</TI>
<SO>Social Sciences Medicine</SO>
<YR>2002</YR>
<VL>55</VL>
<NO>12</NO>
<PG>2201-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mossialos-2004" MODIFIED="2015-05-22 13:25:02 +0200" MODIFIED_BY="Arash Rashidian" NAME="Mossialos 2004" TYPE="BOOK">
<AU>Mossialos E, Mrazek M, Walley T</AU>
<SO>Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality</SO>
<YR>2004</YR>
<PB>Buckingham, Open University Press</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mossialos-2005" MODIFIED="2015-05-22 13:25:09 +0200" MODIFIED_BY="Arash Rashidian" NAME="Mossialos 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mossialos E, Oliver A</AU>
<TI>An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom</TI>
<SO>International Journal of Health Planning and Management</SO>
<YR>2004</YR>
<VL>20</VL>
<PG>291-306</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Narine-1997" MODIFIED="2015-05-22 13:25:17 +0200" MODIFIED_BY="Arash Rashidian" NAME="Narine 1997" TYPE="OTHER">
<AU>Narine L, Senathirajah M</AU>
<TI>Pharmaceutical Cost Containment Policies: Intended and Unintended Impacts</TI>
<SO>Toronto, Ontario: University of Toronto Department of Health Administration Report</SO>
<YR>1997</YR>
<PG>68-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Okunade-2006" MODIFIED="2015-05-22 13:25:26 +0200" MODIFIED_BY="Arash Rashidian" NAME="Okunade 2006" TYPE="JOURNAL_ARTICLE">
<AU>Okunade AA, Suraratdecha C</AU>
<TI>The pervasiveness of pharmaceutical expenditure inertia in the OECD countries</TI>
<SO>Social Sciences Medicine</SO>
<YR>2006</YR>
<VL>63</VL>
<NO>1</NO>
<PG>225-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ostini-2009" MODIFIED="2015-05-22 13:25:36 +0200" MODIFIED_BY="Arash Rashidian" NAME="Ostini 2009" TYPE="JOURNAL_ARTICLE">
<AU>Ostini R, Hegney D, Jackson C, Williamson M, Mackson JM, Gurman K, et al</AU>
<TI>Systematic review of interventions to improve prescribing</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2009</YR>
<VL>43</VL>
<NO>3</NO>
<PG>502-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oxman-2009" MODIFIED="2014-01-02 14:28:18 +0100" MODIFIED_BY="[Empty name]" NAME="Oxman 2009" TYPE="JOURNAL_ARTICLE">
<AU>Oxman AD, Fretheim A</AU>
<TI>Can paying for results help to achieve the Millennium Development Goals? Overview of the effectiveness of results-based financing</TI>
<SO>Journal of Evidence-Based Medicine</SO>
<YR>2009</YR>
<VL>2</VL>
<PG>70-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Painter-2005" MODIFIED="2015-05-22 13:25:43 +0200" MODIFIED_BY="Arash Rashidian" NAME="Painter 2005" TYPE="JOURNAL_ARTICLE">
<AU>Painter MR</AU>
<TI>Reimbursement issues with hormonal therapies for prostate cancer</TI>
<SO>Reviews on Urology</SO>
<YR>2005</YR>
<VL>7 Suppl 5</VL>
<PG>S44-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ramsay-2003" MODIFIED="2015-05-22 13:25:52 +0200" MODIFIED_BY="Arash Rashidian" NAME="Ramsay 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ramsay CR, Matowe L, Grilli R, Grimshaw JM, Thomas RE</AU>
<TI>Interrupted time series design in health technology assessment: lessons from two systematic reviews of behavior change strategies</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>4</NO>
<PG>612-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rashidian-2008" MODIFIED="2015-05-22 13:25:59 +0200" MODIFIED_BY="Arash Rashidian" NAME="Rashidian 2008" TYPE="JOURNAL_ARTICLE">
<AU>Rashidian A</AU>
<TI>Falling on stony ground? A qualitative study of implementation of clinical guidelines' prescribing recommendations in primary care</TI>
<SO>Health Policy</SO>
<YR>2008</YR>
<VL>85</VL>
<NO>2</NO>
<PG>148-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rashidian-2013" MODIFIED="2014-06-25 15:04:22 +0200" MODIFIED_BY="[Empty name]" NAME="Rashidian 2013" TYPE="JOURNAL_ARTICLE">
<AU>Rashidian A, Jahanmehr N, Jabbour S, Zaidi S, Soleymani F, Bigdeli M</AU>
<TI>Bibliographic analysis of research publications on access to and use of medicines in low-income and middle-income countries in the Eastern Mediterranean Region: identifying the research gaps</TI>
<SO>BMJ Open</SO>
<YR>2013</YR>
<VL>3</VL>
<NO>10</NO>
<PG>e003332. doi: 10.1136/bmjopen-2013-003332</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reinhardt-2002" MODIFIED="2015-05-22 13:26:13 +0200" MODIFIED_BY="Arash Rashidian" NAME="Reinhardt 2002" TYPE="JOURNAL_ARTICLE">
<AU>Reinhardt U, Hussey P, Anderson G</AU>
<TI>Cross-national comparisons of health systems using OECD data</TI>
<SO>Health Affairs</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>3</NO>
<PG>169-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rietveld-2002" NAME="Rietveld 2002" TYPE="JOURNAL_ARTICLE">
<AU>Rietveld AdH, Haaijer-Ruskamp FM</AU>
<TI>Policy options for cost containment of pharmaceuticals</TI>
<SO>International Journal of Risk &amp; Safety in Medicine</SO>
<YR>2002</YR>
<VL>15</VL>
<PG>29-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roland-2004" MODIFIED="2015-05-22 13:26:24 +0200" MODIFIED_BY="Arash Rashidian" NAME="Roland 2004" TYPE="JOURNAL_ARTICLE">
<AU>Roland M</AU>
<TI>Linking physicians' pay to the quality of care - a major experiment in the United Kingdom</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>351</VL>
<NO>14</NO>
<PG>1448-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosenthal-2004" MODIFIED="2015-05-22 13:26:35 +0200" MODIFIED_BY="Arash Rashidian" NAME="Rosenthal 2004" TYPE="JOURNAL_ARTICLE">
<AU>Rosenthal M, Fernandopulle R, Song H, Landon B</AU>
<TI>Paying for quality: providers' incentives for quality improvement</TI>
<SO>Health Affairs</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>2</NO>
<PG>127-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosenthal-2006" MODIFIED="2015-05-22 13:26:43 +0200" MODIFIED_BY="Arash Rashidian" NAME="Rosenthal 2006" TYPE="JOURNAL_ARTICLE">
<AU>Rosenthal MB, Landon BE, Normand SL, Frank RG, Epstein AM</AU>
<TI>Pay for performance in commercial HMOs</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>355</VL>
<PG>1895-902</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rowe-2006" NAME="Rowe 2006" TYPE="JOURNAL_ARTICLE">
<AU>Rowe JW</AU>
<TI>Pay-for-performance and accountability: related themes in improving health care</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2006</YR>
<VL>145</VL>
<PG>695-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sarayani-2014" MODIFIED="2014-12-06 14:21:55 +0100" MODIFIED_BY="Arash Rashidian" NAME="Sarayani 2014" TYPE="JOURNAL_ARTICLE">
<AU>Sarayani A, Rashidian A, Gholami K</AU>
<TI>Low utilisation of diabetes medicines in Iran, despite their affordability (2000&#8211;2012): a time-series and benchmarking study</TI>
<SO>BMJ Open</SO>
<YR>2014</YR>
<VL>4</VL>
<PG>e005859 doi:10.1136/bmjopen-2014-005859</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schwartz-1996" MODIFIED="2015-05-22 13:26:58 +0200" MODIFIED_BY="Arash Rashidian" NAME="Schwartz 1996" TYPE="BOOK_SECTION">
<AU>Schwartz FW, Busse R</AU>
<TI>Fixed budgets in the ambulatory care sector: the German experience</TI>
<SO>Fixing Health Budgets: Experience from Europe and North America</SO>
<YR>1996</YR>
<PG>93-108</PG>
<PB>John Wiley &amp; Sons</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schwermann-2003" MODIFIED="2015-05-22 13:27:10 +0200" MODIFIED_BY="Arash Rashidian" NAME="Schwermann 2003" TYPE="JOURNAL_ARTICLE">
<AU>Schwermann T, Greiner W, Schulenburg JM</AU>
<TI>Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany</TI>
<SO>Value in Health</SO>
<YR>2003</YR>
<VL>6 Suppl</VL>
<PG>S20-S30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-1998" MODIFIED="2015-05-22 13:27:18 +0200" MODIFIED_BY="Arash Rashidian" NAME="Smith 1998" TYPE="JOURNAL_ARTICLE">
<AU>Smith RD, Wilton P</AU>
<TI>General practice fundholding: progress to date</TI>
<SO>Britiah Journal of General Practice</SO>
<YR>1998</YR>
<VL>48</VL>
<NO>430</NO>
<PG>1253-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soumerai-1993" MODIFIED="2015-05-22 13:27:26 +0200" MODIFIED_BY="Arash Rashidian" NAME="Soumerai 1993" TYPE="JOURNAL_ARTICLE">
<AU>Soumerai SB, Avorn J, Taylor WC, Wessels M, Maher D, Hawley SL</AU>
<TI>Improving choice of prescribed antibiotics through concurrent reminders in an educational order form</TI>
<SO>Medical Care</SO>
<YR>1993</YR>
<VL>31</VL>
<NO>6</NO>
<PG>552-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steinbrook-2007" MODIFIED="2015-05-22 13:27:34 +0200" MODIFIED_BY="Arash Rashidian" NAME="Steinbrook 2007" TYPE="JOURNAL_ARTICLE">
<AU>Steinbrook R</AU>
<TI>Closing the affordability gap for drugs in low-income countries</TI>
<SO>New England Journal of Medicine</SO>
<YR>2007</YR>
<VL>357</VL>
<NO>20</NO>
<PG>1996-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stewart_x002d_Brown-1995" NAME="Stewart-Brown 1995" TYPE="JOURNAL_ARTICLE">
<AU>Stewart-Brown S, Surender R, Bradlow J, Coulter A, Doll H</AU>
<TI>The effects of fundholding in general practice on prescribing habits three years after introduction of the scheme</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>311</VL>
<PG>1543-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sturm-2005" MODIFIED="2015-05-22 13:27:45 +0200" MODIFIED_BY="Arash Rashidian" NAME="Sturm 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sturm HB, van Gilst WH, Swedberg K, Hobbs FD, Haaijer-Ruskamp FM</AU>
<TI>Heart failure guidelines and prescribing in primary care across Europe</TI>
<SO>BMC Health Services Research</SO>
<YR>2005</YR>
<VL>5</VL>
<PG>57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Takian-2011" MODIFIED="2014-01-02 09:33:10 +0100" MODIFIED_BY="[Empty name]" NAME="Takian 2011" TYPE="JOURNAL_ARTICLE">
<AU>Takian A, Rashidian A, Kabir MJ</AU>
<TI>Expediency and coincidence in re-engineering a health system: an interpretive approach to formation of family medicine in Iran</TI>
<SO>Health Policy Plan</SO>
<YR>2011</YR>
<VL>26</VL>
<NO>2</NO>
<PG>163-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trude-2006" MODIFIED="2015-05-22 13:27:53 +0200" MODIFIED_BY="Arash Rashidian" NAME="Trude 2006" TYPE="JOURNAL_ARTICLE">
<AU>Trude S, Au M, Christianson JB</AU>
<TI>Health plan pay for performance strategies</TI>
<SO>American Journal of Managed Care</SO>
<YR>2006</YR>
<VL>12</VL>
<PG>537-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Herck-2010" MODIFIED="2014-12-05 09:34:15 +0100" MODIFIED_BY="Arash Rashidian" NAME="Van Herck 2010" TYPE="JOURNAL_ARTICLE">
<AU>Van Herck P, De Smedt D, Annemans L, Remmen R, Rosenthal MB, Sermeus W</AU>
<TI>Systematic review: effects, design choices, and context of pay-for-performance in health care</TI>
<SO>BMC Health Services Research</SO>
<YR>2010</YR>
<VL>10</VL>
<PG>247 doi:10.1186/1472-6963-10-247</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walley-1995" NAME="Walley 1995" TYPE="JOURNAL_ARTICLE">
<AU>Walley T, Wilson R, Bligh J</AU>
<TI>Current prescribing in primary care in the UK. Effects of the indicative prescribing scheme and GP fundholding</TI>
<SO>Pharmacoeconomics</SO>
<YR>1995</YR>
<VL>7</VL>
<NO>4</NO>
<PG>320-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walley-2004" MODIFIED="2015-05-22 13:28:03 +0200" MODIFIED_BY="Arash Rashidian" NAME="Walley 2004" TYPE="BOOK_SECTION">
<AU>Walley T, Mossialos E</AU>
<TI>Financial incentives and prescribing</TI>
<SO>Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality</SO>
<YR>2004</YR>
<PG>177-95</PG>
<PB>Open University Press</PB>
<CY>Buckinghamshire, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walley-2005" MODIFIED="2015-05-22 13:28:14 +0200" MODIFIED_BY="Arash Rashidian" NAME="Walley 2005" TYPE="JOURNAL_ARTICLE">
<AU>Walley T, Mrazek M, Mossialos E</AU>
<TI>Regulating pharmaceutical markets: improving efficiency and controlling costs in the UK</TI>
<SO>International Journal of Health Planning and Management</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>4</NO>
<PG>375-98</PG>
<IDENTIFIERS MODIFIED="2014-06-25 15:35:46 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-25 15:35:46 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/hpm.820"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Weiner-1990" MODIFIED="2015-05-22 13:28:24 +0200" MODIFIED_BY="Arash Rashidian" NAME="Weiner 1990" TYPE="BOOK">
<AU>Weiner J, Ferriss D</AU>
<SO>GP Budget Holding in the UK: Lessons from America</SO>
<YR>1990</YR>
<PB>King's Fund</PB>
<CY>London, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilton-1998" MODIFIED="2015-05-22 13:28:34 +0200" MODIFIED_BY="Arash Rashidian" NAME="Wilton 1998" TYPE="JOURNAL_ARTICLE">
<AU>Wilton P, Smith RD</AU>
<TI>Primary care reform: a three country comparison of 'budget holding'</TI>
<SO>Health Policy</SO>
<YR>1998</YR>
<VL>44</VL>
<NO>2</NO>
<PG>149-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Witter-2012" MODIFIED="2014-01-02 15:06:56 +0100" MODIFIED_BY="[Empty name]" NAME="Witter 2012" TYPE="JOURNAL_ARTICLE">
<AU>Witter S, Fretheim A, Kessy FL, Lindahl AK</AU>
<TI>Paying for performance to improve the delivery of health interventions in low- and middle-income countries</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<VL>Issue 2</VL>
<PG>Art. No.:CD007899. DOI: 10.1002/14651858.CD007899.pub2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zaidi-2013" MODIFIED="2015-05-22 13:28:45 +0200" MODIFIED_BY="Arash Rashidian" NAME="Zaidi 2013" TYPE="JOURNAL_ARTICLE">
<AU>Zaidi S, Bigdeli M, Aleem N, Rashidian A</AU>
<TI>Access to essential medicines in Pakistan: policy and health systems research concerns</TI>
<SO>PLoS One</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>5</NO>
<PG>e63515. doi: 10.1371/journal.pone.0063515</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-05-22 13:28:59 +0200" MODIFIED_BY="Arash Rashidian">
<REFERENCE ID="REF-Sturm-2007" MODIFIED="2015-05-22 13:28:59 +0200" MODIFIED_BY="Arash Rashidian" NAME="Sturm 2007" TYPE="COCHRANE_REVIEW">
<AU>Sturm H, Austvoll-Dahlgren A, Aaserud M, Oxman AD, Ramsay C, Vernby A, et al</AU>
<TI>Pharmaceutical policies: effects of financial incentives for prescribers</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2015-04-29 10:11:05 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-04-29 10:11:05 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006731"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-05-26 10:36:26 +0200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-05-26 10:36:26 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-05-22 12:20:18 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Baines-1997c">
<CHAR_METHODS MODIFIED="2015-05-22 11:21:41 +0200" MODIFIED_BY="Arash Rashidian">
<P>CBA<BR/>Serious limitations<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-22 12:18:53 +0200" MODIFIED_BY="Arash Rashidian">
<P>Setting: UK, Lincolnshire and Devon<BR/>Fund-holders (FH)<BR/>(1st to 3rd wave)<BR/>Lincolnshire: 19<BR/>Devon: 22<BR/>Non-FH:<BR/>Linc: 86/Devon: 106<BR/>Unit: practice<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-22 12:18:53 +0200" MODIFIED_BY="Arash Rashidian">
<P>UK, NHS fund-holding</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Drug use (generics) </P>
<P>Costs (per patient)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-22 12:20:18 +0200" MODIFIED_BY="Arash Rashidian">
<P>Only long-term effects were reported in the analysis, as data for waves 1 to 3 have been aggregated by the authors</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-22 12:20:43 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Bradlow-1993">
<CHAR_METHODS MODIFIED="2015-05-22 12:20:42 +0200" MODIFIED_BY="Arash Rashidian">
<P>CBA<BR/>Serious limitations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-22 12:20:42 +0200" MODIFIED_BY="Arash Rashidian">
<P>Setting: UK, Oxford<BR/>FH (1st wave): 5<BR/>Non-FH: 7<BR/>Unit: practice<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-22 12:20:42 +0200" MODIFIED_BY="Arash Rashidian">
<P>UK, NHS fund-holding</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-22 12:20:42 +0200" MODIFIED_BY="Arash Rashidian">
<P>Drug use (items, generics<BR/>Costs (per patient, per item)</P>
<P>Cost: total net cost per 1000 PU, mean cost per item, net cost per 1000 PU, mean cost per item</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-22 12:20:43 +0200" MODIFIED_BY="Arash Rashidian">
<P>Dispensing group was excluded from the analysis as it was not comparable with the control group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-22 12:21:03 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Burr-1992">
<CHAR_METHODS MODIFIED="2015-05-22 12:21:03 +0200" MODIFIED_BY="Arash Rashidian">
<P>CBA<BR/>Serious limitations<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-22 12:21:03 +0200" MODIFIED_BY="Arash Rashidian">
<P>Setting: UK, Mid-Glamorgon<BR/>FH (1st wave): 4<BR/>Non-FH: 4<BR/>Unit: practices<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-22 12:21:03 +0200" MODIFIED_BY="Arash Rashidian">
<P>UK, NHS fund-holding</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-22 12:21:03 +0200" MODIFIED_BY="Arash Rashidian">
<P>Drug use (items)<BR/>Costs (per patient)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-22 12:21:03 +0200" MODIFIED_BY="Arash Rashidian"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-22 12:21:25 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Chou-2008">
<CHAR_METHODS MODIFIED="2012-09-18 23:03:51 +0200" MODIFIED_BY="[Empty name]">
<P>ITS</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-22 12:21:25 +0200" MODIFIED_BY="Arash Rashidian">
<P>Setting: Taiwan, Taipei area</P>
<P>213,570 hypertensive patients (5,937,581 visits) plus 83,985 patients with diabetes (2,613,843 visits)</P>
<P>All patients from 26 hospitals in the Taipei area in Thilanl, then hypertensive and diabetic patients, were included in the study. Hypertensive patients group: 108,142 male (average age 63.5 ± 13.5 years), 105,426 female (64.5 ± 12.2 years). Diabetic patients group: 42,272 male (61.8 ± 13.2 years) and 41,713 female (64.0 ± 12.1 years). Time series data included 8 points before and 12 points after the intervention</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-22 12:21:25 +0200" MODIFIED_BY="Arash Rashidian">
<P>Global budget, based on an &#8221;individual expenditure cap&#8221;. Medical providers will find that the more services they provide, the less net profit they make. Later, the NHI will negotiate an individual expenditure cap with each hospital. Consequently, each hospital will maximise its net profit under the predetermined allowance</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-22 12:21:25 +0200" MODIFIED_BY="Arash Rashidian">
<P>Drug use (items per prescription)<BR/>Costs (per prescription)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-22 12:21:25 +0200" MODIFIED_BY="Arash Rashidian"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-22 12:22:07 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Chu-2008">
<CHAR_METHODS MODIFIED="2012-09-18 23:22:22 +0200" MODIFIED_BY="[Empty name]">
<P>CBA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-22 12:22:07 +0200" MODIFIED_BY="Arash Rashidian">
<P>Setting: Taiwan, Taipei area</P>
<P>Case group: patients with hypertension aged 65 and older in hospitals that implemented physician fee programmes</P>
<P>Control group: hospitals that did not implement physician fee programmes</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-22 12:22:07 +0200" MODIFIED_BY="Arash Rashidian">
<P>For drug reimbursement, with about 20,000 drug items in the list. Healthcare organisations (e.g. hospitals) purchased prescription drugs from pharmaceutical companies and received reimbursements from the BNHI based on predetermined rates. This aimed first to equalise profits among different drugs, then to reduce overall drug profits within the health industry</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-22 12:22:07 +0200" MODIFIED_BY="Arash Rashidian">
<P>Drug use (items per prescription)</P>
<P>Costs (per prescription)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-22 12:22:07 +0200" MODIFIED_BY="Arash Rashidian">
<P>8 points before and 12 points after the intervention with 1- to 3-month interval between January 2002 and December 2007</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-22 12:22:33 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Corney-1997">
<CHAR_METHODS MODIFIED="2015-05-22 12:22:33 +0200" MODIFIED_BY="Arash Rashidian">
<P>CBA<BR/>Serious limitations<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-22 12:22:33 +0200" MODIFIED_BY="Arash Rashidian">
<P>Setting: UK, South Thames region<BR/>FH (2nd wave): 4<BR/>Non-FH: 4<BR/>Unit: practice<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-22 12:22:33 +0200" MODIFIED_BY="Arash Rashidian">
<P>UK, NHS fund-holding</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Costs (per patient)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-22 12:22:33 +0200" MODIFIED_BY="Arash Rashidian">
<P>1st wave experimental group was excluded because no baseline information was provided</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-22 12:23:00 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Doran-2011">
<CHAR_METHODS MODIFIED="2012-12-26 15:56:10 +0100" MODIFIED_BY="[Empty name]">
<P>ITS</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-22 12:22:59 +0200" MODIFIED_BY="Arash Rashidian">
<P>Setting: UK</P>
<P>653,500 patients from 148 practices that provided data to the GPRD continuously between January 2000 and December 2007</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-22 12:22:59 +0200" MODIFIED_BY="Arash Rashidian">
<P>The quality and outcomes framework, introduced in 2004, links up 25% of UK family practitioner income to performance on 76 clinical quality indicators and 70 indicators related to organisation of care and patient experience. Of the clinical indicators, 10 related to maintaining disease registers, 56 to processes of care (including prescribing) and 10 to intermediate outcomes (such as controlling blood pressure). In 2007, each point earned the practice £125 (&#8364;141; $202), adjusted for patient population size and disease prevalence. A maximum of 1000 points was available, equating to £31,000 per physician</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-06 14:49:41 +0100" MODIFIED_BY="Arash Rashidian">
<P>Drug use (percentage of patients receiving the recommended incentivised medicines)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-22 12:23:00 +0200" MODIFIED_BY="Arash Rashidian">
<P>3 points before and 3 points after the intervention with annual interval between January 2000 and December 2007</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-22 12:23:19 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Granlund-2006">
<CHAR_METHODS MODIFIED="2012-09-18 23:10:47 +0200" MODIFIED_BY="[Empty name]">
<P>CBA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-22 12:23:19 +0200" MODIFIED_BY="Arash Rashidian">
<P>Setting: Sweden, Väster botten</P>
<P>Case group: 2 health centres, health centres located in Väster botten (those of Burträsk and Moröbacke), obtained fixed budgets</P>
<P>Control group: other health centres, health centres that had a target<BR/>Budgets</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-22 12:23:19 +0200" MODIFIED_BY="Arash Rashidian">
<P>In 2001, the 2 health centres<BR/>were given fixed budgets for pharmaceutical expenditures, giving them an incentive to decrease expenditures, as they were allowed to keep any surplus (and were forced to repay any deficit) generated during the year</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-06 15:05:29 +0100" MODIFIED_BY="Arash Rashidian">
<P>Drug use (prescription per patient, DDD per prescription)</P>
<P>Costs (per prescription, per DDD)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-22 12:23:19 +0200" MODIFIED_BY="Arash Rashidian"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-22 12:23:45 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Guether-1995">
<CHAR_METHODS MODIFIED="2015-05-22 11:37:46 +0200" MODIFIED_BY="Arash Rashidian">
<P>ITS<BR/>Some limitations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-22 11:37:52 +0200" MODIFIED_BY="Arash Rashidian">
<P>Setting: West Germany Statutory health insurance<BR/>General practitioners: 82<BR/>Unit: GPs. 4 observations before the intervention and 4 observations after the intervention<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>German drug budget</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-22 11:41:53 +0200" MODIFIED_BY="Arash Rashidian">
<P>Drug use (prescriptions)<BR/>Health-care utilisation (referrals)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-22 12:23:58 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Harris-1996">
<CHAR_METHODS MODIFIED="2015-05-22 12:23:58 +0200" MODIFIED_BY="Arash Rashidian">
<P>CITS<BR/>Serious/some limitations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-22 12:23:58 +0200" MODIFIED_BY="Arash Rashidian">
<P>Setting: UK, England<BR/>All general practices<BR/>Unit: practice</P>
<P>Unit: practice</P>
<P>4 observations before and 20 observations after the intervention</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-22 12:23:58 +0200" MODIFIED_BY="Arash Rashidian">
<P>UK, NHS fund-holding</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-22 12:23:58 +0200" MODIFIED_BY="Arash Rashidian">
<P>Drug use (items)</P>
<P>Costs (per patient)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-22 12:23:58 +0200" MODIFIED_BY="Arash Rashidian">
<P>1 year before and 5 years after the intervention, with annual interval between April 1990 and March 1996</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-22 12:24:17 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Martens-2007">
<CHAR_METHODS MODIFIED="2012-09-18 22:31:41 +0200" MODIFIED_BY="[Empty name]">
<P>CBA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-22 12:24:17 +0200" MODIFIED_BY="Arash Rashidian">
<P>Setting: south of Netherland, District Health Authority, in South West England<BR/>Case group: 119 GPs in the intervention region (south of the Netherlands) received a financial incentive</P>
<P>Control group: 118 GPs in a control region (no financial incentive)</P>
<P>Both groups were equally familiar with existing national evidence-based guidelines on antibiotics and gastric drugs and were equally exposed to medical education offered nationwide<BR/>
</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-22 12:24:17 +0200" MODIFIED_BY="Arash Rashidian">
<P>A financial incentive was provided for prescribing according to local guidelines on specific drugs or drug categories. The financial incentive consisted of a 1-off bonus (target payment), which was performance independent and was given to all GPs. In return for this financial incentive, GPs should adhere to relevant prescription guidelines abstracted in a 1-page printed formulary that was developed by a multi-disciplinary committee</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-06 14:57:57 +0100" MODIFIED_BY="Arash Rashidian">
<P>Drug use (prescription per (1000) patient)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-22 12:24:17 +0200" MODIFIED_BY="Arash Rashidian"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-22 12:24:38 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Rafferty-1997">
<CHAR_METHODS MODIFIED="2015-05-22 12:24:38 +0200" MODIFIED_BY="Arash Rashidian">
<P>CITS<BR/>Serious/some limitations<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-22 12:24:38 +0200" MODIFIED_BY="Arash Rashidian">
<P>Setting: UK, Northern Ireland<BR/>Fund-holding (1st wave): 23<BR/>Fund-holding (2nd wave): 34<BR/>Fund-holding (3rd wave): 9<BR/>Non-fund-holding: all in Northern Ireland<BR/>Unit: practice</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-22 12:24:38 +0200" MODIFIED_BY="Arash Rashidian">
<P>UK, NHS fund-holding</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-22 12:24:38 +0200" MODIFIED_BY="Arash Rashidian">
<P>Drug use (prescriptions, generics)<BR/>Costs (per patient, per item)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-22 12:24:38 +0200" MODIFIED_BY="Arash Rashidian">
<P>4 points before and 3 points after the intervention with annual interval between April 1989 and March 1996</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-22 12:24:59 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Sch_x00f6_ffski-1997">
<CHAR_METHODS MODIFIED="2015-05-22 12:24:58 +0200" MODIFIED_BY="Arash Rashidian">
<P>ITS<BR/>Some limitations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-22 12:24:59 +0200" MODIFIED_BY="Arash Rashidian">
<P>Setting: Germany, Statutory Sickness funds<BR/>309 to 382 practices<BR/>Unit: practice<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>German drug budget</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-22 12:24:59 +0200" MODIFIED_BY="Arash Rashidian">
<P>Healthcare utilisation (referral rate, hospitalisation)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-22 12:24:59 +0200" MODIFIED_BY="Arash Rashidian">
<P>12 points before and 12 points after the intervention with 1-month interval between January 1992 and December 1993</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-22 12:25:12 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Serumaga-2011">
<CHAR_METHODS MODIFIED="2012-12-26 16:21:47 +0100" MODIFIED_BY="[Empty name]">
<P>ITS</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-22 12:25:12 +0200" MODIFIED_BY="Arash Rashidian">
<P>Setting: United Kingdom, 4 countries of the United Kingdom (England, Scotland, Wales and Northern Ireland)</P>
<P>470,725 patients with a diagnosis of hypertension during the observation<BR/>period (January 2000 to July 2007)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-22 12:25:12 +0200" MODIFIED_BY="Arash Rashidian">
<P>In April 2004, a large-scale pay for performance policy was applied in the 4 countries of the United Kingdom (England, Scotland, Wales and Northern Ireland). On the basis of the proportions of patients achieving certain quality indicators, general practitioners could receive payments as high as 25% of their total income. 136 quality indicators such as prescribing outcomes were included</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-06 15:05:15 +0100" MODIFIED_BY="Arash Rashidian">
<P>Health outcomes (percentage of patients with controlled blood pressure)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-22 12:25:12 +0200" MODIFIED_BY="Arash Rashidian">
<P>26 points before and 37 points after the intervention with 1-month interval between January 2000 and June 2007</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-22 12:25:30 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Walley--2000">
<CHAR_METHODS MODIFIED="2015-05-22 12:25:30 +0200" MODIFIED_BY="Arash Rashidian">
<P>ITS<BR/>Some limitations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-22 12:25:30 +0200" MODIFIED_BY="Arash Rashidian">
<P>Setting: Ireland, Eastern Health Board cohort of<BR/>223 general practitioners<BR/>Unit: GPs<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ireland Indicative Drug Targeting Savings Scheme (IDTSS)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-22 12:25:30 +0200" MODIFIED_BY="Arash Rashidian">
<P>Drug use (items)<BR/>Costs (per item, per patient)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-22 12:25:30 +0200" MODIFIED_BY="Arash Rashidian">
<P>Cohorts merged, 3 points before and 3 points after the intervention with annual interval between 1990 and 1995</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-22 12:25:49 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Whynes-1997">
<CHAR_METHODS MODIFIED="2015-05-22 12:25:49 +0200" MODIFIED_BY="Arash Rashidian">
<P>CBA<BR/>Serious limitations<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-22 12:25:49 +0200" MODIFIED_BY="Arash Rashidian">
<P>Setting: UK, Lincolnshire<BR/>FH (4th wave): 23<BR/>Non-FH: 63<BR/>Unit: practice<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-22 12:25:49 +0200" MODIFIED_BY="Arash Rashidian">
<P>UK, NHS fund-holding</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-22 12:25:49 +0200" MODIFIED_BY="Arash Rashidian">
<P>Drug use (items, generics)<BR/>Costs (per patient)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-22 12:25:49 +0200" MODIFIED_BY="Arash Rashidian">
<P>Waves 1 to 3 (aggregated) were not included in the analysis because no adequate baseline/intervention period was included</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-22 12:26:10 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Wilson-1995">
<CHAR_METHODS MODIFIED="2015-05-22 12:26:10 +0200" MODIFIED_BY="Arash Rashidian">
<P>CITS<BR/>Serious/some limitations<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-22 12:26:10 +0200" MODIFIED_BY="Arash Rashidian">
<P>Setting: UK, North West Regional Health Authority<BR/>Fund-holding (1st wave): 20<BR/>Fund-holding (2nd wave): 31<BR/>Fund-holding (3rd wave): 49<BR/>Non-fund-holding: 312<BR/>Unit: practice<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-22 12:26:10 +0200" MODIFIED_BY="Arash Rashidian">
<P>UK, NHS fund-holding</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-22 12:26:10 +0200" MODIFIED_BY="Arash Rashidian">
<P>Drug use (items, generics)<BR/>Costs (per patient, per item)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-22 12:26:10 +0200" MODIFIED_BY="Arash Rashidian">
<P>12 points before and 12 points after the intervention with a 1-month interval between April 1990 and March 1994. For each wave, two years of data were provided (i.e. 24 data points)</P>
<P>Wave 1: 90 to 92; wave 2: 91 to 93; wave 3: 92 to 94</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-05-22 12:26:31 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Wilson-1999">
<CHAR_METHODS MODIFIED="2015-05-22 12:26:31 +0200" MODIFIED_BY="Arash Rashidian">
<P>CBA<BR/>Serious limitations<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-22 12:26:31 +0200" MODIFIED_BY="Arash Rashidian">
<P>Setting: UK<BR/>5 health authorities in NW region<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-22 12:26:31 +0200" MODIFIED_BY="Arash Rashidian">
<P>UK, NHS fund-holding</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-22 12:26:31 +0200" MODIFIED_BY="Arash Rashidian">
<P>Drug use (DDD, drug subgroups)<BR/>Costs (per patient, per DDD)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-22 12:26:31 +0200" MODIFIED_BY="Arash Rashidian"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CBA: controlled before-after; CITS: controlled interrupted time series; DDD: defined daily doses; FH: fund-holding; GB: global budget; GP: general practitioner; GPRD: General Practice Research Database; IDTSS: Ireland Indicative Drug Targeting Savings Scheme; ITS: interrupted time series; NHS: National Health Service; PACT: prescribing analysis and cost; PU: prescribing unit.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-05-22 12:35:06 +0200" MODIFIED_BY="Arash Rashidian" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-05-18 04:05:40 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Andersson-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-18 04:05:40 +0200" MODIFIED_BY="[Empty name]">
<P>Uncontrolled after
-only study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-18 04:05:44 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ashworth-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-18 04:05:44 +0200" MODIFIED_BY="[Empty name]">
<P>Uncontrolled after
-only study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:28:48 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Bain-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:28:48 +0200" MODIFIED_BY="Arash Rashidian">
<P>After-only study without control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Baines-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cross-sectional</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Baines-1997b">
<CHAR_REASON_FOR_EXCLUSION>
<P>No baseline data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:29:12 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Bateman-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:29:12 +0200" MODIFIED_BY="Arash Rashidian">
<P>Observational study/ No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-28 08:42:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bergstr_x00f6_m-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-28 08:42:23 +0100" MODIFIED_BY="[Empty name]">
<P>Qualitative case study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-30 10:23:35 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bhargava-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-30 10:23:35 +0200" MODIFIED_BY="[Empty name]">
<P>No relevant intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-30 10:23:42 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bhatti-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-30 10:23:42 +0200" MODIFIED_BY="[Empty name]">
<P>No relevant intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-28 09:02:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Black--2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-28 09:02:14 +0100" MODIFIED_BY="[Empty name]">
<P>No relevant intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:29:31 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Bryant-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:29:31 +0200" MODIFIED_BY="Arash Rashidian">
<P>Type of study (descriptive) and type of intervention (no explicit financial incentive for prescribers)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:29:40 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Campbell-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:29:40 +0200" MODIFIED_BY="Arash Rashidian">
<P>Uncontolled before-after study; too few data points</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:29:47 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Campbell-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:29:47 +0200" MODIFIED_BY="Arash Rashidian">
<P>Uncontolled before-after study; too few data points</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:29:56 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Chang-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:29:56 +0200" MODIFIED_BY="Arash Rashidian">
<P>Uncontolled before-after study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-28 08:43:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-28 08:43:08 +0100" MODIFIED_BY="[Empty name]">
<P>No appropriate control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:30:09 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Chernew-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:30:09 +0200" MODIFIED_BY="Arash Rashidian">
<P>No baseline/ No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:30:20 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Chou-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:30:20 +0200" MODIFIED_BY="Arash Rashidian">
<P>Before-after study without a "no intervention" control group; not enough data for re-analysis as an ITS study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-30 10:31:02 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chu-2008b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-30 10:31:02 +0200" MODIFIED_BY="[Empty name]">
<P>No appropriate control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-15 11:47:54 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chu-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-15 11:47:54 +0200" MODIFIED_BY="[Empty name]">
<P>No relevant intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-27 13:34:52 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chung-2010a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-27 13:34:52 +0200" MODIFIED_BY="[Empty name]">
<P>No baseline data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:30:39 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Chung-2010b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:30:39 +0200" MODIFIED_BY="Arash Rashidian">
<P>Before-after study without "no intervention" control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:30:43 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Coulter-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:30:43 +0200" MODIFIED_BY="Arash Rashidian">
<P>No adequate control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-28 08:45:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Curttis-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-28 08:45:55 +0100" MODIFIED_BY="[Empty name]">
<P>Not a primary study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:31:01 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Danzon-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:31:01 +0200" MODIFIED_BY="Arash Rashidian">
<P>Multiple interventions measured simultaneously; effects of drug budgets cannot be extracted separately</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-28 08:46:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Delmar-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-28 08:46:15 +0100" MODIFIED_BY="[Empty name]">
<P>Not a primary study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-15 11:53:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Doshi-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-15 11:53:32 +0200" MODIFIED_BY="[Empty name]">
<P>Not enough available data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-27 13:04:14 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dusheiko-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-27 13:04:14 +0200" MODIFIED_BY="[Empty name]">
<P>No relevant outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Edgar-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>No baseline data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-27 12:38:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Elhayany-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-27 12:38:48 +0200" MODIFIED_BY="[Empty name]">
<P>No relevant intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:31:20 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Elliott-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:31:20 +0200" MODIFIED_BY="Arash Rashidian">
<P>Uncontrolled before-after study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:31:27 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Etter-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:31:27 +0200" MODIFIED_BY="Arash Rashidian">
<P>2 interventions at the same time not possible with outcomes of the budget cap intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:31:34 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Fear-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:31:34 +0200" MODIFIED_BY="Arash Rashidian">
<P>Evaluated only a pre-fund-holding pilot project with no real incentives</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-15 11:56:28 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hespanhol-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-15 11:56:28 +0200" MODIFIED_BY="[Empty name]">
<P>No relevant intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:31:49 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Hoffman-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:31:49 +0200" MODIFIED_BY="Arash Rashidian">
<P>Uncontrolled before-after study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:31:54 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Hoopmann-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:31:54 +0200" MODIFIED_BY="Arash Rashidian">
<P>Cross-sectional</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:32:01 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Houghton-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:32:01 +0200" MODIFIED_BY="Arash Rashidian">
<P>Some providers had received the intervention at baseline, before the study started</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:32:15 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Howie-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:32:15 +0200" MODIFIED_BY="Arash Rashidian">
<P>Evaluates a "shadow fund-holding" project, pre-fund-holding; overlaps with the start of real fund-holding</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:32:21 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Jacobson-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:32:21 +0200" MODIFIED_BY="Arash Rashidian">
<P>Before-only study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:32:29 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-J_x00fc_nger-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:32:29 +0200" MODIFIED_BY="Arash Rashidian">
<P>Uncontrolled before-after study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-28 08:47:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaestner-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-28 08:47:20 +0100" MODIFIED_BY="[Empty name]">
<P>No relevant intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-27 12:36:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kammerling-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-27 12:36:50 +0200" MODIFIED_BY="[Empty name]">
<P>No relevant outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-30 10:37:39 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Landon-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-30 10:37:39 +0200" MODIFIED_BY="[Empty name]">
<P>No relevant intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-30 10:38:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-30 10:38:48 +0200" MODIFIED_BY="[Empty name]">
<P>No relevant outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-28 08:47:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-28 08:47:45 +0100" MODIFIED_BY="[Empty name]">
<P>No relevant intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:32:52 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Ling-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:32:52 +0200" MODIFIED_BY="Arash Rashidian">
<P>Uncontrolled before-after study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-28 09:09:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-28 09:09:21 +0100" MODIFIED_BY="[Empty name]">
<P>No relevant intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:33:00 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Malcolm-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:33:00 +0200" MODIFIED_BY="Arash Rashidian">
<P>Uncontrolled before-after study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:33:06 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Malcolm-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:33:06 +0200" MODIFIED_BY="Arash Rashidian">
<P>Uncontrolled before-after study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:33:14 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Maxwell-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:33:14 +0200" MODIFIED_BY="Arash Rashidian">
<P>Evaluates a "shadow fund-holding" project, pre-fund-holding; overlaps with the start of real fund-holding</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-15 12:04:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maynard-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-15 12:04:33 +0200" MODIFIED_BY="[Empty name]">
<P>Not a primary study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:33:24 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Millet-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:33:24 +0200" MODIFIED_BY="Arash Rashidian">
<P>Uncontrolled before-after study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-15 12:05:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mossalios-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-15 12:05:19 +0200" MODIFIED_BY="[Empty name]">
<P>Not a primary study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:33:32 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Newton-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:33:32 +0200" MODIFIED_BY="Arash Rashidian">
<P>After-only study without control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:33:47 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-O_x0027_Malley-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:33:47 +0200" MODIFIED_BY="Arash Rashidian">
<P>Not enough data; financial pay for performance incentive is supported by a pharmacist detailing programme</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:33:53 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Ohlsson-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:33:53 +0200" MODIFIED_BY="Arash Rashidian">
<P>After-only study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-28 09:02:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peabody-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-28 09:02:32 +0100" MODIFIED_BY="[Empty name]">
<P>No relevant outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-28 09:00:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prokes-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-28 09:00:22 +0100" MODIFIED_BY="[Empty name]">
<P>No relevant intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-15 12:05:58 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sakshaug-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-15 12:05:58 +0200" MODIFIED_BY="[Empty name]">
<P>No relevant intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 16:46:18 +0100" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Schmidt-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 16:46:18 +0100" MODIFIED_BY="Arash Rashidian">
<P>No control group and no time series data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:34:21 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Schrey_x00f6_gg-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:34:21 +0200" MODIFIED_BY="Arash Rashidian">
<P>Inappropriate selection of time series design to assess effect, as the time series was strongly influenced by historical events (Germany reunification)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:34:27 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Schrey_x00f6_gg-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:34:27 +0200" MODIFIED_BY="Arash Rashidian">
<P>Inappropriate selection of time series design to assess effect, as the time series was strongly influenced by historical events (Germany reunification)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:34:33 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Trifirio-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:34:33 +0200" MODIFIED_BY="Arash Rashidian">
<P>Uncontrolled before-after study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:34:44 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Whynes-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:34:44 +0200" MODIFIED_BY="Arash Rashidian">
<P>Innappropriate selection of research design; intervention groups are at different stages of fund-holding<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-22 12:34:50 +0200" MODIFIED_BY="Arash Rashidian" STUDY_ID="STD-Whynes-1997b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-22 12:34:50 +0200" MODIFIED_BY="Arash Rashidian">
<P>After-only study without control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-28 09:00:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-28 09:00:45 +0100" MODIFIED_BY="[Empty name]">
<P>No relevant intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ITS: Interrupted time series</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-04-29 10:09:52 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2015-04-29 10:06:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chang-2013">
<CHAR_METHODS MODIFIED="2015-04-29 10:06:19 +0200" MODIFIED_BY="[Empty name]">
<P>Not yet assessed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-04-29 10:06:36 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harrison-2014">
<CHAR_METHODS MODIFIED="2015-04-29 10:06:36 +0200" MODIFIED_BY="[Empty name]">
<P>Not yet assessed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-04-29 10:06:38 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kontopantelis-2013">
<CHAR_METHODS MODIFIED="2015-04-29 10:06:38 +0200" MODIFIED_BY="[Empty name]">
<P>Not yet assessed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-04-29 10:06:40 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kristensen-2014">
<CHAR_METHODS MODIFIED="2015-04-29 10:06:40 +0200" MODIFIED_BY="[Empty name]">
<P>Not yet assessed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-04-29 10:06:44 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2014">
<CHAR_METHODS MODIFIED="2015-04-29 10:06:44 +0200" MODIFIED_BY="[Empty name]">
<P>Not yet assessed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-04-29 10:06:46 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-MacBride_x002d_Stewart-2008">
<CHAR_METHODS MODIFIED="2015-04-29 10:06:46 +0200" MODIFIED_BY="[Empty name]">
<P>Not yet assessed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-04-29 10:06:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Naomh-Gallagher-2012">
<CHAR_METHODS MODIFIED="2015-04-29 10:06:48 +0200" MODIFIED_BY="[Empty name]">
<P>Not yet assessed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-04-29 10:09:52 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Park-2014">
<CHAR_METHODS MODIFIED="2015-04-29 10:09:52 +0200" MODIFIED_BY="[Empty name]">
<P>Not yet assessed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-04-29 10:06:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2014">
<CHAR_METHODS MODIFIED="2015-04-29 10:06:50 +0200" MODIFIED_BY="[Empty name]">
<P>Not yet assessed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-04-29 10:06:52 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2014">
<CHAR_METHODS MODIFIED="2015-04-29 10:06:52 +0200" MODIFIED_BY="[Empty name]">
<P>Not yet assessed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-05-26 10:36:26 +0200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-05-22 12:26:20 +0200" MODIFIED_BY="Arash Rashidian" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-23 10:20:35 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Baines-1997c">
<DESCRIPTION>
<P>Random allocation was not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-23 10:22:18 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bradlow-1993">
<DESCRIPTION>
<P>Random allocation was not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-23 10:22:29 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Burr-1992">
<DESCRIPTION>
<P>Random allocation was not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:41 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Chou-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-23 10:22:48 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chu-2008">
<DESCRIPTION>
<P>Random allocation was not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-23 10:22:58 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Corney-1997">
<DESCRIPTION>
<P>Random allocation was not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:10 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Doran-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-23 10:23:17 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Granlund-2006">
<DESCRIPTION>
<P>Random allocation was not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Guether-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:07 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Harris-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-23 10:23:29 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Martens-2007">
<DESCRIPTION>
<P>Random allocation was not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:49 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Rafferty-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sch_x00f6_ffski-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:24 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Serumaga-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:41 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Walley--2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-23 10:23:43 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Whynes-1997">
<DESCRIPTION>
<P>Random allocation was not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:20 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-23 10:23:57 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wilson-1999">
<DESCRIPTION>
<P>Random allocation was not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-05-22 12:26:41 +0200" MODIFIED_BY="Arash Rashidian" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-23 10:25:14 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Baines-1997c">
<DESCRIPTION>
<P>This is a CBA study without adequate allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:54 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Bradlow-1993">
<DESCRIPTION>
<P>This was a CBA study without adequate allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:14 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Burr-1992">
<DESCRIPTION>
<P>This was a CBA study without adequate allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Chou-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:15 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Chu-2008">
<DESCRIPTION>
<P>This was a CBA study without adequate allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:46 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Corney-1997">
<DESCRIPTION>
<P>This was a CBA study without adequate allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:10 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Doran-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:28 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Granlund-2006">
<DESCRIPTION>
<P>This was a CBA study without adequate allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Guether-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:08 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Harris-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:27 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Martens-2007">
<DESCRIPTION>
<P>This was a CBA study without adequate allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:49 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Rafferty-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sch_x00f6_ffski-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:24 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Serumaga-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:41 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Walley--2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:00 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Whynes-1997">
<DESCRIPTION>
<P>This was a CBA study without adequate allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:20 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:41 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Wilson-1999">
<DESCRIPTION>
<P>This was a CBA study without adequate allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" NO="10">
<NAME>Baseline outcome measurements</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:31 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Baines-1997c">
<DESCRIPTION>
<P>Prescribing costs were measured as net ingredient costs per patient before the intervention among fund-holders and non-fund-holders in Lincolnshire and Devon. Results show a difference between the non-fund-holding group and other groups in prescribing per patient during 1990 to 1991 (before the intervention)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:54 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Bradlow-1993">
<DESCRIPTION>
<P>In both intervention and control groups, the number of items prescribed and the cost per item prescribed were measured before the intervention, and no important differences were noted across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:14 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Burr-1992">
<DESCRIPTION>
<P>Costs per 1000 patients were measured in both intervention and control groups. No important differences between outcomes were noted among fund-holder and general practitioner groups before the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Chou-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:15 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Chu-2008">
<DESCRIPTION>
<P>Drug costs and numbers of prescriptions were measured in 1999 to 2000 before the drug reimbursement rate reduction policy was applied in hospitals with and without physician fee programmes. However this was not mentioned exactly in the text. Data delivered in tables showed small differences in baseline data between the 2 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:47 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Corney-1997">
<DESCRIPTION>
<P>Same baseline outcomes were collected from both fund-holding and non-fund-holding groups before the intervention (same questionnaires, costs per prescribing unit, ...). With costs per prescribing unit under consideration, costs of first-wave fund-holders were lower than those of non-fund-holders, and this differential remained unchanged over the 4 years of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:10 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Doran-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:28 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Granlund-2006">
<DESCRIPTION>
<P>Prescription patterns including prices and quantities at treatment health centres (average price per defined daily dose and average number of DDDs per prescription) were measured before implementation of a fixed budget. However this was not mentioned exactly in the text. Data were delivered in tables showing small differences in baseline data between the 2 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Guether-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:08 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Harris-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:27 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Martens-2007">
<DESCRIPTION>
<P>Same outcomes were measured before intervention in both control and intervention groups (number of prescriptions per 1000 patients per GP). However this was not mentioned exactly in the text. Data that were presented in tables show small differences in baseline data between the 2 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:49 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Rafferty-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sch_x00f6_ffski-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:24 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Serumaga-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:41 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Walley--2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:00 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Whynes-1997">
<DESCRIPTION>
<P>In both control and intervention groups, costs per patient were assessed at the baseline period. No important differences in outcome measurements were noted before the fund-holding scheme</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:21 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Wilson-1999">
<DESCRIPTION>
<P>Prescribing patterns were measured before the intervention. No important differences in outcomes were noted before the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" NO="12">
<NAME>Baseline characteristics</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:31 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Baines-1997c">
<DESCRIPTION>
<P>Fund-holders and non-fund-holders in Lincolnshire and Devon were compared, and no matching process was done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:54 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Bradlow-1993">
<DESCRIPTION>
<P>Baseline characteristics of fund-holding and non-fund-holding practices were not similar, and no matching was mentioned in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:14 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Burr-1992">
<DESCRIPTION>
<P>No data were reported in the article about fund-holder and GP characteristics before the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Chou-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:15 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Chu-2008">
<DESCRIPTION>
<P>Characteristics were not reported in text or in tables, and evidence did not show whether differences between controls and hospitals were apparent in physician fee programmes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:47 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Corney-1997">
<DESCRIPTION>
<P>Fund-holder and non-fund-holder groups with different characteristics were compared</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:10 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Doran-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:28 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Granlund-2006">
<DESCRIPTION>
<P>Matching with control group at both health centres was done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Guether-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:08 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Harris-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:27 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Martens-2007">
<DESCRIPTION>
<P>Participants in control and intervention groups were GPs in 2 regions of the Netherlands, and were members of the Dutch Society of General Practitioners. Therefore, it can be assumed that both groups were adequately similar</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:49 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Rafferty-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sch_x00f6_ffski-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:24 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Serumaga-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:41 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Walley--2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:00 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Whynes-1997">
<DESCRIPTION>
<P>No report described baseline characteristics in text or in tables or indicated whether differences between fund-holders and non-fund-holders affected the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:21 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Wilson-1999">
<DESCRIPTION>
<P>The third and fourth waves of fund-holding practices were compared with those of matched non-fund-holding practices; no differences were found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-22 12:20:31 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Baines-1997c">
<DESCRIPTION>
<P>No discussion was provided in the text about missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-22 12:20:54 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Bradlow-1993">
<DESCRIPTION>
<P>No important missing data were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-22 12:21:14 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Burr-1992">
<DESCRIPTION>
<P>This was not specified in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-22 12:21:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Chou-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-22 12:22:15 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Chu-2008">
<DESCRIPTION>
<P>Incomplete outcome data were addressed adequately in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-22 12:22:47 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Corney-1997">
<DESCRIPTION>
<P>Missing data were addressed in the Results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-22 12:23:10 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Doran-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-04-23 10:30:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Granlund-2006">
<DESCRIPTION>
<P>6% of observations with missing data were excluded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Guether-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-22 12:24:08 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Harris-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-22 12:24:27 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Martens-2007">
<DESCRIPTION>
<P>It was mentioned that if any data were missing, they were equally distributed over intervention and control groups, so this had no effect on the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-22 12:24:49 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Rafferty-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Sch_x00f6_ffski-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-22 12:25:24 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Serumaga-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-22 12:25:41 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Walley--2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-22 12:26:01 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Whynes-1997">
<DESCRIPTION>
<P>This was not mentioned in the text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-22 12:26:21 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1999">
<DESCRIPTION>
<P>No obvious data about missing outcomes can be found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-14" LEVEL="STUDY" MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" NO="14">
<NAME>Knowledge of the allocated interventions adequately prevented during the study</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:31 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Baines-1997c">
<DESCRIPTION>
<P>Study authors did not identify whether outcomes were assessed blindly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:54 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Bradlow-1993">
<DESCRIPTION>
<P>It is not clear whether primary outcomes were assessed blindly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:14 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Burr-1992">
<DESCRIPTION>
<P>Primary outcomes were assessed blindly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Chou-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:15 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Chu-2008">
<DESCRIPTION>
<P>Study authors did not specify whether drug costs and other outcomes were assessed blindly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:47 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Corney-1997">
<DESCRIPTION>
<P>Study authors did not specify in the paper whether outcomes were assessed blindly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:10 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Doran-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:28 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Granlund-2006">
<DESCRIPTION>
<P>No blind assessments were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Guether-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:08 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Harris-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:28 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Martens-2007">
<DESCRIPTION>
<P>It was not mentioned whether data were assessed blindly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:49 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Rafferty-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sch_x00f6_ffski-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:24 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Serumaga-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:41 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Walley--2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:01 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Whynes-1997">
<DESCRIPTION>
<P>No data were provided to clarify whether primary outcome variables were assessed blindly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:21 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1999">
<DESCRIPTION>
<P>It is not specified whether outcomes were assessed blindly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-15" LEVEL="STUDY" MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" NO="15">
<NAME>Protection against contamination</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:32 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Baines-1997c">
<DESCRIPTION>
<P>Control groups consisted of non-fund-holders before the introduction of fund-holding; no possibility of contamination</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:54 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Bradlow-1993">
<DESCRIPTION>
<P>Reforms affected only the intervention group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:14 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Burr-1992">
<DESCRIPTION>
<P>The policy affected only the intervention group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Chou-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:15 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Chu-2008">
<DESCRIPTION>
<P>In the control group, hospitals had no physician fee programme and prescribing happened with no drug reimbursement rate reduction policy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:47 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Corney-1997">
<DESCRIPTION>
<P>It is not likely that non-fund-holders as the control group received the intervention before and after the fund-holding scheme</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:10 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Doran-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:28 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Granlund-2006">
<DESCRIPTION>
<P>Both Burtrask and Morobacke health centres were assessed before fixed budgets were introduced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Guether-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:08 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Harris-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:28 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Martens-2007">
<DESCRIPTION>
<P>The contrast between groups consisted of receiving the financial incentive and</P>
<P>being aware of the performance being checked</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:49 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Rafferty-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sch_x00f6_ffski-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:24 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Serumaga-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:41 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Walley--2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:01 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Whynes-1997">
<DESCRIPTION>
<P>Control group did not receive the intervention policy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:21 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Wilson-1999">
<DESCRIPTION>
<P>Non-fund-holders were clear of the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-16" LEVEL="STUDY" MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" NO="16">
<NAME>Selective outcome reporting (reporting bias)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-27 20:11:30 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Baines-1997c">
<DESCRIPTION>
<P>Missing data were not mentioned in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-27 20:11:15 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Bradlow-1993">
<DESCRIPTION>
<P>All related outcome data were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:14 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Burr-1992">
<DESCRIPTION>
<P>This was not specified in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Chou-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:24 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Chu-2008">
<DESCRIPTION>
<P>Prescribing rates and drug costs were reported adequately</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:47 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Corney-1997">
<DESCRIPTION>
<P>It was not specified in the paper whether any evidence suggests that outcomes were selectively reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:10 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Doran-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:28 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Granlund-2006">
<DESCRIPTION>
<P>All data about prescribing quality and quantity were reported in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Guether-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:08 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Harris-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-27 20:09:01 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Martens-2007">
<DESCRIPTION>
<P>All related data were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:49 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Rafferty-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sch_x00f6_ffski-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:24 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Serumaga-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:41 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Walley--2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:01 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Whynes-1997">
<DESCRIPTION>
<P>All prescribing data were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:21 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Wilson-1999">
<DESCRIPTION>
<P>All prescribing data such as costs, volume and&#8230; were adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-17" LEVEL="STUDY" MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" NO="17">
<NAME>Other risks of bias</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:32 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Baines-1997c">
<DESCRIPTION>
<P>It is not clear whether the study was free of other risks of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:54 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Bradlow-1993">
<DESCRIPTION>
<P>It is not clear whether the study was free of other risks of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:14 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Burr-1992">
<DESCRIPTION>
<P>It was not clear whether the study was free of other risks of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Chou-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:24 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Chu-2008">
<DESCRIPTION>
<P>Physicians could prescribe only drugs listed on their hospital formulary. Hospitals may affect physicians&#8217; prescribing behaviour through drug purchase practices. Therefore, changes in drug items in the formulary may fall beyond the control of most physicians</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-27 20:10:21 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Corney-1997">
<DESCRIPTION>
<P>Not clearly free from other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:10 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Doran-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:34 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Granlund-2006">
<DESCRIPTION>
<P>Other risk of bias was possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Guether-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:08 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Harris-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:28 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Martens-2007">
<DESCRIPTION>
<P>Not clearly free of other risks of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:49 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Rafferty-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sch_x00f6_ffski-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:24 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Serumaga-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:41 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Walley--2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:01 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Whynes-1997">
<DESCRIPTION>
<P>It was not clear whether the study was affected by other risks of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:21 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1999">
<DESCRIPTION>
<P>The matching process could not account for all possible confounders and may even have introduced some confounders</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-18" LEVEL="STUDY" MODIFIED="2015-05-26 10:36:26 +0200" MODIFIED_BY="[Empty name]" NO="18">
<NAME>Intervention independent of other changes (ITS)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:32 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Baines-1997c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:54 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Bradlow-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:14 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Burr-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Chou-2008">
<DESCRIPTION>
<P>National Health Insurance (NHI) global budget (GB) programme will be associated with other effective changes during the study period</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:15 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Chu-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:47 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Corney-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:10 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Doran-2011">
<DESCRIPTION>
<P>Achievement rates as an outcome were affected only by intervention (quality and outcomes frameworks); the role of other changes did not seem to be substantial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:28 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Granlund-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 11:32:34 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Guether-1995">
<DESCRIPTION>
<P>Several policies introduced simultaneously (for example reference pricing and copayments)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:08 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Harris-1996">
<DESCRIPTION>
<P>Interventions did not occur independently. Thus other changes would affect outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:28 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Martens-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:49 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Rafferty-1997">
<DESCRIPTION>
<P>Outcomes such as prescribing patterns seem be affected by changes over time</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 11:37:33 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Sch_x00f6_ffski-1997">
<DESCRIPTION>
<P>Results and outcomes were influenced by other confounding factors, not only by drug budgets.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:24 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Serumaga-2011">
<DESCRIPTION>
<P>Outcomes would be influenced by various confounding factors during the years, not only pay for performance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-26 10:36:26 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Walley--2000">
<DESCRIPTION>
<P>The Indicative Drug Target Savings Scheme (IDTSS) was not the only factor that influenced outcomes. Several factors affected the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:01 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Whynes-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:21 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Wilson-1995">
<DESCRIPTION>
<P>Outcomes were influenced by other variables during study periods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-19" LEVEL="STUDY" MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" NO="19">
<NAME>Shape of the intervention effect pre-specified (ITS)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:32 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Baines-1997c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:54 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Bradlow-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:14 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Burr-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-27 20:10:54 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Chou-2008">
<DESCRIPTION>
<P>The point of analysis is not the point of intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:15 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Chu-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:47 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Corney-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:10 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Doran-2011">
<DESCRIPTION>
<P>It was not clear whether the point of intervention and the point of analysis were similar</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:28 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Granlund-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 11:38:47 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Guether-1995">
<DESCRIPTION>
<P>Similar point of intervention and analysis. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:08 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Harris-1996">
<DESCRIPTION>
<P>The intervention point seemed similar to the analysis point</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:28 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Martens-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:49 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Rafferty-1997">
<DESCRIPTION>
<P>The shape of the intervention effect was defined clearly by study authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 11:37:33 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Sch_x00f6_ffski-1997">
<DESCRIPTION>
<P>The point of intervention and the point of analysis were similar</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:24 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Serumaga-2011">
<DESCRIPTION>
<P>Point of intervention and point of analysis were the same</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:41 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Walley--2000">
<DESCRIPTION>
<P>The shape of the intervention effect was defined clearly by the study authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:01 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Whynes-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:21 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Wilson-1995">
<DESCRIPTION>
<P>The point of analysis and the point of intervention were similar</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-20" LEVEL="STUDY" MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" NO="20">
<NAME>Intervention unlikely to affect data collection (ITS)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:32 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Baines-1997c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:54 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Bradlow-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:14 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Burr-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Chou-2008">
<DESCRIPTION>
<P>Data collection method was the same before and after the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:15 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Chu-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:47 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Corney-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:10 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Doran-2011">
<DESCRIPTION>
<P>Both before-intervention and after-intervention data were collected from the General Practice Research Database (GPRD)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:28 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Granlund-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 11:39:01 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Guether-1995">
<DESCRIPTION>
<P>Routine data sources of similar origins were used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:08 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Harris-1996">
<DESCRIPTION>
<P>In before-intervention and after-intervention periods, methods of data collection were the same (Prescription Pricing Authority)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:28 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Martens-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:49 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Rafferty-1997">
<DESCRIPTION>
<P>In all periods of the study, data were collected from the database built from data downloaded from the Central Services Agency, whose system was designed for reimbursing pharmacists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-27 20:08:13 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Sch_x00f6_ffski-1997">
<DESCRIPTION>
<P>The same data bank was used for data gathering before and after drug budget implementation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-27 20:07:57 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Serumaga-2011">
<DESCRIPTION>
<P>The intervention itself was not likely to affect data collection</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:41 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Walley--2000">
<DESCRIPTION>
<P>Methods of data gathering and resources were the same before and after the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:01 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Whynes-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:21 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Wilson-1995">
<DESCRIPTION>
<P>The prescribing analysis and cost (PACT) data were used before and after the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-21" LEVEL="STUDY" MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" NO="21">
<NAME>Knowledge of the allocated interventions adequately prevented during the study (ITS)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:32 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Baines-1997c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:54 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Bradlow-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:14 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Burr-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Chou-2008">
<DESCRIPTION>
<P>It was not mentioned whether main outcomes were assessed blindly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:15 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Chu-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:47 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Corney-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:10 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Doran-2011">
<DESCRIPTION>
<P>Analyses were performed blindly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:28 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Granlund-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 11:39:27 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Guether-1995">
<DESCRIPTION>
<P>Unlike to affect the analysis in this study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:08 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Harris-1996">
<DESCRIPTION>
<P>Primary outcome variables were assessed blindly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:28 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Martens-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:49 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Rafferty-1997">
<DESCRIPTION>
<P>Analysis of primary outcome measures was done blindly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 11:37:33 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Sch_x00f6_ffski-1997">
<DESCRIPTION>
<P>Primary outcomes: Numbers of referrals and hospital admissions were assessed blindly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:24 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Serumaga-2011">
<DESCRIPTION>
<P>Primary outcomes were objective: systolic and diastolic blood pressures over time, rates of blood pressure monitoring, blood pressure control</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Walley--2000">
<DESCRIPTION>
<P>Outcomes were not objective, but the primary outcome variables were assessed blindly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:01 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Whynes-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-27 19:57:44 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Wilson-1995">
<DESCRIPTION>
<P>Primary outcomes were assessed blindly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-22" LEVEL="STUDY" MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" NO="22">
<NAME>Incomplete outcome data adequately addressed (ITS)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:32 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Baines-1997c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:54 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Bradlow-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:14 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Burr-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Chou-2008">
<DESCRIPTION>
<P>No information was provided about the effects of missing outcome data on results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:15 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Chu-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:47 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Corney-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:10 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Doran-2011">
<DESCRIPTION>
<P>Missing outcome data were likely to bias the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:28 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Granlund-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 11:40:52 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Guether-1995">
<DESCRIPTION>
<P>Few data points might have affected the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:08 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Harris-1996">
<DESCRIPTION>
<P>No data were available to show the incomplete outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:28 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Martens-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:49 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Rafferty-1997">
<DESCRIPTION>
<P>No evidence showed whether missing data affected the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 11:37:33 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Sch_x00f6_ffski-1997">
<DESCRIPTION>
<P>Missing outcome data were not clearly addressed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:24 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Serumaga-2011">
<DESCRIPTION>
<P>Missing outcome data were not mentioned by study authors in the article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Walley--2000">
<DESCRIPTION>
<P>It was not clear whether all missing outcomes measures were similar before and after intervention periods, and this was unlikely to bias the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:01 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Whynes-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:21 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Wilson-1995">
<DESCRIPTION>
<P>Missing outcome data in full text were addressed and seem to have not affected the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-23" LEVEL="STUDY" MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" NO="23">
<NAME>Selective outcome reporting (ITS)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:32 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Baines-1997c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:54 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Bradlow-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:14 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Burr-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:58 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Chou-2008">
<DESCRIPTION>
<P>Prescription trends of the before-GB and after-GB periods for patients with hypertension and diabetes mellitus and costs were clearly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:16 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Chu-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:47 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Corney-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:10 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Doran-2011">
<DESCRIPTION>
<P>No evidence of selective data reporting was found; all related data were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:29 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Granlund-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 11:41:08 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Guether-1995">
<DESCRIPTION>
<P>No evidence of selective outcome reporting was observed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:08 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Harris-1996">
<DESCRIPTION>
<P>Relative outcome results were adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:28 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Martens-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:49 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Rafferty-1997">
<DESCRIPTION>
<P>All related outcome measures were reported in the Results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 11:36:50 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Sch_x00f6_ffski-1997">
<DESCRIPTION>
<P>Outcomes in the methods were similar to outcomes reported in the Results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:24 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Serumaga-2011">
<DESCRIPTION>
<P>Related outcomes were reported clearly after analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Walley--2000">
<DESCRIPTION>
<P>All relative outcomes were reported in the Results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:01 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Whynes-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:21 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Wilson-1995">
<DESCRIPTION>
<P>All outcomes were given in the Methods and were reported in the Results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-24" LEVEL="STUDY" MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" NO="24">
<NAME>Other risks of bias (ITS)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:32 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Baines-1997c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:20:54 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Bradlow-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:15 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Burr-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:21:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Chou-2008">
<DESCRIPTION>
<P>Claims data were constructed principally</P>
<P>for reimbursement purposes. As a result, financial incentives influenced the patient's diagnosis included in the medical claims. This fact could change our average cost per patient, but not the total costs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:16 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Chu-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:22:47 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Corney-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:10 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Doran-2011">
<DESCRIPTION>
<P>Changes in case mix over time might have affected achievement rates, particularly if changes in case finding activity occurred under the incentive scheme</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:23:29 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Granlund-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 11:41:26 +0200" MODIFIED_BY="Arash Rashidian" RESULT="YES" STUDY_ID="STD-Guether-1995">
<DESCRIPTION>
<P>No evidence of other risks of biases affecting the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:08 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Harris-1996">
<DESCRIPTION>
<P>It is possible that fund-holding practices gave their patients private prescriptions more often than did non-fund-holders when the cost to the patient was lower than the prescription charge. Non-fund-holding practices as comparators may differ in many ways from fund-holding practices and have undergone different kinds of changes over the 6 years</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:28 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Martens-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:24:49 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Rafferty-1997">
<DESCRIPTION>
<P>The study will contain other risks of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 11:37:07 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Sch_x00f6_ffski-1997">
<DESCRIPTION>
<P>The referral system was changed in 1994 to 1995 by introducing a credit card-like voucher called "Chip Card", which changed referral registration and behaviour again. As the result of missing data and fluctuations in the data bank, only physicians for whom complete data were available for both corresponding months in 1992 and 1993 were included. This means that the data bank was reduced to matched pairs for each month, covering between 309 and 382 physicians</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:24 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Serumaga-2011">
<DESCRIPTION>
<P>Interventions were implemented in all 4 UK countries and had no suitable comparison group. Therefore researchers were not able to follow similar populations for which these interventions were not implemented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:25:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Walley--2000">
<DESCRIPTION>
<P>More effects than interventions should have influenced reported outcomes. It was not mentioned whether all prescribers were blind to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:01 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Whynes-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:21 +0200" MODIFIED_BY="Arash Rashidian" RESULT="NO" STUDY_ID="STD-Wilson-1995">
<DESCRIPTION>
<P>Such incentives focused on cost rather than on cost-effectiveness. Improvements in cost containment must not be made to the detriment of prescribing quality - a point emphasised by local prescribing advisors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-22 12:26:42 +0200" MODIFIED_BY="Arash Rashidian" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-04-23 10:33:43 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-04-23 10:20:18 +0200" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-04-23 10:20:18 +0200" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-04-23 10:20:18 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-04-23 10:20:18 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-05-22 12:40:25 +0200" MODIFIED_BY="Arash Rashidian">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-05-22 12:39:56 +0200" MODIFIED_BY="Arash Rashidian" NO="1">
<TITLE MODIFIED="2014-12-05 17:29:09 +0100" MODIFIED_BY="Arash Rashidian">Summary of findings: drug budget policies</TITLE>
<TABLE COLS="6" ROWS="12">
<TR>
<TD COLSPAN="6">
<P>
<B>People: </B>Physicians/General practitioners/Patients</P>
<P>
<B>Settings (interventions):</B> Germany (collective drug budget "spending caps"), Ireland (Indicative Drug Target Savings Scheme), Sweden (fixed pharmaceutical budget), Taiwan (National Health Insurance Drug Budget Programme), UK (fund-holding)</P>
<P>
<B>Designs:</B> ITS and CITS</P>
<P>
<B>Comparison:</B> no prescribing policies</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Outcomes</B>
</P>
<P>12-month follow-up</P>
</TD>
<TH>
<P>
<B>Impacts - relative changes,</B>
</P>
<P>
<B>Median</B>
</P>
<P>
<B>(range)<SUP>a</SUP>
</B>
</P>
</TH>
<TH>
<P>
<B>Number of</B>
</P>
<P>
<B>studies (comparisons)</B>
</P>
</TH>
<TH>
<P>
<B>Settings</B>
</P>
</TH>
<TH>
<P>
<B>Certainty of the evidence<SUP>b</SUP>
</B>
</P>
<P>
<B>(GRADE)<SUP>c</SUP>
</B>
</P>
</TH>
<TH>
<P>
<B>Comments</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Drug use (item per patient or prescription)</P>
</TD>
<TD>
<P>-2.8%<BR/>(-28.9 to 1.5)</P>
</TD>
<TD>
<P>6 (14)</P>
</TD>
<TD>
<P>Germany, Ireland, Taiwan<SUP>d</SUP>, UK</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>It is possible that the intervention results in modest improvements (reductions in items per patient). Findings were relatively consistent in different countries despite differences between interventions</P>
</TD>
</TR>
<TR>
<TD>
<P>Drug use (generic percentage)</P>
</TD>
<TD>
<P>15%<BR/>(-43.7 to 190.5)</P>
</TD>
<TD>
<P>2 (6)</P>
</TD>
<TD>
<P>UK</P>
</TD>
<TD>
<P>Very low</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Costs per item</P>
</TD>
<TD>
<P>-25.6%</P>
<P>(-49.2 to 0.6)</P>
</TD>
<TD>
<P>3 (6)</P>
</TD>
<TD>
<P>Ireland, UK</P>
</TD>
<TD>
<P>Very low</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Costs per patient or prescription</P>
</TD>
<TD>
<P>-2.5%</P>
<P>(-79.7 to 66.8)</P>
</TD>
<TD>
<P>4 (11)</P>
</TD>
<TD>
<P>Taiwan<SUP>d</SUP>, UK</P>
</TD>
<TD>
<P>Very low</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Total costs</P>
</TD>
<TD>
<P>-38.9%</P>
<P>(-69.6 to -1.8)</P>
</TD>
<TD>
<P>2 (4)</P>
</TD>
<TD>
<P>Ireland, UK</P>
</TD>
<TD>
<P>Very low</P>
</TD>
<TD>
<P>Although the findings from 2 countries are consistent, both studies suffer from too few data points</P>
</TD>
</TR>
<TR>
<TD>
<P>Healthcare utilisation (referral to outpatient specialists)</P>
</TD>
<TD>
<P>-1.1%</P>
<P>(-15.4 to 13.2)</P>
</TD>
<TD>
<P>2 (2)</P>
</TD>
<TD>
<P>Germany</P>
</TD>
<TD>
<P>Very low</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Health outcomes</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<SUP>a</SUP>Note: Presented results are medians (ranges) of results of individual studies; no meta-analyses were performed.</P>
<P>
<SUP>b</SUP>All included ITS studies suffer from too few data points.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<SUP>c</SUP>GRADE Working Group grades of evidence.</P>
<P>
<B>High: </B>It is very likely that the effect will be close to what was found in the research.</P>
<P>
<B>Moderate: </B>It is likely that the effect will be close to what was found in the research, but it may be substantially different.</P>
<P>
<B>Low:</B> It is likely that the effect will be substantially different from what was found in the research, but the research provides an indication of what might be expected.</P>
<P>
<B>Very low:</B> The anticipated effect is very uncertain, and the research does not provide a reliable indication of what might be expected.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<SUP>d</SUP>From Taiwan, only 1 estimate was used in calculating the median, as 2 available estimates were based on 1 intervention assessed in the study.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CITS: controlled interrupted time series; ITS: interrupted time series.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2015-05-22 12:40:25 +0200" MODIFIED_BY="Arash Rashidian" NO="2">
<TITLE MODIFIED="2014-12-05 17:28:24 +0100" MODIFIED_BY="Arash Rashidian">Summary of findings: pay for performance policies</TITLE>
<TABLE COLS="6" ROWS="7">
<TR>
<TD COLSPAN="6">
<P>
<B>People: </B>Physicians/General practitioners/Patients</P>
<P>
<B>Settings (interventions):</B> UK (pay for performance)</P>
<P>
<B>Designs:</B> ITS and CITS</P>
<P>
<B>Comparison:</B> no prescribing policies</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Outcomes</B>
</P>
<P>12-month follow-up</P>
</TD>
<TH>
<P>
<B>Impacts - relative changes</B>
</P>
</TH>
<TH>
<P>
<B>Number of</B>
</P>
<P>
<B>studies (comparisons)</B>
</P>
</TH>
<TH>
<P>
<B>Setting</B>
</P>
</TH>
<TH>
<P>
<B>Certainty of the evidence</B>
</P>
<P>
<B>(GRADE)<SUP>a</SUP>
</B>
</P>
</TH>
<TH>
<P>
<B>Comments</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Drug use</P>
</TD>
<TD>
<P>Range 2.5 to 2.6</P>
</TD>
<TD>
<P>1 (2)</P>
</TD>
<TD>
<P>UK</P>
</TD>
<TD>
<P>Very low</P>
</TD>
<TD>
<P>Some negative impact was reported on non-incentivised non-prescribing outcomes</P>
</TD>
</TR>
<TR>
<TD>
<P>Costs</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Healthcare utilisation</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Health outcomes</P>
</TD>
<TD>
<P>Mean -1.49% (95% CI -6.32 to 3.34)</P>
</TD>
<TD>
<P>1 (1)</P>
</TD>
<TD>
<P>UK</P>
</TD>
<TD>
<P>Very low</P>
</TD>
<TD>
<P>1 comparison (percentage of patients with controlled blood pressure) from 1 setting</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<SUP>a</SUP>GRADE Working Group grades of evidence.</P>
<P>
<B>High: </B>It is very likely that the effect will be close to what was found in the research.</P>
<P>
<B>Moderate: </B>It is likely that the effect will be close to what was found in the research, but it may be substantially different.</P>
<P>
<B>Low:</B> It is likely that the effect will be substantially different from what was found in the research, but the research provides an indication of what might be expected.</P>
<P>
<B>Very low:</B> The anticipated effect is very uncertain, and the research does not provide a reliable indication of what might be expected.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2015-05-22 12:50:05 +0200" MODIFIED_BY="Arash Rashidian">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2015-05-22 12:41:14 +0200" MODIFIED_BY="Arash Rashidian" NO="1">
<TITLE MODIFIED="2015-05-22 12:40:52 +0200" MODIFIED_BY="Arash Rashidian">Databases and websites searched for the first version of this review</TITLE>
<TABLE COLS="1" ROWS="4">
<TR>
<TH>
<P>Databases</P>
</TH>
</TR>
<TR>
<TD>
<UL>
<LI>Effective Practice and Organisation of Care Group Register</LI>
<LI>Evidence-Based Medicine (EBM) Reviews, the Cochrane Central Register of Controlled Trials</LI>
<LI>MEDLINE (Ovid)</LI>
<LI>EMBASE (Ovid)</LI>
<LI>CSA Worldwide Political Science Abstracts</LI>
<LI>EconLit WebSPIRS</LI>
<LI>SIGLE, System for Information on Grey Literature in Europe</LI>
<LI>INRUD, International Network for Rational Use of Drugs</LI>
<LI>International Political Science Abstracts</LI>
<LI>NHS EED, National Health Services Economic Evaluation Database, CRD</LI>
<LI>PubMed for relevant journals not indexed in MEDLINE</LI>
<LI>NTIS, National Technical Information</LI>
<LI>PAIS International, Public Affairs Information Service</LI>
<LI>IPA, International Pharmaceutical Abstract</LI>
<LI>Global Jolis</LI>
<LI>JOLIS</LI>
<LI>WHOLIS</LI>
<LI>Institute for Scientific Information (ISI) Web of Science</LI>
</UL>
</TD>
</TR>
<TR>
<TH>
<P>Websites</P>
</TH>
</TR>
<TR>
<TD>
<UL>
<LI>World Bank e-Library</LI>
<LI>WHO (World Health Organization)</LI>
<LI>OECD (Organisation for Economic Co-operation and Development) Publications &amp; Documents</LI>
<LI>SourceOECD</LI>
<LI>World Bank Documents &amp; Reports</LI>
</UL>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2015-05-22 12:42:33 +0200" MODIFIED_BY="Arash Rashidian" NO="2">
<TITLE MODIFIED="2014-01-02 07:11:01 +0100" MODIFIED_BY="[Empty name]">Description of financial incentive policies of the included studies</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TH>
<P>Country</P>
</TH>
<TH>
<P>Policy/Time period</P>
</TH>
<TH>
<P>Motivation</P>
</TH>
<TH>
<P>Setting of budget</P>
</TH>
<TH>
<P>Physician incentives</P>
</TH>
<TH>
<P>Physician disincentives</P>
</TH>
<TH>
<P>Theoretical effects</P>
</TH>
</TR>
<TR>
<TD>
<P>Taiwan</P>
</TD>
<TD>
<P>Drug reimbursement rate reduction, starting in 2000</P>
</TD>
<TD>
<P>Reducing prescription costs</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Physicians earn a share of the revenue that hospitals gain from selling medicines</P>
</TD>
<TD>
<P>Reducing reimbursement rate reduces physicians' tendency to overprescribe</P>
</TD>
<TD>
<P>Fincianal incentives from drug sales affect physician prescribing. Removing this incentive will help to rationalise physician prescribing</P>
</TD>
</TR>
<TR>
<TD>
<P>Taiwan</P>
</TD>
<TD>
<P>National Health Insurance Drug Budget Programme, starting in 2002</P>
</TD>
<TD>
<P>Reducing prescription costs</P>
</TD>
<TD>
<P>Global budget based on an individual expenditure cap</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Maximum expenditure cap</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>UK</P>
</TD>
<TD>
<P>Pay for performance (quality and outcome framework), starting in 2004</P>
</TD>
<TD>
<P>improving quality of care</P>
</TD>
<TD>
<P>NHS committed 1.8 GBP for funding the programme</P>
</TD>
<TD>
<P>Up to 25% increase in physician income (maximum of 31,000 GBP)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Direct financial incentives may result in improved quality of care, including prescribing</P>
</TD>
</TR>
<TR>
<TD>
<P>Sweden</P>
</TD>
<TD>
<P>Fixed pharmaceutical budget, 2000 to 2003</P>
</TD>
<TD>
<P>Controlling prescription drug costs</P>
</TD>
<TD>
<P>Previous year budget and demographic characteristics of patients</P>
</TD>
<TD>
<P>Remaining pharmaceutical budget was given to the health centre and can be used as bonus payment</P>
</TD>
<TD>
<P>Health centre had to repay any extra pharmaceutical expenditures</P>
</TD>
<TD>
<P>Making the health centres 'residual claimants' (i.e. responsible for deficits or surpluses) will directly affect the physicians prescribing. This may happen via reducing the number of prescriptions, reducing DDD per prescription or selecting cheaper alternative pharmaceuticals</P>
</TD>
</TR>
<TR>
<TD>
<P>Netherlands</P>
</TD>
<TD>
<P>Behaviour-independent financial incentive, 2000 to 2002</P>
</TD>
<TD>
<P>Controlling prescription drug costs</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>On-off bonus payment by the insurance company (paid before-hand, irrespective of physician performance)</P>
</TD>
<TD>
<P>The decision to follow the regional formulary was made democratically in the presence of physician representatives and opinion leaders</P>
</TD>
<TD>
<P>Ownership of the decision via participation in development of the formulary and the decision to adopt the formulary via the insurance organisation is likely to improve physician performance towards the target behaviour</P>
</TD>
</TR>
<TR>
<TD>
<P>Germany</P>
</TD>
<TD>
<P>Collective drug budget "spending caps"<BR/>(Health Care Reform Act),<BR/>1993 to 2002<BR/>(formally abolished in 2001)<BR/>
</P>
</TD>
<TD>
<P>Controlling prescription drug costs</P>
</TD>
<TD>
<P>Based on previous regional spending. From 1998: regional net budget =<BR/>gross budget minus co-payments and rebates from industry<BR/>nationally set in 1993, then regionally<BR/>
<BR/>Negotiated between physician associations and statutory health insurances<BR/>
</P>
</TD>
<TD>
<P>None (savings will not be available to physicians)</P>
</TD>
<TD>
<P>Regional physician associations are responsible for overspending (maximum 5% of total budget). Can decline to pay for excess spending and can request it from individual practice</P>
</TD>
<TD>
<P>Reduction in drugs with disputed effect, savings can facilitate use of more expensive drugs, improve quality of prescribing or increase referrals to save (drug budget is independent of other care)</P>
</TD>
</TR>
<TR>
<TD>
<P>Ireland</P>
</TD>
<TD>
<P>IDTSS (Indicative Drug Target Savings Scheme),<BR/>starting in 1993<BR/>
</P>
</TD>
<TD>
<P>Controlling prescription drug costs</P>
</TD>
<TD>
<P>Individual practice budget based on previous spending and national average<BR/>
<BR/>Negotiated by local medical advisor and practice<BR/>
</P>
</TD>
<TD>
<P>Savings were divided between GP and health authority</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>Decrease in prescribed drug volume and cost per item; improvement in quality of prescribing</P>
</TD>
</TR>
<TR>
<TD>
<P>UK</P>
</TD>
<TD>
<P>Fund-holding<BR/>in Great Britain and Scotland:<BR/>April/1991 to 1997<BR/>(announced in 1990)<BR/>
<BR/>in Wales and Northern Ireland 1993 to 1997<BR/>
</P>
</TD>
<TD>
<P>Controlling prescription drug costs</P>
</TD>
<TD>
<P>Based on previous spending of practice adjusted for patient mix and spending of comparators<BR/>
<BR/>Negotiated by local health authority and practice<BR/>
</P>
</TD>
<TD>
<P>Savings can be invested by each fund-holder to improve services in other budgets, or in the year following the year's drug budget</P>
</TD>
<TD>
<P>Responsible for overspending up to a limit of 5000£. Overspending can be covered by other budgets</P>
</TD>
<TD>
<P>Decrease in prescribed drug volume and cost per item; improvement in quality of prescribing. Referrals are postponed, as these are also part of a budget</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2015-05-22 12:43:41 +0200" MODIFIED_BY="Arash Rashidian" NO="3">
<TITLE MODIFIED="2014-01-02 07:10:34 +0100" MODIFIED_BY="[Empty name]">Description of other identified financial incentive policies that did not meet the inclusion criteria</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TH>
<P>Country</P>
</TH>
<TH>
<P>Policy</P>
</TH>
<TH>
<P>Motivation</P>
</TH>
<TH>
<P>Setting of budget</P>
</TH>
<TH>
<P>Incentives</P>
</TH>
<TH>
<P>Disincentives</P>
</TH>
<TH>
<P>Theoretical effects</P>
</TH>
</TR>
<TR>
<TD>
<P>New Zealand</P>
</TD>
<TD>
<P>Independent practice associations (IPAs): umbrella organisation of general practitioners (GPs), specialists and other healthcare (HC) providers with different budgets for provided care (1993)</P>
</TD>
<TD>
<P>Budgets: to improve quality of care (IPAs: increase power of GPs towards health reforms)</P>
</TD>
<TD>
<P>IPA can choose to take a budget for pharmaceutical expenditures. Historical expenditures (changes from fee-for-service to Integrated capitation based budgets)</P>
<P/>
<P>Regional health authority (or other payers) and IPA</P>
</TD>
<TD>
<P>Savings can be kept by associations to improve quality of care. Savings can be shifted between budgets</P>
</TD>
<TD>
<P>IPA is responsible for overspends, but physicians have refused to take financial responsibility</P>
</TD>
<TD>
<P>GPs within association compete for patients</P>
</TD>
</TR>
<TR>
<TD>
<P>USA</P>
</TD>
<TD>
<P>Managed care withholdings</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Capitation minus, e.g. 20%</P>
<P>Primary care group and HMO</P>
</TD>
<TD>
<P>Bonus if practice balance is positive</P>
</TD>
<TD>
<P>Only partial withholding is paid in cases of deficit</P>
</TD>
<TD>
<P>Keep within the budget</P>
</TD>
</TR>
<TR>
<TD>
<P>USA</P>
</TD>
<TD>
<P>Pharmaceutical capitation</P>
</TD>
<TD>
<P>To have health plans control the growth of their own spending by controlling capitation levels</P>
</TD>
<TD>
<P>Target drug spending amount for a set of patients (per member per month) based on a base rate, adjusted for case mix; providers negotiate with health pan</P>
</TD>
<TD>
<P>Later: Savings will be shared by prescribers</P>
</TD>
<TD>
<P>A percentage of the difference between target and actual spending (around 70%) has to be paid by the physician</P>
</TD>
<TD>
<P>Prescribe fewer and less expensive drugs, irrespective of the capitation rate</P>
</TD>
</TR>
<TR>
<TD>
<P>UK</P>
</TD>
<TD>
<P>Unified budgets for new primary care groups, starting in<BR/>1999<BR/>
</P>
</TD>
<TD>
<P>To ensure that accountability of GPs will help solve problems</P>
</TD>
<TD>
<P>Budget for hospital care, community health services, prescribing, infrastructure costs; funds allocated by health authority. Compulsory for all GPs</P>
</TD>
<TD>
<P>For staff premises and computer costs. GP salary not involved</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Increased monitoring needed. As GP budget grows slower than overall budget, incentive to limit spending</P>
</TD>
</TR>
<TR>
<TD>
<P>Sweden</P>
</TD>
<TD>
<P>Regionalisation: responsibility for drug expenditure moved from federal to regional level, starting in 1998</P>
</TD>
<TD>
<P>To increase cost awareness of county councils</P>
</TD>
<TD>
<P>Government and county council</P>
</TD>
<TD>
<P>Generate savings</P>
</TD>
<TD>
<P>2002 to 2004: Exceeding costs are covered by the government, which compensates county council for up to 75% of overspent costs (ca 9% of budget)</P>
</TD>
<TD>
<P>Development of local initiatives promoting economical prescribing (generic prescribing, drug lists. etc.)</P>
</TD>
</TR>
<TR>
<TD>
<P>Italy</P>
</TD>
<TD>
<P>Benchmarking 1980;<BR/>virtual targets ("budget agreements") 1992;<BR/>guidelines<BR/>
</P>
</TD>
<TD>
<P>To contain costs, decrease growth of drug expenditures</P>
</TD>
<TD>
<P>Local agreement (local health enterprises responsible for drug budget); GP association and local health enterprises</P>
</TD>
<TD>
<P>Regional savings will be distributed in terms of money or other rewards</P>
</TD>
<TD>
<P>None applied</P>
</TD>
<TD>
<P>Drugs versus overall</P>
</TD>
</TR>
<TR>
<TD>
<P>Spain</P>
</TD>
<TD>
<P>Regional target budgets for primary care centres and hospitals, starting in<BR/>2000<BR/>
</P>
</TD>
<TD>
<P>To improve efficiency of care</P>
</TD>
<TD>
<P>Regional</P>
</TD>
<TD>
<P>About 2% of salary is dependent on prescribing targets (Antononaz 2002)</P>
</TD>
<TD>
<P>None (national drug budgets are always covered by industry; physicians are paid by salary)</P>
</TD>
<TD>
<P>No abuse because of constant monitoring</P>
</TD>
</TR>
<TR>
<TD>
<P>Switzerland</P>
</TD>
<TD>
<P>Budget cap plus gate-keeping</P>
</TD>
<TD>
<P>To slow growth of healthcare expenditures</P>
</TD>
<TD>
<P>Per capita expenditure caps</P>
</TD>
<TD>
<P>Physician manager responsible for keeping the budget within limits by supervising physicians</P>
</TD>
<TD>
<P>The insurer is to retain financial responsibility, but penalties would be applied for those exceeding budgets</P>
</TD>
<TD>
<P>Efficient provision of care</P>
</TD>
</TR>
<TR>
<TD>
<P>USA/Michigan</P>
</TD>
<TD>
<P>Pay for performance 2000 to 2003</P>
</TD>
<TD>
<P>To reduce prescription drug costs</P>
</TD>
<TD>
<P>Regional</P>
</TD>
<TD>
<P>Small financial incentive of $250 to $500 every 6 months</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>Financial incentive improves targeted behaviours</P>
</TD>
</TR>
<TR>
<TD>
<P>USA/One locality</P>
</TD>
<TD>
<P>Physician-specific pay for performance on top of fee-for-service payments, 2005 to 2007</P>
</TD>
<TD>
<P>To improve quality of care</P>
</TD>
<TD>
<P>Local</P>
</TD>
<TD>
<P>Small financial incentive, maximum of $5000 per year (about 2% of annual salary)</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>Physician designed pay for performance is more likely to improve behaviour than P4Ps designed without the input of physicians</P>
</TD>
</TR>
<TR>
<TD>
<P>UK</P>
</TD>
<TD>
<P>Indicative prescribing<BR/>scheme,<BR/>
<BR/>1991 to 1997<BR/>
</P>
</TD>
<TD>
<P>To control prescription drug costs</P>
</TD>
<TD>
<P>Based on previous spending practice, negotiated by local medical advisors and statutory health insurances</P>
</TD>
<TD>
<P>Savings to be used within health authority and divided by all GPs</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>Decrease in prescribed drug volume and cost per item. Improvement in quality of prescribing</P>
</TD>
</TR>
<TR>
<TD>
<P>USA</P>
</TD>
<TD>
<P>Medicare Prescription Drug Improvement and Modernization Act of 2003</P>
</TD>
<TD>
<P>To apply reimbursement rate reduction policy</P>
</TD>
<TD>
<P>National</P>
</TD>
<TD>
<P>Physicians earn a share of the revenue that hospitals gain by selling medicines</P>
</TD>
<TD>
<P>Reducing reimbursement rate reduces physicians' tendency to overprescribe</P>
</TD>
<TD>
<P>Fincianal incentives from drug sales affect physician prescribing. Removing this incentive will help to rationalise physician prescribing</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>Literature: New Zealand (<LINK REF="STD-Malcolm-1999" TYPE="STUDY">Malcolm 1999</LINK>; <LINK REF="STD-Malcolm-2001" TYPE="STUDY">Malcolm 2001</LINK>); USA (<LINK REF="REF-Weiner-1990" TYPE="REFERENCE">Weiner 1990</LINK>; <LINK REF="STD-Jacobson-2006" TYPE="STUDY">Jacobson 2006</LINK>; <LINK REF="STD-O_x0027_Malley-2006" TYPE="STUDY">O'Malley 2006</LINK>; <LINK REF="REF-Rosenthal-2006" TYPE="REFERENCE">Rosenthal 2006</LINK>; <LINK REF="REF-Rowe-2006" TYPE="REFERENCE">Rowe 2006</LINK>; <LINK REF="REF-Trude-2006" TYPE="REFERENCE">Trude 2006</LINK>; <LINK REF="STD-Chang-2009" TYPE="STUDY">Chang 2009</LINK>; <LINK REF="STD-Chung-2010a" TYPE="STUDY">Chung 2010a</LINK>; <LINK REF="STD-Doshi-2010" TYPE="STUDY">Doshi 2010</LINK>; <LINK REF="STD-Elliott-2010" TYPE="STUDY">Elliott 2010</LINK>; ); UK (<LINK REF="STD-Bateman-1996" TYPE="STUDY">Bateman 1996</LINK>; <LINK REF="STD-Whynes-1997b" TYPE="STUDY">Whynes 1997b</LINK>; <LINK REF="STD-Ashworth-2004" TYPE="STUDY">Ashworth 2004</LINK>; <LINK REF="REF-Klein-2004" TYPE="REFERENCE">Klein 2004</LINK>); Sweden (<LINK REF="REF-Calltorp-1996" TYPE="REFERENCE">Calltorp 1996</LINK>; <LINK REF="REF-Calltorp-1999" TYPE="REFERENCE">Calltorp 1999</LINK>; <LINK REF="REF-Lundkvist-2002" TYPE="REFERENCE">Lundkvist 2002</LINK>; <LINK REF="STD-Ohlsson-2007" TYPE="STUDY">Ohlsson 2007</LINK>; <LINK REF="STD-Andersson-2009" TYPE="STUDY">Andersson 2009</LINK>); Italy (<LINK REF="REF-Fattore-1998" TYPE="REFERENCE">Fattore 1998</LINK>; <LINK REF="REF-Atella-2000" TYPE="REFERENCE">Atella 2000</LINK>; <LINK REF="REF-Mapelli-2003" TYPE="REFERENCE">Mapelli 2003</LINK>); Spain (<LINK REF="REF-Lopez-Bastida-2000" TYPE="REFERENCE">Lopez Bastida 2000</LINK>; <LINK REF="REF-Antonanzas-2003" TYPE="REFERENCE">Antonanzas 2003</LINK>); Switzerland (<LINK REF="STD-Etter-1998" TYPE="STUDY">Etter 1998</LINK>)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2015-05-22 12:44:01 +0200" MODIFIED_BY="Arash Rashidian" NO="4">
<TITLE MODIFIED="2013-08-27 14:27:47 +0200" MODIFIED_BY="[Empty name]">Risk of bias in CBA studies</TITLE>
<TABLE COLS="10" ROWS="10">
<TR>
<TH>
<P>Bias/Study</P>
</TH>
<TH>
<P>Bradlow</P>
<P>1993</P>
</TH>
<TH>
<P>Burr</P>
<P>1992</P>
</TH>
<TH>
<P>Whynes</P>
<P>1997</P>
</TH>
<TH>
<P>Wilson</P>
<P>1999</P>
</TH>
<TH>
<P>Baines</P>
<P>1997</P>
</TH>
<TH>
<P>Corney</P>
<P>1997</P>
</TH>
<TH>
<P>Martens</P>
<P>2007</P>
</TH>
<TH>
<P>Granlund</P>
<P>2006</P>
</TH>
<TH>
<P>Chu</P>
<P>2008</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Was the allocation sequence adequately generated?</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Was the allocation adequately concealed?</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Were baseline outcome measurements similar?</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Were baseline characteristics similar?</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Were incomplete outcome data adequately addressed?</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Was the study adequately protected against contamination?</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Was the study free of selective outcome reporting?</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Was the study free of other risks of bias?</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>No</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2015-05-22 12:44:16 +0200" MODIFIED_BY="Arash Rashidian" NO="5">
<TITLE MODIFIED="2015-05-22 12:44:09 +0200" MODIFIED_BY="Arash Rashidian">Risk of bias in interrupted time series (ITS) studies</TITLE>
<TABLE COLS="10" ROWS="8">
<TR>
<TH>
<P>Bias/Study</P>
</TH>
<TH>
<P>Walley</P>
<P>2000</P>
</TH>
<TH>
<P>Gouether</P>
<P>1995</P>
</TH>
<TH>
<P>Schoffski</P>
<P>1997</P>
</TH>
<TH>
<P>Harris</P>
<P>1996</P>
</TH>
<TH>
<P>Wilson</P>
<P>1995</P>
</TH>
<TH>
<P>Raferty</P>
<P>1997</P>
</TH>
<TH>
<P>Doran</P>
<P>2011</P>
</TH>
<TH>
<P>Serumaga</P>
<P>2011</P>
</TH>
<TH>
<P>Chou</P>
<P>2008</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Was the intervention independent of other changes?</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Was the shape of the intervention effect prespecified?</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Was the intervention unlikely to affect data collection?</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Were incomplete outcome data adequately addressed?</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>No</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Was the study free of selective outcome reporting?</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Was the study free of other risks of bias?</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2015-05-22 12:46:00 +0200" MODIFIED_BY="Arash Rashidian" NO="6">
<TITLE MODIFIED="2014-01-02 08:39:58 +0100" MODIFIED_BY="[Empty name]">Effect of drug budgetary policies on drug use</TITLE>
<TABLE COLS="10" ROWS="55">
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Setting</P>
</TH>
<TH>
<P>Type of Study</P>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="40">
<P>
<B>UK fund
-holding</B>
</P>
</TH>
<TD ROWSPAN="6">
<P>
<B>Items per patient</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Adjusted absolute change<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>3 months</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>6 months</P>
</TD>
<TD>
<P>Adjusted relative change 12 months</P>
</TD>
<TD>
<P/>
<P>Adjusted relative change 24 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Burr 1992</P>
</TD>
<TD>
<P>Wave 1</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>0.8</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Bradlow 1993</P>
</TD>
<TD>
<P>Wave 1</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>1.8</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Bradlow 1993</P>
</TD>
<TD>
<P>Wave 1</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>3.6**/****</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1999</P>
</TD>
<TD>
<P>Wave 3/4</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>39.2***</P>
</TD>
</TR>
<TR>
<TD>
<P>Whynes 1997</P>
</TD>
<TD>
<P>Wave 4</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-1.2</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="12">
<P>
<B>Items per patient</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Absolute level effect (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>3 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>6 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>12 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>24 months (95% CI)</P>
</TD>
</TR>
<TR>
<TD>
<P>Rafferty 1997</P>
</TD>
<TD>
<P>Wave 1</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-63.6<BR/>(-249.3 to 122.1)</P>
</TD>
<TD>
<P>-2.5<BR/>(-9.8 to 4.9)</P>
</TD>
<TD>
<P>-1<BR/>(-8.8 to 6.8)</P>
</TD>
<TD>
<P>-2.8<BR/>(-11.5 to 5.9)</P>
</TD>
<TD>
<P>0.2<BR/>(-10.3 to 10.7)</P>
</TD>
</TR>
<TR>
<TD>
<P>Harris 1996</P>
</TD>
<TD>
<P>Wave 1</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>0.4<BR/>(-1.1 to 1.8)</P>
</TD>
<TD>
<P>0.4<BR/>(-1.2 to 2)</P>
</TD>
<TD>
<P>0.7<BR/>(-1.3 to 2.7)</P>
</TD>
<TD>
<P>1.4<BR/>(-1.5 to 4.2)</P>
</TD>
<TD>
<P>2.6<BR/>(-2.1 to 7.2)</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1995</P>
</TD>
<TD>
<P>Wave 1</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>1.4<BR/>(-6.6 to 9.4)</P>
</TD>
<TD>
<P>1.9<BR/>(-9.3 to 13.1)</P>
</TD>
<TD>
<P>-4.1<BR/>(4.3 to -4)</P>
</TD>
<TD>
<P>-10.2<BR/>(-10.4 to -10)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Rafferty 1997</P>
</TD>
<TD>
<P>Wave 2</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-43.6<BR/>(-257 to 169.8)</P>
</TD>
<TD>
<P>-1.6<BR/>(-9.2 to 6)</P>
</TD>
<TD>
<P>-2.4<BR/>(-10.3 to 5.5)</P>
</TD>
<TD>
<P>-3.6<BR/>(-12.1 to 4.8)</P>
</TD>
<TD>
<P>-4.2<BR/>(-13.7 to 5.4)</P>
</TD>
</TR>
<TR>
<TD>
<P>Rafferty 1997</P>
</TD>
<TD>
<P>Wave 3</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-44.3<BR/>(-280.1 to 191.4)</P>
</TD>
<TD>
<P>-1.4<BR/>(-9.9 to 7)</P>
</TD>
<TD>
<P>1.5<BR/>(-7.2 to 10.1)</P>
</TD>
<TD>
<P>1.5<BR/>(-7.5 to 10.5)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1995</P>
</TD>
<TD>
<P>Wave 2</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>2.7<BR/>(-9.5 to 14.9)</P>
</TD>
<TD>
<P>7.1<BR/>(-25.1 to 39.2)</P>
</TD>
<TD>
<P>-15.8<BR/>(-16.1 to -15.5)</P>
</TD>
<TD>
<P>-14.5<BR/>(-15.2 to -13.9)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1995</P>
</TD>
<TD>
<P>Wave 3</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>4.8<BR/>(-4.8 to 14.4)</P>
</TD>
<TD>
<P>16.8<BR/>(-17.1 to 50.8)</P>
</TD>
<TD>
<P>-21.3<BR/>(-21.6 to -20.9)</P>
</TD>
<TD>
<P>-28.9<BR/>(-29.4 to -28.3)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Harris 1996</P>
</TD>
<TD>
<P>Wave 2</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-0.5<BR/>(-1.3 to 0.3)</P>
</TD>
<TD>
<P>-0.5<BR/>(-1.3 to 0.3)</P>
</TD>
<TD>
<P>-0.4<BR/>(-1.3 to 0.5)</P>
</TD>
<TD>
<P>-0.3<BR/>(-1.4 to 0.8)</P>
</TD>
<TD>
<P>-0.1<BR/>(-1.7 to 1.5)</P>
</TD>
</TR>
<TR>
<TD>
<P>Harris 1996</P>
</TD>
<TD>
<P>Wave 3</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>0.0<BR/>(-0.7 to 0.7)</P>
</TD>
<TD>
<P>0.0<BR/>(-0.8 to 0.8)</P>
</TD>
<TD>
<P>0.0<BR/>(-0.8 to 0.9)</P>
</TD>
<TD>
<P>0.2<BR/>(-0.7 to 1.2)</P>
</TD>
<TD>
<P>0.4<BR/>(-0.7 to 1.6)</P>
</TD>
</TR>
<TR>
<TD>
<P>Harris 1996</P>
</TD>
<TD>
<P>Wave 4</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>0.3<BR/>(-0.4 to 1)</P>
</TD>
<TD>
<P>0.3<BR/>(-0.4 to 1.1)</P>
</TD>
<TD>
<P>0.1<BR/>(-0.6 to 0.9)</P>
</TD>
<TD>
<P>-0.4<BR/>(-1.2 to 0.5)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Harris 1996</P>
</TD>
<TD>
<P>Wave 5</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-0.2<BR/>(-1 to 0.5)</P>
</TD>
<TD>
<P>-0.2<BR/>(-1 to 0.5)</P>
</TD>
<TD>
<P>-0.2<BR/>(-1 to 0.6)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="7">
<P>
<B>Generic percentage</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Adjusted absolute change<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>3 months</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>6 months</P>
</TD>
<TD>
<P>Adjusted relative change 12 months</P>
</TD>
<TD>
<P/>
<P>Adjusted relative change 24 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Bradlow 1993</P>
</TD>
<TD>
<P>Wave 1</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>4.1</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>8.8</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Bradlow 1993</P>
</TD>
<TD>
<P>Wave 1</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>17.2**/****</P>
</TD>
</TR>
<TR>
<TD>
<P>Baines 1997</P>
</TD>
<TD>
<P>Waves 1 to 3, Lincolns</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>10.7**</P>
</TD>
</TR>
<TR>
<TD>
<P>Baines 1997</P>
</TD>
<TD>
<P>Waves 1 to 3, Devon</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>9.5**</P>
</TD>
</TR>
<TR>
<TD>
<P>Whynes 1997</P>
</TD>
<TD>
<P>Wave 4</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>3.5</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1999*</P>
</TD>
<TD>
<P>Wave 3/4</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>4***</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="7">
<P>
<B>Generic percentage</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Absolute level effect (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>3 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>6 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>12 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>24 months (95% CI)</P>
</TD>
</TR>
<TR>
<TD>
<P>Rafferty 1997</P>
</TD>
<TD>
<P>Wave 1</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>2.8<BR/>(1.5 to 4.1)</P>
</TD>
<TD>
<P>10.8<BR/>(5.6 to 16)</P>
</TD>
<TD>
<P>12.7<BR/>(7.1 to 18.2)</P>
</TD>
<TD>
<P>15.8<BR/>(9.4 to 22.2)</P>
</TD>
<TD>
<P>23<BR/>(15 to 31)</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1995</P>
</TD>
<TD>
<P>Wave 1</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>1.7<BR/>(0.8 to 2.7)</P>
</TD>
<TD>
<P>345.7<BR/>(151.8 to 539.6)</P>
</TD>
<TD>
<P>342.7<BR/>(341.1 to 344.4)</P>
</TD>
<TD>
<P>190.5<BR/>(189 to 192)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Rafferty 1997</P>
</TD>
<TD>
<P>Wave 2</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>1.3<BR/>(-0.2 to 2.9)</P>
</TD>
<TD>
<P>5.1<BR/>(-0.9 to 11.1)</P>
</TD>
<TD>
<P>5.9<BR/>(-0.4 to 12.2)</P>
</TD>
<TD>
<P>8.5<BR/>(1.6 to 15.5)</P>
</TD>
<TD>
<P>13.6<BR/>(5.4 to 21.7)</P>
</TD>
</TR>
<TR>
<TD>
<P>Rafferty 1997</P>
</TD>
<TD>
<P>Wave 3</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>0.5<BR/>(-1 to 1.9)</P>
</TD>
<TD>
<P>1.8<BR/>(-3.9 to 7.4)</P>
</TD>
<TD>
<P>5.7<BR/>(-0.1 to 11.5)</P>
</TD>
<TD>
<P>14.2<BR/>(8.1 to 20.4)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1995</P>
</TD>
<TD>
<P>Wave 2</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>1.0<BR/>(-0.1 to 2.1)</P>
</TD>
<TD>
<P>45.4<BR/>(-2.4 to 93.2)</P>
</TD>
<TD>
<P>66.5<BR/>(66.1 to 66.8)</P>
</TD>
<TD>
<P>68.1<BR/>(67.6 to 68.7)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1995</P>
</TD>
<TD>
<P>Wave 3</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>1.9<BR/>(0.8 to 3)</P>
</TD>
<TD>
<P>35.5<BR/>(15.1 to 55.9)</P>
</TD>
<TD>
<P>-12.2<BR/>(-12.4 to -12.1)</P>
</TD>
<TD>
<P>-43.7<BR/>(-43.5 to -44.0)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>All antiulcer drugs (DDD)</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Adjusted absolute change<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>3 months</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>6 months</P>
</TD>
<TD>
<P>Adjusted relative change 12 months</P>
</TD>
<TD>
<P/>
<P>Adjusted relative change 24 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1999</P>
</TD>
<TD>
<P>Wave 3/4</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-6.7***</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Percentage PPI of all antiulcer drugs (DDD)</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Adjusted absolute change<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>3 months</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>6 months</P>
</TD>
<TD>
<P>Adjusted relative change 12 months</P>
</TD>
<TD>
<P/>
<P>Adjusted relative change 24 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1999</P>
</TD>
<TD>
<P>Wave 3/4</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-7.9***</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>All antidepressant drugs (DDD)</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Adjusted absolute change<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>3 months</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>6 months</P>
</TD>
<TD>
<P>Adjusted relative change 12 months</P>
</TD>
<TD>
<P/>
<P>Adjusted relative change 24 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1999</P>
</TD>
<TD>
<P>Wave 3/4</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-7.9***</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Percentage SSRIs of all antidepressant drugs (DDD)</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Adjusted absolute change<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>3 months</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>6 months</P>
</TD>
<TD>
<P>Adjusted relative change 12 months</P>
</TD>
<TD>
<P/>
<P>Adjusted relative change 24 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1999</P>
</TD>
<TD>
<P>Wave 3/4</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-0.8***</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2">
<P>
<B>Ireland indicative drug budgets</B>
</P>
</TH>
<TD ROWSPAN="2">
<P>
<B>Items per patient</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Absolute level effect (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>3 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>6 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>12 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>24 months (95% CI)</P>
</TD>
</TR>
<TR>
<TD>
<P>Walley 2000</P>
</TD>
<TD>
<P>IDTSS</P>
</TD>
<TD>
<P>ITS</P>
</TD>
<TD>
<P>-0.8</P>
<P>(-1.4 to -0.2)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-8.2</P>
<P>(-14.4 to -2.0)</P>
</TD>
<TD>
<P>-10.1</P>
<P>(-17.5 to -2.7)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2">
<P>
<B>German drug budget</B>
</P>
</TH>
<TD ROWSPAN="2">
<P>
<B>Items per patient</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Absolute level effect (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>3 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>6 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>12 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>24 months (95% CI)</P>
</TD>
</TR>
<TR>
<TD>
<P>Guether 1995</P>
</TD>
<TD>
<P>Social insurance</P>
</TD>
<TD>
<P>ITS</P>
</TD>
<TD>
<P>-34,552<BR/>(-99,896 to 30,791)</P>
</TD>
<TD>
<P>-11.2<BR/>(-32.3 to 10.0)</P>
<P/>
</TD>
<TD>
<P>-12.1<BR/>(-37.8 to 13.7)</P>
</TD>
<TD>
<P>-13.4<BR/>(-48.9 to 22.1)</P>
<P/>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3">
<P>Taiwan National Health Insurance (NHI) Drug Budget Programme</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Items per prescription</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Absolute level effect (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>3 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>6 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>12 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>24 months (95% CI)</P>
</TD>
</TR>
<TR>
<TD>
<P>Chou 2008</P>
<P>(for hypertension)</P>
</TD>
<TD>
<P>NHI</P>
</TD>
<TD>
<P>ITS</P>
</TD>
<TD>
<P>0.000 (-0.001 to 0.014)</P>
</TD>
<TD>
<P>-0.01 (-0.05 to 0.03)º</P>
</TD>
<TD>
<P>- 0.01 (-0.06 to 0.03) º</P>
</TD>
<TD>
<P>-0.01 (-0.06 to 0.04)</P>
</TD>
<TD>
<P>-0.01 (-0.08 to 0.06)</P>
</TD>
</TR>
<TR>
<TD>
<P>Chou 2008 (for diabetes)</P>
</TD>
<TD>
<P>NHI</P>
</TD>
<TD>
<P>ITS</P>
</TD>
<TD>
<P>-0.01 (-0.02 to -0.005)</P>
</TD>
<TD>
<P>-0.02 (-0.04 to 0.04) º º</P>
</TD>
<TD>
<P>-0.01 (-0.05 to 0.03) º º</P>
</TD>
<TD>
<P>-0.02 (-0.05 to 0.03)</P>
</TD>
<TD>
<P>-0.06 (-0.13 to 0.006)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="6">
<P>Sweden fixed budgets for pharmaceutical expenditures</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Prescription per patient</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Adjusted absolute change<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>3 months</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>6 months</P>
</TD>
<TD>
<P>Adjusted relative change 12 months</P>
</TD>
<TD>
<P/>
<P>Adjusted relative change 24 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Granlund 2006</P>
</TD>
<TD>
<P>Sweden, Burtrask</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-0.03</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-0.05 º º º</P>
</TD>
</TR>
<TR>
<TD>
<P>Granlund 2006</P>
</TD>
<TD>
<P>Sweden, Morobacke</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>0.39</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>0.70</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>
<B>DDDs per prescription</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Adjusted absolute change<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>3 months</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>6 months</P>
</TD>
<TD>
<P>Adjusted relative change 12 months</P>
</TD>
<TD>
<P/>
<P>Adjusted relative change 24 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Granlund 2006</P>
</TD>
<TD>
<P>Sweden, Burtrask</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-2.35</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-0.055 º º º</P>
</TD>
</TR>
<TR>
<TD>
<P>Granlund 2006</P>
</TD>
<TD>
<P>Sweden, Morobacke</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>2.12</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>0.05</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>*Median.</P>
<P>**3-year f/u.</P>
<P>***Combined wave 4: 1-year f/u; wave 3: 2-year f/u.</P>
<P>****Data from <LINK REF="REF-Stewart_x002d_Brown-1995" TYPE="REFERENCE">Stewart-Brown 1995</LINK>.</P>
<P>º Data were available for 4 months after the intervention.</P>
<P>º º Data were available for 8 months after the intervention.</P>
<P>º º º Data were available for 20 months after the intervention.</P>
<P>CBA: controlled before-after; CITS: controlled interrupted time series; DDD: defined daily doses; IDTSS: Indicative Drug Target Savings Scheme; ITS: interrupted time series.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" MODIFIED="2015-05-22 12:48:13 +0200" MODIFIED_BY="Arash Rashidian" NO="7">
<TITLE MODIFIED="2014-01-02 08:40:11 +0100" MODIFIED_BY="[Empty name]">Effect of drug budgetary policies on drug expenditures</TITLE>
<TABLE COLS="10" ROWS="59">
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Setting</P>
</TH>
<TH>
<P>Type of study</P>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="44">
<P>
<B>UK fund-holding</B>
</P>
</TH>
<TD ROWSPAN="5">
<P>
<B>Costs per item</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Adjusted absolute change<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>3 months</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>6 months</P>
</TD>
<TD>
<P>Adjusted relative change 12 months</P>
</TD>
<TD>
<P/>
<P>Adjusted relative change 24 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Bradlow 1993</P>
</TD>
<TD>
<P>Wave 1</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-0.5</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-6.3</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Bradlow 1993</P>
</TD>
<TD>
<P>Wave 1</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-5.2*/***</P>
</TD>
</TR>
<TR>
<TD>
<P>Rafferty 1997</P>
</TD>
<TD>
<P>Wave 3</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-0.5</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-5.3</P>
</TD>
<TD>
<P>n.a.</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1999</P>
</TD>
<TD>
<P>Wave 3/4</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-2.8**</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="6">
<P>
<B>Costs per item</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Absolute level effect (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>3 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>6 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>12 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>24 months (95% CI)</P>
</TD>
</TR>
<TR>
<TD>
<P>Rafferty 1997</P>
</TD>
<TD>
<P>Wave 1</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-0.4<BR/>(-0.8 to 0)</P>
</TD>
<TD>
<P>-4.9<BR/>(-10.1 to 0.4)</P>
</TD>
<TD>
<P>
<BR/>-5.8<BR/>(-11,3 to -0,3)</P>
</TD>
<TD>
<P>-7<BR/>(-13 to -1)</P>
</TD>
<TD>
<P>-9.2<BR/>(-16.1 to -2.3)</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1995</P>
</TD>
<TD>
<P>Wave 1</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-0.2<BR/>(-0.3 to -0.1)</P>
</TD>
<TD>
<P>-31.4<BR/>(-50 to -13.1)</P>
</TD>
<TD>
<P>-41.6<BR/>(-41.8 to -41.4)</P>
</TD>
<TD>
<P>-47.8<BR/>(-48.2 to -47.5)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Rafferty 1997</P>
</TD>
<TD>
<P>Wave 2</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-0.3<BR/>(-0.8 to 0.2)</P>
</TD>
<TD>
<P>-3.5<BR/>(-9.2 to 2.2)</P>
</TD>
<TD>
<P>-4.2<BR/>(-10.1 to 1.6)</P>
</TD>
<TD>
<P>-6.2<BR/>(-12.4 to 0)</P>
</TD>
<TD>
<P>-9.8<BR/>(-16.7 to -3)</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1995</P>
</TD>
<TD>
<P>Wave 2</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-0.2<BR/>(-0.4 to -0)</P>
</TD>
<TD>
<P>-36.9<BR/>(-71.1 to -2.7)</P>
</TD>
<TD>
<P>-45.1<BR/>(-45.5 to -44.7)</P>
</TD>
<TD>
<P>-49.2<BR/>(-49.9 to 48.5)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1995</P>
</TD>
<TD>
<P>Wave 3</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-0.3<BR/>(-0.5 to -0.1)</P>
</TD>
<TD>
<P>-99.6<BR/>(-157.4 to -41.8)</P>
</TD>
<TD>
<P>-85.3<BR/>(-86 to -84.6)</P>
</TD>
<TD>
<P>-44.3<BR/>(-45.7 to 42.9)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Costs per item (PPIs)</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
<P>Adjusted relative change 24 months</P>
</TD>
<TD>
<P>Adjusted absolute change<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>3 months</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>6 months</P>
</TD>
<TD>
<P>Adjusted relative change 12 months</P>
</TD>
<TD>
<P/>
<P>Adjusted relative change 24 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1999</P>
<P/>
</TD>
<TD>
<P>Wave 3/4</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-1**</P>
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Costs per item (SSRIs)</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
<P>Adjusted relative change 24 months</P>
</TD>
<TD>
<P>Adjusted absolute change<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>3 months</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>6 months</P>
</TD>
<TD>
<P>Adjusted relative change 12 months</P>
</TD>
<TD>
<P/>
<P>Adjusted relative change 24 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1999</P>
<P/>
</TD>
<TD>
<P>Wave 3/4</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-1.9</P>
<P/>
</TD>
<TD>
<P>-2.7**</P>
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="8">
<P>
<B>Costs per patient</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
<P>Adjusted relative change 24 months</P>
</TD>
<TD>
<P>Adjusted absolute change<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>3 months</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>6 months</P>
</TD>
<TD>
<P>Adjusted relative change 12 months</P>
</TD>
<TD>
<P/>
<P>Adjusted relative change 24 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Burr 1992</P>
</TD>
<TD>
<P>Wave 1</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-0.6</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-4.5</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Bradlow 1993</P>
</TD>
<TD>
<P>Wave 1</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-0.8</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-4.6</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Bradlow 1993</P>
</TD>
<TD>
<P>Wave 1</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-1.1</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-6.2</P>
</TD>
<TD>
<P>0.4*/***</P>
</TD>
</TR>
<TR>
<TD>
<P>Baines 1997</P>
</TD>
<TD>
<P>Wave 1-3, Lincolns</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-18.5*</P>
</TD>
</TR>
<TR>
<TD>
<P>Baines 1997</P>
</TD>
<TD>
<P>Wave 1-3, Devon</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-16.4*</P>
</TD>
</TR>
<TR>
<TD>
<P>Whynes 1997</P>
</TD>
<TD>
<P>Wave 4</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-0.7</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Corney 1997</P>
</TD>
<TD>
<P>Wave 2</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>0.2</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>0.5</P>
</TD>
<TD>
<P>-4.8</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="12">
<P>
<B>Costs per patient</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Absolute level effect (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>3 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>6 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>12 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>24 months (95% CI)</P>
</TD>
</TR>
<TR>
<TD>
<P>Rafferty 1997</P>
</TD>
<TD>
<P>Wave 1</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-922.7<BR/>(-2045.8 to 200.4)</P>
</TD>
<TD>
<P>-4.9<BR/>(-10.8 to 1.1)</P>
</TD>
<TD>
<P>-4<BR/>(-10.2 to 2.3)</P>
</TD>
<TD>
<P>-7.3<BR/>(-14.2 to -0.4)</P>
</TD>
<TD>
<P>-9.1<BR/>(-17.1 to -1.1)</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1995</P>
</TD>
<TD>
<P>Wave 1</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-0<BR/>(-0.1 to 0.1)</P>
</TD>
<TD>
<P>-6<BR/>(-26.5 to 14.6)</P>
</TD>
<TD>
<P>6.7<BR/>(6.5 to 6.9)</P>
</TD>
<TD>
<P>1<BR/>(0.6 to 1.3)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Harris 1996</P>
</TD>
<TD>
<P>Wave 1</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-1.2<BR/>(-3 to 0.7)</P>
</TD>
<TD>
<P>-1.2<BR/>(-3.1 to 0.7)</P>
</TD>
<TD>
<P>-0.8<BR/>(-3.3 to 1.7)</P>
</TD>
<TD>
<P>0.1<BR/>(-4 to 4.2)</P>
</TD>
<TD>
<P>2<BR/>(-5.9 to 10)</P>
</TD>
</TR>
<TR>
<TD>
<P>Rafferty 1997</P>
</TD>
<TD>
<P>Wave 2</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-566.6<BR/>(-1594.6 to 461.4)</P>
</TD>
<TD>
<P>-2.6<BR/>(-7.3 to 2)</P>
</TD>
<TD>
<P>-3.4<BR/>(-8.2 to 1.4)</P>
</TD>
<TD>
<P>-6.7<BR/>(-11.7 to -1.6)</P>
</TD>
<TD>
<P>-11<BR/>(-16.5 to -5.5)</P>
</TD>
</TR>
<TR>
<TD>
<P>Rafferty 1997</P>
</TD>
<TD>
<P>Wave 3</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-192.6<BR/>(-1482.6 to 1097.5)</P>
</TD>
<TD>
<P>-0.6<BR/>(-6 to 4.9)</P>
</TD>
<TD>
<P>-2.3<BR/>(-7.9 to 3.3)</P>
</TD>
<TD>
<P>-5.6<BR/>(-11.3 to 0.2)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1995</P>
</TD>
<TD>
<P>Wave 2</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-0.1<BR/>(-0.2 to -0)</P>
</TD>
<TD>
<P>-166.8<BR/>(-306.9 to -26.5)</P>
</TD>
<TD>
<P>128.6<BR/>(127.9 to 129.4)</P>
</TD>
<TD>
<P>66.8<BR/>(65.6 to 67.9)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1995</P>
</TD>
<TD>
<P>Wave 3</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-0<BR/>(-0.1 to 0.1)</P>
</TD>
<TD>
<P>-1.2<BR/>(-42.4 to 39.9)</P>
</TD>
<TD>
<P>-61.5<BR/>(-61.8 to -61.2)</P>
</TD>
<TD>
<P>-79.7<BR/>(-80.2 to -79.3)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Harris 1996</P>
</TD>
<TD>
<P>Wave 2</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-2.9<BR/>(-4.1 to -1.7)</P>
</TD>
<TD>
<P>-2.9<BR/>(-4.1 to -1.7)</P>
</TD>
<TD>
<P>-2.8<BR/>(-4.1 to -1.4)</P>
</TD>
<TD>
<P>-2.5<BR/>(-4.1 to -0.9)</P>
</TD>
<TD>
<P>-2<BR/>(-4.3 to 0.3)</P>
</TD>
</TR>
<TR>
<TD>
<P>Harris 1996</P>
</TD>
<TD>
<P>Wave 3</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-0.6<BR/>(-2 to 0.7)</P>
</TD>
<TD>
<P>-0.6<BR/>(-2 to 0.7)</P>
</TD>
<TD>
<P>-0.6<BR/>(-2 to 0.9)</P>
</TD>
<TD>
<P>-0.5<BR/>(-2.3 to 1.4)</P>
</TD>
<TD>
<P>-0.3<BR/>(-3.4 to 2.8)</P>
</TD>
</TR>
<TR>
<TD>
<P>Harris 1996</P>
</TD>
<TD>
<P>Wave 4</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-1.5<BR/>(-2.9 to 0)</P>
</TD>
<TD>
<P>-1.5<BR/>(-3 to 0)</P>
</TD>
<TD>
<P>-1.9<BR/>(-3.4 to -0.5)</P>
</TD>
<TD>
<P>-2.8<BR/>(-4.5 to -1.2)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Harris 1996</P>
</TD>
<TD>
<P>Wave 5</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-1.2<BR/>(-2.3 to -0)</P>
</TD>
<TD>
<P>-1.2<BR/>(-2.4 to -0)</P>
</TD>
<TD>
<P>-2.1<BR/>(-3.1 to -1)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Costs per patient (antiulcer drugs)</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
<P/>
</TD>
<TD>
<P>Adjusted absolute change<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>3 months</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>6 months</P>
</TD>
<TD>
<P>Adjusted relative change 12 months</P>
</TD>
<TD>
<P/>
<P>Adjusted relative change 24 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1999</P>
</TD>
<TD>
<P>Wave 3/4</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-10.6**</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Costs per patient (antidepressants)</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
<P/>
</TD>
<TD>
<P>Adjusted absolute change<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>3 months</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>6 months</P>
</TD>
<TD>
<P>Adjusted relative change 12 months</P>
</TD>
<TD>
<P/>
<P>Adjusted relative change 24 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1999</P>
</TD>
<TD>
<P>Wave 3/4</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-1.9**</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="5">
<P>
<B>Total prescribing costs</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Absolute level effect (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>3 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>6 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>12 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>24 months (95% CI)</P>
</TD>
</TR>
<TR>
<TD>
<P>Harris 1996</P>
</TD>
<TD>
<P>Wave 2</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-1.4<BR/>(-3.6 to 0.9)</P>
</TD>
<TD>
<P>37.6<BR/>(-24.1 to 99.3)</P>
</TD>
<TD>
<P>13.4<BR/>(-57.2 to 84.1)</P>
</TD>
<TD>
<P>-27.3<BR/>(-109.4 to 54.9)</P>
</TD>
<TD>
<P>-89.6<BR/>(-183.6 to 4.4)</P>
</TD>
</TR>
<TR>
<TD>
<P>Harris 1996</P>
</TD>
<TD>
<P>Wave 3</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>1<BR/>(-1.5 to 3.4)</P>
</TD>
<TD>
<P>-18.8<BR/>(-65.6 to 28.4)</P>
</TD>
<TD>
<P>-35.9<BR/>(-87.6 to 15.8)</P>
</TD>
<TD>
<P>-69.6<BR/>(-127.4 to -11.9)</P>
</TD>
<TD>
<P>-97<BR/>(-160.7 to -33.3)</P>
</TD>
</TR>
<TR>
<TD>
<P>Harris 1996</P>
</TD>
<TD>
<P>Wave 4</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-0.3<BR/>(-3.7 to 3)</P>
</TD>
<TD>
<P>10.3<BR/>(-90.6 to 111.2 )</P>
</TD>
<TD>
<P>-14.2<BR/>(-121.6 to 93.3)</P>
</TD>
<TD>
<P>-50.6<BR/>(-166.2 to 65.1)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Harris 1996</P>
</TD>
<TD>
<P>Wave 5</P>
</TD>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>-0.9<BR/>(-3 to 1.2)</P>
</TD>
<TD>
<P>38.7<BR/>(-50.5 to 127.9)</P>
</TD>
<TD>
<P>21.2<BR/>(-63.9 to 106.2)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="4">
<P>Ireland Indicative drug budgets</P>
</TH>
<TD ROWSPAN="2">
<P>
<B>Costs per item </B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Absolute level effect (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>3 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>6 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>12 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>24 months (95% CI)</P>
</TD>
</TR>
<TR>
<TD>
<P>Walley 2000</P>
</TD>
<TD>
<P>IDTSS</P>
</TD>
<TD>
<P>ITS</P>
</TD>
<TD>
<P>0.1<BR/>(-2.5 to 2.8)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>0.6<BR/>(-10.1 to 11.7)</P>
</TD>
<TD>
<P>1.2<BR/>(-12.9 to 15.3)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Total prescribing costs</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Absolute level effect (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>3 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>6 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>12 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>24 months (95% CI)</P>
</TD>
</TR>
<TR>
<TD>
<P>Walley 2000</P>
</TD>
<TD>
<P>IDTSS</P>
</TD>
<TD>
<P>ITS</P>
</TD>
<TD>
<P>-5.2<BR/>(-10 to -0.4)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-18.0<BR/>(-34.6 to -1.4)</P>
</TD>
<TD>
<P>-21.7<BR/>(-41.7 to -1.8)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="6">
<P>Sweden fixed budgets for pharmaceutical expenditures</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Costs per prescription</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Adjusted absolute change<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>3 months</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>6 months</P>
</TD>
<TD>
<P>Adjusted relative change 12 months</P>
</TD>
<TD>
<P/>
<P>Adjusted relative change 24 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Granlund 2006</P>
</TD>
<TD>
<P>Sweden, Burtrask</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>23.19</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>0.14****</P>
</TD>
</TR>
<TR>
<TD>
<P>Granlund 2006</P>
</TD>
<TD>
<P>Sweden, Morobacke</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-3.8</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-0.022</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>
<B>Costs per DDD</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Adjusted absolute change<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>3 months</P>
</TD>
<TD>
<P>Adjusted relative change<BR/>6 months</P>
</TD>
<TD>
<P>Adjusted relative change 12 months</P>
</TD>
<TD>
<P/>
<P>Adjusted relative change 24 months</P>
</TD>
</TR>
<TR>
<TD>
<P>Granlund 2006</P>
</TD>
<TD>
<P>Sweden, Burtrask</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>0.39</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>0.06****</P>
</TD>
</TR>
<TR>
<TD>
<P>Granlund 2006</P>
</TD>
<TD>
<P>Sweden, Morobacke</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-0.05</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-0.007</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3">
<P>Taiwan National Health Insurance Drug Budget Programme</P>
</TH>
<TD ROWSPAN="3">
<P>
<B>Costs per prescription</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Absolute level effect (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>3 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>6 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>12 months (95% CI)</P>
</TD>
<TD>
<P>Relative change<BR/>24 months (95% CI)</P>
</TD>
</TR>
<TR>
<TD>
<P>Chou 2008</P>
</TD>
<TD>
<P>NHI; for hypertension</P>
</TD>
<TD>
<P>ITS</P>
</TD>
<TD>
<P>0.005 (-0.005 to 0.01)</P>
</TD>
<TD>
<P>0.001 (-0.05 to 0.05)</P>
</TD>
<TD>
<P>-0.004 (-0. 05 to 0.061)</P>
</TD>
<TD>
<P>0.01 (-0.05 to 0.07)</P>
</TD>
<TD>
<P>0.02 (-0.05 to 0.1)</P>
</TD>
</TR>
<TR>
<TD>
<P>Chou 2008</P>
</TD>
<TD>
<P>NHI; for diabetes</P>
</TD>
<TD>
<P>ITS</P>
</TD>
<TD>
<P>0.00 (-0.007 to 0.005)</P>
</TD>
<TD>
<P>0.01 (-0.02 to 0.05)</P>
</TD>
<TD>
<P>0.01 (-0.02 to 0.06)</P>
</TD>
<TD>
<P>0.01 (-0.03 to 0.06)</P>
</TD>
<TD>
<P>0.01 (-0.04 to 0.08)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>*3-year f/u.</P>
<P>**Combined wave 4: 1-year f/u; wave 3: 2-year f/u.</P>
<P>***Data from <LINK REF="REF-Stewart_x002d_Brown-1995" TYPE="REFERENCE">Stewart-Brown 1995</LINK>.</P>
<P>****Data were available for 20 months after the intervention.</P>
<P>Costs of drugs dispensed from UK PACT data.</P>
<P>If not otherwise noted, price year not specified in the paper.</P>
<P>All Rafferty outcomes: difference in mean (costs per item results for year 3 were not re-analysable); all Harris outcomes: percentage of non-fund-holders; all Wilson outcomes: differences in median.</P>
<P>If not otherwise noted, price year not specified in the paper.</P>
<P>CBA: controlled before-after; CITS: controlled interrupted time series; IDTSS: Indicative Drug Target Savings Scheme; ITS: interrupted time series; PPI: proton pump inhibitors; SSRI: selective serotonin reuptake inhibitor.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-08" MODIFIED="2015-05-22 12:48:48 +0200" MODIFIED_BY="Arash Rashidian" NO="8">
<TITLE MODIFIED="2015-05-22 12:48:40 +0200" MODIFIED_BY="Arash Rashidian">Effect of drug budgetary policies on healthcare utilisation</TITLE>
<TABLE COLS="10" ROWS="6">
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Setting</P>
</TH>
<TH>
<P>Type of study</P>
</TH>
<TH>
<P>Absolute level effect (95% CI)</P>
</TH>
<TH>
<P>Relative change<BR/>3 months (95% CI)</P>
</TH>
<TH>
<P>Relative change<BR/>6 months (95% CI)</P>
</TH>
<TH>
<P>Relative change<BR/>12 months (95% CI)</P>
</TH>
<TH>
<P>Relative change<BR/>24 months (95% CI)</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="5">
<P>German drug budget</P>
</TH>
<TD COLSPAN="9">
<P>Referral to outpatient specialists</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Guether 1995</P>
</TD>
<TD>
<P>Social insurance</P>
</TD>
<TD>
<P>interrupted time series (ITS)</P>
</TD>
<TD>
<P>1543<BR/>(-5095.6 to 8181.7)</P>
</TD>
<TD>
<P>3.4<BR/>(-11.3 to 18.1)</P>
</TD>
<TD>
<P>-3.5<BR/>(-21.9 to 14.9)</P>
</TD>
<TD>
<P>-15.4<BR/>(-40.3 to 9.5)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Schoffski 1997</P>
</TD>
<TD>
<P>Social insurance</P>
</TD>
<TD>
<P>ITS</P>
</TD>
<TD>
<P>7.5<BR/>(-2 to 17)</P>
</TD>
<TD>
<P>22.8<BR/>(-6 to 51.6)</P>
</TD>
<TD>
<P>8.4<BR/>(-25 to 41.8)</P>
</TD>
<TD>
<P>13.2<BR/>(-59.3 to 85.7)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="9">
<P>Referral to hospitals</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Schoffski 1997</P>
</TD>
<TD>
<P>Social insurance</P>
</TD>
<TD>
<P>ITS</P>
</TD>
<TD>
<P>0.1<BR/>(0 to 0.2)</P>
</TD>
<TD>
<P>13.3<BR/>(1.2 to 25.5)</P>
</TD>
<TD>
<P>10.8<BR/>(-3.1 to 24.7)</P>
</TD>
<TD>
<P>13.3<BR/>(-16.6 to 43.2)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-09" MODIFIED="2015-05-22 12:49:42 +0200" MODIFIED_BY="Arash Rashidian" NO="9">
<TITLE MODIFIED="2013-10-22 18:53:57 +0200" MODIFIED_BY="[Empty name]">Effect of pay for performance policies on drug use and health outcomes</TITLE>
<TABLE COLS="10" ROWS="21">
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Setting</P>
</TH>
<TH>
<P>Type of study</P>
</TH>
<TH>
<P>Adjusted absolute change</P>
</TH>
<TH>
<P>Adjusted relative change<BR/>3 months</P>
</TH>
<TH>
<P>Adjusted relative change<BR/>6 months</P>
</TH>
<TH>
<P>Adjusted relative change 12 months</P>
</TH>
<TH>
<P>Adjusted relative change 24 months</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="10">
<P>Drug use</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="11">
<P>
<B>Financial incentive for prescribing according to local guidelines </B>
</P>
</TD>
<TD COLSPAN="9">
<P>
<B>Prescription per patient</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Chinolones</P>
</TD>
<TD>
<P>Martens 2007</P>
</TD>
<TD>
<P>The Netherlands</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-0.1</P>
</TD>
<TD>
<P>-0.02*</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-0.13</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Nitrofurantoin</P>
</TD>
<TD>
<P>Martens 2007</P>
</TD>
<TD>
<P>The Netherlands</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0**</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>0.037</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Trimethoprim</P>
</TD>
<TD>
<P>Martens 2007</P>
</TD>
<TD>
<P>The Netherlands</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>0.3</P>
</TD>
<TD>
<P>0.10**</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-0.03</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Amoxicilin plus clavulanic acid drugs (long-term, short-term)</P>
</TD>
<TD>
<P>Martens 2007</P>
</TD>
<TD>
<P>The Netherlands</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-0.6</P>
</TD>
<TD>
<P>-0.19**</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-0.12</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Amoxicillin</P>
</TD>
<TD>
<P>Martens 2007</P>
</TD>
<TD>
<P>The Netherlands</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-1.8</P>
</TD>
<TD>
<P>-0.20*</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-0.03</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Doxycycline</P>
</TD>
<TD>
<P>Martens 2007</P>
</TD>
<TD>
<P>The Netherlands</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>-0.7</P>
</TD>
<TD>
<P>-0.16**</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-0.12</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Mupirocin</P>
</TD>
<TD>
<P>Martens 2007</P>
</TD>
<TD>
<P>The Netherlands</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>0.5</P>
</TD>
<TD>
<P>0.41**</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Recommended gastric drugs</P>
</TD>
<TD>
<P>Martens 2007</P>
</TD>
<TD>
<P>The Netherlands</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>1.7</P>
</TD>
<TD>
<P>0.18*</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>0.27</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Neutrally advised gastric drugs (short-term, long-term)</P>
</TD>
<TD>
<P>Martens 2007</P>
</TD>
<TD>
<P>The Netherlands</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>0.4</P>
</TD>
<TD>
<P>0.01*</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-0.02</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>Newly introduced drugs (short-term, long-term)</P>
</TD>
<TD>
<P>Martens 2007</P>
</TD>
<TD>
<P>The Netherlands</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>0.1</P>
</TD>
<TD>
<P>0.01*</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-0.12</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>
<B>Implementation of Quality and Outcomes Framework</B>
</P>
</TD>
<TD COLSPAN="9">
<P>
<B>Drug use - percentage of patients with coronary heart disease treated with a &#946;-blocker (incentivised outcome)</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Doran 2011</P>
</TD>
<TD>
<P>UK</P>
</TD>
<TD>
<P>ITS</P>
</TD>
<TD>
<P>2.91 (2.75 to 3.65)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>2.61 (0.09 to 5.14)</P>
</TD>
<TD>
<P>0.96 (-2.15 to 4.09)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="9">
<P>
<B>Drug use - percentage of patients with coronary heart disease and left ventricular dysfunction treated with current</B> <B>ACE inhibitors (incentivised outcome)</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Doran 2011</P>
</TD>
<TD>
<P>UK</P>
</TD>
<TD>
<P>ITS</P>
</TD>
<TD>
<P>-1.31 (-2.91 to 0.31)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>2.5 (-1.35 to 6.35)</P>
</TD>
<TD>
<P>1.20 (-3.56 to 5.96)</P>
</TD>
</TR>
<TR>
<TH COLSPAN="10">
<P>
<B>Health outcomes</B>
</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Financial incentive based on the proportions of patients achieving certain quality indicators</B>
</P>
</TD>
<TD COLSPAN="9">
<P>
<B>Percentage of patients with controlled blood pressure</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Serumaga 2011</P>
</TD>
<TD>
<P>UK</P>
</TD>
<TD>
<P>ITS</P>
</TD>
<TD>
<P>-0.61 (-0.33 to 0.21)</P>
</TD>
<TD>
<P>-0.931 (-3.82 to 1.96)</P>
</TD>
<TD>
<P>-1.12 (-4.6 to 2.35)</P>
</TD>
<TD>
<P>-1.49 (-6.32 to 3.34)</P>
</TD>
<TD>
<P>-2.21 (-10.08 to 5.65)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>*Mean.</P>
<P>**Median.</P>
<P>CBA: controlled before-after; ITS: interrupted time series.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-10" MODIFIED="2015-05-22 12:49:54 +0200" MODIFIED_BY="Arash Rashidian" NO="10">
<TITLE MODIFIED="2014-01-02 08:40:51 +0100" MODIFIED_BY="[Empty name]">Effect of drug reimbursement rate reduction policies on drug use and expenditures</TITLE>
<TABLE COLS="10" ROWS="5">
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Setting</P>
</TH>
<TH>
<P>Type of study</P>
</TH>
<TH>
<P>Adjusted absolute change<BR/>
<BR/>
</P>
</TH>
<TH>
<P>Adjusted relative change<BR/>3 months</P>
</TH>
<TH>
<P>Adjusted relative change<BR/>6 months</P>
</TH>
<TH>
<P>Adjusted relative change 12 months</P>
</TH>
<TH>
<P/>
<P>Adjusted relative change 24 months</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="4">
<P>Drug reimbursement rate reduction 
</P>
</TH>
<TD COLSPAN="9">
<P>Costs per prescription (hypertension)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Chu 2008</P>
</TD>
<TD>
<P>Taiwan</P>
</TD>
<TD>
<P>controlled before-after (CBA)</P>
</TD>
<TD>
<P>0.012</P>
</TD>
<TD>
<P>0.008</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="9">
<P>Items per prescription (hypertension)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Chu 2008</P>
</TD>
<TD>
<P>Taiwan</P>
</TD>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>0.49</P>
</TD>
<TD>
<P>0.028</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-11" MODIFIED="2015-05-22 12:50:05 +0200" MODIFIED_BY="Arash Rashidian" NO="11">
<TITLE MODIFIED="2014-12-06 13:36:17 +0100" MODIFIED_BY="Arash Rashidian">Potential modifying factors of the effectiveness and outcomes of financial incentive policies for prescribers</TITLE>
<TABLE COLS="3" ROWS="2">
<TR>
<TH VALIGN="TOP">
<P>Financial incentive policy</P>
</TH>
<TH VALIGN="TOP">
<P>Pharmaceutical budgets</P>
</TH>
<TH VALIGN="TOP">
<P>Pay for performance</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Potential modifying factors</P>
</TH>
<TD VALIGN="TOP">
<P>Formula for calculation of the budget (e.g. link to patient needs, link to past pharmaceutical expenditures &#8230;)</P>
<P/>
<P>Level of application of the budget (healthcare system, health settings, organisation or individual prescribers)</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Size of the incentive (absolute size, proportional to total revenue of the prescriber)</P>
<P>Nature of the incentive (positive financial incentive vs negative financial incentive)</P>
<P>Level of application of the incentive (individual prescriber vs group or organisation)</P>
<P>Target outcomes for incentives (and as compared with outcomes not covered by the incentive)</P>
<P>Target group of pay for performance (targeting specific groups or whole population)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-01-06 14:47:25 +0100" MODIFIED_BY="[Empty name]"/>
<FIGURES MODIFIED="2015-05-26 10:52:30 +0200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-05-26 10:52:30 +0200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqkAAANMCAYAAAB/2DRCAAB8UklEQVR42uy9D0Re/////2ZmMjMj
mUwmkiTJSDIvMyMz8/IxMXmZeXkZM5nMjLckSWIySTKSvCUTk5fMJCYzMy8xmczMSJKZGZmXzMzz
97s/v56Xc52dc57nXNdV68/txqXrus45z/N8PK/H8/G89/x3/mMC/Oc//+HFi1fKF2QDn6F+AABk
ajeCDQgAZBNdQFkBvzkAbKNIJZgA0BBTRsBvDwC7LIYQRABoiCkbwAcAAJEKQCNM2QA+AACASAWg
EaZsAB8AAEQqAI0wUDaADwAAIhWARpiyAXwAABCpAEAjTNkAPgAAiNQ3b97wSwGNMGUD+AAAIFL/
H1++fDGnTp3KvT99+nTBN3ry5Ik5fPiwaWpqynztkSNHShootytolirdYtPZzut3usHJcr9S5u1X
3fcgCZTdEl8QcNgIAHtQpM7OzpqOjg77/vHjx+batWsF30gNyNOnT39ZkNtLgXI3i1TEFeVVqnLc
LfEFAYeNALAHRWpvb68ZGxuz7+/du2cePXqUmJjOOXr0qCkrKzPnzp0z6+vruSDle6az6wk5dOiQ
aWhoMIuLi7HXRqUR/O7Hjx/m1q1b5tixY6aystJMT08n9qT29fWZ48eP27x3dXWlypcvGOv9xMSE
qaqqsteGG9Fv377ZRlllVVtba16+fBmbTjG2+uxLc32hNmbxEZfeq1evTEVFhTlz5kzsb6W8njhx
woyMjMSWlS9vHz58MJcvX7b50DH9BhJNiNSdEyg7GV+ifMtXN5LqaCG+7KtrWWINIhUADqxIDQf9
NI3A0NCQFQ0KxHqp8Qn2jPgCVVBEzM/Pm+rq6thrfcLtwYMHZmBgwObj06dP5uzZs7FiRvmUmNG5
379/tw3H4OBgqnz5BJxEkGu4lIbScvT09JiZmRn7fm5uztTV1RUkUn22+uzzXV+MjYX4SGdnpz22
sbHx0/1kx927d3N5bW1tTRSpSXlrbGw0U1NTubwoXxIUiNTtFyi/Ir5E+ZavbiTV0UJ82VfXssQa
RCoAHPieVPVWqTdBnDx50mxtbcWeW19fnzvX9UKUl5enDlQSCK5B8AU5n3BTz0UwL0tLS7FiRnPY
1GgECTYOSfnyCbhgz0r4uBq88H0LEak+W332+a4vxsZCfCQpvZaWFvPx48dUv2vWvAn1YCFSd06g
7GR8ifIHX91IqqOF+LKvrmWJNYhUADjQIvX169e2p0oo2Lr3aRr4YM9A2kClngOdo4ZDw4DFiNRw
b54amjgxo3PDPTlBW5LyVYy4TOpxLCadsK0++3zXF5O3UvhI8LvwArqk3zVN3jQcq94yzYuU6Ch0
cR2NcPay2en4EnU8a90oNj++upYl1iBSAeDAitRChuOiAnrWRl+iQcNqbW1tdli3VCI1KS9RjU3a
fO1GkZrVPt/1pRSphfhIof98+NKanJy0PWXj4+NmYWHBDskiUndGoPyK+BJ1vJC6UUx+0tS1tLEG
kQoAB1akCs2vUkMurl+/7l3UoIn+4eGvYM9XlkC1vLycGPDDn1dXV38aFg7mZWVlJTY95Xtzc7Og
fBUjuGpqagoa7s9qq88+3/WlFKmF+Ejwu+bmZjuXz6HeuEJFqhavBMslXK6I1O0VKDsdX6KO++pG
Uh0tJD9Z6pov1iBSAeBAi9RLly6ZZ8+e/fQ+Di0kGB4ezi0kGB0dtUE+baBSr5ZWt4rwIhetntWQ
oAvwwQUGa2trdoFMMH0tiOnv788tUDh//nysAFG+3WIGvfRZK3XT5KsYAadhZg3vCZVt3MKpYm31
2ee7vpQitRAfSVo4JTsKFala9e9W80ssSAAjUndOoOx0fIk67qsbSXW0kPz46lqWWINIBYADLVLV
0+REobZoCfYAxOG2ZNFLPSXv379PHag0zKV5gW67IBeshVbcqpfC9VS4AK5z1TDo3HD69+/ftwsZ
lHetvE0SIN3d3dZepS8R6Fbj+vJVjIDTIpH29nabptLXIoqo84q11WdfmutLJVIL8ZHwd2rklU9t
4aO8xvVe+dJ6/vy5XSSjspU40IIVROrOCZSdji9xx5PqRlIdLTQ/SXUtS6xBpO4t+3nx4pXulVqk
Aux2JCLcE4tohBEogA9gO8D+qjOIVNgzqAdKi0rcvpbqydoNi0uoQ5QN4APYDVD6uoNIhT2DVuFr
r0kNzWqPzTt37lixSmNEQw34ADYD7L86hEgFoEGibAAfwGYARCoADRJlA/gANgMAIhWABomyAXwA
mwEQqQA0SEDZACIVABCpADRIlA3gA9gMgEgFABqkvVQ2b9682RVlsVvyQf3AZtgbHNSY8UtEKpUW
aJAom7RlVsoyDT6VLJy2nuqkpzs1NTWV5L5J1yflYz/7MiI1ny9fvuQeQqL3p0+fLvg+Yf8lZu58
XogZ/9nWdOlJBaAR3nVlU8oyTUpLDbwePbwT94p4kgoi9QD6/ezsrOno6LDvHz9+bB+pWyil9l9E
6u66/qDGjFQiVd/rWdIVFRV2A3VHX1+ffe60nlfd1dVlv/v69av9z1CPqQyi53E3NDREGhKVjtB/
lZ8/f7bvV1dX7XX//POP/fzx48fcf50IAyDg7t2yCX6vJ4jdunXLHDt2zFRWVprp6enU8cKlNTEx
YaqqqnLPvXcNd9RzoYN/446luW+afAfzGHWv4eHhyHwnxWA9aU35KSsrM+fOnTPr6+uJ5R1lk/Ks
B2KMjIyEn+6SmCfqR/E29/b2mrGxsdxv+ejRo8S04n5v3zPPs7bjwXZbwln3q62tNS9fvkyVn7j7
+eqJ6w2Wv0kvLC4uJpZHXN6vXr1qnj17lpfuxYsXvTaF/X87YxUxo8QitbOz0xbqxsaG/U4VS42B
eyylCnhwcNAeu3nzphkaGspL48GDB9a4sNFJ6fzxxx/2v0uhyqvubleh9bmY/zoBEKm7T6QqTgwM
DNh48OnTJ3P27NnU8cKldfny5VzgVYBUoEzTG5F0zHdfX77T9IpcunQpMd/hGKwYq0ZC3+mlPAZj
oq/BkT16lLDLc2tr60/lkZQn6kfhNodFRxqRWcjvXUw7Lnp6eszMzIx9r8dQ19XVZcpP+H6+ehIU
NfPz86a6ujrWnqS8637Nzc32mDrMlM7bt2+9NmURqcXGKmJGiUVqUG0LzXtRRoM4h5IzqDfVHddf
9XoG/+tLk87k5KQVvOKvv/6ywyJuaOT69ev2RwdApO4fkar/+NXT4VhaWkodL+JiVVohmnTMd19f
vtM0OL58h4/X19fn3VPvy8vLUzc4LS0tdkQqLs++PFE/irdZvVHuNzx58uRPI5DF/t7FtONCAi58
PEt+wvfz1RP1+jkB6cOXdwkwCUEJw9u3b6eyKYtILTZWETNKLFLDSB2H//tT967jt99+s6pbTE1N
2d6NqPSS0pHYbWxstO/V9b+8vJybZK5uek0BAECk7h+RGv6vW0E+bbxIE2QLFam++/rynabBydpg
Bu8flQ9fmuGFGOE8pxn6o34UbvPr169tT5RQw+7ex1HI711sO57UC1ZIfnz1RL2n+iyBp6kQSfjy
7oSiRJibNuizKYv/FxuriBnbLFKjjA2ibnQJSScwFxYWItPzpaP/NNWt7MSp5jqsrKzkPgMgUvev
SM0aL7ZLpPru68v3djQ4vnsW28giUrfP7wsZ7i/k9y62HU8SdIXkJ0090TxK6Ye2tjY7tJxFJIfR
0LN6TndCpBIzdplIlfDc3NxMTFiCUt3t4W01gun50rly5Yr5888/c8P8bsjffQZApO4fkarhpOBw
lP4hzRIvtkuk+u7ry/d2NDjKU3joLtjTEb7GLT51aM6eOgAc6tlDpO6c32suoKa0CU1f8y2ayvp7
l6Idr6mpiR0aLyQ/WeqJRk6TbPLlfXR01I7mjo+P5w33J9mU5P/h+lNsrCJmbLNI1QRcN+lXL33W
SrEgmguiVWvBycLh9HzpaKWYuuvlcOLhw4d2VZqbSgCASN0/IlVTg/r7+3MT88+fP58pXviCpGKH
hlZdoE4rUn339eU7TFI+0jY4yoPio8uTYqQa4GCvh1uEsra2ZqdcJS2CkD2I1J3ze/XyuRXowfdx
+H7vQkSqz6+1yEhD8EL5Cy+cypofXz1R+lqJL3yLbpLyroVCwekTEmfv3r3z2hS3iCuq/hQbq4gZ
2yxSRXd3t92KQEpcxrgVZA51setYUHlHpZeUzosXL/K2nnITdZ3DIQwAkbp/RKq4f/++/cdUW7do
8UOWeOELkvqHWde53oO0IjVNvPPlO/wPfFw+0jY4wm0no5d65t6/f5875hp5DTuqIVLjH05HjaTy
q84E5dnXE4ZILZ3N8iUnOPQbBHu44kj6vQt9KEaSX2shV3t7u/UjLbpR+1tsfpLqiYb6dR+3fZET
rHHE5V15Dop+vXfrYpJsCuYlTf0pJlYRM0ooUgGARpiy2d+o8d7uuf6IVABiBiIVgAaJsoFE1IOj
BSpuH0f1sCQtVMEHsBmIGTsdMxCpADRIlM0BRDuuaK9GDddpF5U7d+7YhgcfwGaA3RIzEKkANEiU
DeAD2Aywq+sQIhWABomyAXwAmwEQqQA0SJQN4APYDACIVAAaJMoG8AFsBkCkAtAgAWUDiFQAQKQC
0CAduLJ58+YNhUv92HM2J/ktPg2ASAWgEd6lZZPl3OATT/iNqB97xeaw3wbPSzqGfwAiFQAIsntE
pGYtc34j6sdusDmpLHyP6AVApAIAjfAOlI2eXnLr1i37jGs9D3p6ejrv3A8fPtjnXpeVldnnStfW
1prZ2dlcmsGX73x3zfr6un1utc65ePFi3vO7fdfredbu+dYNDQ1mcXExz56+vj77bGs9G7urq4sf
HpEa+V3Yb4N/444V4mNJ/vrt27dcPZCfv3z5Mi+Pr169MhUVFXYD97T3TjquNCcmJkxVVZXNj/Kl
58VHlZXvXHcvxQ1tLD8yMpLq2fWASAWgEYbUZfPgwQMzMDBgxeqnT5/M2bNn885tbGw0U1NT9rhe
aozUcMalm+b8lpYW8/HjR3v88ePH5vr166mvDzaW8/Pzprq6OndsbGzMNqzusYES3IODg/z4iFTv
90kCK/g5q48l+WtPT4+ZmZmx7/W4y7q6urx7dnZ22vtsbGykurfvuNLUP4D6J1EoX8pfXBkknav7
6JGcLm60trYSfxGpAEAjXNqyUS+NenQc6tX0laN6VrKUefj8YM+pGrmmpqbU10uwuoY9jNJRekGC
ogAfQKQWK1Kz+liSv0qUhtMK3tMJxLT39h2PSjPObt+57h/NLHEDEKkAVCbIVDbB3hEnGsPnathR
vT4dHR2mvr7eO6yX9fxwHpKuV2+UPqtB7u3t/Smd8HBtUODiA4jUYkVqVh/z+WuWfPvu7TseN/Uh
TRmEvwsvLouKG4BIBQBEaklFavjcyclJ2+MzPj5uFhYW7NBjUmOW9fxwg+e73olYDY+2tbXZIUcH
gpT6sd0itRAfi/PXrCLVd2/f8VKK1DT/3AIiFQAQqUWVjYbtgsP9KysreedqYcTm5mbu8+rqamJj
lub8t2/f5j7r3qdOnUp9fZDl5eW8Y1qYErwWqB+lFqnF+FjYX2tqahKH+8P47u07XkqR2tzcbOei
Ol6/fk38RaQCAI1wactGi5T6+/tzCyDOnz+fd65W97rV9RKwapyCx7UyWXPXnND1na/3Fy5cMJ8/
f7b31KKt4MIp3/XqZdWKaRFezDE0NJRbBKaXPp87d44fH5H6E2G/TfLp4LGsPpbkr5rSoukA4tmz
Zz8tnArju7fveClFanjhlO5D/EWkAgCNcMnL5v79+6a8vNxuXaMVwsFznz9/bhdfqHFVI6pFIMHj
Wj2s4Xo3ZO87X+91D91L10iwBhdo+K7X0KnmqbptcZwAcHR3d9veWKWt1cluZTQgUoOE/TbJp8Np
ZPGxJH/d2toy7e3t9nudE1xQGJdv372TjpdSpAr9c6t6rK3rVKeD03aIxQdQpMqhNTwQxb1796xj
6j9AOX1w1R0AjTBQNoBIhe1C+iQ4bQcOmEjVnmdXrlyJrHDqBdFegq6LX//dMMQFNMJA2QAiFb/f
DjTyosVgbk9WdZQFF4XBAROpEp1ra2uRFU5DY//++2/ed0mrBgFokCgbwAf2i01ZHnEKpUE7b2iP
ZQ3x64lTd+7csWIVDqhIlUOkqXBa2adHlWl/QQAaYaBs4CCI1KjHmeL3ADskUtNUuKtXr9rn9eql
7SAAaISBsoGIxuZAvQBgF4hUh+aGaL80AIQYUDawn32AnlSAPSZSNS+EOalAIwyUDRwUkYrfA+xS
kVpRUZH35AdtQKyVdwA0wkDZwEH2Afwe4BeLVA3v9/b25rag+u9//2tfADRIQNkAIhUAfplI1fB+
Z2en3QpCi6YkWgFohGGvlY0vj/y+1A9sBtjFIhUAaJAOqkgFyhebARCpADRIB6Rs9CxxLbTUs8W1
K8ji4mLece27rOdza5Smq6sr79iHDx/s88H1OGalUVtba2ZnZ/PuqWeXa968Nv4WmjN/7do1e43O
f/nyZd75w8PDpqqqKves86dPn0baoPcTExOx57q863HR2mxcT+U76Ku+sRkAEKkANEh7pmyC4m5+
ft4+wc4xNjZmhaB79OH09LQZHBzMHW9sbDRTU1O5+fASghKkwXtqKpKObWxs2O96enrMzMyMfa/H
KtbV1eWdf+nSJbO+vm4/K1/BnUrCIlMCOe5c5VuPadS9tbC0tbX1wPsHIhUAEKkANEh7pmwkKp1o
DNPU1GRFXpCgiI1CvZrBezoR6ZAoDaeZdH5c76fv3JaWFvPx48fc56WlJUQqIhUAEKkANEh7pWzU
e6pjEqTaJSSIeibDm6QHRajQcL56R/Uo5vr6eu+QetIezlHnJ4nUpHO1kDSIhDEiFZEKAIhUABqk
PVQ2Epoaem9ra7ND5I6wIA0zOTlpe0bHx8fNwsKCHdLfLSI1fB9EKiIVABCpADRIe7RslpeX887T
QqrNzc3Y87UoKXh8dXXVKyRramoSh/tLJVKbm5vzHnLy+vVrRCoiFQAQqQA0SHulbNQTqhX+Irz4
aGhoyAwMDOQWRunzuXPncse1st6t5l9ZWbHC0CckNTVAUwzEs2fPflo4VSqRGl44pXwjUhGpAIBI
BaBB2iNlo6F+zSV12zg5wero7u62Paaa46nV9G6Vvnj+/LldSKXrJDa1AMsnJLe2tkx7e7u9RvfV
gqbtEKmiv7/fbp9VWVlpdyoIzlNFsGEzACBSAWiQKJtfjsTxqVOn8AFszn3vWxTo/EZTVMJ8/frV
7verf3zKy8vtHsJfvnxJfT0AIhWABgkOaNlIOGgxmNvjVY+LDi4KwwewOcjff/9tRw2CyG+uXLkS
mcaNGzfsnsFuKoweQqFz014PgEgFoEGCA1o22m1AT7lST5eeOHXnzh0rGvABbA4jkakHU6h3NIjm
Ma+trUWmIb8KLgDUe02LSXs9ACIVgAYJKBtApCai+crhXlT3j05cGmGRqsf9hvfmTboeAJEKQIME
lA0gUhNRL6q2T8uShuajaohfQlXzTm/fvh27rzB1DxCpAEBjQNkAPpDJ5rdv39qt07KmoUVSV69e
tbtUaGGUtlUL96RS9wCRCgA0BpQN4AMF2azeUC2qK7bctE+wtjqj3AGRCgA0BpQN4ANF26zV99oF
othye/z4seno6KDcAZEKADTClA3gA8XbrIdRBB9QkTYNPbxCwlR8+PDBtLW15T2YgroHiNRdyJs3
b/hF9yl74belMaBsAB/IYrPmlAZX6adNQ4JUW5y5Oal62hrlDgdWpGpS9qVLl/K+055umktz8uRJ
W1H0NBV93tzc/GXGxE0c36uBtNi87PT121l2pfhtaYQpG8AHsBlgn4nUpqYmuwrRoT3Zzp49awYG
Bsznz5/td/pvUM/hvnDhwi8TqqUICIjU3SlS90Kwp0GibAAfwO8BdlCkvnjxwgrPIBKnQ0NDkedP
Tk6anp6evBtMTEyYqqoqu4+bel2fPn2ad01fX585fvy4OXr0qH0GcRJPnjyxaSithoYGs7i4mLtP
8BUXIILfSVjfunXLPqlDKyOnp6ft8ffv39u968LoiTHqMQ4/GcRnh7YKefbsWZ4NFy9ezAl+7XlX
VlZmamtrzcuXLyPzWqgtacs5zfVZzvflN8vvHvXbCvXc61qVnZ6usr6+ToNEYw34ADYDHBSRqk2C
JTyDSMDF9ZZ++vTJ1NfX593g8uXLOQEhgSqR6dDTNiRi3TOuJXb0TOI4giJX0xA08TwuIPiE0oMH
D6zg1r2Vb/UOu+Pnz5/PCWCH8qlnJkeRZIcmxmsvPLfxsvLseqYl6N18Iq3y1IT4QkRqki1pytl3
fRjf+b78Zv3dw+npn6SRkZHcs6uVnsQ+DRKNNeAD2AxwQESqxJX2YAvimx8YPK50wz1cwXtpKkF4
4nhQeIapqKiInSSeVaRq4rl6Mh2ajO6OSzBqxWQQnf/69evIe/vskIiSsJMQk/B3SJTGTZzPIvqS
bEmTP9/1YXzn+/Kb9XcPp6d/hIL31/vy8nIaJBprwAewGeCgiFQNpYbFRFaRmlRx1TMaHs6Ne7yb
UO+pzpHI6e3tLUqkBnt0hewMHtcUBdfj6VZTxpHGDuVZQsrN443KQ6Ei1WeLL3++66PsTTq/1L97
OL2oc5PKkgaJxhrwAWwG2GciNUoMSGzFzcv8999/7VzRtGIlSZjEoQVarqfz7t27JROp4eP9/f3m
5s2b9r2Gkh8+fBibpzR2aIcE9ZzuhEjNWs6+67OeX+rfPZxe1vzSINFYAz6AzQD7TKRG9aRqPqAe
5xbF7Oys6e7uTi1WJGgL3Q1geXk5URiFP6+uruZ919LSkjdkrGkNweOaayn7P378aBf4aD5pHD47
RkdH7RzM8fHxvOF+7XFXyHB/Vlt8+fNdn/V8X36z/u7h9HR9eLj/V29TRYNE2QA+gN8D7KBI1ZzU
8JMstNBFC4skVJ3QkNDSCnatWv/y5UtqkSrB6xbg6KXPWqkdh3oitTpehBdhSVBq/qsTL8FFVmtr
a3YBV/DeU1NTtrfULf6RTeH8qgf1999/N52dnYkFmWSHFk61trbmCax3797Z91o4pSkMQuUXt3Cq
WFt85ZymLIL4zvflN+vvHv5t3T9K7nr9EyDBT4NEYw34ADYDHBCRql4/LfoJo15F9Zhq3qbbzF9D
70GBmkakCqWjrYzUEyYxk/SYOA31a9GM287KCVahRUlKw/WoORGrcyVgdG743vfv37fzRNVTKjvD
x7UllL5L88SjODva29vztqDSex135ajjyqfsCv5DEMxLKWzxlbPv+jBJ56fJb5bfPfzbCrcFlV76
Z0Jbh9Eg7a3GWqMU//d//2d/V/0jorqgf3qC6HeWn7jjuibt9WnSB+oHNgPsUZEqkZbUw7XfkXCS
EAegQSp92agH/tGjR7kecb0P7susf4SCW42p9z4Yj3zX+44D9QObAfawSBVaKLUXnp1eatSoqbcv
vIsAAA1SacomagFc8DttS6bFmHHHfdf7jgP1A5sB9rhI1dCt5mUeNDQ8qF6XpAVTADRIhZeN6+l0
aA/k3377LfJczX/XU8o6OjpSX58lfaB+YDPAHhSpAECDtB1lo32IT5w4kdsrV+/d3sRB9GhhN/84
+EAN3/Vp0wfqBzYDIFIBaJAomxxaMKedGtycUc1BvXLlSmw6WkQV3IfZd33W9IH6gc0AiFQAGiTK
xq66D+4TrPeaZhOHtr8Lzin1XZ81faB+YDMAIhWABomy+UkwSkRqSN9RUVGRt2WU9snVtmdpr/cd
B+oHdgPs/rqDSAWgMdrxstFDMvQUNvWQSkA+ePDA3Lp1K3dcw/vaXcMN1//3v/+1r7TX+44D9QPb
AXZ/nTmQInW7t9U6iNt2UakgS9lo5wwJSfegBgnI4G4aEpfuuHpAJVqzXO87DtSPnbSfFy9e6V4R
9ec/OxZYdkuw2u5nvf/qZ8nHocUkwSdgAY0wZQP4AADs4vjxn5282YEImrs1KGsLnjNnzuD1NMKU
DeADALB3RWpo4qp59eqVXczgRE7Ud0KbbuuZ7hqi6+rqSgxWUed+/frVnDp16qehOS2ccFvQfPjw
wfYKanGEVvzW1taa2dnZvPtMTEzYx5rqGfI6Rw8mcMeSupYd7vnwuocex7i+vp4YdAMr0X5KX3nX
M+aVlvKqR85muZfm1mnRiPZ61Abl2lpHzzQP2pWm/IUeUvDixQs8n0aYsgF8AAD2h0jV/C4tQNAz
7eO+Gxsbs+JQ32lO2fT0tBkcHIxMM+ncmzdvWiEWRAsfJMBEY2OjmZqayi2q0DO+JZaD95GIdWJP
Qi64fY0vaOreweeGK68SmWlEatTxnp4e+8QbMTc3Z+rq6jLd6/r167aM/v77bytOb9y4YT+H7fKV
v5DgvX37Np5PI0zZAD4AAPtDpAZ79+K+a2pqytubUOgZ3FFpJp2rYWn1prrj+nv69Omf7hdEPaa+
/KYNmvX19bb30xHe/iarSJUoDdua5V7hnlU9JjJrmTpWVlZMc3Mznk8jTNkAPgAA+0Okpgk86tUL
D3eHxWPac/WcbfUKCvWaqmc0iKYaqIdSz/OW0MuSX1/QDOYjmN9C0w9eW+y9kj77ytQJfvaLpBGm
bAAfAIADJVKjBFfcNb5zNSyu+ZtCc1EXFhZyxyYnJ23vpIau9b2mG5RSpEaJymLSTxKpWe+V9NlX
pmnyAzTClA3gAwCw70SqxGRwKDrpGt+5QgufNBdVQ/1BNC8zeO3q6mpJRaryFh6CD24rFb7ed/+a
mprY4f6s90r6nKZMNVeVnlQaYcoG8AEAOFAiVYuABgYGcouA9Fmr1aOu8Z0rtOinsrLyp8U/Eq9u
Nb+bY5klv1pFr3meQXEYtmN4eDiXt9HRUSs0HcFV9Wtra3YqQlL6mpYwPz9v32uf0vDCqaR7ZRGp
acr09evXzEmlEaZsAB8AgIMlUkV3d7ft6VRvoMSbW/kfdU3SueLz58/2WPAZ3uL58+d2QZDEogSf
Vs5nya9Er3sSTRxuWyi9tNr+/fv3uWNuVb2G1yUonzx5kpi+ttNqb2+312j+7NLSUup7ZRGpacr0
4cOHrO6nEaZsAB8AgL0rUmF/cvbsWbvoDGiEKRvABwAAkQq7Ak2N0DZVQCNM2QA+AACIVNg1/P77
73ZOLNAIUzaADwAAIhWARpiyAXwAAACRCkAjTNkAPgAAiFQAKhGFQNkAPgAAiFQAGmHKB/jtAQCR
CgA0xJQR8JsDACIVgMZ4v5YTr4PzAgBApAIgUgH/AABApAIAIgTwDwAARCoAIgTwDwAARCoAIEIA
/wAAQKQCIEIA/wAAAEQqACIE8A8AAEQqACIE8A8AAECkAiBCAP8AAECkAlCJKATAPwAA9pJIffPm
DSVMWSJCAP8AAIDSidRSPO7uyJEjJQvmpQr0xabzq67PWpa+e29Xw/nkyRNz+PBh09TUhAgBwD8A
AEovUksRZLNetxPBfK+K1FKUzU6UrwTq06dPESEA+AcAwK8Vqffu3TNHjx41ZWVl5ty5c2Z9fT13
Tbj39cOHD+by5cv2XImZ2tpaMzs7m+o+4V7AiYkJU1VVZQ4dOvSTMPr27Zu5du2avY/u8fLly9h0
ku7z48cPc+vWLXPs2DFTWVlppqenf7qmr6/PHD9+3JZBV1dX3rE01wdxvZCyqaGhwSwuLsaWZbF5
z2JHXL6i7h+Vz1evXpmKigpz5swZr9+4a8bHx015ebk5ceKEefTokRkaGrK27EYRjAgB/AMAYJeJ
VAmHkZERK4j0Ghsbs+Iw7rrGxkYzNTWVO1/XSrwUIlIldp2wkWiReHH09PSYmZkZ+35ubs7U1dUV
JFIfPHhgBgYGbF4/ffpkzp49m3dc9kos6/j379+tEBwcHEx9fZigAJufnzfV1dWxeS0271nsSMqX
z1f0ubOz06a9sbGR2m+uX79u8/L3339bcXrjxg37OfxbI0IAkQoAgEj9ifr6ettr6dB79X5lCc7q
nStEpAZ73sLHJUolftKkk3RcPX9B+5aWlvKOa95l+D5BAee7PowEuxPXacRfMXnPYkdSvtLkM/xb
pfGbcM/q5ubmrm30ESGAfwAA7DKRGhSYjmAvV9R1GvpVT2dHR4cVK2kX82QRl0k9bcWkIyEXPh4e
4g6Wie/6MOql1HGJxt7e3qJEqu/eWexIylchYjqr36RJExECiFQAAERqohhMEoGTk5O2l1PzDRcW
Fuzw714SqeHjUWIrS/lEIRGvKQptbW3m7t27JROpSbb77EjKVyEiNavfIFIBkQoAgEjNFGS1iCY8
bBvcKil8neYWBodtV1dXt0Wk1tTUFDTcH85PS0tLnn0rKyt5x2V/0J4wvuuTWF5eziTcsuY9ix1J
+SpEpGb1G0QqIFIBABCpmYKsFsAMDw/nFsCMjo5agejQym3NLXSCRKvx3Wp+iabm5uZtEamaTqAh
avHs2bPYhVPBBUFra2t2MVbwuBZ59ff35xYfnT9/Pu+47HeLk/TSZ61UT3t9GOVTK+lFeIFQuCyL
zXsWO5LyVYhI9fkNIhUQqQAAULItqPTSCu3379/njmmFuHrIXC/Z8+fP7YIciRwJHy3G2Q6RurW1
Zdrb2+19NO9Vi4aiznOCS8PdEkkSYuG079+/bxf1aHsmrUIPH+/u7rY9xLJRQtGtYE97fRANqSu/
blstJwyjyrLYvGexIylfhYhUn98gUgGRCgAA/yGAAiBCAP8AAECkAiBCAP8AAABEKgAiBPAPAABE
KgAiBAD/AABApAIgQgD/AABApAIAIgTwDwAARCoAIgTwDwAARCoAIEIA/wAAQKQCIEIA/wAAgG0U
qVnS+lX3pcEBfALwDwCAAyZSaQQAEQKAfwAAbLtIdc9XLysrM+fOnTPr6+t5gVfPdK+oqDBnzpyJ
DMZ9fX32efAnTpwwIyMjsc+O1/uJiQlTVVWVez68nk3v+PDhg32evPKhY7W1tWZ2djZVIxCVT5c3
PdNe9nV1ddnvvn79ak6dOmW2trby0vj27ZtpaGiItTGcjjh9+rT5/Pmzfb+6umqv++eff+znjx8/
2uM0YIgQwD8AACCjSB0aGrLC8sePH/Y1NjZmrl27lhd4Ozs77bGNjY2fgrFE5927d+3xT58+mdbW
1kSRKhHqRLAEqsSoo7Gx0UxNTeXyonxJdKYVqeF8yhblT999//7dTE9Pm8HBQXvs5s2b1vYgDx48
sGI0fK+kdP744w/z+PFj+/7Ro0fmyJEj9nz3OViWgAiB/ekX4RcAAJRApNbX19seRIfel5eX5wXg
YM9quLFuaWmxPYaOpaWlRJGalFYU6nFNK1LDaTc1NVlhGaS6utr+ffv2re1Ndcf1V72eLo3gvZLS
mZyctIJX/PXXX6ajo8O+xPXr162gBUQqIFIBACCjSA2KQEewdzPquuB36jkMIjGXJFJ9Db+G7Ht6
eqzQk4D2XZ90THaEG4+gvb/99pvtIRXqwVUvb1R6SelI7KoHWGiqwPLyshW/QtMVNAUAEKlwcIQq
AACUSKQGBWkhwjJ8fTEiVb2SdXV1Znx83CwsLNhh+2JEapQADzI3N2eFpBOYumdUer50NBdXUx2c
ONWc25WVldxnQKQCIhUAADKKVImz8HB/sHfUJyybm5utQHO8fv26YJGqxVebm5u5z24hUqEiVbYF
04tCglJzUd0Cp6j0fOlcuXLF/Pnnn7lhfjfk7z4DIhUQqQAAkFGkavHQ8PBwbrHS6OioqampSS0s
wwuntDtAoSJVgtGt5ldPpARwMSJVtg0MDORs02flL4gWQFVWVuYWQkWl50tH5ad5vCo78fDhQ7tD
gZtKAIhUQKQCAEBGkSrcFlR6aTX6+/fvUwtL0d/fb7dnktjTyva4nlhfWs+fP7cLkjSFQMP+MzMz
RYlU0d3dbXtolSfNOXUr/x3aPkrHgr3BUeklpfPixYu8rafc4rF3794hcBCpgH8AAEChIrWUaO9R
5mICIgTwDwAA+KUiVcPcWoDk9hBVr6yG/wEQIQe3nHgdnBfg9/g97FqRqhXxesKThsG1yv3OnTtW
rAIgUikj4DenDIDfHH6ZSAUgKAHlw2+P7cBvD4hUAAISZQP4ADYDPoBIBQCCEWUD+AA2Az6ASAUg
GFE2gA9gM+ADiFQAIBhRNoAPYDPgA4hUAIIRZQP4ADYDPgCIVACCEWUD+AA2Az6ASAUgGFE2gA9g
M+ADgEgFIBjt5rL58uVL7lHJen/69OmC7/PkyRNz+PBh09TUhO9gI36PT2AjIhUACEaFl83s7Kzp
6Oiw7x8/fmyuXbtW8H3UUD99+hTfwUb8Hp/ARkQqABCMiiub3t5eMzY2Zt/fu3fPPHr0KDEtnXP0
6FFTVlZmzp07Z9bX13P38D07W9+/evXKVFRU2Mc1O/r6+szx48dtul1dXXnXfPv2zQoI3a+2tta8
fPkyVX7i7vfjxw9z69Ytc+zYMVNZWWmmp6fz8ut6xQ4dOmQaGhrM4uIi9QO/x+/xe0QqABCMdqps
wo1rmsZ2aGjIjIyM2AZPLzXywR4o32+g452dnfbajY0N+53SmJiYsN99//7dNp6Dg4O5a3p6eszM
zIx9Pzc3Z+rq6jLlJ3y/Bw8emIGBAfvdp0+fzNmzZ/PyHewVm5+fN9XV1dQP/B6/x+8RqQBAMNrp
sjlx4oTttREnT540W1tbsefW19fnznW9PeXl5Zka62CPj9A8PjWcQYINpBrn8PEs+QnfTz1LwWuW
lpby8q3eJycOqB/4PX6P3wMiFYBg9AvK5vXr16a1tdW+V6Pm3sehocAw6oHJ0lhHXR/uzQreJ5h+
KfITTk9CIHieepH0WSJCQ8LUD/wev8fvaUMoSACC0Q6WTSHDnlENZ/DcQhrrqAbXd89i8uO7Rmg+
n4ZY29razN27d6kf+D1+j98jUgGAYLSTZaN5bJOTk/b99evXvYtHtKAiPMx45MiRohprpbm5uRl7
TU1NTeywZyH5aWlpybtmZWUlNt/Ly8v7xq8Qqfg9fg/bJlI1X0ZOG+bff/81N2/etKv85KTt7e12
zzcAGiTwlc2lS5fMs2fPfnofhxZsDA8P5xZsjI6O5sWlQhprpekWdOilz1qt7NACEg1FCuUvvIAk
a36mpqZMf39/bgHJ+fPn885T+lrpLLSQJKlHi/qB3+P3+P2BF6la+XflypXIwr59+7Z1UOes2pZC
QhWABgl8ZaPtaFzvirbCCfa0xOG2vtFLPVLv378vqrEW3d3dNi/6R/vy5cu5FcnuH3TFNDWaWjCi
BR/F5uf+/ft2oYls1sro4Hka8tR9NByre7qGm/qB3+P3+D0iNQL9d7W2thZZ2FqhGBwSkKANdvsD
IFKBsgFEKuD3sC0idWFhIXVh6z9CbSUBQDACygYQqYDfw7aK1CyF/b///c/OZQEgGAFlA4hUwO9h
V4jUz58/m6tXr9ohfwCCEVA2gEgF/B5+uUiVMP3jjz/sqj0AghFQNoBIxe/xe3zgl4tU9aBqG6rV
1VVKEghGQNkAPoDfAz7w60XqixcvzG+//WY+fvxIKQLBCCgbwAfwe8AHdodIPXXqVOpHuwEQjCgb
wAewGfABKLlIBQCCEWUD+AA2Az6ASAUgGFE22E1ZYPO23+tXX48PACIVgGBE2WA3ZYFIRaTi94hU
AIIRJJWNns+t53Tred0NDQ1mcXExd0xPr9MzwcvKykxtba15+fJlXnp61reebnfmzJnc9319ffa5
4HqeeFdX10/3SzquNCcmJkxVVVXu+eFPnz5Nfb0eD33r1i37LPTKykozPT2dZ/dB9w9Eajpf1F7j
z549y6sjFy9eTFUnku4b/M7nq/g6fo9IBSAYHfiyCQrB+fl5U11dnTumJ9fNzMzY93Nzc6auri4v
vc7OTttYbmxs2O/GxsasyNR32rdZDefg4GDuGt9xpXn58mWzvr5uPytfyl/a6x88eGAGBgbsce0X
ffbsWXwCkRr5fZIvyZ+bm5vtsa2tLVsn3r59m6pOpBWpPl/F1/F7RCoAwejAl416Ql2jG0YNsBrB
uPScmHQ0NTX9dH5Q9PqOR6UZzLfvevXoqqfLsbS0hE8gUiO/9/mSRKKEoITh7du3U9eJtCLV56v4
On6PSAUgGB34slHvqY6pUezt7c07FuzFTJOezg9vhadh+7THfQ17mvSDqJHHJxCpUfh8yQnF8vJy
+7CcrHUijS8n+Sq+jt8jUgEIRpTN/4/mlmrosq2tzdy9e7dgkRpu5LMe9zXsvuuj8otPIFIL8UVx
6dIl23O6EyIVX8fvEakABCPKJoHl5eW882pqalINbTq08GpzczM2fd9xX8Puu76lpSVvCHRlZQWf
QKQW5Iujo6N2Tuj4+HjecH/aOhG+rx5ZHvzO56v4On6PSAUgGB34slFPkVYvi/BCJS0S0XQAodXO
cYtEHENDQ7nFHHrp87lz51If94lU3/VTU1Omv78/t5jk/Pnz+AQiNfL7JF/SwqnW1tY8wfju3btM
dSK4IHFtbc0uCAwe9/kqvo7fI1IBCEYHvmw01F9fX5/b8skJVqGVze3t7fZ7naPFGb70uru77bY4
R44csQ2zW/mf5rhPpKZJ//79+3Yeobbu0eIXtuVBpMYR50vy+eAWVHqv41nqhPuHT/VKva+qV+G8
JPkqvo7fI1IBCEaUDeAD2Az4ACBSAQhGlA3gA9gM+AAiFYBgBJQN7GMfcNsz4feADyBSAQhGlA3g
A7tOpIZf+D3gA4hUAIIRZQN7zAfihN1+fQF+DyUoRwoTgEBE+QA+kM0melKB2LdDIpUCBSAIUUaA
D2QTqfg94AM7JFKT/jvkxYsXw3kEasAHsBnwgV8mUgFnB8B3AR/AZsAHEKmAswO+C/gANgM+AIhU
nB0A3wV8AJsBH0CkAs4O+C7gA9gM+AAgUnF2AHwX8AFsBnwAkQo4OwC+C/gAfg/4ACIVZwfAdwEf
wGbABxCpgLMD4LuAD2Az4AOIVMDZAd8FfACbAR8ARCrODoDvAj6AzYAPIFIBZwd8F/ABbAZ8ABCp
ODvALvbdra0tU1NTk/n4169fzbVr18yRI0dMeXm56erqMl++fMm7b/h16NAhfhDi1572+yAzMzOx
90lzPeD3iFTA2QHfjeH79+/mypUrseckHb9x44YZHBw0P378sK/h4WF7bhx///236e7u5gchfu1p
v3esra2Zc+fORZ6T5nrA7xGpgLMDvpvgu2pk1djGnZN0XD2oEqcOvT927FhkOjrW2Nhoe1+B+LWX
/d7R1tZm3r17F3lOmusBv0ekAs4O+G6C7y4sLCSek3Q8LFK/fftmv4tibGyMXlTi177we9Hf329G
RkZiz/FdD/g9IhVwdoCUvus7J+q45qNqiF9CVfPvbt++HTvnVL2oq6ur/BjErz3v9//884+5cOFC
qjRoN/B7RCrg7AC/oLHWIqmrV6+aw4cP2wUi8/PzkT2pb9++Nc3NzfwQxK897/earnLmzBnz8eNH
RCp+j0gFnB1gt4rUMCsrK6aysvKn79Xbeu/ePX4I4tee9/vr16+bx48fp06DdgO/R6QCzg6wC0Sq
Gu+Ojo6fvtcq57m5OX4I4tee9/uobdXci3LH7xGpgLMD7BKRWldXl+tV+vDhg13tvLS09NN51dXV
ZmNjgx+C+LUv/zmjJxW/R6QCzg6wyxprCVLNz3NzUrWxeRQ6HtwFAIhfiFTA7xGpgLMD4LuASAX8
HhCpODsAvgv4ADYDPoBIBZwdAN8FfACbAR9ApOLsAPgu4APYDPgAIhVwdgB8F/ABbAZ8AJEKODvg
u4APYDPgA4BIxdkB8F3AB7AZ8AFEKuDsgO8CPoDNgA8AIhVnB8B3AR/AZsAHEKmAswPgu4AP4PeA
DyBScXYAfBfwAWwGfACRCjg7AL4L+AA2Az6ASAWcHfBdwAewGfABRCrg7AD4LuAD2Az4ACIVcHbA
dwEfwGbABwCRirMD4LuAD2Az4AOIVMDZAfBffntsB357QKTi8AD4MPCbUwbAb45IBZweIKMf8zo4
L8Dv8XtApCJSAYD6CwCASAUaOQCg/gIAIFKBRg6A+gsAgEgFGjkAoP4CACBSgUYOgPoLAACIVBo5
AKD+AgAgUoFGDoD6CwAAiFQaOQCg/gIAIFKBRg4AqL8AAIhUGjkAoP4CACBSgUYOAKi/AACIVKCR
A6D+AgAgUoFGDgCovwAAiFSgkQOg/gIAACKVRg4AqL8AAIhUoJEDAOovAAAilUYOAKi/AACIVKCR
AwDqLwAAIpUfiUYOgPoLAIBIBRo5AKD+AgAgUoFGDoD6CwAAiFQaOQCg/gIAIFKBRg6A+gsAAIhU
GjkAoP4CACBSgUYOAKi/AACIVBo5AKD+AgAgUoFGDgCovwAAiFSgkQOg/gIAIFKBRg4AqL8AAIhU
oJEDoP4CAAAilUYOAKi/AACIVKCRAwDqLwAAIpVGDgB2Yb0NvwAAAJGKSAUARCoAACIVEKkAkCRU
AQAAkYpIBQBEKgAAIhUQqQCASAUAQKQiUgEAkQoAgEgFRCoAUH8BABCpQCMHQP0FAECkAo0c7Bc/
4cWLV7oXACBSAZEK+AgAdQYAEKkEU8A/AIC6A4BIBQIp4BsA1CEAQKQSRAHwDQDqEAAiFQiigG8A
UIcAAJEKBFHANwCoQwBA7SSIAr4BQB0CAEQqEEQB3wCgDgEAIpUgCvjGnubNmze7Kp3tThOoQwCA
SCWIwr72jS9fvphTp07l3p8+fbrg+zx58sQcPnzYNDU1FXQ8Kd8+/z5y5EhJyqpU6SSlmbauUqd3
TzzktwBApAJBFHbYN2ZnZ01HR4d9//jxY3Pt2rWC7yMB+vTp04KPFyNSS+X/21GPCk2TOo1IBQBE
KkEZDqxv9Pb2mrGxMfv+3r175tGjR4lp6ZyjR4+asrIyc+7cObO+vp67R9Izz6OOx52XVaTG3buv
r88cP37c5rerqyv3/dWrV82zZ89yn9XDe/HixVTPbf/w4YO5fPmytV+iu7a21gr9YF5evXplKioq
zJkzZ7x2f/v2zf5joPSU1suXL2NtjrPH2aD8HDp0yDQ0NJjFxcXY8vLZkJSW7z6F5rGYdH/8+GFu
3bpljh07ZiorK8309DQiFQCRCohU2Ku+ERZPaQTa0NCQGRkZsaJAL4nbYM9r1t7OUonUqOPK28TE
hM3n9+/frXAZHBy0xzY2Nkxzc7M9trW1Zaqrq83bt29T3aexsdFMTU3lykDlIUEazEdnZ6c9pvv4
7O7p6TEzMzP2/dzcnKmrq4s8L8keEeylnp+ftzYVakNSWknHisljMek+ePDADAwM2OOfPn0yZ8+e
RaQCIFIBkQp73TdOnDhhe/PEyZMnrWiLo76+Pneu0Pvy8vJdKVI171WiJUhY+EjcSOzcvn27qHqk
3r/g9a53OY3dEqXhfEad57NHItOJ3UII2pCUVtKxYvJYTLrqsQ765dLSEiIVAJEKiFTYy77x+vVr
09raat9LWLn3aYSMQz1gu1GkKl/h3uFw/iV+JLI/f/6cqR5pOF89oJrLK+Huy2eS3cHyS7rOZ496
H/WdbNIUjmJsSEor6VgxeSwm3XAZStAiUgEQqYBIhT3qG4UM90cJqmKEZCEiNS6f4bSiBHWYS5cu
2Z7MLCJ1cnLSXjM+Pm4WFhbskP5OiNQ09kh4aspAW1ubuXv3bsE2+NKKO1ZsHgtN1+eXxFcARCog
UmGP+Ybmk0qwiOvXr3sXTWlBS3i4P7i9UrEidXV1tWQ9qcrr5uZm7Pmjo6N2nqOEWpbhfi3OCaab
lOc0dtfU1KQa7vfZE2R5eTnRDp8NadMKHytVHrOm29LSkueXKysriFQARCogUmEv+4Z6Et0q9+D7
OLRwanh4OLfgRkJPIqtQIRlcLLO2tmZXnBcqUrVSXVMWnFhRXt1iGr30WbsRCPUcBqc2SAS9e/cu
Mp0wVVVVuZXwEkNagOXLZzjN8MIpDXULlX/cwqkke4Su0wp5oTJN6qH12ZCUVtKxYvJYTLpaBNbf
359bOHX+/HlEKgAiFRCpsJd9Qz1qTjhpe584YRbEbUGll3pi379/X7BIdWJEw7kSuxIphYpULYBS
r26wZ7e7u9vaqO8kgN1q+/b29jxBrvc6HpdOkOfPn9tFO8q3hJUW+/jyGU4zeI4Wqik/Sk9zQ7Xo
Jy6tOHuEhsp1vcpSaTnBV4gNSWn57lNoHotJV9y/f9/OL5Yfa1EcIhUAkQqIVMA3AKhDAIBIBYIo
4BsA1CEAQKQSRAHfAKAOUYcAEKlAEAV8A4A6BACIVIIo4BsAQB0CQKQCQRTwDQDqEAAgUgmiAPgG
AHUIAJEKBFHANwCoQwCASAWCKOAbBfDmzRsKAahDAIhUIIjCbvQNPdVHT/dpamr6JXnJ4rNZrkvz
1Kq4J0oBEF8BEKlAEIVf7BsSqHo06V7z00LFLfUFiK8AiFQgiMIu9w19F3w57t27Z44ePWrKysrM
uXPnzPr6et41esZ6RUWFOXPmTOz9+vr67DPUlU5XV1dsXsL50nV6PvuJEyfMyMhIYo+o8nXt2jWb
z4sXL8Y+8z7qfdj2xsbGn2z4/v27OXXqlPn69St1C/ABAEQqEERhJ30j/P3Q0JAVhz9+/LCvsbEx
KwSD53d2dtpjGxsbkWnqmomJCXuOhN709LQZHBz0Ckhdc/fuXXvdp0+fTGtra6LYbGlpMR8/frTn
P3782Fy/fj21SA2/P3/+vFlcXMyzQ/m5ceMGzgPEVwBEKhBE4VeL1Pr6evPt27fcZ70vLy/POz/Y
sxqF5rdKOAaprq72CkUnOh3qGU0SmMGeU90vOK82q0idm5szbW1teXlWT/Hr169xHiC+AiBSgSAK
v1qkHjp06KdzNG81i4/p/PBwejDdtAuZJDzTCExfPtOmUVVVZd6+fZsTyEnTGYA6BACIVCCIwg6K
1KDQSysOw0QJ3TTphe+dVaQGRW4hIrW/v9/cvHnTvtcUh4cPH+I4QHwFQKQCQRR2g0htaGj4abg/
TvzFoTQ2Nzczi9Tm5mY7F9WhofYkgel6PV0+tcipGJGqe2sRlqYcaNHX1tYWjgPEVwBEKhBEYTeI
VC2cGh4ezi2cGh0dNTU1NZl8TGkMDAzk0tBn7RLgE4rhhVO6JklgXrhwwXz+/Nmer/tlXTglQar5
tUFRrh7U33//3S4OAyC+AiBSgSAKu0SkCrcFlV4Sbe/fv8/sY93d3XYrKfXCXr58OW8nAN+Qu3ox
Kysr7S4BSUP4Oq5zdY4Ea3irLN977Tiga4P3ePnypT0n/DQq6hbgAwCIVCCIAr5h0XB7cAh/J5CY
1gIqAOIrACIVCKKAb1i01ZW2gnL7q6pHV8P/O4Xuqx7g3t5eHAaIrwCIVCCIAr7x/1hYWLDbPmn4
XU+cunPnjhWrO4XmqGraAAumgPgKgEgFgijgGwDUIQBApBJEAd8AAOoQACIVCKKAbwBQhwAAkUoQ
5WcCfAOAOgSASAWCKOAbANQhAECkAkEU8A0A6hAAIFIJooBvAAB1CACRCgRRwDcAqEMAgEgliAK+
AQDUIQBEKhBEAd8AoA4BACKVIAqAbwBQhwAQqUAQBXwDgDoEAIhUIIgCvgFAHQJApAJBFPANAOoQ
ACBSgSAK+AYAdQgAEKkEUcA3AIA6BIBIBYIo/FLf2NzctMfCryDT09Pm9OnT5siRI6a5udksLy9T
oEAdAgBEKhBEYft8Y25uzrS3t8de988//5iWlhazurpqfvz4YaampkxdXR0FCtQhAECkAkEUts83
+vv7zfDwcOx1HR0d5v79+xQgUIeIrwCIVCCIws75xpUrV8yFCxfM8ePHzbFjx8y9e/fyjldVVZk3
b95QgEAdIr4CIFKBIAo75xsnT540//vf/+x7Dec/fPjQ9PT05I4fPnzYzM/Pm9raWlNWVmanBnz5
8oUCBeoQACBSgSAKO+cbEqoSrsHrbt68aRdY6djY2JidAgBAHQIARCoQRGFHfePQoUO595oC8O3b
tzwRq1X+ANQhAECkAkEUts03ysvLzdevX3OfJUg1tO+4ePFi3vkSqRr2B6AOAQAiFQiisG2+cefO
HdPX12fFp16Dg4NmdHQ0d3xmZsa+3HHtBKC9UgGoQwCASAWCKGybb2xtbZkbN27YIfwTJ06YgYGB
n86RMK2oqLDnXL582bx7944CBeoQACBSgSAK+AYAdQgAEKkEUcA3AIA6BIBIBYIo4BsA1CEAQKQS
RAHfAADqEAAiFQiigG8AUIcAAJFKEAXANwCoQwCIVCCIAr4BQB0CAEQqEEQB3wCgDgEAIpUgCvgG
AHWIOgSASAWCKOAbANShXWc/r4PzQqQCQRTwDQDqELYDvzkiFacCfAMAqEPYDfvtt8dLcSjANwCo
Q9gM+AAiFQgogG8AUIewGfABRCrOBPgGAFCHiBuASAUCCuAbANQhbAZ8AJGKMwG+AQDUIWwGRCrg
TIBvAFCHsBnwAUQqEFBgz/vGmzdv+LGAOoTNey7m7NfYhUgFAgr8Ut+Yn583ly5dKsl9ZmZmivLD
I0eOlNTW7aoTT548MYcPHzZNTU3EFurQgbT5y5cv5tSpU7n3p0+f3rb6lLW+ZYkBpYg5pUwHv0ek
EkQB3wigwP/27dui77G2tmbOnTtXlB+Wwod3oh6owXz69CmORR06sDbPzs6ajo4O+/7x48fm2rVr
21afsta3LCK1VL/rfvUPRCoQROGX+caLFy/MhQsXSuJTbW1t5t27d95rXK/IoUOHTENDg1lcXMzd
K/zs6Ki0gt/9+PHD3Lp1yxw7dsxUVlaa6enpxAaqr6/PHD9+3Bw9etR0dXWlylfU/aPy+erVK1NR
UWHOnDmTO/fevXv2XmVlZVbAr6+v56UzPj5uysvLzYkTJ8yjR4/M0NCQtcXXKOvayclJe63S7+zs
NFtbW3nHo/ITZf/Xr19tj1jwevHt2zdbDlHl6LMr6TdLW87E191tc29vrxkbG8v5g/w3iTif8T0z
vpC4kFakxt07Lk5cvXrVPHv2LM+XL168uOefe49IBZwJdqVv3L5924qdYn2qv7/fjIyMpLomKMA0
1aC6ujr2fr7G6MGDB2ZgYMCK1U+fPpmzZ8/GNlBqUCcmJuy5379/t4J2cHAwVb585aLPEopKe2Nj
w34nwaky0Xd66f7B3iZdc/36dZuXv//+24rTGzdu2M/Kh/KTdH/1gKuhV9pqVPVbJuUnyf6bN2/a
/AZR2SrdsL1p7EoqryzlTHzdfTaHBVkagVaIz/jqWylEatTxpHqiutTc3GyP6Z86+a4bhaInFZEK
BFEosW8o4K6srBTlU//8809eb6zvGvXuae5qKRoj9RKqx8+xtLQU20BJ1KlxCRIUSEn5SpPPYG+i
qK+vz8ub3qvnM+4afd7c3EzdA/Ty5cvc53///Tc3PzAuP0n2q6HV9e64/mqOYbC3K4tdSeWVpZyJ
r7vXZvX+Oz84efLkTz3xWevCbhGpvjghEat/4CRcw/8YoisQqUAQhRL6hobewgE5Sy+JhoolFD9+
/JjaD9V75noCNWRYTGMU7m2ULXENlM4N26Mh5zT5KqTRDKYdlV9fGj6RGv7dktJOY/9vv/1me5DE
1NSUuXz5cmR6We0Kf5elnImvu9Pm169fm9bWVvte/8i493EU4jO/SqT66okTshLZnz9/RqQiUoEg
CtvlG1GNRxaf0nC1Fk1k9UPNl5ybm7PzWO/evVsykZrUQPlsTcpXIY1mlrwVIlKzNvo++2V3bW2t
fa+5ogsLC0WXedx3acuZ+Lr7bC5kuL8Qnym1SI3LZzitNHFCu6HU1dUhUhGpQBCF7fSNqJ7ULD6V
tbEKs7y8nEm4ra6u5n3X0tKSN4yoqQtx6Ul4BYfTs+SrkEZT9wsPcQa3qSlWpCqPDm0BpDmtvvz4
7K+qqrJDmeHthMLlmMWu8G+WpZyJr7vTZs0ndXPZ9Y+qb9FUVp/JWt/CPlaMAPbVk9HRUTvioEWP
DPcjUoEgCtvoG5qTqnmcpfQp3zXqgdCqWBFeICTRrOFD16AFF9loiysNQQfT17C0Fm25hVPnz5+P
baC0eMMtstJLn7XKOE2+ChGpSn94eDh3PzVuNTU1JROpyrtsVtr//e9/zZUrV7z5SbJfaJ6ddkkI
LiiLKscku3y/WZZyJr7uTpvVk+hWuQffx5G1Lvjy4fOxLCI1HHOS6okWTgWnNkjQakeTqHTQFYhU
IIhCkb6hngC3jcxO+aGGerWQQsNqamycYHEiST0srpfFiRidq0ZN54bTv3//vp0fpi1jZEtSA9Xd
3W17HJW+Gja38t2Xr0JEqnDb7uil3qf379+XTKRqn0otWNFCpDt37tjeVN+1SfYLDV/qmMRvUl6S
7PL9ZlnKmfi6O22WDzkxpnqXRphlqQu+fPh8LItIDcecpHrS3t6eJ8j13s3djkoHXYFIBUQqFOEb
WiEe7k0D6jpQ5vgZIFKBgAK/3De0UnW/Pneaug6UOTYDIhVwJtijvqGhs99//51C2kPs1+eEE1+x
GfABRCrOBPgGAFCHsBkQqYAzAb4BQB3CZsAHEKk4EwC+AUAdwmZApALOBPgGAHUImwEfQKQCAQXw
DQDqEDYDPoBIxZkA39jNlHoLLbbkokyIr6W1mTqFDyBScSYKAXatb2xnHsJbMhV7r72yxVMxdrpr
06ZRijLJ8iQg6tD+srnQOrqXyr3YvP7q6xGpQBAFfGMH7NuNwX63ltlOioW9XK6I1F+TFiIVkYpI
JaDAAfSNU6dOma2trbzv9AzuhoaG3Oe+vj77bG49b7urq+unNPUcdj07/syZM/Y7PUPbPVNb6Swu
LsbmwT3Lu6yszD6adX19Pe/ciYkJU1VVlXvGux46EGdb8OW+Gx4ejr3+w4cP9pnbureO1dbWmtnZ
2dj0gpw+fdo+416srq7ac/755x/7+ePHj/Z4oeXnuybpd81SZkL3Df5N+v3iyjgpPz9+/DC3bt2y
z0CvrKw009PTiT2pSXYn+RXxdedtTqo/Ub7t8x/FnWvXrtn0lJYe17wTfhKX1tWrV82zZ8/y0r14
8WKmvBZbP3y2prkekQqIVNizvnHz5k0zNDSU992DBw9sYBRjY2NW9CgYfv/+3QbBwcHBvDQ7Ozvt
8Y2NDftdUBjNz8+b6urqyDzoviMjI/ZavXQvBf7guWoEnXBVmko7rX36fOnSpdjrGxsbzdTUVO7+
yktQrCXVpT/++MM8fvzYvn/06JEdxlT+3WdnRyHl57vGJ1KzlJl+/+DfLL9fmkZYvjQwMGBt+fTp
kzl79mxsI+6zOylfxNedtzlN/Qn7dpL/9PT0mJmZGft+bm7O1NXVbbufJKWlPDc3N9tj+kde6bx9
+zZTXoutHz5bfdcjUgGRCnvaNxR01ZuqIOf+M1cvoBM5TU1NuWOOsGgJ9n66XjkXwJPyUF9fb3sk
gj0p5eXliWkn+XdUA5jleqHelzTnTk5O5oTdX3/9ZTo6OuxLXL9+3TYmhZaf7xqfSM1qc5i0v1+a
Rlg9aMHfeGlpKbYR99mdlC/i6+6wOVx/fL4Y/CyhF/79t9tPfGlJJEoIShjevn07c16LrR++/Pmu
R6QCIhX2vG/89ttv9r91oZ4R9cQFeyXCw3Q+IafeC32vANvb2xubh2A6wfulDfDFCiih4Uj1ikhg
SjSnXdQjca+eJKEhxeXlZSv2hYb/NAWg0PLzXVNMo5iGtL9fmvuFe3HV4Mbl12d3Ur6Ir7/G5qz1
J8l/0o6SlNJP0tQ1paN/nt30nix5LbZ++PLnux6RCohU2PO+oeEqCSsnuBYWFhKFZJo01Xgp3ba2
NnP37t3UjVIxgiurgFJvqHpExsfHrc0a3suy8vzEiRN2iM2JU80DXVlZyX0utPx812y3SE37+xXS
CCflN43dcfkivu68zYXUn1KI1FL6SZq0NGVIdu6ESM1qq+96RCogUmFf+IYEloa1ggt+nGjd3Nws
2N/UwxgXtJV2eLg/uEXNdotULTYI2uYWQKW17cqVK+bPP//MDfO7IX/3udDy812zEyI1ze8X9Tlc
hi0tLXm/sUR8kj+ktTucL+LrzttcSP1J8p+amppUQ+il9BNfWqOjo3aUSUI8ONyfNq/F1g9f/nzX
I1IBkQr7wjc050qrQ8MLdLS4yU3M10uftQo/KU31OmglrAgv3AkvnNLqe5e2GgQF/0IFl1baag6c
C9q+6yXM3WpkBXctkggeD6cXRnnXMKDyLR4+fGivcVMnCi0/3zXbLVKTfr9wmQQXqaytrdmpIsH7
afpIf39/bmHH+fPnY/PrszspX8TXnbfZV3+irkuqo5o2oKF6oVX1cYuRSuknSWmpZ7i1tTVPML57
9y5TXoutHz5bfdcjUgGRCvvCNzSUpV5MBbow3d3dttdExxVk3UrduDQ11Kb5aW4LJNdgRJ3vtqDS
Syvi379/X7DgksBWHl1vrO/658+f20UIyqMaGS22CB4PpxfmxYsXeVtPuUULriErtPx812y3SE36
/cJl4kSAztU/GDo3fL/79+9bMa9tdLQQJSm/SXYn5Yv4uvM2++pP1HVJdVQr6Nvb2216+p1Vn3bC
T+LSUl6CW1DpvZuvnzavxdaPNLHAd/1B2tsY9YNIBXwDgDqEzbBH0O4jiFQgoAC+AUAdwmbYVWhq
AiIVCCiAbwBQh7AZ8AFEKhBQAN8AoA5hM+ADiFScCfANAOoQNgM+gEgFAgrgGwDUIWwGfACRijMB
vgEA1CFsBkQqEFAA3wCgDmEz4AOIVJwJ8I1d4htv3rzhx+B3oA4dMJvxN3wAkQqIVNiVvhG8d/gJ
TvjsryHudwj+HnrCTfCpO9QhRCr1Hr9HpAJBFPatb+Cju9MfokTq27dvzZkzZygsROq2+Rvg94hU
nAkg1jc+fPhge8zKysrsc6Zra2vN7OysPXb69Gnz+fNn+351dTXvWfUfP360x31phAVQ8BXOl95P
TEyYqqqq3LO39fzrIH19ffZZ1idOnDAjIyOJPu/Ll56l7Z6t3dDQYBYXF1Mdc/nQ87KPHj1qurq6
8o4Vmq5sGR8ft8/iln2PHj0yQ0ND1t64sojLQ1JZRv0OFRUVeX8dFy5cMC9evKACIVJzpI0Lvno/
PDycWNfD+Xj16pX1z+A/Tkl1oJj6L+7du2fT1fXnzp0z6+vrqWOVr57j94hUgihACt9obGw0U1NT
5sePH/Yl4eeEyh9//GEeP35s30swachubGws9/natWveNKKEaFy+9F6NimsMFPQV6B1qFO7evWvv
8enTJ9Pa2pro8758BRuW+fl5U11dneqYykB5UZrfv38309PTZnBwsOh0Zcv169dtmn///bcVpzdu
3LCfw2Xhy4OvLMPldvPmzby/Donm27dvU4H2aXwNCse0NqeNC756f+nSpVj/jMpHZ2en9feNjY1U
daCY+q9/DnW+u1b3cnalqV9JaeP3iFSCKEARvqH//sXk5GROtPz111+mo6PDvoTElBoFXxpZRWqw
tyJ8vKWlxfbUOJaWljL7fDBfarBmZmYiz0s61tTUZBuuIMFGqNB0w/br8+bmZmRZ+PLgK8u05bay
smKam5upQPtcpEb1dsbZnDYu+Op9kn/66kaaOlBM/a+vrzffvn3LfdZ7jXCkzX9S2vg9IpUgCpDB
NzSM1tPTYxsaBWd3ruYkqjdCaMhqeXnZnDp1yn7W0JmG+nxpZBWpSfkOL75QA+Xz+aR8qYdDn9XY
9fb25l2XdEy9JOFGPdj4FZqub95e8LMvD76yTBsrVMYa8oT44ev9/gqTNi6krfdpRWoYXx0opv6H
03H3S5v/pLTRFYhUhAhASt9Qr0hdXZ0d1l1YWLBDacFzNTdSQ+uuEdIcLPWuuc9p0iiVSA0PB/pE
qi9frhGbm5szbW1tdipBmmNRDViUOM6abhaR6stDqURqVLlTh/aXTVl7UtPGhe0Wqb46UEz9j/L5
LLHKFwPwe0QqQRQghW9o3mNwSNkthHBcuXLF/Pnnn7nhPDe05z6nSaNUIlXDzmoYHa9fv070eV++
gqg3KO0x9R4F000iS7pZRKovD6USqZrrR0/q/hepWW1OExe2W6T66kAx9V9ph4f7gyM5WfKfFAPw
e0QqQRQgwTfUA+JWvLr5h8FztQJXc7FGR0ft54cPH9rVrlqwkDaN4Htdq7lcrgHIIlLDC6e04jbJ
5335Ui+LVuGK8MKHpGNaVDEwMJBbVKHPykux6WYRqb48+Moy/DvEoX8EmJN6cONrnM1p4kLael+o
SPXVgWLqv9KSjS5t2VlTU5O6fiWljd8jUgmiACl94/nz53axgYKoAqsm+wfP1fZDwS1m3GKld+/e
pU4j+F6rb9Uj4Xolsg6h9ff32y1nKisr7Yrb8DzVLLZpOE7z1NwWMq5R8R0T3d3dtqdG99cqX7fi
uJh0s4hUXx58ZRn+HeKQ+GB1PyI1TJq4kLbeFypSfXWgmPov3BZUemll//v371PXryz1HL9HpBJE
Ad/Yh76xtbWVNwcOSs/Zs2dtgwuIVMDvEalAQAF8IwYNL2ohgtsXUT0de3lBwm5HQ6RanQyIVMDv
EalAQAF8IwGt0NXTZjS0p9XFd+7csWIVtofff//dPHv2jIJApAJ+j0gFAgrgGwDUIWwGfACRijMB
vgEA1CFsBkQq4EyAbwBQh7AZ8AFEKs4EgG8AUIewGRCpgDMBvgFAHcJmwAcQqUBAAXwDgDqEzYBI
5afCmQDfAKAOYTPgA4hUIKAAvgFAHcJmwAcQqTgT4BsAQB0ibgAiFQgogG8AUIewGfABRCrOBPgG
AFCHsBkQqYAzAb4BQB3CZsAHEKlAQAF8A4A6hM2ASAWcCfANAOoQNgM+gEgFAgrgGwDUIWwGfACR
ijMBvvELePPmDT8Y5UIdwmbABxCpOBMcdN+Yn583ly5dSpXO1taWqamp+en7L1++mMuXL5uysjJz
9OhRc/XqVfPp06eC8nrkyJGS2ruX60Uw7+Fyob4TX3eDzTMzM4nn+Y4Dfo9IxZkA34g91tTUZN6+
fetN4/v37+bKlSuRafX19Zne3l7z48cP+/rf//5nuru7f5kf78e6QP2m/HebzWtra+bcuXOx5/mO
A36PSMWZAGJ948WLF+bChQup0lBjo0YnKi2lsbKykidoL168GJvWkydPzOHDh82hQ4dMQ0ODWVxc
zOUz+IrLe/A7ieJbt26ZY8eOmcrKSjM9PZ3YkypBffz4cdvj29XVlSpfUXz48CHXe6xramtrzezs
rD12+vRp8/nzZ/t+dXXV5uGff/6xnz9+/GiP+9II5t1XLno/MTFhqqqqbN6V1tOnT3+yW2V04sQJ
MzIyQrwgvhZtc1tbm3n37l3seb7jgN8jUnEmgFjfuH37tpmcnEyVxsLCQmxaEj8Si+Hv4giKKE03
qK6ujs2rT6Q+ePDADAwM2PtrisHZs2djRerY2JgVczpXQlqCdnBwMFW+wjQ2Npqpqalc77GEX0VF
hT32xx9/mMePH9v3jx49skP1urf7fO3aNW8aUUI0rgz0XmJ3fX3dfpYNssUhm+/evZsro9bWVuIF
8bUom/v7+62/xp3nOw74PSIVZwJI9I3m5ua8HtBC0woKoqTvHBJimquWJn2fSD1z5oz59u1b7vPS
0lKsuNPUhrCYDgrRpHylQb2YQsL/5s2b9v1ff/1lOjo67Etcv37dimNfGllFqhOoUcdbWlpsD25c
GQHxNYvNGhUIjsCEz/MdB/wekYozAXh9Q8PMYdFWSFpBYZVGpKqXUulINGouazEiNXwf2RMn7nRu
eOg8mPekfEXx6tUr09PTYwVofX197l6a46teUqFpA8vLy+bUqVP2s4b0NQXAl0ZWkZpURuFFV+Ey
AuJrWpu/fv1q/zEM/tMTPM93HPB7RCrOBJDKN8LiMmruY5q0oob2k4b7nTibm5uz89Y0FF0qkZok
4KLEdNp8hVFvaV1dnRkfH7dTITY2NvLupbmfGlp34lTzRdVr7T6nSaNUItUn5IH4mtZmjQS4qSxR
5/mOA36PSMWZAFL5Rql6UiXo/v3339xnbVWlhVZpUC9jWjEm3EIkh4ayg8P9EoJx6alXc3Nzs6B8
RYnwYFrhfGknhD///DM3zO+G/N3nNGmUSqRqWkdwS7DXr18TL4ivBdkc/kc2akFf0nHA7xGpOBNA
Kt+QeNH8xGLT0spxt3hJL/UMJg2Xq/dQK+lFeJGPhLPmVzrhGVzMpN0FtEAomActPNIiDbco6Pz5
87ECbmhoKC+f+hwU00n5CqOeUbcSX8JYZRm81/DwsCkvLzejo6P288OHD61tWsSUNo3g+3C5ZBGp
4YVTbAtEfC2lzb7z8DX8HpEKBALI7Bta3e9WnReTloapJQ4191EvPRxAG/zHoSF1zb902yU5YSi0
2t6lExSLOlcPEtC54Tzcv3/fCkJtLSV7kgSc9m9VD6bSl+BV3tPkK8zz58/toiudJ3Eb3rRc23sF
t55yi5W0JU/aNILvw+WSRaQKCXmVj7bpUhmV4qEJ1CFsRqTiA4hUIIjCtvjGy5cvUw/Lw/5B0zGC
c2OB+IrNgEgFnAl2nW9oJTvPhd/fqJdZi8Hc/rD37t1LXBQGxFfaFECkAgEFfrlvaDj9999/p5D2
Mdo5QNsCaYhfuw7cuXPHilUgvmIzIFIBZwJ8A4A6hM2ADyBScSYAfAOAOoTNgEgFnAnwDQDqEDYD
PoBIBQIK4BsA1CFsBnwAkYozAb4BQB3CZsAHEKlAQAF8ozSwvRZQh7AZEKmAM8E+8o2d8KfgPfR0
Jz15Sfu2lvL+4ScrldIuPbHq2bNnOBh1CJsBH0CkAgEF9pNIDSKBqj1b91K9ePv2rd1/FKhD2Az4
ACIVCChQQt/49u2buXbtmikrKzO1tbX2MalR13z48MH2Guo8iUmdOzs7mzvuekH1zPuGhgazuLiY
6pi7h/4GX+H7J+UzKW++dIWevnT06FF7vR4Ru76+npe/iYkJU1VVZfMfJaQvXLhgXrx4gZMRX7EZ
8AFEKhBQoFS+0dPTY2ZmZux7PTazrq4u8prGxkYzNTVlH6up18jIiKmoqMgdD4q3+fl5U11dnepY
8B7hPAY/J+XTl7ekdIeGhuz57tqxsTErhoPnSgA74So7ZE+Q8fFxc/v2bZyM+IrNgA8gUoGAAqXy
DYk9ibNC/Ek9iw6JQiciwyQdSytSk/Lpy1tSuvX19baX1qH3es598Nxgz2pUeisrK6a5uRknI75i
M+ADiFQgoECpfCPcK5h0zatXr2yPZkdHhxV3wePqIdVnLXrq7e3Nuy7pWFqRmpRPX96S0g2K2ah7
RZVb+DuJZ00XAOIrNgM+gEgFAgrssEidnJy0vZka2l5YWDAbGxuRIlZD8W1tbebu3bupjpVCpPry
ljXdpGvjvvOJaCC+YjPgA4hUnAkgg2/U1NSkGu4/duyY2dzczH1eXV2NTXN5eTn1sbRiMimfvrwl
pauFXOHh/uCWVWlE6vfv3+lJJb5iN/DbI1KBYAKl9A0NkWs4Xmi/z7iFU1rd7lbMuzmY4TmjWsUv
wouLko5lWTgVl09f3rRqX/NKnRgNL5waHh7OLZwaHR21gjiLSH39+jVzUomv2A785ohUIJBAKX1j
a2vLtLe3W+GouZxLS0uR1zx//tyuytd5EohaCBU8ruF8Xe+2aXKi1HcsrUhNyqcvb4ODg7Z31PWQ
xm1BpZdW9r9//z6TSH348CGr+4mvB8J+Xgfntef8kxBFEAV8A37m7NmzVogDdQgAEKlAEAV8Y1eg
6QXuMa5AHQIARCoQRAHf2BX8/vvvdo4sUIcAAJEKBFHANwCoQwCASCWIAr4BANQhAEQqEEQB3wCg
DgEAIpUgCvgGAFCHABCpQBAFfAOAOgQAiFSCKAC+AUAdAkCkAkEU8A0A6hAAIFKBIAr4BgB1CACR
CgRRwDcAqEMAgEgFgijgGwDUIQBApBJEAd8AAOoQACIVCKKAbwBQhwAAkUoQBXwDAKhDAIhUIIgC
vgFAHQIARCpBFADfAKAOASBSgSAK+AYAdQgAEKlAEAV8A4A6BACIVIIo4BsA1CHqEAAiFQiigG8A
UIcAAJFKEAV8AwCoQwCIVCCIAr4BQB0CAEQqQRQA3wCgDgEgUoEgCvgGAHUIABCpQBAFfAOAOgSA
SAWCKOAbANQhAECkAkEU8A0A6hAAIFIJooBvAAB1CACRCgRRwDcAqEMAgEgliAK+AQDUIQBEKhBE
Ad8AoA4BACKVIAqAbwBQhwAQqUAQBXwDgDoEAIhUIIgCvgFAHQIARCpBFPANAOoQACBSgSAK+AYA
dQgAEKkEUcA3AIA6BIBIBYIo4BsA1CEAQKQSRAHfwDcAqEMAiFQgiAK+AUAdAgBEKhBEAd8AoA4B
IFKBIAr4BgB1CAAQqUAQBXwDgDoEAIhUgijgGwBAHQJApAJBFPANAOoQACBSCaKAb5SMN2/e7Iky
KFU+t8PevVKG1CEAQKQCQRR2xDf0fdwrLUeOHCmZnz558sQcPnzYNDU1ZU7Ll+es+dzudJLSTFv+
u6XOb25uJvrQly9fzOXLl01ZWZk5evSouXr1qvn06RPxFQAQqYhUwDf+s23+k/W6pPMlUJ8+fVpQ
Wr58lKp+bEc926my3y7m5uZMe3t77PG+vj7T29trfvz4YV//+9//THd3N/EVABCpCBHAN4oTqffu
3bM9YOoJO3funFlfX89dE+45+/DhQ67XTKKztrbWzM7Oeu8TlVbUuXHCNCn/cT18Ek/Hjx+3tnV1
deW+V0/fs2fPcp/Vw3vx4sVUvc1p7H/16pWpqKgwZ86c8dr97ds3c+3aNZue0nr58mWszXH2OBuU
n0OHDpmGhgazuLhYMv/q7+83w8PDsccvXLhgVlZWcp+/f/9uy5P4CgCIVIQI4BsFnzM0NGRGRkZy
vWBjY2NWNMVd19jYaKampnLn61oJsrRi0penQkRq1HHZMTExYfMo0TQ9PW0GBwftsY2NDdPc3GyP
bW1tmerqavP27dtU90ljf2dnpz2m+/js7unpMTMzM/a9eizr6uoiz0uyRwR7qefn561NaUW9bwrI
lStXrBCVQD527Jj9pyaIvlO+wt8RXwEAkYoQAXyj4HPq6+ttb55D78vLyzOlrd673SZSNe81LJyC
wk2i78GDB1bo3b59u6h6Frbf9USnsVuiNJzPqPN89kgoO7Fbak6ePGmH8IXy8PDhQyuugwI5TNR3
xFcAQKQiUgHfSH1OUGBFCYyo6zScLZHS0dFhRW6WYfmdEqmyIdxTGLZVwk+C/PPnz5nKMqv9SXYn
ibnweUn2qPdU38kmzQ/dTiRUJVzT+hDxFQAQqQgRwDcynxMlJpJE1+TkpO39Gx8fNwsLC3ZIeydF
atwQdTitKOEU5tKlS9aWLCK1EPtLIVLT2CPxrCkDbW1t5u7du4npFrPjQzg/UUP7DPcDACIVIQJQ
lEjVIpvwcH9wy6TwdRIf2pLIsbq6WjKRmpRW1p5U2RXMZ5jR0VE7x1NiM8twfyH2J9ldU1OTarjf
Z0+Q5eXlksYL9TZ//fo1z0e0yMshUfzvv//mPmuerxbgEV8BAJGKEAF8o+BztHBKK7fdQiCJNwkn
h1ada46lE7JVVVW51exa0a0FSIWK1OBin7W1NbtqvlCRGs6n7BoYGMjZpc9OOKn3s7W1NU8Avnv3
LjKdMIXYH04zvHBKQ/VCOw7ELZxKskfoOq3wFyrTUg6337lzx+4s4O6tebzyE4eOBfMm4b/dUw6I
rwCIVCCIwj4XqcJtQaWXVva/f/8+d0yCRD2rrnf1+fPndsGORJCEkRbrFCpSnZjS0LGEsURWoSI1
nE+hvTrV86nvJIDdanvt+RncgkrvdTwunSCF2B9OM3iOeh2VH6Wn+a1LS0uxacXZIzTUr+tVlkrL
CdZSoDzeuHHD3vfEiRNWkAZRPs6fP5+zUdMotME/8RUAEKkIEcA3KAQA6hAAIhUIooBvAFCHAACR
CgRRwDcAqEMAiFQgiAK+AUAdAgBEKhBE4f9r734jKs37B44/GEmSDMnIyIgkyUisrKxkWWv0YI15
kpWx9snIuOW2llvGShJJMkaWlXmQjBjzIBkZxrqtMUasJGOsmyQZWUNutyT5/nyvn+s450znz1Rb
M9vrxTGnTudP9bmu79s5XWfMBtiGAJFqJ4rZAGxDIFKxE8VsgG0IEKl2opgNwDYEIhU7UcwG2IYA
kWonCmYDbEMgUrETxWyAbQgQqdiJYjbANgSIVDtRzAbYhgCRip0oZgNsQ4BItRPFbAC2IRCp2Ili
NsA2BIhUO1HMh/kA2w6IVOxIMSNgmwFEKnamfMCcODk5lXcCRCoiFWwfAIhUizDYPgAQqViEwfYB
gEi1CAO2DwCRikUYbB8AiFQswmD7AMDe3SIMtg8ARCoWYbB9ACBSLcJg+wBApGIRBtsHACLVIgy2
DwBEKhZhsH0AIFKxCIPtA0CkYhEG2wcAIhWLMNg+ABCpFmGwfQAgUrEIg+0DAJFqEQbbBwAiFYsw
2D4AEKkWYcD2ASBSsQiD7QMAkYpFGGwfACIVizDYPgAQqViEwfYBgEi1CIPtAwCRikUYbB8AiFSL
MNg+ABCpWITB9gGASPVLsgiD7QNApGIRBtsHACIVizDYPgAQqRZhsH0AIFKxCMNfsl3knwAQqYhU
EKkAiFSRChQLVQBEKiIVRCoAItVC7NcEIhVApCJSQaQCIFIRqWD7AECkWoTB9gGASMUizNnMidPF
OQGIVEQqZgS/cwCRisUI84HfPSBSsRBhNjADACIVixBmAzMAIFItQpgNzACASMUihNnADACIVIsQ
ZgMzACBSsQhhNjADACLVL8kihNn4IGtra2YAQKRiEeJjnI13796Fq1evZs5fu3bt2PeztLQUKioq
QkdHxyfxc6msrDzVn+3HvA3aPwAiFYsQn9RsPHnyJPT39yfnHz9+HAYGBo59PzFQnz59eqG2mU9l
u7N/AEQqFiE+qdn46aefwszMTHL+xx9/DI8ePSp6W/FrqqurQ1VVVejp6QlbW1uZ+yj1f8bHz8/O
zobGxsZw6dKlI6N2ZGQk1NbWJvcxNDSU+Xx8hvfPP/9Mzm9sbCS39erVq+Tjt2/fFnwGOH12N95f
e3t7+PXXXws+3qMed/bnDg8Pw+DgYKipqQkNDQ1hfn6+6DOphb6XYo/L/gFApIpULvRs5EdaOZE5
OTkZ7t+/n8RaPMW4zX7mtdQMxsv7+voyYRsDNYZaKt5ejNh42wcHB0kEjo+PJ5d9++23yTO9UQzp
+FJ9Gtfx40LPAGeH8PLycmhqair4eEtF6tTUVBgbG0se387OTuju7i4YqcW+l1KPy/4BQKSKVC78
bFy+fDns7+8n569cuRL29vYKfm1bW1vma6N4vq6u7oMiNQ3Uo64T/5Y1Rl22NN4ePnwY7ty5k5z/
/vvvkz9RSP9M4fbt20kEHqW+vj4sLCyU9XMpFamdnZ053//KykrBSC32vZR6XPYPACJVpHKhZ+P3
338Pn3/+eXI+xmN6vpD40nS+7GdCy4nUYp+Lt5X/jG56n69fvw7Xr19PzseXx1dXVzMHfLW0tCR/
AnCU+CxlvJ0YjfFPG04SqdnfaxQjtFCkFvteSj0u+wcAkSpSubCzcZyX+/MjLf+2TxqpR0Vwtvis
b3yZPY3T+Let6+vrmY8LefnyZVhcXAxfffVV+OGHH04tUot9/6W+l2KPy/4BQKSKVC70bMS/44wv
o0fxJfNSB03FZzDzX+7Pfhunk0ZqvP3d3d2C179582b47rvvMi/zpy/5px+XEp99LRbV+R+nB2il
urq6cr7/GMiFbq/U91Lscdk/AIhUkcqFno0bN26E58+fv3e+kHjg1PT0dObAqQcPHoTm5uZTi9R4
++mBSfEUP47vIJCK9x3/Bjbeb/Tzzz8n7zIQD1AqpLW1NTmSPso/UCteN/6ZQxqe2QczbW5uJgd5
ZT++ubm5MDo6mjlwqre3t2Cklvpeij0u+wcAkSpSudCzEd9KKQ20+FZJ2c8SFpK+BVU8xWdi//jj
j1OL1Gh4eDh5XPEZ2hiJ29vbmct+++23nLeeSg9cevPmTcH7jC+pxwO+0re8SsMwikfbx/tJnw1O
YzF+bYzv+LX5j29iYiIJ5fjzikfwF3tmttj3Uuxx2T8AiFSRitnADACIVCxCmA3MAIBItQiB2cAM
ACIVixBmAzMAIFKxCGE2MAOASMUihNnADACIVCxCmA3MAIBItQhhNjADACIVixBm46O1trZmBgBE
KhYhzno2TmtmTno7f+X1T3Lb6f9E9XfYxuwfAJGKRYgLNxsfc6Se5u2KVACRikWIM5iN/P93fnZ2
NjQ2Nmb+P/n4f9mn9vf3w8DAQKiqqgotLS3hxYsXBW+n2P0cHh6GwcHB5P+0b2hoCPPz8+9dZ2Rk
JNTW1obq6uowNDSUc1k51z/u95h/vexT+rnp6emi1y/22O0fAESqEIFjRGpfX1/Y2tpKPo7xFSMs
de/evbCwsJCcX1xcDK2trceK1KmpqTA2NpbE5s7OTuju7s65fGZmJgnJePnBwUESoePj42Vf/yTf
Y6mfW/z4xo0bBa9f6rHbPwCIVCECx4jUNL6OujxGaYyvcm6n2OWdnZ3Js7KplZWVnMs7Ojreu5+m
pqayr3+S77GcSC12/VKP3f4BQKQKEThGpBa7vNxnHD/0dmLU5V+e/1J7fGm93Ouf5LGVE6mlvrdi
j93+AUCkChH4RCI1//JSUVfq+ucZqR9LkNo/ACIVixAXJlKbm5uP9XL/xsZGzue6urpyXq5fX1/P
uby9vT3s7u4W/F5KXf88I7XUY7d/ABCpQgROOVLjgVPLy8vJ+efPnxc8cCr7iPfNzc3kQKXsy+fm
5sLo6GjmwKfe3t6cyycnJzMHRsVT/Linp6fs659mpMZ3Moh/g5pGcanrl3rs9g8AIlWIwClH6t7e
Xrh161YSoW1tbckBS0d9XXrEe3zpOz77urS09N5tT0xMhLq6uuStmuIR8fmXDw8PJ28xFd9MP0bu
9vb2B13/tCI1HpkfH0P6pv7lXL/UY7d/ABCpQgTMBmYAEKlYhDAbmAEAkYpFCLOBGQBEKhYhzAZm
AECkYhHCbGAGAESqRQizgRkAEKlYhDAbmAEAkWoRwmxgBgBEKhYhzEZRa2trfjn2DwAi1SKE2fi4
7iv9n5ywfwAQqRYhzMZHc19m1v4BQKRahDAbZX0+//+6f/jwYairqwvV1dXh7t27YW9vL3P54eFh
GBwcTP6v+oaGhjA/P59z/f/85z/J/19fVVUVKioqQktLS3jy5EnmtrNPqZGRkVBbW5vc39DQkBm3
fwAQqRYhROr7kdrR0RG2traSII0B+Y9//CNz+dTUVBgbG0su29nZCd3d3TnXv379epibm0suj6f7
9++H+vr6gvc/MzMTZmdnk689ODhIond8fNwv0P4BQKRahBCpuZH64sWLzMf/+9//wtWrVzMfd3Z2
hv39/czHKysrJefw0qVLBe8/BnEM1GxNTU1+gfYPACLVIoRIzY3U/GiML9sfdT6KX5t/my9fvgz3
7t0L/f39oa2t7b3bz7/t/D8DyI5a7B8ARKpFCJF65OXFIjX/OvHvWVtbW8Mvv/wSnj17Fra3t4ve
viC1fwAQqRYhzMZ7n9/Y2HgvIldXVzMfv3v3LjlIKtXV1ZXzcv/6+nrO9ePX7u7uFr39bO3t7Tlf
j/0DgEi1CHEBZyM+E/r06dPk/ObmZnIkfn5E9vT0JAdFxZfy//Wvf4WbN29mLo8HRY2OjmYOnOrt
7c25fmNjY+Zo/hiwn332Wc7l8aj/eFBWGrqTk5OZA7HiKX4c7x/7BwCRahHiAs1GDNQYqvFl9ubm
5rC0tPRepMbIvHLlSnJU/j//+c/k2dRsExMTyVtUxbeNikfnZ1//3//+d3LgU7yP+LL/wsJCzuXx
yP34hv7Zb+o/PDycPAMbPxejOf6JgBm3fwAQqRYhzIaZMgMAIhWLECIV+wcAkWoRwmyULftleOwf
AEQqFiHMBmYAQKRahDAbmAEAkYpFCLOBGQAQqRYhzAZmAECkYhHCbGAGAEQqFiHMBmYAEKlYhDAb
mAEAkYpFCLOBGQAQqRYhzAZmAECkYhHCbGAGAESqRQizgRkAEKlYhDAbmAEAkWoRArOBGQBEKhYh
zAZmAECkYhHCbGAGAESqRQizgRkAEKlYhDij2Zifnw/Xrl0LlZWV4bPPPgurq6t+YPYPACIVixDn
NxuvXr0KXV1dYWNjIxweHoa5ubnQ2trqB2b/ACBSsQhxfrPR398fJiYm/IDsHwBEKhYhPp7ZaGxs
DGtra35A9g8AIhWLEB/PbFRUVITl5eXQ0tISqqqqwq1bt8K7d+/8wOwfAEQqFiHObzbi5+/cuRN2
d3eTv0mdmZlJ/gQA+wcAkYpFiHObjZqamrC/v5/5OIZqPMof+wcAkYpFiHObja+//jrn4xip8WV/
7B8ARCoWIc5tNhYWFpJTjNN4mp6eTt4rFfsHAJGKRYhznY0YpvX19cnL/H19feHNmzd+YPYPACIV
ixBmAzMAIFItQpgNzACASMUihNnADACIVIsQmA3MACBSsQhhNjADACIVixBmAzMAIFItQpgNzACA
SMUihNnADACIVIsQZgMzACBSsQhhNjADACLVIgRmAzMAiFQsQpgNzACASMUihNnADAAiFYsQZgMz
ACBSsQhhNjADACLVIoTZwAwAiFQsQpgP/O4BRKqFCDOC3zmASMVixMc2J04X5wQgUhGpYPsAQKRi
EQbbB4BIxSIMtg8ARCoWYbB9ACBSLcJg+wBApGIRBtsHACLVIgy2DwBEKhZhsH0AIFL9kizCYPsA
EKlYhMH2AYBIxSIMtg8ARKpFGGwfAIhULMJg+wBApFqEwfYBgEjFIgy2DwBEqkUYsH0AiFQswmD7
AECkYhEG2weASMUiDLYPAEQqFmGwfQAgUv8Gi7CTk1PhEwAiFWw0oggARCqIVAAQqYBIBQCRCiIV
ABCpIFIBQKSCSAUARCqIVAAQqSBSAQCRCiIVAEQqIFIBQKSCSAUA660fAZQfp/7PeAAQqSBSAUCk
Ah8SqgCASAWRCgAiFRCpACBSQaQCACIVThKqAIBIBZEKACIVyo81p4tzAgCRyicRqPidA4BIRazg
dw+ASAWRghkAQKQiUDADACBSESiYAQBEKgIFMwAAIhWBghkAQKQiUDADACBSEShHW1tb84sSqQCI
VATK/3v37l24evVq5vy1a9eOfT9LS0uhoqIidHR0fPB1KysrT/X7FGUiFQCRyiccKE+ePAn9/f3J
+cePH4eBgYFj308M1KdPn55bRAkxPxsARCp/k0D56aefwszMTHL+xx9/DI8ePSp6W/FrqqurQ1VV
Vejp6QlbW1uZ+yj1f8anz7ReunQptLe3h19//bXgdY+6jezPHR4ehsHBwVBTUxMaGhrC/Px80WdS
R0ZGQm1tbfLYh4aGynpcIhUARCpnHCj5YVhOZE5OTob79+8ngRhPMW6zn3ktFULZz7QuLy+Hpqam
gtctFalTU1NhbGwseRw7Ozuhu7u7YKTGxzk7O5t87cHBQRK04+PjZT0ukQoAIpVzCJTLly+H/f39
5PyVK1fC3t5ewa9ta2vLfG0Uz9fV1ZUdQvX19WFhYaGsx1gqUjs7O3Mey8rKSsFIjX8jGwM1W3aI
FntcIhUARCpnHCi///57+Pzzz5Pz8WX79Hwh8eXwfPFZyHJDKD5LGb8mRmP8M4OTRGr2/UYxQgtF
avza/GeKs7+XYo9LpAKASOUMA+U4L/fnh2H+bZcTQi9fvgyLi4vhq6++Cj/88MOpRWqxx3JUXJf7
uEQqAIhUzjhQ4t+TPnz4MDl/+/btkgdNxYOK8l/uz37rqA8JodXV1aKBm//xxsZGzue6urpyHsv6
+nrB24uPe3d391iPS6QCgEjljAPlxo0b4fnz5++dLyQeODU9PZ05cOrBgwehubm57BBqbW1NjqSP
4oFK2c+GxncLiH9ykIZn9sFMm5uboa+vL+f25+bmwujoaObAqd7e3oKRGh93epBVPMWP4zsTlPO4
RCoAiFTOOFDi2zelURjfnin7mclC0regiqf4TOwff/xRdgjFl9TjwVfx5fcYgmkYRvFo+/isbPrM
bBqL8WtjCMevzb/9iYmJ5MCt+NjjEfzFnpkdHh5Ovt94+zF4t7e3y3pcIhUARCoCBTMAgEhFoGAG
AECkIlAwAwCIVBAomAEARCoCBTMAgEgFgYIZAECkIlAwAwAgUhEomAEARCoChSxra2tmAABEKmcd
KKcVLie9nb/y+ie57fR/v/o7hJ5IBUCkcuEC5WOO1NO8XZEKACKVMwiU/P/rfnZ2NjQ2Nmb+D/un
T59mLt/f3w8DAwOhqqoqtLS0hBcvXhS8nWL3c3h4GAYHB0NNTU1oaGgI8/Pz711nZGQk1NbWhurq
6jA0NJRzWTnXP+73mH+97FP6uenp6aLXL/bYRSoAIhWOEal9fX1ha2sr+TjGV4yw1L1798LCwkJy
fnFxMbS2th4rUqempsLY2FgSmzs7O6G7uzvn8pmZmSQk4+UHBwdJhI6Pj5d9/ZN8j6V+bvHjGzdu
FLx+qccuUgEQqXCMSE3j66jLY5TG+Crndopd3tnZmTwrm1pZWcm5vKOj4737aWpqKvv6J/key4nU
Ytcv9dhFKgAiFY4RqcUuL/cZxw+9nRh1+Zfnv9QeX1ov9/oneWzlRGqp763YYxepAIhU+EQiNf/y
UlFX6vrnGakfS5CKVABEKhcmUpubm4/1cv/GxkbO57q6unJerl9fX8+5vL29Pezu7hb8Xkpd/zwj
tdRjF6kAiFQ45UiNB04tLy8n558/f17wwKnsI943NzeTA5WyL5+bmwujo6OZA596e3tzLp+cnMwc
GBVP8eOenp6yr3+akRrfySD+DWoaxaWuX+qxi1QARCqccqTu7e2FW7duJRHa1taWHLB01NelR7zH
l77js69LS0vv3fbExESoq6tL3qopHhGff/nw8HDyFlPxzfRj5G5vb3/Q9U8rUuOR+fExpG/qX871
Sz12kQqASAWBghkAQKQiUDADAIhUECiYAQBEKgIFMwAAIhWBghkAQKQiUDADACBSESiYAQBEKgIF
MwAAIhWBghkAQKTC+QaKEDIDAIhUECiYAQBEKn+/QImff/nyZaivrw+dnZ2Zz4+MjITa2tpQXV0d
hoaGks/997//DVevXg17e3s5t7G/vx/a29uPvJ+jbie6du1a+PPPP5PzGxsbyfVevXqVfPz27dvk
cmElUgEQqVzgSL179244PDwM29vbyedmZmbC7Oxs8rmDg4MwPz8fxsfHk8vu3LkTJicnc25jamoq
idH8+yl2O99++214/Phxcv7Ro0ehsrIy+fr044GBAb80kQqASOUiR+rW1lbO5zo6OpKwzNbU1JT8
+/r16+TZ1PTy+G981jO9jez7KXY7Dx8+TII3+v7770N/f39yim7fvp0ELSIVAJHKBY7UfBUVFcnn
s0+XLl3KXP7FF18kz5BGc3Nzoa+v78jbK3Y7MXavX7+enI9/KrC6uprEb9TS0pL8CQAiFQCRikjN
yA7SoywuLiYhmQbms2fPjry9Urdz+fLlsLOzk4nTxsbGsL6+nvkYkQqASEWkZsTw3N3dLXp7MSjj
36KmBzgddXulbufmzZvhu+++y7zMn77kn36MSAVApCJSM+KBUWNjY8nfk8ZT/Linpyfna+IBUA0N
DZkDoY66vVK3Mz09Herq6sKDBw+Sj3/++edQVVWV+VMCRCoAIhWRmmN4eDjU1NQkR93HvzlNj/xP
xbePipfFl+uL3V6x2/ntt99y3npqZWUl+fjNmzfCSqQCIFIRKJgBABCpCBTMAAAiFQQKZgAAkYpA
wQwAIFJBoGAGABCpCBTMAACIVAQKZgAAkYpAwQwAgEhFoGAGABCpCBTMAACIVAQKZgAAkQoCBTMA
gEhFoGAGAECkIlAwAwCIVAQKZgAARCoCBTMAgEhFoGAGAECkIlAwAwCIVBAomAEARCqfXKDs7e2F
5ubm9z7/9u3b8M0334TKyspQVVUVbt26FXZ2dvxARSoAiFT+2kA5ODgIN2/ePPJrent7w6NHj8Lh
4WFyiue//PJLP1CRCgAilb82UHp6esLm5uaRX1NRUVHW5xCpACBSOdVAefbsWcGvSZ9JTS0sLIQv
vvjCD1SkAoBI5WwC5aivef36dbh8+XJyWTzF8/FziFQAEKmcW6T29fWFycnJzN+kTkxMJH+/ikgF
AJHKuUVqPKo/xmkqno9H+SNSAUCkcm6Rmh+kMVKrq6v9QEUqAIhUzi9S7969G3755ZfkbapioE5N
TYXBwUE/UJEKACKV84vU+Cb/MVTjy/7xFAM1fg6RCgAiFYGCGQBApCJQMAMAIFIRKJgBAEQqAgUz
AAAiFYGCGQBApIJAwQwAIFIRKJgBABCpCBTMAAAiFYGCGQAAkYpAwQwAIFIRKJgBABCpCBTMAAAi
FQMjUMyAGQBApCJQMAMAiFQQKJgBAEQqAgUzAAAiFZGC3z0AIhWxgt85AIhUzjhanC7OCQDO0v8B
rzeBl0PhcS8AAAAASUVORK5CYII=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-05-22 13:32:56 +0200" MODIFIED_BY="Arash Rashidian">
<APPENDIX ID="APP-01" MODIFIED="2015-05-22 13:30:01 +0200" MODIFIED_BY="Arash Rashidian" NO="1">
<TITLE MODIFIED="2015-02-18 15:18:18 +0100" MODIFIED_BY="[Empty name]">All search strategies (run 2015)</TITLE>
<APPENDIX_BODY MODIFIED="2015-05-22 13:30:01 +0200" MODIFIED_BY="Arash Rashidian">
<P>
<B>CENTRAL</B>
</P>
<TABLE COLS="3" ROWS="57">
<TR>
<TD VALIGN="TOP">
<P>ID</P>
</TD>
<TD VALIGN="TOP">
<P>Search</P>
</TD>
<TD VALIGN="TOP">
<P>Hits</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#1</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Physician's Practice Patterns] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>1095</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#2</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Group Practice] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>39</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#3</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Institutional Practice] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#4</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Partnership Practice] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#5</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Private Practice] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>84</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#6</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Family Practice] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>2130</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#7</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Physicians] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>613</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#8</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Physicians, Family] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>465</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#9</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Physicians, Primary Care] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>62</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#10</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Professional Practice] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>122</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#11</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Nurses] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>330</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#12</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Nurse Clinicians] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>182</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#13</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Nurse Practitioners] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>309</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#14</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Pharmacists] explode all trees</P>
</TD>
<TD VALIGN="TOP">
<P>443</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#15</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Pharmacies] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>78</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#16</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Pharmacy] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#17</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Hospitals] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>339</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#18</P>
</TD>
<TD VALIGN="TOP">
<P>(physician* or GP or "gps" or doctor* or prescriber* or professional next pract* or group next pract* or institutional next pract* or partnership next pract* or family next pract* or general next pract* or office next pract* or private next pract* or primary next pract* or nurse or nurses or pharmacist* or pharmacies or pharmacy or hospital or hospitals):ti,ab</P>
</TD>
<TD VALIGN="TOP">
<P>76128</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#19</P>
</TD>
<TD VALIGN="TOP">
<P>#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18</P>
</TD>
<TD VALIGN="TOP">
<P>77177</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#20</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Drug Information Services] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>46</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#21</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Pharmacists] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>443</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#22</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Community Pharmacy Services] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>208</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#23</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Reminder Systems] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>609</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#24</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Feedback] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>967</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#25</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Education, Continuing] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>93</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#26</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Education, Medical, Continuing] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>630</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#27</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Education, Nursing, Continuing] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>248</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#28</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Education, Pharmacy, Continuing] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>26</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#29</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Guidelines as Topic] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>308</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#30</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Practice Guidelines as Topic] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>1759</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#31</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Guideline Adherence] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>737</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#32</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Budgets] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>63</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#33</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Contract Services] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#34</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Motivation] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>3093</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#35</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Physician Incentive Plans] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#36</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Capitation Fee] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#37</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Reimbursement, Incentive] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>62</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#38</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Income] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>230</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#39</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Salaries and Fringe Benefits] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>49</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#40</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Benchmarking] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>98</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#41</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Drug Monitoring] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>1107</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#42</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Adverse Drug Reaction Reporting Systems] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>109</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#43</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Product Surveillance, Postmarketing] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>98</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#44</P>
</TD>
<TD VALIGN="TOP">
<P>("drug information" or reminder* or feedback or "continuing education" or capitation or salaries or salary or income* or wage or wages or fringe next benefit* or benchmarking or bench next marking or outreach or visit or visits or letter or letters or mail or mails or telephon* or "phone" or "phoning" or academic next detailing or group next detailing or fundhold* or fund next hold* or prescrib* next scheme* or prescrip* next scheme*):ti,ab</P>
</TD>
<TD VALIGN="TOP">
<P>38496</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#45</P>
</TD>
<TD VALIGN="TOP">
<P>guideline* near/1 (disseminat* or implement* or compliance or adherence or distribut*):ti,ab</P>
</TD>
<TD VALIGN="TOP">
<P>341</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#46</P>
</TD>
<TD VALIGN="TOP">
<P>(drug or drugs or pharmaceutic* or prescrib* or prescrip*) near/1 budget*:ti,ab</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#47</P>
</TD>
<TD VALIGN="TOP">
<P>incentive* near/1 (plan or plans or money* or financ* or payment* or reimburs*):ti,ab</P>
</TD>
<TD VALIGN="TOP">
<P>308</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#48</P>
</TD>
<TD VALIGN="TOP">
<P>(review or report* or monitor* or surveillance or evaluat*) near/1 ("drug use" or "drug utilization" or "drug utilisation" or prescrib* or prescrip*):ti,ab</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#49</P>
</TD>
<TD VALIGN="TOP">
<P>#20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48</P>
</TD>
<TD VALIGN="TOP">
<P>45945</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#50</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Drug Prescriptions] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>465</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#51</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Drug Utilization] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>396</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#52</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Drug Utilization Review] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>122</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#53</P>
</TD>
<TD VALIGN="TOP">
<P>(prescrib* or prescrip*) near/2 (attitude or variation* or behavior or behaviour or pattern* or practice* or habit or habits or accurate or trend or trends or cost or costs or effect* or change or changes or shift* or rational or reduce reduction or improv* or influenc* or expenditure* or rate or rates or data):ti,ab</P>
</TD>
<TD VALIGN="TOP">
<P>1257</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#54</P>
</TD>
<TD VALIGN="TOP">
<P>("drug use" or "drug utilization" or "drug utilisation"):ti,ab</P>
</TD>
<TD VALIGN="TOP">
<P>1952</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#55</P>
</TD>
<TD VALIGN="TOP">
<P>#50 or #51 or #52 or #53 or #54</P>
</TD>
<TD VALIGN="TOP">
<P>3761</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#56</P>
</TD>
<TD VALIGN="TOP">
<P>#19 and #49 and #55 in Trials</P>
</TD>
<TD VALIGN="TOP">
<P>631</P>
</TD>
</TR>
</TABLE>
<P/>
<P>
<B>NHSEED</B>
</P>
<TABLE COLS="3" ROWS="57">
<TR>
<TD VALIGN="TOP">
<P>ID</P>
</TD>
<TD VALIGN="TOP">
<P>Search</P>
</TD>
<TD VALIGN="TOP">
<P>Hits</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#1</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Physician's Practice Patterns] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>1095</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#2</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Group Practice] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>39</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#3</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Institutional Practice] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#4</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Partnership Practice] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#5</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Private Practice] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>84</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#6</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Family Practice] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>2130</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#7</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Physicians] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>613</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#8</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Physicians, Family] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>465</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#9</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Physicians, Primary Care] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>62</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#10</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Professional Practice] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>122</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#11</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Nurses] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>330</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#12</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Nurse Clinicians] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>182</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#13</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Nurse Practitioners] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>309</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#14</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Pharmacists] explode all trees</P>
</TD>
<TD VALIGN="TOP">
<P>443</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#15</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Pharmacies] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>78</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#16</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Pharmacy] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#17</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Hospitals] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>339</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#18</P>
</TD>
<TD VALIGN="TOP">
<P>(physician* or GP or "gps" or doctor* or prescriber* or professional next pract* or group next pract* or institutional next pract* or partnership next pract* or family next pract* or general next pract* or office next pract* or private next pract* or primary next pract* or nurse or nurses or pharmacist* or pharmacies or pharmacy or hospital or hospitals)</P>
</TD>
<TD VALIGN="TOP">
<P>207696</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#19</P>
</TD>
<TD VALIGN="TOP">
<P>#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18</P>
</TD>
<TD VALIGN="TOP">
<P>207696</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#20</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Drug Information Services] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>46</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#21</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Pharmacists] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>443</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#22</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Community Pharmacy Services] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>208</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#23</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Reminder Systems] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>609</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#24</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Feedback] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>967</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#25</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Education, Continuing] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>93</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#26</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Education, Medical, Continuing] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>630</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#27</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Education, Nursing, Continuing] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>248</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#28</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Education, Pharmacy, Continuing] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>26</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#29</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Guidelines as Topic] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>308</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#30</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Practice Guidelines as Topic] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>1759</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#31</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Guideline Adherence] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>737</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#32</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Budgets] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>63</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#33</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Contract Services] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#34</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Motivation] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>3093</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#35</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Physician Incentive Plans] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#36</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Capitation Fee] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#37</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Reimbursement, Incentive] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>62</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#38</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Income] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>230</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#39</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Salaries and Fringe Benefits] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>49</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#40</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Benchmarking] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>98</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#41</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Drug Monitoring] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>1107</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#42</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Adverse Drug Reaction Reporting Systems] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>109</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#43</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Product Surveillance, Postmarketing] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>98</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#44</P>
</TD>
<TD VALIGN="TOP">
<P>("drug information" or reminder* or feedback or "continuing education" or capitation or salaries or salary or income* or wage or wages or fringe next benefit* or benchmarking or bench next marking or outreach or visit or visits or letter or letters or mail or mails or telephon* or "phone" or "phoning" or academic next detailing or group next detailing or fundhold* or fund next hold* or prescrib* next scheme* or prescrip* next scheme*)</P>
</TD>
<TD VALIGN="TOP">
<P>115956</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#45</P>
</TD>
<TD VALIGN="TOP">
<P>guideline* near/1 (disseminat* or implement* or compliance or adherence or distribut*)</P>
</TD>
<TD VALIGN="TOP">
<P>1147</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#46</P>
</TD>
<TD VALIGN="TOP">
<P>(drug or drugs or pharmaceutic* or prescrib* or prescrip*) near/1 budget*</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#47</P>
</TD>
<TD VALIGN="TOP">
<P>incentive* near/1 (plan or plans or money* or financ* or payment* or reimburs*)</P>
</TD>
<TD VALIGN="TOP">
<P>461</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#48</P>
</TD>
<TD VALIGN="TOP">
<P>(review or report* or monitor* or surveillance or evaluat*) near/1 ("drug use" or "drug utilization" or "drug utilisation" or prescrib* or prescrip*)</P>
</TD>
<TD VALIGN="TOP">
<P>383</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#49</P>
</TD>
<TD VALIGN="TOP">
<P>#20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48</P>
</TD>
<TD VALIGN="TOP">
<P>122420</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#50</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Drug Prescriptions] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>465</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#51</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Drug Utilization] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>396</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#52</P>
</TD>
<TD VALIGN="TOP">
<P>MeSH descriptor: [Drug Utilization Review] this term only</P>
</TD>
<TD VALIGN="TOP">
<P>122</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#53</P>
</TD>
<TD VALIGN="TOP">
<P>(prescrib* or prescrip*) near/2 (attitude or variation* or behavior or behaviour or pattern* or practice* or habit or habits or accurate or trend or trends or cost or costs or effect* or change or changes or shift* or rational or reduce reduction or improv* or influenc* or expenditure* or rate or rates or data)</P>
</TD>
<TD VALIGN="TOP">
<P>1781</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#54</P>
</TD>
<TD VALIGN="TOP">
<P>("drug use" or "drug utilization" or "drug utilisation")</P>
</TD>
<TD VALIGN="TOP">
<P>4065</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#55</P>
</TD>
<TD VALIGN="TOP">
<P>#50 or #51 or #52 or #53 or #54</P>
</TD>
<TD VALIGN="TOP">
<P>5773</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>#56</P>
</TD>
<TD VALIGN="TOP">
<P>#19 and #49 and #55 in Economic Evaluations</P>
</TD>
<TD VALIGN="TOP">
<P>223</P>
</TD>
</TR>
</TABLE>
<P/>
<P>
<B>MEDLINE, Ovid SP</B>
</P>
<TABLE COLS="3" ROWS="104">
<TR>
<TD VALIGN="TOP">
<P>
<B>#</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Searches</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Results</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>*Physician's Practice Patterns/</P>
</TD>
<TD VALIGN="TOP">
<P>25568</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>*Group Practice/</P>
</TD>
<TD VALIGN="TOP">
<P>5359</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>*Institutional Practice/</P>
</TD>
<TD VALIGN="TOP">
<P>548</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>*Partnership Practice/</P>
</TD>
<TD VALIGN="TOP">
<P>589</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>*Private Practice/</P>
</TD>
<TD VALIGN="TOP">
<P>3572</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>*Family Practice/</P>
</TD>
<TD VALIGN="TOP">
<P>37643</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>*Physicians/</P>
</TD>
<TD VALIGN="TOP">
<P>41449</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>*Physicians, Family/</P>
</TD>
<TD VALIGN="TOP">
<P>9765</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>*Physicians, Primary Care/</P>
</TD>
<TD VALIGN="TOP">
<P>998</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>*Professional Practice/</P>
</TD>
<TD VALIGN="TOP">
<P>7835</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>*Nurses/</P>
</TD>
<TD VALIGN="TOP">
<P>22020</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>*Nurse Clinicians/</P>
</TD>
<TD VALIGN="TOP">
<P>5521</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>*Nurse Practitioners/</P>
</TD>
<TD VALIGN="TOP">
<P>10913</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>*Pharmacists/</P>
</TD>
<TD VALIGN="TOP">
<P>7324</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>*Pharmacies/</P>
</TD>
<TD VALIGN="TOP">
<P>2678</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>*Pharmacy/</P>
</TD>
<TD VALIGN="TOP">
<P>7168</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>*Hospitals/</P>
</TD>
<TD VALIGN="TOP">
<P>33359</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>(physician$ or GP? or doctor? or prescriber? or professional pract* or group pract* or institutional pract* or partnership pract* or family pract* or general pract* or office pract* or private pract* or primary pract* or nurse or nurses).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>653098</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>(pharmacist? or pharmacies or pharmacy).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>43679</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>hospital?.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>762207</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>21</P>
</TD>
<TD VALIGN="TOP">
<P>or/1-20</P>
</TD>
<TD VALIGN="TOP">
<P>1424970</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>*Drug Information Services/</P>
</TD>
<TD VALIGN="TOP">
<P>2315</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>*Community Pharmacy Services/</P>
</TD>
<TD VALIGN="TOP">
<P>2285</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>*Reminder Systems/</P>
</TD>
<TD VALIGN="TOP">
<P>1355</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>*Feedback/</P>
</TD>
<TD VALIGN="TOP">
<P>4796</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>26</P>
</TD>
<TD VALIGN="TOP">
<P>*Education, Continuing/</P>
</TD>
<TD VALIGN="TOP">
<P>3217</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>*Education, Medical, Continuing/</P>
</TD>
<TD VALIGN="TOP">
<P>12484</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>*Education, Nursing, Continuing/</P>
</TD>
<TD VALIGN="TOP">
<P>12373</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>29</P>
</TD>
<TD VALIGN="TOP">
<P>*Education, Pharmacy, Continuing/</P>
</TD>
<TD VALIGN="TOP">
<P>447</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>*Guidelines as Topic/</P>
</TD>
<TD VALIGN="TOP">
<P>8220</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>*Practice Guidelines as Topic/</P>
</TD>
<TD VALIGN="TOP">
<P>27646</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>32</P>
</TD>
<TD VALIGN="TOP">
<P>*Guideline Adherence/</P>
</TD>
<TD VALIGN="TOP">
<P>9988</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>*Budgets/</P>
</TD>
<TD VALIGN="TOP">
<P>3905</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>*Contract Services/</P>
</TD>
<TD VALIGN="TOP">
<P>5529</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>35</P>
</TD>
<TD VALIGN="TOP">
<P>*Motivation/</P>
</TD>
<TD VALIGN="TOP">
<P>19524</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P>*Physician Incentive Plans/</P>
</TD>
<TD VALIGN="TOP">
<P>1250</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>37</P>
</TD>
<TD VALIGN="TOP">
<P>*Capitation Fee/</P>
</TD>
<TD VALIGN="TOP">
<P>1987</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>38</P>
</TD>
<TD VALIGN="TOP">
<P>*Reimbursement, Incentive/</P>
</TD>
<TD VALIGN="TOP">
<P>1970</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>39</P>
</TD>
<TD VALIGN="TOP">
<P>*Income/</P>
</TD>
<TD VALIGN="TOP">
<P>6515</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>40</P>
</TD>
<TD VALIGN="TOP">
<P>*"Salaries and Fringe Benefits"/</P>
</TD>
<TD VALIGN="TOP">
<P>6805</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>41</P>
</TD>
<TD VALIGN="TOP">
<P>*Benchmarking/</P>
</TD>
<TD VALIGN="TOP">
<P>4213</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>42</P>
</TD>
<TD VALIGN="TOP">
<P>*Drug Monitoring/</P>
</TD>
<TD VALIGN="TOP">
<P>5064</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>43</P>
</TD>
<TD VALIGN="TOP">
<P>*Adverse Drug Reaction Reporting Systems/</P>
</TD>
<TD VALIGN="TOP">
<P>3119</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>*Product Surveillance, Postmarketing/</P>
</TD>
<TD VALIGN="TOP">
<P>2654</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P>drug information.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>2620</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>46</P>
</TD>
<TD VALIGN="TOP">
<P>reminder?.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>7406</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>47</P>
</TD>
<TD VALIGN="TOP">
<P>feedback.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>86642</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>48</P>
</TD>
<TD VALIGN="TOP">
<P>(continuing adj1 education).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>10530</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>49</P>
</TD>
<TD VALIGN="TOP">
<P>(guideline? adj1 (disseminat* or implement* or compliance or adherence or distribut*)).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>2534</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>50</P>
</TD>
<TD VALIGN="TOP">
<P>((drug? or pharmaceutic* or prescrib* or prescrip*) adj1 budget?).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>285</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>51</P>
</TD>
<TD VALIGN="TOP">
<P>(incentive? adj1 (plan? or money* or financ* or payment? or reimburs*)).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>3294</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>52</P>
</TD>
<TD VALIGN="TOP">
<P>capitation.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>2247</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>53</P>
</TD>
<TD VALIGN="TOP">
<P>(salaries or salary or income? or wage or wages or fringe benefit?).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>73762</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>54</P>
</TD>
<TD VALIGN="TOP">
<P>(benchmarking or bench marking).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>4015</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>55</P>
</TD>
<TD VALIGN="TOP">
<P>((review or report* or monitor* or surveillance or evaluat*) adj1 (drug use? or drug utilization or drug utilisation or prescrib* or prescrip*)).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>1930</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>56</P>
</TD>
<TD VALIGN="TOP">
<P>outreach.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>8281</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>57</P>
</TD>
<TD VALIGN="TOP">
<P>visit?.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>110185</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>58</P>
</TD>
<TD VALIGN="TOP">
<P>(letter? or mail?).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>80884</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>59</P>
</TD>
<TD VALIGN="TOP">
<P>(telephon* or phone or phoning).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>52135</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>60</P>
</TD>
<TD VALIGN="TOP">
<P>((academic or group) adj1 detailing).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>357</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>61</P>
</TD>
<TD VALIGN="TOP">
<P>(fundhold* or fund hold*).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>429</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>62</P>
</TD>
<TD VALIGN="TOP">
<P>((prescrib* or prescrip*) adj1 scheme?).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>51</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>63</P>
</TD>
<TD VALIGN="TOP">
<P>or/22-62</P>
</TD>
<TD VALIGN="TOP">
<P>536617</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>64</P>
</TD>
<TD VALIGN="TOP">
<P>*Drug Prescriptions/</P>
</TD>
<TD VALIGN="TOP">
<P>12792</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>65</P>
</TD>
<TD VALIGN="TOP">
<P>*Drug Utilization/</P>
</TD>
<TD VALIGN="TOP">
<P>5752</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>66</P>
</TD>
<TD VALIGN="TOP">
<P>*"Drug Utilization Review"/</P>
</TD>
<TD VALIGN="TOP">
<P>1780</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>67</P>
</TD>
<TD VALIGN="TOP">
<P>((prescrib* or prescrip*) adj2 (attitude or variation? or behavior or behaviour or pattern? or practice? or habit? or accurate or trend? or cost? or effect* or change? or shift* or rational or reduc* or improv* or influenc* or expenditure? or rate? or data)).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>16016</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>68</P>
</TD>
<TD VALIGN="TOP">
<P>(drug use? or drug utilization or drug utilisation).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>36804</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>69</P>
</TD>
<TD VALIGN="TOP">
<P>or/64-68</P>
</TD>
<TD VALIGN="TOP">
<P>65348</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>70</P>
</TD>
<TD VALIGN="TOP">
<P>random$.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>738650</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>71</P>
</TD>
<TD VALIGN="TOP">
<P>multicenter study.pt.</P>
</TD>
<TD VALIGN="TOP">
<P>177607</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>72</P>
</TD>
<TD VALIGN="TOP">
<P>randomized controlled trial.pt.</P>
</TD>
<TD VALIGN="TOP">
<P>382639</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>73</P>
</TD>
<TD VALIGN="TOP">
<P>controlled clinical trial.pt.</P>
</TD>
<TD VALIGN="TOP">
<P>88504</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>74</P>
</TD>
<TD VALIGN="TOP">
<P>clinical trial.pt.</P>
</TD>
<TD VALIGN="TOP">
<P>488404</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>75</P>
</TD>
<TD VALIGN="TOP">
<P>intervention studies/</P>
</TD>
<TD VALIGN="TOP">
<P>7175</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>76</P>
</TD>
<TD VALIGN="TOP">
<P>experiment$.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>1491236</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>77</P>
</TD>
<TD VALIGN="TOP">
<P>(time adj series).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>16766</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>78</P>
</TD>
<TD VALIGN="TOP">
<P>(pre test or pretest or (posttest or post test)).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>16741</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>79</P>
</TD>
<TD VALIGN="TOP">
<P>random allocation/</P>
</TD>
<TD VALIGN="TOP">
<P>81767</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>80</P>
</TD>
<TD VALIGN="TOP">
<P>impact.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>527216</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>81</P>
</TD>
<TD VALIGN="TOP">
<P>control*.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>2687048</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>82</P>
</TD>
<TD VALIGN="TOP">
<P>intervention?.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>549968</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>83</P>
</TD>
<TD VALIGN="TOP">
<P>chang*.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>2239496</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>84</P>
</TD>
<TD VALIGN="TOP">
<P>evaluation studies/</P>
</TD>
<TD VALIGN="TOP">
<P>198985</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>85</P>
</TD>
<TD VALIGN="TOP">
<P>evaluat*.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>2291066</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>86</P>
</TD>
<TD VALIGN="TOP">
<P>effect?.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>3950017</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>87</P>
</TD>
<TD VALIGN="TOP">
<P>comparative studies/</P>
</TD>
<TD VALIGN="TOP">
<P>1684725</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>88</P>
</TD>
<TD VALIGN="TOP">
<P>compar*.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>3684936</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>89</P>
</TD>
<TD VALIGN="TOP">
<P>Non-Randomized Controlled Trials as Topic/</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>90</P>
</TD>
<TD VALIGN="TOP">
<P>Interrupted Time Series Analysis/</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>91</P>
</TD>
<TD VALIGN="TOP">
<P>Controlled Before-After Studies/</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>92</P>
</TD>
<TD VALIGN="TOP">
<P>or/70-91</P>
</TD>
<TD VALIGN="TOP">
<P>11101193</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>93</P>
</TD>
<TD VALIGN="TOP">
<P>editorial.pt.</P>
</TD>
<TD VALIGN="TOP">
<P>367122</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>94</P>
</TD>
<TD VALIGN="TOP">
<P>comment.pt.</P>
</TD>
<TD VALIGN="TOP">
<P>607484</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>95</P>
</TD>
<TD VALIGN="TOP">
<P>or/93-94</P>
</TD>
<TD VALIGN="TOP">
<P>859199</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>96</P>
</TD>
<TD VALIGN="TOP">
<P>animals/</P>
</TD>
<TD VALIGN="TOP">
<P>5364245</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>97</P>
</TD>
<TD VALIGN="TOP">
<P>humans/</P>
</TD>
<TD VALIGN="TOP">
<P>13645983</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>98</P>
</TD>
<TD VALIGN="TOP">
<P>96 not (96 and 97)</P>
</TD>
<TD VALIGN="TOP">
<P>3883013</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>99</P>
</TD>
<TD VALIGN="TOP">
<P>95 or 98</P>
</TD>
<TD VALIGN="TOP">
<P>4709197</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD VALIGN="TOP">
<P>92 not 99</P>
</TD>
<TD VALIGN="TOP">
<P>8497522</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>101</P>
</TD>
<TD VALIGN="TOP">
<P>21 and 63 and 69 and 100</P>
</TD>
<TD VALIGN="TOP">
<P>4418</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>102</P>
</TD>
<TD VALIGN="TOP">
<P>(201210* or 201211* or 201212* or 2013* or 2014* or 2015*).ed,ep,yr.</P>
</TD>
<TD VALIGN="TOP">
<P>2879170</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>103</P>
</TD>
<TD VALIGN="TOP">
<P>101 and 102</P>
</TD>
<TD VALIGN="TOP">
<P>758</P>
</TD>
</TR>
</TABLE>
<P/>
<P>
<B>EMBASE, Ovid SP</B>
</P>
<TABLE COLS="3" ROWS="85">
<TR>
<TD VALIGN="TOP">
<P>
<B>#</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Searches</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Results</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>Clinical Practice/</P>
</TD>
<TD VALIGN="TOP">
<P>177478</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>General Practice/</P>
</TD>
<TD VALIGN="TOP">
<P>68317</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>Medical Practice/</P>
</TD>
<TD VALIGN="TOP">
<P>76094</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>Private Practice/</P>
</TD>
<TD VALIGN="TOP">
<P>11215</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>Professional Practice/</P>
</TD>
<TD VALIGN="TOP">
<P>50325</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>Group Practice/</P>
</TD>
<TD VALIGN="TOP">
<P>8045</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>General Practitioner/</P>
</TD>
<TD VALIGN="TOP">
<P>62743</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>Physician/</P>
</TD>
<TD VALIGN="TOP">
<P>189628</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>Nurse/</P>
</TD>
<TD VALIGN="TOP">
<P>79073</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>Nurse Practitioner/</P>
</TD>
<TD VALIGN="TOP">
<P>18163</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>Pharmacist/</P>
</TD>
<TD VALIGN="TOP">
<P>49418</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>Pharmacy/</P>
</TD>
<TD VALIGN="TOP">
<P>55645</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>Hospital Pharmacy/</P>
</TD>
<TD VALIGN="TOP">
<P>12486</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>Clinical Pharmacy/</P>
</TD>
<TD VALIGN="TOP">
<P>6403</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>Hospital/</P>
</TD>
<TD VALIGN="TOP">
<P>278315</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>(physician$ or GP? or doctor? or prescriber? or professional pract* or group pract* or institutional pract* or partnership pract* or family pract* or general pract* or office pract* or private pract* or primary pract* or nurse or nurses).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>796622</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>(pharmacist? or pharmacies or pharmacy).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>85844</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>hospital?.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>1023242</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>or/1-18</P>
</TD>
<TD VALIGN="TOP">
<P>2166281</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>*Drug Information/</P>
</TD>
<TD VALIGN="TOP">
<P>7168</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>21</P>
</TD>
<TD VALIGN="TOP">
<P>*Reminder System/</P>
</TD>
<TD VALIGN="TOP">
<P>749</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>*Feedback System/</P>
</TD>
<TD VALIGN="TOP">
<P>9978</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>*Continuing Education/</P>
</TD>
<TD VALIGN="TOP">
<P>8383</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>*Medical Education/</P>
</TD>
<TD VALIGN="TOP">
<P>95718</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>*Education/</P>
</TD>
<TD VALIGN="TOP">
<P>48676</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>26</P>
</TD>
<TD VALIGN="TOP">
<P>*Nursing Education/</P>
</TD>
<TD VALIGN="TOP">
<P>54320</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>*Practice guideline/</P>
</TD>
<TD VALIGN="TOP">
<P>38300</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>*Budget/</P>
</TD>
<TD VALIGN="TOP">
<P>4671</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>29</P>
</TD>
<TD VALIGN="TOP">
<P>*Motivation/</P>
</TD>
<TD VALIGN="TOP">
<P>19299</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>*Capitation Fee/</P>
</TD>
<TD VALIGN="TOP">
<P>1644</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>*Medical Fee/</P>
</TD>
<TD VALIGN="TOP">
<P>4229</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>32</P>
</TD>
<TD VALIGN="TOP">
<P>*Income/</P>
</TD>
<TD VALIGN="TOP">
<P>6147</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>*Physician Income/</P>
</TD>
<TD VALIGN="TOP">
<P>382</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>*Salary/</P>
</TD>
<TD VALIGN="TOP">
<P>547</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>35</P>
</TD>
<TD VALIGN="TOP">
<P>*Drug Monitoring/</P>
</TD>
<TD VALIGN="TOP">
<P>16974</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P>*Postmarketing surveillance/</P>
</TD>
<TD VALIGN="TOP">
<P>1573</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>37</P>
</TD>
<TD VALIGN="TOP">
<P>*Drug Surveillance Program/</P>
</TD>
<TD VALIGN="TOP">
<P>9341</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>38</P>
</TD>
<TD VALIGN="TOP">
<P>drug information.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>4287</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>39</P>
</TD>
<TD VALIGN="TOP">
<P>reminder?.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>10023</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>40</P>
</TD>
<TD VALIGN="TOP">
<P>feedback.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>98828</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>41</P>
</TD>
<TD VALIGN="TOP">
<P>(continuing adj1 education).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>12183</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>42</P>
</TD>
<TD VALIGN="TOP">
<P>(guideline? adj1 (disseminat* or implement* or compliance or adherence or distribut*)).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>3528</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>43</P>
</TD>
<TD VALIGN="TOP">
<P>((drug? or pharmaceutic* or prescrib* or prescrip*) adj1 budget?).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>455</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>(incentive? adj1 (plan? or money* or financ* or payment? or reimburs*)).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>3787</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P>capitation.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>2385</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>46</P>
</TD>
<TD VALIGN="TOP">
<P>(salaries or salary or income? or wage or wages or fringe benefit?).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>83247</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>47</P>
</TD>
<TD VALIGN="TOP">
<P>(benchmarking or bench marking).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>5142</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>48</P>
</TD>
<TD VALIGN="TOP">
<P>((review or report* or monitor* or surveillance or evaluat*) adj1 (drug use? or drug utilization or drug utilisation or prescrib* or prescrip*)).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>2854</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>49</P>
</TD>
<TD VALIGN="TOP">
<P>outreach.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>10391</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>50</P>
</TD>
<TD VALIGN="TOP">
<P>visit?.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>157665</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>51</P>
</TD>
<TD VALIGN="TOP">
<P>(letter? or mail?).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>151925</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>52</P>
</TD>
<TD VALIGN="TOP">
<P>(telephon* or phone or phoning).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>69704</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>53</P>
</TD>
<TD VALIGN="TOP">
<P>((academic or group) adj1 detailing).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>463</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>54</P>
</TD>
<TD VALIGN="TOP">
<P>(fundhold* or fund hold*).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>518</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>55</P>
</TD>
<TD VALIGN="TOP">
<P>((prescrib* or prescrip*) adj1 scheme?).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>70</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>56</P>
</TD>
<TD VALIGN="TOP">
<P>or/20-55</P>
</TD>
<TD VALIGN="TOP">
<P>860810</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>57</P>
</TD>
<TD VALIGN="TOP">
<P>*Prescription/</P>
</TD>
<TD VALIGN="TOP">
<P>24569</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>58</P>
</TD>
<TD VALIGN="TOP">
<P>*"Drug Use"/</P>
</TD>
<TD VALIGN="TOP">
<P>12342</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>59</P>
</TD>
<TD VALIGN="TOP">
<P>*Drug Utilization/</P>
</TD>
<TD VALIGN="TOP">
<P>4395</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>60</P>
</TD>
<TD VALIGN="TOP">
<P>((prescrib* or prescrip*) adj2 (attitude or variation? or behavior or behaviour or pattern? or practice? or habit? or accurate or trend? or cost? or effect* or change? or shift* or rational or reduc* or improv* or influenc* or expenditure? or rate? or data)).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>23584</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>61</P>
</TD>
<TD VALIGN="TOP">
<P>(drug use? or drug utilization or drug utilisation).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>47416</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>62</P>
</TD>
<TD VALIGN="TOP">
<P>or/57-61</P>
</TD>
<TD VALIGN="TOP">
<P>97429</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>63</P>
</TD>
<TD VALIGN="TOP">
<P>randomized controlled trial/</P>
</TD>
<TD VALIGN="TOP">
<P>356342</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>64</P>
</TD>
<TD VALIGN="TOP">
<P>time series analysis/</P>
</TD>
<TD VALIGN="TOP">
<P>14784</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>65</P>
</TD>
<TD VALIGN="TOP">
<P>random$.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>923916</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>66</P>
</TD>
<TD VALIGN="TOP">
<P>experiment*.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>1555371</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>67</P>
</TD>
<TD VALIGN="TOP">
<P>(time adj series).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>18724</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>68</P>
</TD>
<TD VALIGN="TOP">
<P>(pre test or pretest or post test or posttest).tw.</P>
</TD>
<TD VALIGN="TOP">
<P>21759</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>69</P>
</TD>
<TD VALIGN="TOP">
<P>impact.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>708271</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>70</P>
</TD>
<TD VALIGN="TOP">
<P>control*.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>3198418</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>71</P>
</TD>
<TD VALIGN="TOP">
<P>intervention?.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>705702</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>72</P>
</TD>
<TD VALIGN="TOP">
<P>chang*.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>2557152</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>73</P>
</TD>
<TD VALIGN="TOP">
<P>evaluat*.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>2935804</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>74</P>
</TD>
<TD VALIGN="TOP">
<P>effect?.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>4444256</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>75</P>
</TD>
<TD VALIGN="TOP">
<P>compar*.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>4442940</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>76</P>
</TD>
<TD VALIGN="TOP">
<P>or/63-75</P>
</TD>
<TD VALIGN="TOP">
<P>12126117</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>77</P>
</TD>
<TD VALIGN="TOP">
<P>editorial.pt.</P>
</TD>
<TD VALIGN="TOP">
<P>459038</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>78</P>
</TD>
<TD VALIGN="TOP">
<P>nonhuman/</P>
</TD>
<TD VALIGN="TOP">
<P>4432890</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>79</P>
</TD>
<TD VALIGN="TOP">
<P>or/77-78</P>
</TD>
<TD VALIGN="TOP">
<P>4857801</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>80</P>
</TD>
<TD VALIGN="TOP">
<P>19 and 56 and 62 and 76</P>
</TD>
<TD VALIGN="TOP">
<P>6719</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>81</P>
</TD>
<TD VALIGN="TOP">
<P>80 not 79</P>
</TD>
<TD VALIGN="TOP">
<P>6628</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>82</P>
</TD>
<TD VALIGN="TOP">
<P>limit 81 to embase</P>
</TD>
<TD VALIGN="TOP">
<P>5631</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>83</P>
</TD>
<TD VALIGN="TOP">
<P>(201210* or 201211* or 201212* or 2013* or 2014* or 2015*).dd,yr.</P>
</TD>
<TD VALIGN="TOP">
<P>3136633</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>84</P>
</TD>
<TD VALIGN="TOP">
<P>82 and 83</P>
</TD>
<TD VALIGN="TOP">
<P>1519</P>
</TD>
</TR>
</TABLE>
<P/>
<P>
<B>International Network for Rational Use of Drugs (INRUD) </B>
</P>
<P>(Search field: All Non-Indexed Text Files)</P>
<P>Two individual search strategies</P>
<P>1. {prescribing behavior} or {prescribing behaviour} or {prescribing habit} or {prescribing pattern } or {prescribing practice} or {change in prescri} or {changes in prescri} or {shift in prescri} <B>AND </B>{randomis} or {randomiz} or {randomly} or {intervention} or {control} or {group} or {before and after} or {pretest} or {posttest} or {pre test} or {post test} or {quasiexperiment} or {quasi experiment} or {evaluat} or {effect} or {impact} or {time series} or {time point} or {repeated measur}</P>
<P>2. {prescriber} or {financ} or {econom} or {pay} or {monetary} <B>AND</B> {incentive} <B>AND</B> {randomis} or {randomiz} or {randomly} or {intervention} or {control} or {group} or {before and after} or {pretest} or {posttest} or {pre test} or {post test} or {quasiexperiment} or {quasi experiment} or {evaluat} or {effect} or {impact} or {time series} or {time point} or {repeated measur}</P>
<P>
<B>EconLit, ProQuest</B>
</P>
<P>ALL(prescrib* or prescrip*) NEAR/2 ALL(attitude* or variation* or behavior or behaviour or pattern or patterns or practice* or habit or habits or accurate or trend or trends or cost or costs or effect* or change* or shift* or rational* or reduc* or improve* or influenc* or expenditure* or rate or rates or data or "drug use" or "drug utilization" or "drug utilisation") and ALL(randomised or randomized or randomly or trial or intervention or interventions or controlled or "control group" or "control groups" or "before and after" or "pre and post" or pretest or "pre test" or posttest or "post test" or quasiexperiment* or "quasi experiment" or "quasi experiments" or "quasi experimental" or evaluat* or effect or effects or impact* or "time series" or "time point" or "time points" or "repeated measure" or "repeated measures" or "repeated measurement" or "repeated measurements")</P>
<P>
<B>Science Citation Index an Social Sciences Citation Index, ISI Web of Knowledge</B>
</P>
<P>Citation search for included studies: <LINK REF="STD-Baines-1997c" TYPE="STUDY">Baines 1997c</LINK>, <LINK REF="STD-Bradlow-1993" TYPE="STUDY">Bradlow 1993</LINK>, <LINK REF="STD-Burr-1992" TYPE="STUDY">Burr 1992</LINK>, <LINK REF="STD-Chou-2008" TYPE="STUDY">Chou 2008</LINK>, <LINK REF="STD-Chu-2008" TYPE="STUDY">Chu 2008</LINK>, <LINK REF="STD-Corney-1997" TYPE="STUDY">Corney 1997</LINK>,<LINK REF="STD-Doran-2011" TYPE="STUDY">Doran 2011</LINK>, <LINK REF="STD-Granlund-2006" TYPE="STUDY">Granlund 2006</LINK>, <LINK REF="STD-Guether-1995" TYPE="STUDY">Guether 1995</LINK>, <LINK REF="STD-Harris-1996" TYPE="STUDY">Harris 1996</LINK>, <LINK REF="STD-Martens-2007" TYPE="STUDY">Martens 2007</LINK>, <LINK REF="STD-Rafferty-1997" TYPE="STUDY">Rafferty 1997</LINK>, <LINK REF="STD-Sch_x00f6_ffski-1997" TYPE="STUDY">Schöffski 1997</LINK>, <LINK REF="STD-Serumaga-2011" TYPE="STUDY">Serumaga 2011</LINK>, <LINK REF="STD-Walley--2000" TYPE="STUDY">Walley 2000</LINK>, <LINK REF="STD-Whynes-1997" TYPE="STUDY">Whynes 1997</LINK>, <LINK REF="STD-Wilson-1995" TYPE="STUDY">Wilson 1995</LINK>, <LINK REF="STD-Wilson-1999" TYPE="STUDY">Wilson 1999</LINK>.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-05-22 13:32:56 +0200" MODIFIED_BY="Arash Rashidian" NO="2">
<TITLE MODIFIED="2015-02-27 17:12:11 +0100" MODIFIED_BY="Arash Rashidian">All search strategies used in the previous version of the review</TITLE>
<APPENDIX_BODY MODIFIED="2015-05-22 13:32:56 +0200" MODIFIED_BY="Arash Rashidian">
<TABLE COLS="1" ROWS="42">
<TR>
<TH>
<P>MEDLINE Ovid search strategy uses both medical subject heading (MeSH) terms and text words</P>
</TH>
</TR>
<TR>
<TD>
<P>1. *Physician's Practice Patterns/<BR/>2. *Group Practice/<BR/>3. *Institutional Practice/<BR/>4. *Partnership Practice/<BR/>5. *Private Practice/<BR/>6. *Family Practice/<BR/>7. *Physicians/<BR/>8. *Physicians, Family/<BR/>9. *Professional Practice/<BR/>10. *Nurses/<BR/>11. *Nurse Clinicians/<BR/>12. *Nurse Practitioners/<BR/>13. *Pharmacists/<BR/>14. *Pharmacies/<BR/>15. *Pharmacy/<BR/>16. *Hospitals/<BR/>17. (physician$ or GP? or doctor? or prescriber? or group pract$ or institutional pract$ or partnership pract$ or family pract$ or general pract$ or office pract$ or private pract$ or primary pract$ or nurse or nurses).tw.<BR/>18. (pharmacist? or pharmacies or pharmacy).tw.<BR/>19. hospital?.tw.<BR/>20. or/1-19<BR/>21. *Drug Information Services/<BR/>22. *Pharmacists/<BR/>23. *Community Pharmacy Services/<BR/>24. *Reminder Systems/<BR/>25. *Feedback/<BR/>26. *Education, Continuing/<BR/>27. *Education, Medical, Continuing/<BR/>28. *Education, Nursing, Continuing/<BR/>29. *Education, Pharmacy, Continuing/<BR/>30. *Guidelines/<BR/>31. *Practice Guidelines/<BR/>32. *Guideline Adherence/<BR/>33. *Budgets/<BR/>34. *Motivation/<BR/>35. *Physician Incentive Plans/<BR/>36. *Capitation Fee/<BR/>37. *Reimbursement, Incentive/<BR/>38. *Income/<BR/>39. *"Salaries and Fringe Benefits"/<BR/>40. *Benchmarking/<BR/>41. *Drug Monitoring/<BR/>42. *Adverse Drug Reaction Reporting Systems/<BR/>43. *Product Surveillance, Postmarketing/<BR/>44. drug information.tw.<BR/>45. pharmacist?.tw.<BR/>46. reminder?.tw.<BR/>47. feedback.tw.<BR/>48. (continuing adj1 education).tw.<BR/>49. (guideline? adj1 (disseminat$ or implement$ or compliance or adherence or distribut$)).tw.<BR/>50. ((drug? or pharmaceutic$ or prescrib$ or prescrip$) adj1 budget?).tw.<BR/>51. (incentive? adj1 (plan? or money$ or financ$ or payment? or reimburs$)).tw.<BR/>52. capitation.tw.<BR/>53. (salaries or salary or income? or wages or fringe benefit?).tw.<BR/>54. benchmarking.tw.<BR/>55. ((review or report$ or monitor$ or surveillance or evaluat$) adj1 (drug use? or drug utilization or drug utilisation or prescrib$ or prescrip$)).tw.<BR/>56. outreach.tw.<BR/>57. visit?.tw.<BR/>58. (letter? or mail$).tw.<BR/>59. (telephon$ or phon$).tw.<BR/>60. ((academic or group) adj1 detailing).tw.<BR/>61. fundhold$.tw.<BR/>62. ((prescrib$ or prescrip$) adj1 scheme?).tw.<BR/>63. or/21-62<BR/>64. *Prescriptions, Drug/<BR/>65. *Drug Utilization/<BR/>66. *"Drug Utilization Review"/<BR/>67. ((prescrib$ or prescrip$) adj2 (attitude or variation? or behavior or behaviour or pattern? or practice? or habit? or accurate or trend? or cost? or effect? or change? or shift$ or rational or reduc$ or improv$ or influenc$ or expenditure? or rate? or data)).tw.<BR/>68. (drug use? or drug utilizarion or drug utilisation).tw.<BR/>69. or/64-68<BR/>70. random$.tw.<BR/>71. multicenter study.pt.<BR/>72. randomized controlled trial.pt.<BR/>73. controlled clinical trial.pt.<BR/>74. clinical trial.pt.<BR/>75. intervention studies/<BR/>76. experiment$.tw.<BR/>77. (time adj series).tw.<BR/>78. (pre test or pretest or (posttest or post test)).tw.<BR/>79. random allocation/<BR/>80. impact.tw.<BR/>81. intervention?.tw.<BR/>82. chang$.tw.<BR/>83. evaluation studies/<BR/>84. evaluat$.tw.<BR/>85. effect?.tw.<BR/>86. comparative studies/<BR/>87. compar$.tw.<BR/>88. or/70-87<BR/>89. editorial.pt.<BR/>90. letter.pt.<BR/>91. comment.pt.<BR/>92. or/89-91<BR/>93. animals/<BR/>94. humans/<BR/>95. 93 not 94<BR/>96. 92 or 95<BR/>97. 20 and 63 and 69 and 88<BR/>98. 97 not 96<BR/>
</P>
</TD>
</TR>
<TR>
<TH>
<P>EMBASE Ovid</P>
</TH>
</TR>
<TR>
<TD>
<P>Search fields: A combination of EMTAGS and text words<BR/>1. Clinical Practice/<BR/>2. General Practice/<BR/>3. Medical Practice/<BR/>4. Private Practice/<BR/>5. Professional Practice/<BR/>6. Group Practice/<BR/>7. General Practitioner/<BR/>8. Physician/<BR/>9. Nurse/<BR/>10. Nurse Practitioner/<BR/>11. Pharmacist/<BR/>12. Pharmacy/<BR/>13. Hospital Pharmacy/<BR/>14. Clinical Pharmacy/<BR/>15. Hospital/<BR/>16. (physician$ or GP? or doctor? or prescriber? or group pract$ or institutional pract$ or partnership pract$ or family pract$ or general pract$ or office pract$ or private pract$ or primary pract$ or nurse or nurses).tw.<BR/>17. (pharmacist? or pharmacies or pharmacy).tw.<BR/>18. hospital?.tw.<BR/>19. or/1-18<BR/>20. *Drug Information/<BR/>21. *Pharmacist/<BR/>22. *Reminder System/<BR/>23. *Feedback System/<BR/>24. *Continuing Education/<BR/>25. *Medical Education/<BR/>26. *Education/<BR/>27. *Nursing Education/<BR/>28. *Practice guideline/<BR/>29. *Budget/<BR/>30. *Motivation/<BR/>31. *Capitation Fee/<BR/>32. *Medical Fee/<BR/>33. *Income/<BR/>34. *Physician Income/<BR/>35. *Salary/<BR/>36. *Drug Monitoring/<BR/>37. *Postmarketing surveillance/<BR/>38. *Drug Surveillance Program/<BR/>39. drug information.tw.<BR/>40. pharmacist?.tw.<BR/>41. reminder?.tw.<BR/>42. feedback.tw.<BR/>43. (continuing adj1 education).tw.<BR/>44. (guideline? adj1 (disseminat$ or implement$ or compliance or adherence or distribut$)).tw.<BR/>45. ((drug? or pharmaceutic$ or prescrib$ or prescrip$) adj1 budget?).tw.<BR/>46. (incentive? adj1 (plan? or money$ or financ$ or payment? or reimburs$)).tw.<BR/>47. capitation.tw.<BR/>48. (salaries or salary or income? or wages or fringe benefit?).tw.<BR/>49. benchmarking.tw.<BR/>50. ((review or report$ or monitor$ or surveillance or evaluat$) adj1 (drug use? or drug utilization or drug utilisation or prescrib$ or prescrip$)).tw.<BR/>51. outreach.tw.<BR/>52. visit?.tw.<BR/>53. (letter? or mail$).tw.<BR/>54. (telephon$ or phon$).tw.<BR/>55. ((academic or group) adj1 detailing).tw.<BR/>56. fundhold$.tw.<BR/>57. ((prescrib$ or prescrip$) adj1 scheme?).tw.<BR/>58. or/20-57<BR/>59. *Prescription/<BR/>60. *"Drug Use"/<BR/>61. *Drug Utilization/<BR/>62. ((prescrib$ or prescrip$) adj2 (attitude or variation? or behavior or behaviour or pattern? or practice? or habit? or accurate or trend? or cost? or effect? or change? or shift$ or rational or reduc$ or improv$ or influenc$ or expenditure? or rate? or data)).tw.<BR/>63. (drug use? or drug utilization or drug utilisation).tw.<BR/>64. or/59-63<BR/>65. randomized controlled trial/<BR/>66. random$.tw.<BR/>67. experiment$.tw.<BR/>68. (time adj series).tw.<BR/>69. (pre test or pretest or post test or posttest).tw.<BR/>70. impact.tw.<BR/>71. intervention?.tw.<BR/>72. chang$.tw.<BR/>73. evaluat$.tw.<BR/>74. effect$.tw.<BR/>75. compar$.tw.<BR/>76. or/65-75<BR/>77. letter.pt.<BR/>78. editorial.pt.<BR/>79. nonhuman/<BR/>80. or/77-79<BR/>81. 19 and 58 and 64 and 76<BR/>82. 81 not 80</P>
</TD>
</TR>
<TR>
<TH>
<P>Effective Practice and Organisation of Care Group Register, Idealist Database</P>
</TH>
</TR>
<TR>
<TD>
<P>Searched terms anywhere in text<BR/>drug [or] drugs [or] pharmaceutic* [or] medicines [or] medicat* [or] prescrip* [or] prescrib*</P>
</TD>
</TR>
<TR>
<TH>
<P>CENTRAL, the Cochrane Central Register of Controlled Trials, Ovid</P>
</TH>
</TR>
<TR>
<TD>
<P>Search fields: A combination of MeSH terms and text words<BR/>
<BR/>1. (regulat$ or requirement? or restrict$ or monitor$ or control$).tw.<BR/>2. (legislation? or law? or act? or policy or policies or politics or reform$ or system? or plan$ or program$ or strateg$).tw. or Policy Making/ or Legislation, Drug/ or Public Policy/ or Health Policy/ or Politics/ or Health Care Reform/<BR/>3. (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$).tw. or exp Pharmaceutical Preparation/ or Drug Utilization/<BR/>4. (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$).tw. or exp Pharmaceutical Preparation/ or Drug Industry/ or Drug Utilization/<BR/>5. (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$).tw. or exp Pharmaceutical Preparation/ or Prescriptions, Drug/ or Drug Utilization/<BR/>6. Drug Approval/ or (approv$ adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>7. Licensure/ and 4<BR/>8. Drug Labeling/<BR/>9. ((licens$ or registrat$ or label$) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>10. (6 or 7 or 8 or 9) and (1 or 2)<BR/>11. Classification/ and 3 and 2<BR/>12. ((classify$ or classification?) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw. and 2<BR/>13. 11 or 12<BR/>14. 10 or 13<BR/>15. Patents/ and 4<BR/>16. (patent? adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>17. ((profit$ adj3 (control$ or reduc$ or regulat$ or fix$ or restrict$)) and (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>18. (15 or 16 or 17) and (1 or 2)<BR/>19. (Marketing/ or Marketing of Health Services/ or Advertising/) and 4<BR/>20. ((advert$ or promot$ or market$) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>21. (19 or 20) and (1 or 2)<BR/>22. (Insurance, Hospitalization/ or Insurance, health, reimbursement/ or Reimbursement Mechanisms/ or Reimbursement, disproportionate share/ or Reimbursement, incentive/) and 5<BR/>23. Insurance, pharmaceutical services/<BR/>24. ((reimburse$ or insur$ or (third party adj1 pay$) or benefit plan?) adj3 (drug or drugs or pharmaceutic$ or pharmacy or pharmacies or medicines or medicament? or medicat$)).tw.<BR/>25. (22 or 23 or 24) and (1 or 2)<BR/>26. Formularies/ and 5<BR/>27. Formularies, Hospital/ and 3<BR/>28. ((formulary or formularies or positive list? or negative list?) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$ or hospital?)).tw.<BR/>29. (26 or 27 or 28) and (1 or 2)<BR/>30. Drugs, Essential/<BR/>31. (essential adj3 (drug? or pharmaceutic$ or medicine? or medicament?)).tw.<BR/>32. ((drug? or pharmaceutic$ or medicine? or medicament?) adj3 list?).tw.<BR/>33. 31 and 32<BR/>34. 30 or 33<BR/>35. ((pre-authori#ation? or preauthori#ation? or prior authori#ation?) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>36. Reminder Systems/ and 5 and 2<BR/>37. (reminder? adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw. and 2<BR/>38. Prescriptions, Drug/<BR/>39. (continu$ adj3 education).tw.<BR/>40. Education, Continuing/<BR/>41. Education, Pharmacy, Continuing/<BR/>42. (improv$ or incentive?).tw.<BR/>43. 39 or 40 or 41 or 42<BR/>44. 38 and 43 and (1 or 2)<BR/>45. (((prescrib$ or prescription?) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)) and ((continu$ adj1 education) or (improv$ or incentive?))).tw. and (1 or 2)<BR/>46. (Guidelines/ or Practice Guidelines/ or Guideline Adherence/) and 2 and 5<BR/>47. (((guideline? or recommendation?) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)) and (disseminat$ or implement$ or complian$ or adherence)).tw. and 2<BR/>48. 46 or 47<BR/>49. (((generic$ adj3 prescrib$) or (generic$ adj3 prescription?)) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>50. ((local$ or global$) adj3 budget$).tw.<BR/>51. (budget$ adj3 (general pract$ or GP? or physician? or doctor?)).tw.<BR/>52. 50 and 51<BR/>53. (fundhold$ adj3 (general pract$ or GP? or physician? or doctor?)).tw.<BR/>54. 52 or 53<BR/>55. 54 and 3<BR/>56. "Pharmacy and Therapeutics Committee"/ and 2 and 5<BR/>57. ((drug? or formulary or pharmac$) adj3 committee?).tw. and 2<BR/>58. 56 or 57<BR/>59. (Drug Monitoring/ or Adverse Drug Reaction Reporting Systems/ or (safe$ adj1 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.) and 2<BR/>60. Product Surveillance, Postmarketing/ and 3 and 2<BR/>61. 59 or 60<BR/>62. 36 or 37 or 44 or 45 or 48 or 49 or 55 or 58 or 61<BR/>63. (Cost Control/ or Cost Savings/) and 5 and 2<BR/>64. ((control$ or containment or curtailment or reduc$ or save or saving) adj3 cost?).tw.<BR/>65. (cost? adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>66. 64 and 65 and 2<BR/>67. ((control$ or reduc$ or cut$ or regulat$ or negotiat$ or fix$) adj3 (price? or pricing)).tw.<BR/>68. ((price? or pricing) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>69. 67 and 68 and 2<BR/>70. (reference$ adj3 (price? or pricing)).tw.<BR/>71. ((price? or pricing) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>72. 70 and 71<BR/>73. (index$ adj3 (price? or pricing)).tw.<BR/>74. ((price? or pricing) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>75. 73 and 74<BR/>76. (maxim$ adj3 (price? or pricing)).tw.<BR/>77. ((price? or pricing) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>78. 76 and 77<BR/>79. (cost? effect$ adj3 (price? or pricing)).tw.<BR/>80. ((price? or pricing) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>81. 79 and 80<BR/>82. (reimbursement contract? adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>83. (Drug Cost/ or Economics, Pharmaceutical/) and (1 or 2)<BR/>84. (Purchasing, Hospital/ or Group, Purchasing/) and 3<BR/>85. (purchas$ adj3 (group? or join$ or hospital? or shared)).tw.<BR/>86. ((group? or join$ or hospital? or shared) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>87. 85 and 86 and 2<BR/>88. (procurement$ adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw. and 2<BR/>89. (rebate? adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw. and 2<BR/>90. 63 or 66 or 69 or 72 or 75 or 78 or 81 or 82 or 83 or 84 or 87 or 88 or 89<BR/>91. Marketing/ or Marketing of Health Services/ or Advertising/ or Licensure/ or Drug Labeling/<BR/>92. Pharmacies/ or Pharmacists/ or (pharmacy or pharmacies or pharmacist? or retailer? or wholesaler? or supplier? or dispens$).tw.<BR/>93. 91 and 92 and 3 and (1 or 2)<BR/>94. (advert$ or promot$ or market$).tw.<BR/>95. Pharmacies/ or Pharmacists/ or (pharmacy or pharmacies or pharmacist? or retailer? or wholesaler? or supplier? or dispens$).tw.<BR/>96. 94 and 95 and 3 and (1 or 2)<BR/>97. 93 or 96<BR/>98. ((control$ or reduc$ or regulat$ or fix$ or restrict$) adj3 profit?).tw.<BR/>99. (profit? adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>100. Pharmacies/ or Pharmacists/ or (pharmacy or pharmacies or pharmacist? or retailer? or wholesaler? or supplier? or dispens$).tw.<BR/>101. 98 and 99 and 100<BR/>102. (generic$ adj3 substitut$).tw.<BR/>103. (substitut$ adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>104. 102 and 103<BR/>105. (licens$ adj3 (pharmacy or pharmacies)).tw.<BR/>106. (((supply or supplies or distribut$ or sale$) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament$ or medicat$)) and (pharmacy or pharmacies or retailer? or wholesaler? or supplier? or dispens$)).tw. and (1 or 2)<BR/>107. 97 or 101 or 104 or 105 or 106<BR/>108. Cost Sharing/ and 5<BR/>109. (cost? adj3 (sharing or share)).tw.<BR/>110. ((sharing or share) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>111. 109 and 110<BR/>112. (out of pocket? adj3 pay$).tw.<BR/>113. (pay$ adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>114. 112 and 113<BR/>115. ((copay$ or co pay$) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>116. ((prescrib$ or prescription? or pharmaceutic$ or pharmacy or pharmacies or dispens$) adj3 (charg$ or fee?)).tw.<BR/>117. ((charg$ or fee?) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>118. 116 and 117<BR/>119. ((prescrib$ or prescription?) adj3 (limit$ or cap$)).tw.<BR/>120. ((limit$ or cap$) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>121. 119 and 120<BR/>122. ((coinsurance or deductible?) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament$ or medicat$)).tw.<BR/>123. "Deductibles and Coinsurance"/ and 5<BR/>124. Fees, Pharmaceutical/<BR/>125. Prescription Fees/<BR/>126. Capitation Fee/ and 5<BR/>127. 108 or 111 or 114 or 115 or 118 or 121 or 122 or 123 or 124 or 125 or 126<BR/>128. Drug Information Services/ and (patient? or consumer?).tw. and 2<BR/>129. Drug Labeling/ and (patient? or consumer?).tw. and 2<BR/>130. Patient Education/ and 3 and (1 or 2)<BR/>131. ((educat$ or inform$) adj3 (patient? or consumer?)).tw.<BR/>132. ((patient? or consumer?) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)).tw.<BR/>133. 131 and 132 and (1 or 2)<BR/>134. 128 or 129 or 130 or 133<BR/>135. 14 or 18 or 21 or 25 or 29 or 34 or 35 or 62 or 90 or 107 or 127 or 134<BR/>
</P>
</TD>
</TR>
<TR>
<TH>
<P>CSA Worldwide Political Science Abstracts</P>
</TH>
</TR>
<TR>
<TD>
<P>Search field: 'Key Words'</P>
<P>KW=(legislation OR law* OR act* OR policy OR policies OR politics OR reform* OR system* OR plan* program* OR strateg* OR regulat* OR requirement* OR restrict* OR monitor* OR control)<BR/>AND<BR/>KW=(drug* OR pharmaceutic* OR medicines OR medicament* OR medicat*)<BR/>AND<BR/>KW=(random* OR intervention* OR control* OR compar* OR evaluat* OR time OR longitud* OR repeated measure* OR pretest OR posttest OR pre test OR post test OR impact* OR chang* OR effect* OR experiment*)</P>
</TD>
</TR>
<TR>
<TH>
<P>EconLit, WebSPIRS</P>
</TH>
</TR>
<TR>
<TD>
<P>Search filed: 'Terms Anywhere'<BR/>regulat* or requirement or restrict* or monitor* or control* or legislation or law? or act? or policy or policies or politics or reform* or system? or plan* or program? or strateg*)<BR/>and<BR/>(drug? or pharmaceutic* or medicines or medicament? or medicat*)<BR/>and<BR/>(random* or intervention? or control* or compar* or evaluat* or time or pretest or posttest or pre test or post test or impact? or chang* or effect? or experiment?)<BR/>
</P>
</TD>
</TR>
<TR>
<TH>
<P>SIGLE, System for Information on Grey Literature in Europe, WebSPIRS</P>
</TH>
</TR>
<TR>
<TD>
<P>Search field: 'Terms Anywhere'<BR/>(regulat* or requirement or restrict* or monitor* or control* or legislation or law? or act? or policy or policies or politics or reform* or system? or plan* or program? or strateg*)<BR/>and<BR/>(drug? or pharmaceutic* or medicines or medicament? or medicat*)<BR/>and<BR/>(random* or intervention? or control* or compar* or evaluat* or time or pretest or posttest or pre test or post test or impact? or chang* or effect? or experiment?)</P>
</TD>
</TR>
<TR>
<TH>
<P>INRUD, International Network for Rational Use of Drugs</P>
</TH>
</TR>
<TR>
<TD>
<P>Search field: 'All non-indexed fields'<BR/>{drug} or {pharmaceutic} or {medicines} or {medicament} or {medicat}<BR/>AND<BR/>{regulat} or {requirement} or {restrict} or {monitor} or {control} or {legislation} or {law} or {act} or {policy} or {policies} or {politics} or {reform} or {system} or {plan} or {program} or {strateg}<BR/>AND<BR/>{random} or {intervention} or {control} or {compar} or {evaluat} or {time} or {pretest} or {posttest} or {pre test} or {post test} or {impact} or {chang} or {effect} or {experiment}</P>
</TD>
</TR>
<TR>
<TH>
<P>PAIS International, Public Affairs Information Service, WebSPIRS</P>
</TH>
</TR>
<TR>
<TD>
<P>Search fields: 'Descriptors' or 'Title' or 'Abstract'<BR/>1.((explode "Drug-stores" in DE) or (explode "Pharmacists" in DE) or (explode "Prescriptions" in DE) or (explode "Drugs" in DE) or (explode "Pharmaceutical-industry" in DE)<BR/>OR<BR/>(( ((drug? or pharmaceutic* or medicines or medicament? or medicat*)) in AB )<BR/>OR<BR/>( ((drug? or pharmaceutic* or medicines or medicament? or medicat*)) in TI )))<BR/>AND<BR/>(( ((random* or intervention? or control* or compar* or evaluat* or time or pretest or posttest or pre test or post test or impact? or chang* or effect? or experiment?)) in AB )<BR/>OR<BR/>( ((random* or intervention? or control* or compar* or evaluat* or time or pretest or posttest or pre test or post test or impact? or chang* or effect? or experiment?)) in TI ))<BR/>AND<BR/>(( ((regulat* or requirement or restrict* or monitor* or control* or legislation or law? or act? or policy or policies or politics or reform* or system? or plan* or program? or strateg*)) in AB )<BR/>OR<BR/>( ((regulat* or requirement or restrict* or monitor* or control* or legislation or law? or act? or policy or policies or politics or reform* or system? or plan* or program? or strateg*)) in TI ))<BR/>2.((narco* or crim* or war? or terror* or weapon? or addict* or abus* or traffic* or illicit*) in AB)<BR/>OR<BR/>((narco* or crim* or war? or terror* or weapon? or addict* or abus* or traffic* or illicit*) in TI)<BR/>3. (1 AND 2) NOT 3<BR/>
</P>
</TD>
</TR>
<TR>
<TH>
<P>International Political Science Abstracts, WebSPIRS</P>
</TH>
</TR>
<TR>
<TD>
<P>Search field: 'Terms Anywhere'<BR/>(regulat* or requirement or restrict* or monitor* or control* or legislation or law? or act? or policy or policies or politics or reform* or system? or plan* or program? or strateg*)<BR/>and<BR/>(drug? or pharmaceutic* or medicines or medicament? or medicat*)<BR/>and<BR/>(random* or intervention? or control* or compar* or evaluat* or time or pretest or posttest or pre test or post test or impact? or chang* or effect? or experiment?)</P>
</TD>
</TR>
<TR>
<TH>
<P>NHS EED, National Health Services Economic Evaluation Database, CRD</P>
</TH>
</TR>
<TR>
<TD>
<P>Search fields: A combination of 'Subject Headings' and 'All fields'<BR/>Search done in 6 separate stages<BR/>1.drug-approval or licensure or drug-labeling or classification or patents or marketing or marketing-of-health-services or advertising/Subject Headings<BR/>AND<BR/>drug or pharmac or medicin or medica or prescri/All fields<BR/>AND<BR/>regulat or require or restrict or monitor or control or legislation or law or act or policy or policies or politics or reform or system or plan or program or strateg/All fields<BR/>2.insurance-hospitalization or insurance-health-reimbursement or reimbursement- mechanisms or reimbursement-disproportionate-share or reimbursement-incentive or insurance-pharmaceutical-services/Subject Headings<BR/>AND<BR/>drug or pharmac or medicin or medica or prescri/All fields<BR/>AND<BR/>regulat or require or restrict or monitor or control or legislation or law or act or policy or policies or politics or reform or system or plan or program or strateg/All fields<BR/>3.formularies or formularies-hospital or drugs-essential or reminder-systems or prescriptions-drug or education-continuing or education-pharmacy-continuing or guidelines or practice-guidelines or guideline-adherence/Subject Headings<BR/>AND<BR/>drug or pharmac or medicin or medica or prescri/All fields<BR/>AND<BR/>regulat or require or restrict or monitor or control or legislation or law or act or policy or policies or politics or reform or system or plan or program or strateg/All fields<BR/>4.drug-monitoring or adverse-drug-reaction-reporting-systems or product-surveillance-postmarketing/Subject Headings<BR/>AND<BR/>drug or pharmac or medicin or medica or prescri/All fields<BR/>AND<BR/>regulat or require or restrict or monitor or control or legislation or law or act or policy or policies or politics or reform or system or plan or program or strateg/All fields<BR/>5.deductibles or coinsurance or fees-pharmaceutical or prescription-fees or capitation-fee or drug-information-services or patient-education /Subject Headings<BR/>AND<BR/>drug or pharmac or medicin or medica or prescri/All fields<BR/>6.cost-control or cost savings or drug-cost or economics-pharmaceutical or purchasing-hospital or group-purchasing or pharmacies or pharmacists or cost-sharing/Subject Headings<BR/>AND<BR/>drug or pharmac or medicin or medica or prescri/All fields<BR/>AND<BR/>regulat or require or restrict or monitor or control or legislation or law or act or policy or policies or politics or reform or system or plan or program or strateg/All fields</P>
</TD>
</TR>
<TR>
<TH>
<P>NTIS, National Technical Information Service</P>
</TH>
</TR>
<TR>
<TD>
<P>Search fields: A combination of 'Index Terms' (KT), 'Key Words/Phrases' (no tag) and 'Title'<BR/>#1. KT=PHARMACEUTICALS OR KT=DRUGS OR KT=MEDICATIONS OR KT= PRESCRIPTION DRUGS OR KT=DRUG #PRESCRIPTIONS<BR/>#2. REGULAT* OR REQUIR* OR RESTRICT* OR LEGISLAT* OR LAW? OR ACT? OR POLICY OR POLICIES<BR/>#3. COMPAR* OR EVALUAT* OR EFFECT?<BR/>#4. NARCO* OR CRIM* OR WAR? OR ADDICT* OR ABUS* OR TRAFFIC* OR ILLICIT*<BR/>#5. TI=MANUAL? OR TI=CANCER OR TI=REGISTRATION FILE OR TI=RETIRED REGISTRANTS<BR/>#6. (#1 AND #2 AND #3) NOT #4<BR/>#7. #6 NOT #5</P>
</TD>
</TR>
<TR>
<TH>
<P>IPA, International Pharmaceutical Abstract, WebSPIRS</P>
</TH>
</TR>
<TR>
<TD>
<P>Search fields: A combination of 'Descriptors' and 'Terms Anywhere'<BR/>1.((approval*) in DE) or ((licensing) in DE) or ((licensure) in DE) or ((labeling) in DE) or ((classification) in DE) or ((patent*) in DE) or ((marketing) in DE) or ((advertising) in DE) or ((insurance) in DE) or ((reimbursement) in DE) or ((formularies) in DE) or ((formulary) in DE) or ((essential) in DE) or (reminder system*) or ((Education-pharmaceutical-continuing) in DE) or ((Education-continuing) in DE) or ((Hospitals-pharmacy-and-therapeutics-committee) in DE) or (drug* near1 monitoring) or ((Drugs-adverse-reactions-reports) in DE) or ((Reports-drugs-adverse-reactions) in DE) or ((Costs-drugs) in DE) or ((Pricing-drugs) in DE) or ((pharmacoeconomics) in DE) or (reference near2 pric*) or ((Costs-prescription-drugs) in DE) or ((purchasing) in DE) or (cost adj sharing) or ((copayment*) in DE) or (deductibles) or (coinsurance) or ((drug information services) in DE) or (patient adj education)<BR/>
<BR/>(regulat* or restrict* or control* or legislat* or law or laws or act or acts or policy or policies or program or programs) and (control* or compar* or evaluat* or time series or impact* or effect or effects) and ((sc=20) or (sc=22))<BR/>2.(regulat* or restrict* or control* or legislat* or law or laws or act or acts or policy or policies or program or programs) and (control* or compar* or evaluat* or time series or impact* or effect or effects) and ((sc=20) or (sc=22))<BR/>3.(1 and 2) not sc=6</P>
</TD>
</TR>
<TR>
<TH>
<P>OECD (Organisation for Economic Co-operation and Development)<BR/>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Searched: Publications &amp; Documents, limited to OECD Publications only<BR/>drug or drugs or pharmaceutical or pharmaceuticals or medicaments or medicines or prescription or prescriptions or prescribe or prescribing</P>
</TD>
</TR>
<TR>
<TH>
<P>SourceOECD<BR/>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Search fields: 'Title' or 'Abstract'<BR/>drug or drugs or pharmaceutic* or medicament* or medicines or prescrip*or prescrib*</P>
</TD>
</TR>
<TR>
<TH>
<P>World Bank Documents &amp; Reports<BR/>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Limited to sectors: Health, Nutrition and Population or Hospitals, Secondary &amp; Tertiary or Primary health or Reform and Financing<BR/>drug or drugs or pharmaceutical or pharmaceuticals or medicament or medicaments or medicines or prescription or prescriptions or prescribe or prescribed or prescribing</P>
</TD>
</TR>
<TR>
<TH>
<P>World Bank e-Library<BR/>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Search fields: 'Title' or 'Abstract' or 'Keywords'<BR/>drug or drugs or pharmaceutical or pharmaceuticals or pharmaceutic or pharmaceutics or medicament or medicaments or medicines or prescription or prescriptions or prescribe or prescribed or prescribing</P>
</TD>
</TR>
<TR>
<TH>
<P>WHO (World Health Organization)</P>
</TH>
</TR>
<TR>
<TD>
<P>browsed The Essential Drugs and Medicines web site</P>
</TD>
</TR>
<TR>
<TH>
<P>WHOLIS, the WHO library database<BR/>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Search field: 'Words or phrase'<BR/>words or phrase "prescrib$ or prescrip$"<BR/>AND<BR/>words or phrase "regulat$ or requirement$ or restrict$ or monitor$ or control$ or legislation$ or law? or act or acts or policy or policies or politics or reform$ or system? or plan or plans or planning or program? or strateg$ or incentive$"</P>
</TD>
</TR>
<TR>
<TH>
<P>JOLIS, The Library Network, serving the World Bank Group and IMF<BR/>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Search field: &#8217;Keywords Anywhere&#8217;. Search done in two separate stages<BR/>keywords anywhere &#8220;prescrib$ or prescrip$&#8221;<BR/>AND<BR/>keywords anywhere &#8220;drug or drugs or pharmaceutic$ or medica$ or medicines&#8221;<BR/>AND<BR/>keywords anywhere &#8220;regulat$ or requirement$ or restrict$ or monitor$ or control$ or legislation$ or law? or act or acts or policy or<BR/>policies or politics or reform$ or system? or plan or plans or planning or program? or strateg$ or incentive$&#8221;</P>
</TD>
</TR>
<TR>
<TH>
<P>Global Jolis, online catalogue for the World Bank Country Office PIC/Libraries<BR/>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Search field: &#8217;Words or Phrase&#8217;. Search done in two separate stages<BR/>1. prescrib$ or prescrip$<BR/>AND<BR/>drug or drugs or pharmaceutic$ or medica$ or medicines<BR/>AND<BR/>regulat$ or requirement$ or restrict$ or monitor$ or control$ or legislation$ or law? or act or acts or policy or policies or politics 2.<BR/>prescrib$ or prescrip$<BR/>AND<BR/>drug or drugs or pharmaceutic$ or medica$ or medicines<BR/>AND<BR/>reform$ or system? or plan or plans or planning or program? or strateg$ or incentive$</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2015-05-22 13:31:20 +0200" MODIFIED_BY="Arash Rashidian" NO="3">
<TITLE MODIFIED="2015-04-27 20:01:45 +0200" MODIFIED_BY="Arash Rashidian">EPOC suggested risk of bias criteria</TITLE>
<APPENDIX_BODY MODIFIED="2015-05-22 13:31:20 +0200" MODIFIED_BY="Arash Rashidian">
<TABLE COLS="1" ROWS="4">
<TR>
<TH>
<P>
<B>Risk of bias for studies with a separate control group (RCTs, NRCTs, CBAs)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Nine standard criteria are used for all RCTs, NRCTs and CBAs. Further information can be obtained from the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>section on risk of bias and from the draft methods paper on risk of bias under the EPOC-specific resources section of the EPOC website.</P>
<P/>
<P>
<B>Was the allocation sequence adequately generated?</B>
</P>
<P>Score: &#8220;low risk&#8221; if a random component in the sequence generation process is described (e.g. referring to a random number table). Score &#8220;high risk&#8221; when a non-random method is used (e.g. performed by date of admission). NRCTs and CBA studies should be scored &#8220;high risk&#8221;. Score &#8220;unclear risk&#8221; if not specified in the paper.</P>
<P/>
<P>
<B>Was the allocation adequately concealed?</B>
</P>
<P>Score &#8220;low risk&#8221; if the unit of allocation was by institution, team or professional and allocation was performed on all units at the start of the study; or if the unit of allocation was by patient or episode of care, and some form of centralised randomisation scheme, an on-site computer system or sealed opaque envelopes were used. CBA studies should be scored &#8220;high risk&#8221;. Score &#8220;unclear risk&#8221; if not specified in the paper.</P>
<P/>
<P>
<B>Were baseline outcome measurements similar?<SUP>1,2</SUP>
</B>
</P>
<P>Score &#8220;Low risk&#8221; if performance or patient outcomes were measured prior to the intervention, and no important differences were present across study groups. In RCTs, score &#8220;Low risk&#8221; if imbalanced but appropriate adjusted analysis was performed (e.g. Analysis of covariance). Score &#8220;High risk&#8221; if important differences were present and not adjusted for in analysis. If RCTs have no baseline measure of outcome, score &#8220;Unclear risk&#8221;.</P>
<P/>
<P>
<B>Were baseline characteristics similar?</B>
</P>
<P>Score &#8220;Low risk&#8221; if baseline characteristics of the study and control providers are reported and similar. Score &#8220;Unclear risk&#8221; if it is not clear in the paper (e.g. characteristics are mentioned in text but no data were presented). Score &#8220;High risk&#8221; if there is no report of characteristics in text or tables or if there are differences between control and intervention providers. Note that in some cases imbalance in patient characteristics may be due to recruitment bias whereby the provider was responsible for recruiting patients into the trial.</P>
<P/>
<P>
<B>Were incomplete outcome data adequately addressed?<SUP>1</SUP>
</B>
</P>
<P>Score &#8220;low risk&#8221; if missing outcome measures were unlikely to bias the results (e.g. the proportion of missing data was similar in the intervention and control groups, or the proportion of missing data was less than the effect size, i.e. unlikely to overturn the study result). Score &#8220;high risk&#8221; if missing outcome data were likely to bias the results. Score &#8220;unclear risk&#8221; if not specified in the paper (do not assume 100% follow-up unless stated explicitly).</P>
<P/>
<P>
<B>Was knowledge of the allocated interventions adequately prevented during the study?</B>
<SUP>1</SUP>
</P>
<P>Score &#8220;low risk&#8221; if study authors state explicitly that the primary outcome variables were assessed blindly, or if the outcomes are objective (e.g. length of hospital stay). Primary outcomes are those variables that correspond to the primary hypothesis or question as defined by study authors. Score &#8220;high risk&#8221; if the outcomes were not assessed blindly. Score &#8220;unclear risk&#8221; if this is not specified in the paper.</P>
<P/>
<P>
<B>Was the study adequately protected against contamination?</B>
</P>
<P>Score &#8220;low risk&#8221; if allocation was by community, institution or practice, and it is unlikely that the control group received the intervention. Score &#8220;high risk&#8221; if it is likely that the control group received the intervention (e.g. if patients rather than professionals were randomly assigned). Score &#8220;unclear risk&#8221; if professionals were allocated within a clinic or practice, and it is possible that communication between intervention and control professionals could have occurred (e.g. physicians within practices were allocated to intervention or control).</P>
<P/>
<P>
<B>Was the study free of selective outcome reporting?</B>
</P>
<P>Score &#8220;low risk&#8221; if no evidence suggests that outcomes were selectively reported (e.g. all relevant outcomes in the Methods section are reported in the Results section). Score &#8220;high risk&#8221; if some important outcomes are subsequently omitted from the results. Score &#8220;unclear risk&#8221; if not specified in the paper.</P>
<P/>
<P>
<B>Was the study free of other risks of bias?</B>
</P>
<P>Score &#8220;low risk&#8221; if no evidence suggests other risks of bias.</P>
<P/>
<P>_________________</P>
<P>
<SUP>1</SUP>If some primary outcomes were imbalanced at baseline, assessed blindly or affected by missing data and others were not, each primary outcome can be scored separately.</P>
<P/>
<P>
<SUP>2</SUP>If &#8220;unclear&#8221; or &#8220;no&#8221;, but sufficient data are provided in the paper for an adjusted analysis (e.g. baseline adjustment analysis, intention-to-treat analysis), the criteria should be rescored to &#8220;yes&#8221;.</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>Risk of bias for interrupted time series (ITS) studies</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Seven standard criteria are used for all ITS studies. Further information can be obtained from the<I> Cochrane Handbook on Systematic Reviews of Interventions</I> section on risk of bias and from the draft methods paper on risk of bias under the EPOC specific resources section of the EPOC website.</P>
<P/>
<P>Note: If the ITS study has ignored secular (trend) changes and performed a simple t-test of before versus after intervention periods without further justification, the study should not be included in the review unless reanalysis is possible.</P>
<P/>
<P>
<B>Was the intervention independent of other changes? </B>
</P>
<P>Score &#8220;low risk&#8221; if compelling arguments indicate that the intervention occurred independently of other changes over time, and that the outcome was not influenced by other confounding variables/historic events during the study period. If events/variables were identified, note what they are. Score &#8220;high risk&#8221; if it is reported that the intervention was not independent of other changes in time.</P>
<P/>
<P>
<B>Was the shape of the intervention effect prespecified?</B>
</P>
<P>Score &#8221;low risk&#8221; if point of analysis is the point of intervention OR a rational explanation for the shape of the intervention effect was given by the study author(s). When appropriate, this should include an explanation if the point of analysis is NOT the point of intervention; score &#8220;high risk&#8221; if it is clear that the condition above is not met.</P>
<P/>
<P>
<B>Was the intervention unlikely to affect data collection?</B>
</P>
<P>Score &#8220;low risk&#8221; if it is reported that the intervention itself was unlikely to affect data collection (e.g. sources and methods of data collection were the same before and after the intervention); score &#8220;high risk&#8221; if the intervention itself was likely to affect data collection (e.g. any change in source or method of data collection reported).</P>
<P/>
<P>
<B>Was knowledge of the allocated interventions adequately prevented during the study?*** </B>
</P>
<P>Score &#8220;low risk&#8221; if study authors state explicitly that the primary outcome variables were assessed blindly, or if the outcomes are objective (e.g. length of hospital stay). Primary outcomes are those variables that correspond to the primary hypothesis or question as defined by study authors. Score &#8220;high risk&#8221; if the outcomes were not assessed blindly. Score &#8220;unclear risk&#8221; if this is not specified in the paper.</P>
<P/>
<P>
<B>Were incomplete outcome data adequately addressed?***</B>
</P>
<P>Score &#8220;low risk&#8221; if missing outcome measures were unlikely to bias the results (e.g. the proportion of missing data was similar in the before- and after-intervention periods, or if the proportion of missing data was less than the effect size (i.e. unlikely to overturn the study result). Score &#8220;high risk&#8221; if missing outcome data were likely to bias the results. Score &#8220;unclear risk&#8221; if this was not specified in the paper. (Do not assume 100% follow-up unless this was stated explicitly.)</P>
<P/>
<P>
<B>Was the study free of selective outcome reporting?</B>
</P>
<P>Score &#8220;low risk&#8221; if no evidence suggests that outcomes were selectively reported (e.g. all relevant outcomes in the Methods section were reported in the Results section). Score &#8220;high risk&#8221; if some important outcomes are subsequently omitted from the results. Score &#8220;unclear risk&#8221; if this was not specified in the paper.</P>
<P/>
<P>
<B>Was the study free of other risks of bias?</B>
</P>
<P>Score &#8220;low risk&#8221; if no evidence suggests other risks of bias</P>
<P>(e.g. should consider if seasonality is an issue, i.e. if January to June constitutes the preintervention period, and July to December the post, could the &#8220;seasons&#8217; have caused a spurious effect?).</P>
<P/>
<P>***If some primary outcomes were assessed blindly or were affected by missing data and others were not, each primary outcome can be scored separately.</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2015-05-22 13:31:52 +0200" MODIFIED_BY="Arash Rashidian" NO="4">
<TITLE MODIFIED="2015-05-22 13:31:34 +0200" MODIFIED_BY="Arash Rashidian">PRISMA checklist</TITLE>
<APPENDIX_BODY MODIFIED="2015-05-22 13:31:52 +0200" MODIFIED_BY="Arash Rashidian">
<TABLE COLS="4" ROWS="19">
<TR>
<TD>
<P>
<B>Section/Topic </B>
</P>
</TD>
<TD>
<P>
<B>#</B>
</P>
</TD>
<TD>
<P>
<B>Checklist item </B>
</P>
</TD>
<TD>
<P>
<B>Reported in the review</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>
<B>TITLE </B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Title</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>Identify the report as a systematic review, meta-analysis or both</P>
</TD>
<TD VALIGN="TOP">
<P>Yes *</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>
<B>ABSTRACT </B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Structured summary</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>Provide a structured summary including, as applicable, the following: background; objectives; data sources; study eligibility criteria, participants and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>
<B>INTRODUCTION </B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Rationale</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>Describe the rationale for the review in the context of what is already known</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Objectives</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes and study design (PICOS)</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>
<B>METHODS </B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Protocol and registration</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>Indicate whether a review protocol exists, if and where it can be accessed (e.g. Web address); if available, provide registration information including registration number</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Eligibility criteria</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>Specify study characteristics (e.g. PICOS, length of follow-up) and report characteristics (e.g. years considered, language, publication status) used as criteria for eligibility, giving rationale</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Information sources</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>Describe all information sources (e.g. databases with dates of coverage, contact with study authors to identify additional studies) in the search and the date last searched</P>
</TD>
<TD VALIGN="TOP">
<P>
<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Search</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>Present full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated</P>
</TD>
<TD VALIGN="TOP">
<P>Appendices 1-21</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Study selection</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis)</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Data collection process</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>Describe method of data extraction from reports (e.g. piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Data items</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>List and define all variables for which data were sought (e.g. PICOS, funding sources) and any assumptions and simplifications made</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Risk of bias in individual studies</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>Describe methods used in assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Summary measures</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>State the principal summary measures (e.g. risk ratio, difference in means)</P>
</TD>
<TD VALIGN="TOP">
<P>Yes (median values)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Synthesis of results</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g. I<SUP>2</SUP>), for each meta-analysis</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
</TABLE>
<TABLE COLS="4" ROWS="17">
<TR>
<TD>
<P>
<B>Section/Topic </B>
</P>
</TD>
<TD>
<P>
<B>#</B>
</P>
</TD>
<TD>
<P>
<B>Checklist item </B>
</P>
</TD>
<TD>
<P>
<B>Reported on page # </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Risk of bias across studies</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>Specify any assessment of risk of bias that may affect the cumulative evidence (e.g. publication bias, selective reporting within studies)</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Additional analyses</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>Describe methods of additional analyses (e.g. sensitivity or subgroup analyses, meta-regression), if done, indicating which were prespecified</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>
<B>RESULTS </B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Study selection</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>Give numbers of studies screened, assessed for eligibility and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram</P>
</TD>
<TD VALIGN="TOP">
<P>Yes. In the text - also "Characteristics of excluded studies"</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Study characteristics</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>For each study, present characteristics for which data were extracted (e.g. study size, PICOS, follow-up period) and provide the citations</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Risk of bias within studies</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12)</P>
</TD>
<TD VALIGN="TOP">
<P>Additional Tables 3, 4; Appendices 4, 5</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Results of individual studies</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>For all outcomes considered (benefits or harms), present, for each study, the following: (a) simple summary data for each intervention group, and (b) effect estimates and confidence intervals, ideally with a forest plot</P>
</TD>
<TD VALIGN="TOP">
<P>Tables of "Characteristics of included studies"</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Synthesis of results</P>
</TD>
<TD VALIGN="TOP">
<P>21</P>
</TD>
<TD VALIGN="TOP">
<P>Present results of each meta-analysis done, including confidence intervals and measures of consistency</P>
</TD>
<TD VALIGN="TOP">
<P>N/A</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Risk of bias across studies</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>Present results of any assessment of risk of bias across studies (see Item 15)</P>
</TD>
<TD VALIGN="TOP">
<P>Summary of findings tables</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Additional analysis</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>Give results of additional analyses, if done (e.g. sensitivity or subgroup analyses, meta-regression [see Item 16])</P>
</TD>
<TD VALIGN="TOP">
<P>Tables 6 to 10</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>
<B>DISCUSSION </B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Summary of evidence</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>Summarise the main findings including strength of the evidence for each main outcome; consider their relevance to key groups (e.g. healthcare providers, users and policy makers)</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Limitations</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>Discuss limitations at study and outcome levels (e.g. risk of bias) and at review level (e.g. incomplete retrieval of identified research, reporting bias)</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Conclusions</P>
</TD>
<TD VALIGN="TOP">
<P>26</P>
</TD>
<TD VALIGN="TOP">
<P>Provide a general interpretation of the results in the context of other evidence, and implications for future research</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>
<B>FUNDING </B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Funding</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>Describe sources of funding for the systematic review and other support (e.g. supply of data); the role of funders for the systematic review</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
</TR>
</TABLE>
<P>* The "Yes" indicates that the relevant information can be found under the subheading in the RevMan file, as it was not possible to identify page numbers within the RevMan file</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2015-05-22 13:32:28 +0200" MODIFIED_BY="Arash Rashidian" NO="5">
<TITLE MODIFIED="2013-08-25 10:35:56 +0200" MODIFIED_BY="[Empty name]">Abbreviations</TITLE>
<APPENDIX_BODY MODIFIED="2015-05-22 13:32:28 +0200" MODIFIED_BY="Arash Rashidian">
<TABLE COLS="2" ROWS="26">
<TR>
<TD>
<P>CBA</P>
</TD>
<TD>
<P>Controlled before-and-after</P>
</TD>
</TR>
<TR>
<TD>
<P>CCT</P>
</TD>
<TD>
<P>Controlled clinical trial</P>
</TD>
</TR>
<TR>
<TD>
<P>CI</P>
</TD>
<TD>
<P>Confidence interval</P>
</TD>
</TR>
<TR>
<TD>
<P>CITS</P>
</TD>
<TD>
<P>Controlled interrupted time series</P>
</TD>
</TR>
<TR>
<TD>
<P>CRM</P>
</TD>
<TD>
<P>Controlled repeated measures</P>
</TD>
</TR>
<TR>
<TD>
<P>DDD</P>
</TD>
<TD>
<P>defined daily doses</P>
</TD>
</TR>
<TR>
<TD>
<P>DMP</P>
</TD>
<TD>
<P>Disease management programme</P>
</TD>
</TR>
<TR>
<TD>
<P>EPOC</P>
</TD>
<TD>
<P>Effective Practice and Organisation of Care</P>
</TD>
</TR>
<TR>
<TD>
<P>FH</P>
</TD>
<TD>
<P>Fund-holding (fund-holders)</P>
</TD>
</TR>
<TR>
<TD>
<P>H2RA</P>
</TD>
<TD>
<P>Histamine-2 receptor antagonist</P>
</TD>
</TR>
<TR>
<TD>
<P>GP</P>
</TD>
<TD>
<P>General practitioner</P>
</TD>
</TR>
<TR>
<TD>
<P>Item</P>
</TD>
<TD>
<P>Defined as each preparation on the prescription</P>
</TD>
</TR>
<TR>
<TD>
<P>ITS</P>
</TD>
<TD>
<P>Interrupted time series</P>
</TD>
</TR>
<TR>
<TD>
<P>IDTSS</P>
</TD>
<TD>
<P>Indicative Drug Target Savings Scheme (Ireland)</P>
</TD>
</TR>
<TR>
<TD>
<P>NIC</P>
</TD>
<TD>
<P>Net ingredient costs</P>
</TD>
</TR>
<TR>
<TD>
<P>OECD</P>
</TD>
<TD>
<P>Organisation for Economic Co-operation and Development</P>
</TD>
</TR>
<TR>
<TD>
<P>PACT</P>
</TD>
<TD>
<P>Prescribing analysis and cost (data used in British fund-holding)</P>
</TD>
</TR>
<TR>
<TD>
<P>PPI</P>
</TD>
<TD>
<P>Proton pump inhibitors</P>
</TD>
</TR>
<TR>
<TD>
<P>PU</P>
</TD>
<TD>
<P>Prescribing unit; allows for demographic differences between practices. Patients younger than age 65 are counted as a single prescribing unit, and those aged 65 and over count as three. Astro PU in addition corrects for age, sex and temporary residency</P>
</TD>
</TR>
<TR>
<TD>
<P>RCT</P>
</TD>
<TD>
<P>Randomised controlled trial</P>
</TD>
</TR>
<TR>
<TD>
<P>RM</P>
</TD>
<TD>
<P>Repeated measures</P>
</TD>
</TR>
<TR>
<TD>
<P>RR</P>
</TD>
<TD>
<P>Risk ratio (intervention vs control group)</P>
</TD>
</TR>
<TR>
<TD>
<P>RR (adj)</P>
</TD>
<TD>
<P>Risk ratio (adjusted for preintervention differences) = RR after intervention/RR before intervention</P>
</TD>
</TR>
<TR>
<TD>
<P>SPR</P>
</TD>
<TD>
<P>Standard prescribing ratio</P>
</TD>
</TR>
<TR>
<TD>
<P>SSRI</P>
</TD>
<TD>
<P>Selective serotonin reuptake inhibitors</P>
</TD>
</TR>
<TR>
<TD>
<P>WHO</P>
</TD>
<TD>
<P>World Health Organization</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of studies included in the review:&lt;/p&gt;&lt;p&gt;18&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of studies included in original review:&lt;/p&gt;&lt;p&gt;13&lt;/p&gt;&lt;p&gt;(One study excluded due to irrelevant outcome)&lt;/p&gt;&lt;p&gt;Total included studies from original review:&lt;/p&gt;&lt;p&gt;12&lt;/p&gt;&lt;p&gt;&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;# of new studies included in the update:&lt;/p&gt;&lt;p&gt;6&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of full-text articles assessed for eligibility:&lt;/p&gt;&lt;p&gt;56&lt;/p&gt;&lt;p&gt;(+ 4 studies from previous version that were in &amp;quot;studies awaiting assessment&amp;quot;)&lt;/p&gt;&lt;p&gt;(-10 studies awaiting classification)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Total full-text articles = 50&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of records screened:&lt;/p&gt;&lt;p&gt;1197&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of records identified through database searching:&lt;/p&gt;&lt;p&gt;8388&lt;/p&gt;" WIDTH="120">
<OUT TEXT="&lt;p&gt;# of records excluded through title screening:&lt;/p&gt;&lt;p&gt;7191&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;# of records excluded:&lt;/p&gt;&lt;p&gt;1141&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;# of full-text articles excluded, with reasons:&lt;/p&gt;&lt;p&gt;44&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>